US20200048223A1 - Wnt signaling pathway inhibitors and therapeutic applications thereof - Google Patents
Wnt signaling pathway inhibitors and therapeutic applications thereof Download PDFInfo
- Publication number
- US20200048223A1 US20200048223A1 US16/653,217 US201916653217A US2020048223A1 US 20200048223 A1 US20200048223 A1 US 20200048223A1 US 201916653217 A US201916653217 A US 201916653217A US 2020048223 A1 US2020048223 A1 US 2020048223A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- independently selected
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004156 Wnt signaling pathway Effects 0.000 title abstract description 15
- 239000003112 inhibitor Substances 0.000 title abstract description 5
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 170
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 76
- 150000004820 halides Chemical class 0.000 claims description 69
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 62
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 47
- 229910052760 oxygen Inorganic materials 0.000 claims description 39
- 229910052717 sulfur Inorganic materials 0.000 claims description 38
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 37
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 34
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 34
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 30
- 125000005842 heteroatom Chemical group 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 20
- -1 —OH Chemical group 0.000 claims description 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 18
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 125000005549 heteroarylene group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000000732 arylene group Chemical group 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 10
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 9
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 102000013814 Wnt Human genes 0.000 claims description 7
- 108050003627 Wnt Proteins 0.000 claims description 7
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 6
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 claims description 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000004442 acylamino group Chemical group 0.000 claims description 6
- 125000005256 alkoxyacyl group Chemical group 0.000 claims description 6
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims description 6
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 206010050207 Skin fibrosis Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 3
- 230000004761 fibrosis Effects 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 201000002793 renal fibrosis Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052722 tritium Inorganic materials 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 364
- 238000005160 1H NMR spectroscopy Methods 0.000 description 219
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 185
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 132
- 239000000203 mixture Substances 0.000 description 132
- 235000019439 ethyl acetate Nutrition 0.000 description 82
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 71
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 65
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 64
- 239000007787 solid Substances 0.000 description 60
- 239000000243 solution Substances 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 239000007832 Na2SO4 Substances 0.000 description 49
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 49
- 229910052938 sodium sulfate Inorganic materials 0.000 description 49
- 238000001816 cooling Methods 0.000 description 47
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 45
- 238000010898 silica gel chromatography Methods 0.000 description 44
- 239000012044 organic layer Substances 0.000 description 39
- 239000003208 petroleum Substances 0.000 description 31
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 28
- 0 [1*]N(*[U])*CC Chemical compound [1*]N(*[U])*CC 0.000 description 26
- 239000012267 brine Substances 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 23
- 239000012299 nitrogen atmosphere Substances 0.000 description 22
- 238000010992 reflux Methods 0.000 description 21
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 19
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- OETBVLCSPLXDGL-UHFFFAOYSA-N CC1=NC=CC(=C1)C1=CC=C(CNC2=CC(=NC=N2)N2C(C3=C(N=C(N=C3)SC)CC2)=O)C=C1 Chemical compound CC1=NC=CC(=C1)C1=CC=C(CNC2=CC(=NC=N2)N2C(C3=C(N=C(N=C3)SC)CC2)=O)C=C1 OETBVLCSPLXDGL-UHFFFAOYSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000002810 primary assay Methods 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- KFSALLZNNHJKRD-UHFFFAOYSA-N FC=1C(=NC=NC=1C1=CC2=CC=CC=C2C=C1)NCC1=CC=C(C=C1)C1=CC(=NC=C1)C Chemical compound FC=1C(=NC=NC=1C1=CC2=CC=CC=C2C=C1)NCC1=CC=C(C=C1)C1=CC(=NC=C1)C KFSALLZNNHJKRD-UHFFFAOYSA-N 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- XQBRZPOJKUYHLB-UHFFFAOYSA-N N1=CC=CC=2CN(CCC1=2)C1=C(C(=NC=N1)NCC=1C=NC(=NC=1)C1=CC(=NC=C1)C)F Chemical compound N1=CC=CC=2CN(CCC1=2)C1=C(C(=NC=N1)NCC=1C=NC(=NC=1)C1=CC(=NC=C1)C)F XQBRZPOJKUYHLB-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- OXZKYECAINWQBY-UHFFFAOYSA-N 4-(7,8-dihydro-5H-1,6-naphthyridin-6-yl)-3-fluoro-N-[[5-fluoro-6-(2-methylpyridin-4-yl)pyridin-3-yl]methyl]pyridin-2-amine Chemical compound N1=CC=CC=2CN(CCC1=2)C1=C(C(=NC=C1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)F)F OXZKYECAINWQBY-UHFFFAOYSA-N 0.000 description 7
- BYSUWZLWJRDTGS-UHFFFAOYSA-N CC1=NC=CC(=C1)C1=CC=C(CNC2=NC=CC(=C2)C2=CC3=CC=CC=C3C=C2)C=C1 Chemical compound CC1=NC=CC(=C1)C1=CC=C(CNC2=NC=CC(=C2)C2=CC3=CC=CC=C3C=C2)C=C1 BYSUWZLWJRDTGS-UHFFFAOYSA-N 0.000 description 7
- UALOISYPNDYERH-UHFFFAOYSA-N CNC=1N=CC2=C(N=1)CCN(C2=O)C1=NC=NC(=C1)NCC1=CC=C(C=C1)C1=CC(=NC=C1)C Chemical compound CNC=1N=CC2=C(N=1)CCN(C2=O)C1=NC=NC(=C1)NCC1=CC=C(C=C1)C1=CC(=NC=C1)C UALOISYPNDYERH-UHFFFAOYSA-N 0.000 description 7
- MDVWEWSBXBXAOT-UHFFFAOYSA-N COC=1C(=NC=C(C=1)CNC1=NSC(=N1)C=1C=C2C=CC=NC2=CN=1)C1=CC(=NC=C1)C Chemical compound COC=1C(=NC=C(C=1)CNC1=NSC(=N1)C=1C=C2C=CC=NC2=CN=1)C1=CC(=NC=C1)C MDVWEWSBXBXAOT-UHFFFAOYSA-N 0.000 description 7
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 7
- LBPURGIIEPFEDZ-UHFFFAOYSA-N FC=1C(=NC=NC=1C1=CC2=CC=CC=C2C=C1)N(CC1=CC=C(C=C1)C1=CC(=NC=C1)C)C Chemical compound FC=1C(=NC=NC=1C1=CC2=CC=CC=C2C=C1)N(CC1=CC=C(C=C1)C1=CC(=NC=C1)C)C LBPURGIIEPFEDZ-UHFFFAOYSA-N 0.000 description 7
- HOZMPHCGCXTCBK-UHFFFAOYSA-N FC=1C(=NC=NC=1C=1C=C2C=CC=NC2=CC=1)NCC=1C=C2C=CC(=CC2=CC=1)C(=O)N Chemical compound FC=1C(=NC=NC=1C=1C=C2C=CC=NC2=CC=1)NCC=1C=C2C=CC(=CC2=CC=1)C(=O)N HOZMPHCGCXTCBK-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- TYRHDAZPKQQYLT-UHFFFAOYSA-N N1=CC=CC2=CC(=CC=C12)C1=NC(=NC=C1)NCC1=CC=C2C=C(C=NC2=C1)C#N Chemical compound N1=CC=CC2=CC(=CC=C12)C1=NC(=NC=C1)NCC1=CC=C2C=C(C=NC2=C1)C#N TYRHDAZPKQQYLT-UHFFFAOYSA-N 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- OZGGZUJZNCGVTF-UHFFFAOYSA-N 2-[[5-fluoro-6-(2-methylpyridin-4-yl)pyridin-3-yl]methylamino]-4-(1,5-naphthyridin-2-yl)pyridin-3-ol Chemical compound FC=1C(=NC=C(C=1)CNC1=NC=CC(=C1O)C1=NC2=CC=CN=C2C=C1)C1=CC(=NC=C1)C OZGGZUJZNCGVTF-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000015735 Beta-catenin Human genes 0.000 description 6
- 108060000903 Beta-catenin Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- KEVDQJIWMUMWQF-UHFFFAOYSA-N FC=1C(=NC=NC=1C#CC=1C=NC=CC=1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)F Chemical compound FC=1C(=NC=NC=1C#CC=1C=NC=CC=1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)F KEVDQJIWMUMWQF-UHFFFAOYSA-N 0.000 description 6
- NMDFRINJWNMIRB-UHFFFAOYSA-N FC=1C(=NC=NC=1C=1C=C2C=CC=NC2=CC=1)NCC1=CC=C(C=C1)C1=CC(=[N+](C=C1)[O-])C Chemical compound FC=1C(=NC=NC=1C=1C=C2C=CC=NC2=CC=1)NCC1=CC=C(C=C1)C1=CC(=[N+](C=C1)[O-])C NMDFRINJWNMIRB-UHFFFAOYSA-N 0.000 description 6
- ILEIXYBRCAFHCY-UHFFFAOYSA-N FC=1C(=NC=NC=1C=1C=C2C=CC=NC2=CC=1)NCC=1C=C2C=CC(=CC2=CC=1)C#N Chemical compound FC=1C(=NC=NC=1C=1C=C2C=CC=NC2=CC=1)NCC=1C=C2C=CC(=CC2=CC=1)C#N ILEIXYBRCAFHCY-UHFFFAOYSA-N 0.000 description 6
- KYNLSOOSQQBSNS-UHFFFAOYSA-N FC=1C(=NC=NC=1C=1C=C2C=CC=NC2=CN=1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)F Chemical compound FC=1C(=NC=NC=1C=1C=C2C=CC=NC2=CN=1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)F KYNLSOOSQQBSNS-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- PFEVMXYWVNKFOP-UHFFFAOYSA-N N1=CC=CC2=CC(=NC=C12)C1=NC(=NC=C1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)C#N Chemical compound N1=CC=CC2=CC(=NC=C12)C1=NC(=NC=C1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)C#N PFEVMXYWVNKFOP-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000003636 chemical group Chemical group 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 6
- MBTULFIFECUURA-UHFFFAOYSA-N 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound C1=NC(C)=CC(B2OC(C)(C)C(C)(C)O2)=C1 MBTULFIFECUURA-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- MPQBAYYHPBVJDB-UHFFFAOYSA-N N1=CC=CC=2CN(CCC1=2)C1=NC(=NS1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)C#N Chemical compound N1=CC=CC=2CN(CCC1=2)C1=NC(=NS1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)C#N MPQBAYYHPBVJDB-UHFFFAOYSA-N 0.000 description 5
- LRFASXOTTIOBEW-UHFFFAOYSA-N [5-fluoro-6-(2-methylpyridin-4-yl)pyridin-3-yl]methanamine Chemical compound C1=NC(C)=CC(C=2C(=CC(CN)=CN=2)F)=C1 LRFASXOTTIOBEW-UHFFFAOYSA-N 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- CEUHPOVLEQUFCC-UHFFFAOYSA-N 3,5-dichloro-1,2,4-thiadiazole Chemical compound ClC1=NSC(Cl)=N1 CEUHPOVLEQUFCC-UHFFFAOYSA-N 0.000 description 4
- DGMIGAHDDPJOPN-UHFFFAOYSA-N 4,6-dichloro-5-fluoropyrimidine Chemical compound FC1=C(Cl)N=CN=C1Cl DGMIGAHDDPJOPN-UHFFFAOYSA-N 0.000 description 4
- VMFALDWCEQUFSX-UHFFFAOYSA-N 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(N=CC=C2)C2=C1 VMFALDWCEQUFSX-UHFFFAOYSA-N 0.000 description 4
- YYPUJGIABYEZLD-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC(C4=CC5=C(C=N4)N=CC=C5)=CC=N3)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC(C4=CC5=C(C=N4)N=CC=C5)=CC=N3)C=N2)=C1 YYPUJGIABYEZLD-UHFFFAOYSA-N 0.000 description 4
- PZQKWTWYIPIHKJ-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5NN=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5NN=CC5=C4)=NC=N3)C=C2)=C1 PZQKWTWYIPIHKJ-UHFFFAOYSA-N 0.000 description 4
- VFOOGXATFTUPNT-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCN5C(=NN=C5C(F)(F)F)C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCN5C(=NN=C5C(F)(F)F)C4)=NC=N3)C=C2)=C1 VFOOGXATFTUPNT-UHFFFAOYSA-N 0.000 description 4
- VJISYXSHMPQVPM-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=N2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=N2)=C1 VJISYXSHMPQVPM-UHFFFAOYSA-N 0.000 description 4
- IMRLQPSUKZVRMF-UHFFFAOYSA-N FC=1C(=NC=CC=1C=1C=C2C=CC=NC2=CN=1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)C#N Chemical compound FC=1C(=NC=CC=1C=1C=C2C=CC=NC2=CN=1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)C#N IMRLQPSUKZVRMF-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- FPEAARFNXIWCTP-UHFFFAOYSA-N 5,6,7,8-tetrahydro-1,6-naphthyridine Chemical compound C1=CC=C2CNCCC2=N1 FPEAARFNXIWCTP-UHFFFAOYSA-N 0.000 description 3
- FFBVBZPIQJQLEF-UHFFFAOYSA-N 5-fluoro-4-(1,7-naphthyridin-6-yl)-1H-pyrimidin-6-one Chemical compound FC=1C(=NC=NC=1C=1C=C2C=CC=NC2=CN=1)O FFBVBZPIQJQLEF-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- LPVPZEUXWSEDMB-UHFFFAOYSA-N C1=CC2=CC=C(C3=NC=NC(NCC4=CC=C(C5=CC=NC=C5)C=C4)=C3)C=C2C=C1 Chemical compound C1=CC2=CC=C(C3=NC=NC(NCC4=CC=C(C5=CC=NC=C5)C=C4)=C3)C=C2C=C1 LPVPZEUXWSEDMB-UHFFFAOYSA-N 0.000 description 3
- BSISFSBMWRTCHH-UHFFFAOYSA-N CC1=CC(CNC2=C(F)C(C3=CC=C4C=CC=CC4=C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound CC1=CC(CNC2=C(F)C(C3=CC=C4C=CC=CC4=C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 BSISFSBMWRTCHH-UHFFFAOYSA-N 0.000 description 3
- JEBAMXIYYFQGBF-UHFFFAOYSA-N CC1=CC(CNC2=NC(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound CC1=CC(CNC2=NC(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)=CN=C1C1=CC(C)=NC=C1 JEBAMXIYYFQGBF-UHFFFAOYSA-N 0.000 description 3
- PYBBXKXFHWVCIE-UHFFFAOYSA-N CC1=CN(C2=CC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)C=N1 Chemical compound CC1=CN(C2=CC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)C=N1 PYBBXKXFHWVCIE-UHFFFAOYSA-N 0.000 description 3
- VBPGYERZBIPUSI-UHFFFAOYSA-N CC1=CN(C2=CC=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=C2)C=N1 Chemical compound CC1=CN(C2=CC=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=C2)C=N1 VBPGYERZBIPUSI-UHFFFAOYSA-N 0.000 description 3
- FVRRKEUZIBVUES-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC=C5N=CC=NC5=C4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC=C5N=CC=NC5=C4)=C3F)C=N2)=C1 FVRRKEUZIBVUES-UHFFFAOYSA-N 0.000 description 3
- WSISQVPJAYZOLO-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CN(C)C(=O)C=C4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CN(C)C(=O)C=C4)=C3F)C=N2)=C1 WSISQVPJAYZOLO-UHFFFAOYSA-N 0.000 description 3
- SPWVYHARWPWOTP-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(N4CCS(=O)(=O)CC4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(N4CCS(=O)(=O)CC4)=C3F)C=N2)=C1 SPWVYHARWPWOTP-UHFFFAOYSA-N 0.000 description 3
- DEZXIFVPJAEXJB-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(NCC4=CN=CC=C4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(NCC4=CN=CC=C4)=C3F)C=N2)=C1 DEZXIFVPJAEXJB-UHFFFAOYSA-N 0.000 description 3
- MLDXRSBXKDIDKA-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(C(C)NC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(C(C)NC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)=C1 MLDXRSBXKDIDKA-UHFFFAOYSA-N 0.000 description 3
- OMSZWINGPLTOMW-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C(Cl)C(Cl)=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C(Cl)C(Cl)=C4)=NC=N3)C=C2)=C1 OMSZWINGPLTOMW-UHFFFAOYSA-N 0.000 description 3
- YSMNUGKULQAQJF-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=CC=NC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=CC=NC5=C4)=NC=N3)C=C2)=C1 YSMNUGKULQAQJF-UHFFFAOYSA-N 0.000 description 3
- GGBAMKJUHWJWAI-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=C(C)C=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=C(C)C=CC5=C4)=NC=N3)C=C2)=C1 GGBAMKJUHWJWAI-UHFFFAOYSA-N 0.000 description 3
- SDJGJODYBHOEBT-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=CC=N3)C=C2)=C1 SDJGJODYBHOEBT-UHFFFAOYSA-N 0.000 description 3
- SISCIDMMDZCUEF-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=C2)=C1 SISCIDMMDZCUEF-UHFFFAOYSA-N 0.000 description 3
- CIPFYNFITXOXQZ-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CN5C=CN=C5C=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CN5C=CN=C5C=C4)=NC=N3)C=C2)=C1 CIPFYNFITXOXQZ-UHFFFAOYSA-N 0.000 description 3
- HVVZVOXDUYSXAC-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CN5C=NN=C5C=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CN5C=NN=C5C=C4)=NC=N3)C=C2)=C1 HVVZVOXDUYSXAC-UHFFFAOYSA-N 0.000 description 3
- FLWJLIICDLMSSO-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CN=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CN=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 FLWJLIICDLMSSO-UHFFFAOYSA-N 0.000 description 3
- JXABAYOWOVRPOR-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=C(F)C=C5)C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=C(F)C=C5)C4)=NC=N3)C=C2)=C1 JXABAYOWOVRPOR-UHFFFAOYSA-N 0.000 description 3
- WZHBGULYDGAKOC-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=C5F)C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=C5F)C4)=NC=N3)C=C2)=C1 WZHBGULYDGAKOC-UHFFFAOYSA-N 0.000 description 3
- LTHNWEPAYWXIBD-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC5=C(C=CC=C5)C=C4)=NC=C3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC5=C(C=CC=C5)C=C4)=NC=C3)C=C2)=C1 LTHNWEPAYWXIBD-UHFFFAOYSA-N 0.000 description 3
- IRYZAALZEHELAA-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=NC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=NC=CC5=C4)=NC=N3)C=C2)=C1 IRYZAALZEHELAA-UHFFFAOYSA-N 0.000 description 3
- FTHHPKXHYMAWQH-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=NC=N3)C=C2)=C1 FTHHPKXHYMAWQH-UHFFFAOYSA-N 0.000 description 3
- UKUMRYVFQNSMEI-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=N5)C4)=NC=C3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=N5)C4)=NC=C3)C=C2)=C1 UKUMRYVFQNSMEI-UHFFFAOYSA-N 0.000 description 3
- BJOKDODAJJIWRF-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5N=CSC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5N=CSC5=C4)=NC=N3)C=C2)=C1 BJOKDODAJJIWRF-UHFFFAOYSA-N 0.000 description 3
- FKEOZTLXIRNBAI-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CN5N=CN=C5C=C4)=CC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CN5N=CN=C5C=C4)=CC=N3)C=C2F)=C1 FKEOZTLXIRNBAI-UHFFFAOYSA-N 0.000 description 3
- QWBPNFSFWCATIH-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=C2)=C1 QWBPNFSFWCATIH-UHFFFAOYSA-N 0.000 description 3
- HPVFSBUBBHCLLE-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=C2F)=C1 HPVFSBUBBHCLLE-UHFFFAOYSA-N 0.000 description 3
- ZKGSPUDCGXFJSU-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=NC=NC(N4CCN5N=NN=C5C4)=C3F)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=NC=NC(N4CCN5N=NN=C5C4)=C3F)C=C2F)=C1 ZKGSPUDCGXFJSU-UHFFFAOYSA-N 0.000 description 3
- PIHIQRKIJZATHS-UHFFFAOYSA-N COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=C(F)C(C3=CC4=C(C=N3)N=CC=C4)=NC=N2)=C1 Chemical compound COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=C(F)C(C3=CC4=C(C=N3)N=CC=C4)=NC=N2)=C1 PIHIQRKIJZATHS-UHFFFAOYSA-N 0.000 description 3
- WZGYPQICNKVOQO-UHFFFAOYSA-N COC1=CC(CNC2=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=NC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound COC1=CC(CNC2=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=NC=N2)=CN=C1C1=CC(C)=NC=C1 WZGYPQICNKVOQO-UHFFFAOYSA-N 0.000 description 3
- CNMFNCINJHNIDT-UHFFFAOYSA-N CS(=O)(=O)CCNC1=NC=C(CNC2=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=NC=N2)C=C1 Chemical compound CS(=O)(=O)CCNC1=NC=C(CNC2=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=NC=N2)C=C1 CNMFNCINJHNIDT-UHFFFAOYSA-N 0.000 description 3
- VGOIUMGBLMUEGU-UHFFFAOYSA-N CSC1=NC=CC(=N1)C=1C=C2C=CC=NC2=CC=1 Chemical compound CSC1=NC=CC(=N1)C=1C=C2C=CC=NC2=CC=1 VGOIUMGBLMUEGU-UHFFFAOYSA-N 0.000 description 3
- DSNCFDPCEPPERK-UHFFFAOYSA-N ClC1=C(C(=NC=N1)NCC1=CC=C(C=C1)C1=CC(=NC=C1)C)F Chemical compound ClC1=C(C(=NC=N1)NCC1=CC=C(C=C1)C1=CC(=NC=C1)C)F DSNCFDPCEPPERK-UHFFFAOYSA-N 0.000 description 3
- UUMPJFVDEMRPNY-UHFFFAOYSA-N ClC1=NSC(=N1)N1CC=2C=CC=NC=2CC1 Chemical compound ClC1=NSC(=N1)N1CC=2C=CC=NC=2CC1 UUMPJFVDEMRPNY-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WEDLBPFHLZQRRJ-UHFFFAOYSA-N FC1=C(NCC2=CC=C3C=NC=CC3=C2)N=CN=C1C1=CC=C2N=CC=CC2=C1 Chemical compound FC1=C(NCC2=CC=C3C=NC=CC3=C2)N=CN=C1C1=CC=C2N=CC=CC2=C1 WEDLBPFHLZQRRJ-UHFFFAOYSA-N 0.000 description 3
- RIYMALQOHRXRRB-UHFFFAOYSA-N FC=1C(=NC=C(C=1)CNC1=NC=CC(=N1)C=1C=C2C=CC=NC2=CC=1)C1=CC(=NC=C1)C Chemical compound FC=1C(=NC=C(C=1)CNC1=NC=CC(=N1)C=1C=C2C=CC=NC2=CC=1)C1=CC(=NC=C1)C RIYMALQOHRXRRB-UHFFFAOYSA-N 0.000 description 3
- IZVZZMLJXHRKRT-UHFFFAOYSA-N FC=1C(=NC=NC=1OC)C=1C=C2C=CC=NC2=C(N=1)O Chemical compound FC=1C(=NC=NC=1OC)C=1C=C2C=CC=NC2=C(N=1)O IZVZZMLJXHRKRT-UHFFFAOYSA-N 0.000 description 3
- RGOUMCCQGQALBH-UHFFFAOYSA-N FC=1C(=NC=NC=1OC)C=1C=C2C=CC=NC2=CN=1 Chemical compound FC=1C(=NC=NC=1OC)C=1C=C2C=CC=NC2=CN=1 RGOUMCCQGQALBH-UHFFFAOYSA-N 0.000 description 3
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 3
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- SIRVMZWOVRBAHB-UHFFFAOYSA-N N#CC1=CC2=NC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2C=C1 Chemical compound N#CC1=CC2=NC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2C=C1 SIRVMZWOVRBAHB-UHFFFAOYSA-N 0.000 description 3
- KEWQOEQVFSBVLX-UHFFFAOYSA-N N1=CC=CC2=CC(=CC=C12)C1=NC(=NS1)NCC=1C=NC2=CC(=CC=C2C=1)C#N Chemical compound N1=CC=CC2=CC(=CC=C12)C1=NC(=NS1)NCC=1C=NC2=CC(=CC=C2C=1)C#N KEWQOEQVFSBVLX-UHFFFAOYSA-N 0.000 description 3
- VDTBUCSXFLNVSG-UHFFFAOYSA-N NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)C#N Chemical compound NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)C#N VDTBUCSXFLNVSG-UHFFFAOYSA-N 0.000 description 3
- 229910019213 POCl3 Inorganic materials 0.000 description 3
- 102000044880 Wnt3A Human genes 0.000 description 3
- 108700013515 Wnt3A Proteins 0.000 description 3
- SVYZKQKYGWWEJP-UHFFFAOYSA-N [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=NC=C4N=CC=CC4=C3)=C2F)=C1 Chemical compound [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=NC=C4N=CC=CC4=C3)=C2F)=C1 SVYZKQKYGWWEJP-UHFFFAOYSA-N 0.000 description 3
- DMNPKBPQANBKGR-UHFFFAOYSA-N [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(N3CCC4=C(C=CC=N4)C3)=N2)=C1 Chemical compound [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(N3CCC4=C(C=CC=N4)C3)=N2)=C1 DMNPKBPQANBKGR-UHFFFAOYSA-N 0.000 description 3
- LMFADJNRYOECLA-UHFFFAOYSA-N [C-]#[N+]C1=CC2=C(C=C1)C=C(CNC1=NSC(C3=CC=C4N=CC=CC4=C3)=N1)C=N2 Chemical compound [C-]#[N+]C1=CC2=C(C=C1)C=C(CNC1=NSC(C3=CC=C4N=CC=CC4=C3)=N1)C=N2 LMFADJNRYOECLA-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000001066 destructive effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 2
- LJEFUOGGCMPGHN-UHFFFAOYSA-N (2,3-difluoropyridin-4-yl)boronic acid Chemical compound OB(O)C1=CC=NC(F)=C1F LJEFUOGGCMPGHN-UHFFFAOYSA-N 0.000 description 2
- WWEHSVLHWVCRCW-UHFFFAOYSA-N (6-chloro-5-fluoropyridin-3-yl)methanamine Chemical compound NCC1=CN=C(Cl)C(F)=C1 WWEHSVLHWVCRCW-UHFFFAOYSA-N 0.000 description 2
- RTRJSEFSLOIKTN-UHFFFAOYSA-N 1,7-naphthyridin-6-yl trifluoromethanesulfonate Chemical compound C1=CN=C2C=NC(OS(=O)(=O)C(F)(F)F)=CC2=C1 RTRJSEFSLOIKTN-UHFFFAOYSA-N 0.000 description 2
- AEROXRIZWDKASJ-UHFFFAOYSA-N 2-bromo-5-(bromomethyl)pyridine-3-carbonitrile Chemical compound BrC1=C(C#N)C=C(C=N1)CBr AEROXRIZWDKASJ-UHFFFAOYSA-N 0.000 description 2
- ORTHGCWYABMWNU-UHFFFAOYSA-N 3-chloro-5-quinolin-6-yl-1,2,4-thiadiazole Chemical compound ClC1=NSC(=N1)C=1C=C2C=CC=NC2=CC=1 ORTHGCWYABMWNU-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- PPYZUBLDYPTDSU-UHFFFAOYSA-N 4-naphthalen-2-ylpyridin-2-amine Chemical compound C1=C(C=CC2=CC=CC=C12)C1=CC(=NC=C1)N PPYZUBLDYPTDSU-UHFFFAOYSA-N 0.000 description 2
- IIUTXCOBPSSCDS-UHFFFAOYSA-N 6-(aminomethyl)naphthalene-2-carbonitrile Chemical compound C1=C(C#N)C=CC2=CC(CN)=CC=C21 IIUTXCOBPSSCDS-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VLCWWCSDVFKUBL-UHFFFAOYSA-N BrC1=CC=C(CNC2=NC=CC(=C2)C2=CC3=CC=CC=C3C=C2)C=C1 Chemical compound BrC1=CC=C(CNC2=NC=CC(=C2)C2=CC3=CC=CC=C3C=C2)C=C1 VLCWWCSDVFKUBL-UHFFFAOYSA-N 0.000 description 2
- NSHWFQZFOHJQRU-UHFFFAOYSA-N BrCC1=CC=C2C=C(C=NC2=C1)C#N Chemical compound BrCC1=CC=C2C=C(C=NC2=C1)C#N NSHWFQZFOHJQRU-UHFFFAOYSA-N 0.000 description 2
- DGCFPQYUJXXRTR-UHFFFAOYSA-N BrCC=1C=NC2=CC(=CC=C2C=1)C#N Chemical compound BrCC=1C=NC2=CC(=CC=C2C=1)C#N DGCFPQYUJXXRTR-UHFFFAOYSA-N 0.000 description 2
- HHXFOHMHPMAPOY-UHFFFAOYSA-N C(C)(C)(C)NC(C1=NC=CC=C1CC(=O)C1=NC(=NC=C1)SC)=O Chemical compound C(C)(C)(C)NC(C1=NC=CC=C1CC(=O)C1=NC(=NC=C1)SC)=O HHXFOHMHPMAPOY-UHFFFAOYSA-N 0.000 description 2
- YNSCANJAMMRRFR-UHFFFAOYSA-N C(C)(C)(C)NC(C1=NC=CC=C1CC(=O)C1=NC=NC(=C1F)OC)=O Chemical compound C(C)(C)(C)NC(C1=NC=CC=C1CC(=O)C1=NC=NC(=C1F)OC)=O YNSCANJAMMRRFR-UHFFFAOYSA-N 0.000 description 2
- XRIDOQKIWZPHIS-UHFFFAOYSA-N C1=CC2=C(C=CC(C3=CC=NC(NCC4=CC=C(N5C=CN=C5)C=C4)=N3)=C2)N=C1 Chemical compound C1=CC2=C(C=CC(C3=CC=NC(NCC4=CC=C(N5C=CN=C5)C=C4)=N3)=C2)N=C1 XRIDOQKIWZPHIS-UHFFFAOYSA-N 0.000 description 2
- KBXIUMXGWPDZCB-UHFFFAOYSA-N CC1=CC(CNC2=C(F)C(C3=CC=C4N=CC=CC4=C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound CC1=CC(CNC2=C(F)C(C3=CC=C4N=CC=CC4=C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 KBXIUMXGWPDZCB-UHFFFAOYSA-N 0.000 description 2
- ALNDVULLOAXAOT-UHFFFAOYSA-N CC1=CC(CNC2=C(F)C(C3=CC=C4N=CSC4=C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound CC1=CC(CNC2=C(F)C(C3=CC=C4N=CSC4=C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 ALNDVULLOAXAOT-UHFFFAOYSA-N 0.000 description 2
- RXBHRCKYXBAOMK-UHFFFAOYSA-N CC1=CC(CNC2=C(F)C(N3CCC4=C(C=CC=N4)C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound CC1=CC(CNC2=C(F)C(N3CCC4=C(C=CC=N4)C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 RXBHRCKYXBAOMK-UHFFFAOYSA-N 0.000 description 2
- UOEYJXSAEXLADB-UHFFFAOYSA-N CC1=CC2=C(C=C1)C=C(C)C=C2.CC1=CC=C(C)C=C1 Chemical compound CC1=CC2=C(C=C1)C=C(C)C=C2.CC1=CC=C(C)C=C1 UOEYJXSAEXLADB-UHFFFAOYSA-N 0.000 description 2
- HQPIILKGTFWSDJ-UHFFFAOYSA-N CC1=CN(C)C(=O)C=C1 Chemical compound CC1=CN(C)C(=O)C=C1 HQPIILKGTFWSDJ-UHFFFAOYSA-N 0.000 description 2
- DONHFJKQYCASQY-UHFFFAOYSA-N CC1=NC=CC(=C1)C1=NC=C(C=N1)CN Chemical compound CC1=NC=CC(=C1)C1=NC=C(C=N1)CN DONHFJKQYCASQY-UHFFFAOYSA-N 0.000 description 2
- YZPDLSYRLABEJP-UHFFFAOYSA-N CC1=NC=CC(C2=C(C#N)C=C(CNC3=NN=C(C4=CC=C5N=CC=CC5=C4)S3)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(C#N)C=C(CNC3=NN=C(C4=CC=C5N=CC=CC5=C4)S3)C=N2)=C1 YZPDLSYRLABEJP-UHFFFAOYSA-N 0.000 description 2
- ABHDFEJTVPJGJS-UHFFFAOYSA-N CC1=NC=CC(C2=C(C)C=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(C)C=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=N2)=C1 ABHDFEJTVPJGJS-UHFFFAOYSA-N 0.000 description 2
- KDJAPUWDKYSAPW-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CN)C=N2)=C1.CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC=C5N=CC=CC5=N4)=C3O)C=N2)=C1.FC1=NC=CC(C2=CC=C3N=CC=CC3=N2)=C1F Chemical compound CC1=NC=CC(C2=C(F)C=C(CN)C=N2)=C1.CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC=C5N=CC=CC5=N4)=C3O)C=N2)=C1.FC1=NC=CC(C2=CC=C3N=CC=CC3=N2)=C1F KDJAPUWDKYSAPW-UHFFFAOYSA-N 0.000 description 2
- GCRJNRVEHOAVGG-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC(Cl)=CN=C4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC(Cl)=CN=C4)=C3F)C=N2)=C1 GCRJNRVEHOAVGG-UHFFFAOYSA-N 0.000 description 2
- MWISBIUHDBQQCY-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC(F)=CN=C4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC(F)=CN=C4)=C3F)C=N2)=C1 MWISBIUHDBQQCY-UHFFFAOYSA-N 0.000 description 2
- IYDANXFHFZQTQU-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC5=NON=C5C=C4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC5=NON=C5C=C4)=C3F)C=N2)=C1 IYDANXFHFZQTQU-UHFFFAOYSA-N 0.000 description 2
- XUSOEKYCGDCQLD-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC=C5N=CC=CC5=N4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC=C5N=CC=CC5=N4)=C3F)C=N2)=C1 XUSOEKYCGDCQLD-UHFFFAOYSA-N 0.000 description 2
- HHLFDWKPKJMBDR-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC=C5N=NC=CC5=C4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=CC(C4=CC=C5N=NC=CC5=C4)=C3F)C=N2)=C1 HHLFDWKPKJMBDR-UHFFFAOYSA-N 0.000 description 2
- BMKKOIJXIWQAHN-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(N4CCC(O)CC4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(N4CCC(O)CC4)=C3F)C=N2)=C1 BMKKOIJXIWQAHN-UHFFFAOYSA-N 0.000 description 2
- CYXDHZYTVCGBTR-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(N4CCNC(=O)C4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(N4CCNC(=O)C4)=C3F)C=N2)=C1 CYXDHZYTVCGBTR-UHFFFAOYSA-N 0.000 description 2
- IEQVLZFIFZAHDN-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(NCC4CC4)=C3F)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(NCC4CC4)=C3F)C=N2)=C1 IEQVLZFIFZAHDN-UHFFFAOYSA-N 0.000 description 2
- PZLXUSHGIDZAHH-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NSC(C4=CC5=C(C=N4)N=CC=C5)=N3)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NSC(C4=CC5=C(C=N4)N=CC=C5)=N3)C=N2)=C1 PZLXUSHGIDZAHH-UHFFFAOYSA-N 0.000 description 2
- CIQJQPKRJFFZRU-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=N2)=C1 Chemical compound CC1=NC=CC(C2=C(F)C=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=N2)=C1 CIQJQPKRJFFZRU-UHFFFAOYSA-N 0.000 description 2
- JNKRGUQLCVPPAF-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(C(C)NC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(C(C)NC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 JNKRGUQLCVPPAF-UHFFFAOYSA-N 0.000 description 2
- DAUSGHZJGXLDEP-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(C(C)NC3=CC(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(C(C)NC3=CC(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 DAUSGHZJGXLDEP-UHFFFAOYSA-N 0.000 description 2
- KMMFRWZITFHPQY-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(C#N)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(C#N)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 KMMFRWZITFHPQY-UHFFFAOYSA-N 0.000 description 2
- PMFRHJPIUYXKTE-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(C)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(C)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 PMFRHJPIUYXKTE-UHFFFAOYSA-N 0.000 description 2
- RBVQCJQYSNAZFD-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C(Cl)C=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C(Cl)C=C4)=NC=N3)C=C2)=C1 RBVQCJQYSNAZFD-UHFFFAOYSA-N 0.000 description 2
- QYXKJTHVPUXJJF-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C(=C4)C=NN5C)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C(=C4)C=NN5C)=NC=N3)C=C2)=C1 QYXKJTHVPUXJJF-UHFFFAOYSA-N 0.000 description 2
- HCNREDKDPVLVFF-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)S2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)S2)=C1 HCNREDKDPVLVFF-UHFFFAOYSA-N 0.000 description 2
- WHKGSNPMEUJAGF-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=CN=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=CN=CC5=C4)=NC=N3)C=C2)=C1 WHKGSNPMEUJAGF-UHFFFAOYSA-N 0.000 description 2
- KPFINQXZDRDHEA-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=NC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=NC=CC5=C4)=NC=N3)C=C2)=C1 KPFINQXZDRDHEA-UHFFFAOYSA-N 0.000 description 2
- TZFALZPUZPMWLZ-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CN=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CN=CC5=C4)=NC=N3)C=C2)=C1 TZFALZPUZPMWLZ-UHFFFAOYSA-N 0.000 description 2
- IHRQBYUCLQSVKA-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CSC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CSC5=C4)=NC=N3)C=C2)=C1 IHRQBYUCLQSVKA-UHFFFAOYSA-N 0.000 description 2
- YLLKIHAJKCUAKH-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5NC=NC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5NC=NC5=C4)=NC=N3)C=C2)=C1 YLLKIHAJKCUAKH-UHFFFAOYSA-N 0.000 description 2
- LTYUBEJKUOXJEG-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5OCCOC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5OCCOC5=C4)=NC=N3)C=C2)=C1 LTYUBEJKUOXJEG-UHFFFAOYSA-N 0.000 description 2
- NNZZUISCOXQUDZ-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=CC(Cl)=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=CC(Cl)=C4)=NC=N3)C=C2)=C1 NNZZUISCOXQUDZ-UHFFFAOYSA-N 0.000 description 2
- CDYVOJNXCKFLJR-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=CC=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=CC=C4)=NC=N3)C=C2)=C1 CDYVOJNXCKFLJR-UHFFFAOYSA-N 0.000 description 2
- VGNMDTKFWYEYFO-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=CC=C4Cl)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=CC=C4Cl)=NC=N3)C=C2)=C1 VGNMDTKFWYEYFO-UHFFFAOYSA-N 0.000 description 2
- VZXAOUQVRLIICJ-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CN5N=CN=C5C=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CN5N=CN=C5C=C4)=NC=N3)C=C2)=C1 VZXAOUQVRLIICJ-UHFFFAOYSA-N 0.000 description 2
- VOBXDIPKECUZTA-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CC5=C(C=CC=C5)C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CC5=C(C=CC=C5)C4)=NC=N3)C=C2)=C1 VOBXDIPKECUZTA-UHFFFAOYSA-N 0.000 description 2
- AIINUHYSRKDOMU-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C4)SC=N5)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C4)SC=N5)=NC=N3)C=C2)=C1 AIINUHYSRKDOMU-UHFFFAOYSA-N 0.000 description 2
- OLAQGSWSKBRTGC-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=C5)C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=C5)C4)=NC=N3)C=C2)=C1 OLAQGSWSKBRTGC-UHFFFAOYSA-N 0.000 description 2
- VVOMPSLODZZPOZ-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=C5)C4C)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=C5)C4C)=NC=N3)C=C2)=C1 VVOMPSLODZZPOZ-UHFFFAOYSA-N 0.000 description 2
- FAHNTXLQRAFENJ-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=C5Br)C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=C5Br)C4)=NC=N3)C=C2)=C1 FAHNTXLQRAFENJ-UHFFFAOYSA-N 0.000 description 2
- OCRKYUTUEGUUOI-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=C5C#N)C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=C5C#N)C4)=NC=N3)C=C2)=C1 OCRKYUTUEGUUOI-UHFFFAOYSA-N 0.000 description 2
- HTDBGIKCSYGYQT-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=C2)=C1 HTDBGIKCSYGYQT-UHFFFAOYSA-N 0.000 description 2
- XXHRUGCVMHMTKV-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)=C1 XXHRUGCVMHMTKV-UHFFFAOYSA-N 0.000 description 2
- TWXRLQJUAUZXJY-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC5=C(C=CC=C5)C=C4)=CN=C3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC5=C(C=CC=C5)C=C4)=CN=C3)C=C2)=C1 TWXRLQJUAUZXJY-UHFFFAOYSA-N 0.000 description 2
- KCLKDXMVQXXZFE-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=CC=C3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=CC=C3)C=C2)=C1 KCLKDXMVQXXZFE-UHFFFAOYSA-N 0.000 description 2
- NIIDVAPEIQNACW-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=NC(C)=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=NC(C)=N3)C=C2)=C1 NIIDVAPEIQNACW-UHFFFAOYSA-N 0.000 description 2
- ZZNHXGHHAHACQX-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=NC(N)=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=NC(N)=N3)C=C2)=C1 ZZNHXGHHAHACQX-UHFFFAOYSA-N 0.000 description 2
- PRJUINCAMQHSKN-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=NC(N4CCCC4)=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=NC(N4CCCC4)=N3)C=C2)=C1 PRJUINCAMQHSKN-UHFFFAOYSA-N 0.000 description 2
- CGBZIKFQTDXTDP-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 CGBZIKFQTDXTDP-UHFFFAOYSA-N 0.000 description 2
- SGVIEACHTFQADK-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(N4CCC5=C(C=CC=C5)C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(N4CCC5=C(C=CC=C5)C4)=NC=N3)C=C2)=C1 SGVIEACHTFQADK-UHFFFAOYSA-N 0.000 description 2
- MBTJRXNRBHSYGR-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(N4CCC5=C(C=CC=C5)C4=O)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(N4CCC5=C(C=CC=C5)C4=O)=NC=N3)C=C2)=C1 MBTJRXNRBHSYGR-UHFFFAOYSA-N 0.000 description 2
- LIGISKIWNGVHRW-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5C=CC=CC5=C4)=CC=C3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5C=CC=CC5=C4)=CC=C3)C=C2)=C1 LIGISKIWNGVHRW-UHFFFAOYSA-N 0.000 description 2
- LPBQLGHWTYXITN-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5C=CC=CC5=C4)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5C=CC=CC5=C4)=CC=N3)C=C2)=C1 LPBQLGHWTYXITN-UHFFFAOYSA-N 0.000 description 2
- ODYDJBYGVSDJPD-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5C=CC=CC5=C4)=NC=C3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5C=CC=CC5=C4)=NC=C3)C=C2)=C1 ODYDJBYGVSDJPD-UHFFFAOYSA-N 0.000 description 2
- PNDFZIWAARKTFU-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 PNDFZIWAARKTFU-UHFFFAOYSA-N 0.000 description 2
- ZQEULYRNZOEODQ-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5N=CC=CC5=C4)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5N=CC=CC5=C4)=CC=N3)C=C2)=C1 ZQEULYRNZOEODQ-UHFFFAOYSA-N 0.000 description 2
- DPESURHSJRBKFU-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5N=CC=CC5=C4)=NC=C3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5N=CC=CC5=C4)=NC=C3)C=C2)=C1 DPESURHSJRBKFU-UHFFFAOYSA-N 0.000 description 2
- MBYGHOKJNMNNCU-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5N=CN=CC5=C4)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(C4=CC=C5N=CN=CC5=C4)=CC=N3)C=C2)=C1 MBYGHOKJNMNNCU-UHFFFAOYSA-N 0.000 description 2
- AOBNEEVIVWFRJX-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=C5)C4)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=C5)C4)=CC=N3)C=C2)=C1 AOBNEEVIVWFRJX-UHFFFAOYSA-N 0.000 description 2
- JAROEOCUWDRSOX-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=C5)C4)=NC(Cl)=C3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=C5)C4)=NC(Cl)=C3)C=C2)=C1 JAROEOCUWDRSOX-UHFFFAOYSA-N 0.000 description 2
- MBUZDMVZWUBVFB-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=C5)C4)=NC(N4CCCC4)=C3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=C5)C4)=NC(N4CCCC4)=C3)C=C2)=C1 MBUZDMVZWUBVFB-UHFFFAOYSA-N 0.000 description 2
- QBLFFPXJUDXLMF-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=N5)C4)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=N5)C4)=CC=N3)C=C2)=C1 QBLFFPXJUDXLMF-UHFFFAOYSA-N 0.000 description 2
- BPMJZSVIGFMQBK-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=N5)C4)=NC=C3F)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NC(N4CCC5=C(C=CC=N5)C4)=NC=C3F)C=C2)=C1 BPMJZSVIGFMQBK-UHFFFAOYSA-N 0.000 description 2
- QRXJNMBZLNZDFE-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=C2)=C1 QRXJNMBZLNZDFE-UHFFFAOYSA-N 0.000 description 2
- WXHWVVCBQIVGIK-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=N2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=N2)=C1 WXHWVVCBQIVGIK-UHFFFAOYSA-N 0.000 description 2
- WUMQBEVCNGNVPC-UHFFFAOYSA-N CC1=NC=CC(C2=CN=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CN=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 WUMQBEVCNGNVPC-UHFFFAOYSA-N 0.000 description 2
- OVKLGRIVNJKOCY-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C#CC4=CC=CC=C4)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C#CC4=CC=CC=C4)=NC=N3)C=C2F)=C1 OVKLGRIVNJKOCY-UHFFFAOYSA-N 0.000 description 2
- RWFLXUYKBAXCSI-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)=C1 RWFLXUYKBAXCSI-UHFFFAOYSA-N 0.000 description 2
- HLGJLZUIZMALMN-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=NC=N3)C=N2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=NC=N3)C=N2)=C1 HLGJLZUIZMALMN-UHFFFAOYSA-N 0.000 description 2
- NMOUVZMYALECSR-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=NC=N3)N=C2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=NC=N3)N=C2)=C1 NMOUVZMYALECSR-UHFFFAOYSA-N 0.000 description 2
- CDMWLFMSIIDXJZ-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=N4)N=CC=C5)=CC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=N4)N=CC=C5)=CC=N3)C=C2F)=C1 CDMWLFMSIIDXJZ-UHFFFAOYSA-N 0.000 description 2
- FILPLPCFCSLCNP-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 FILPLPCFCSLCNP-UHFFFAOYSA-N 0.000 description 2
- FAWIKFMWUAGKDX-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2F)=C1 FAWIKFMWUAGKDX-UHFFFAOYSA-N 0.000 description 2
- LVEKXZYIOBHPTL-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=CC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=CC=N3)C=C2F)=C1 LVEKXZYIOBHPTL-UHFFFAOYSA-N 0.000 description 2
- XRGJIQGBQBYHLH-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=C2)=C1 XRGJIQGBQBYHLH-UHFFFAOYSA-N 0.000 description 2
- HSTRIMADQZKBND-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=C2F)=C1 HSTRIMADQZKBND-UHFFFAOYSA-N 0.000 description 2
- UCPFVQYWTJYNHT-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5N=CSC5=C4)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(C4=CC=C5N=CSC5=C4)=NC=N3)C=C2F)=C1 UCPFVQYWTJYNHT-UHFFFAOYSA-N 0.000 description 2
- NDZAEIVPEPHOTA-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CC5=C(C4)N=CC=C5)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CC5=C(C4)N=CC=C5)=NC=N3)C=C2F)=C1 NDZAEIVPEPHOTA-UHFFFAOYSA-N 0.000 description 2
- WRSCGDXAFUGMEZ-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C4)N=CC=N5)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C4)N=CC=N5)=NC=N3)C=C2F)=C1 WRSCGDXAFUGMEZ-UHFFFAOYSA-N 0.000 description 2
- PIDLPQJKBCMOEI-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C4)SC=N5)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C4)SC=N5)=NC=N3)C=C2F)=C1 PIDLPQJKBCMOEI-UHFFFAOYSA-N 0.000 description 2
- HBLSICVIVNGYAV-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C=NC=N5)C4)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C=NC=N5)C4)=NC=N3)C=C2F)=C1 HBLSICVIVNGYAV-UHFFFAOYSA-N 0.000 description 2
- ZBQVHHQVXNOHJG-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCN5N=CC=C5C4)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCN5N=CC=C5C4)=NC=N3)C=C2F)=C1 ZBQVHHQVXNOHJG-UHFFFAOYSA-N 0.000 description 2
- SYQWRAZPZXWCHC-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCN5N=CN=C5C4)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCN5N=CN=C5C4)=NC=N3)C=C2F)=C1 SYQWRAZPZXWCHC-UHFFFAOYSA-N 0.000 description 2
- UZKQROLTKUZJRJ-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCN5N=NC=C5C4)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCN5N=NC=C5C4)=NC=N3)C=C2F)=C1 UZKQROLTKUZJRJ-UHFFFAOYSA-N 0.000 description 2
- UUZDERLNTMDJFI-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCOC5=C(C=CC=N5)C4)=NC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCOC5=C(C=CC=N5)C4)=NC=N3)C=C2F)=C1 UUZDERLNTMDJFI-UHFFFAOYSA-N 0.000 description 2
- LOAVBJQNXMFADL-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=CC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2F)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=CC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2F)=C1 LOAVBJQNXMFADL-UHFFFAOYSA-N 0.000 description 2
- ZIEIBNTWCAQAAP-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)=C1 ZIEIBNTWCAQAAP-UHFFFAOYSA-N 0.000 description 2
- KNZPGAODPHNLNG-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=N2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=N2)=C1 KNZPGAODPHNLNG-UHFFFAOYSA-N 0.000 description 2
- DSVLZSOLOYMTAY-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)N=C2)=C1 Chemical compound CC1=NC=CC(C2=NC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)N=C2)=C1 DSVLZSOLOYMTAY-UHFFFAOYSA-N 0.000 description 2
- YHSAGKINPMUWJS-UHFFFAOYSA-N CCNC1=NC(NCC2=CC=C(C3=CC(C)=NC=C3)C=C2)=CC(C2=CC=C3C=CC=CC3=C2)=N1 Chemical compound CCNC1=NC(NCC2=CC=C(C3=CC(C)=NC=C3)C=C2)=CC(C2=CC=C3C=CC=CC3=C2)=N1 YHSAGKINPMUWJS-UHFFFAOYSA-N 0.000 description 2
- KYJPOKCULQHNTG-UHFFFAOYSA-N CN1CCS(=O)(=O)CC1.CNCCS(C)(=O)=O Chemical compound CN1CCS(=O)(=O)CC1.CNCCS(C)(=O)=O KYJPOKCULQHNTG-UHFFFAOYSA-N 0.000 description 2
- JRZJGPUASADVAJ-UHFFFAOYSA-N CN1N=C(CNC2=NC=NC(C3=CC=C4N=CC=CC4=C3)=C2F)C=CC1=O Chemical compound CN1N=C(CNC2=NC=NC(C3=CC=C4N=CC=CC4=C3)=C2F)C=CC1=O JRZJGPUASADVAJ-UHFFFAOYSA-N 0.000 description 2
- GERVTTINNMJGJQ-UHFFFAOYSA-N CN1N=CC=C1C1=CC=C(CNC2=C(F)C(C3=CC=C4C=CC=CC4=C3)=NC=N2)C=C1 Chemical compound CN1N=CC=C1C1=CC=C(CNC2=C(F)C(C3=CC=C4C=CC=CC4=C3)=NC=N2)C=C1 GERVTTINNMJGJQ-UHFFFAOYSA-N 0.000 description 2
- XVDKYOWIYNXOCX-UHFFFAOYSA-N CN1N=CC=C1C1=CC=C(CNC2=C(F)C(C3=CC=C4N=CC=CC4=C3)=CC=N2)C=C1 Chemical compound CN1N=CC=C1C1=CC=C(CNC2=C(F)C(C3=CC=C4N=CC=CC4=C3)=CC=N2)C=C1 XVDKYOWIYNXOCX-UHFFFAOYSA-N 0.000 description 2
- SRZKWINCNLFWEE-UHFFFAOYSA-N COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC(C3=CC4=C(C=N3)N=CC=C4)=CC=N2)=C1 Chemical compound COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC(C3=CC4=C(C=N3)N=CC=C4)=CC=N2)=C1 SRZKWINCNLFWEE-UHFFFAOYSA-N 0.000 description 2
- SGDJIGHTMZJFAP-UHFFFAOYSA-N COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CC=C4N=CC=CC4=N3)=C2F)=C1 Chemical compound COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CC=C4N=CC=CC4=N3)=C2F)=C1 SGDJIGHTMZJFAP-UHFFFAOYSA-N 0.000 description 2
- XQJXKLCKHGBVRK-UHFFFAOYSA-N COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=NC=C4N=CC=CC4=C3)=C2F)=C1 Chemical compound COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=NC=C4N=CC=CC4=C3)=C2F)=C1 XQJXKLCKHGBVRK-UHFFFAOYSA-N 0.000 description 2
- AMUIWYCJJKEUHY-UHFFFAOYSA-N COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(C3=CC=C4N=CC=CC4=C3)=N2)=C1 Chemical compound COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(C3=CC=C4N=CC=CC4=C3)=N2)=C1 AMUIWYCJJKEUHY-UHFFFAOYSA-N 0.000 description 2
- GRDBIJVHYJQNPX-UHFFFAOYSA-N COC1=CC(CNC2=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound COC1=CC(CNC2=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)=CN=C1C1=CC(C)=NC=C1 GRDBIJVHYJQNPX-UHFFFAOYSA-N 0.000 description 2
- PMFRTMYUIHWRNZ-UHFFFAOYSA-N COC1=CC(CNC2=NC(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound COC1=CC(CNC2=NC(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)=CN=C1C1=CC(C)=NC=C1 PMFRTMYUIHWRNZ-UHFFFAOYSA-N 0.000 description 2
- SFCQHKRMNFAVBL-UHFFFAOYSA-N COC1=CC(CNC2=NC=NC(N3CCN4N=CC=C4C3)=C2F)=CN=C1C1=CC(C)=NC=C1 Chemical compound COC1=CC(CNC2=NC=NC(N3CCN4N=CC=C4C3)=C2F)=CN=C1C1=CC(C)=NC=C1 SFCQHKRMNFAVBL-UHFFFAOYSA-N 0.000 description 2
- IIUKHAXOZDXSIT-UHFFFAOYSA-N COC=1C(=NC=C(C=1)CN)C1=CC(=NC=C1)C Chemical compound COC=1C(=NC=C(C=1)CN)C1=CC(=NC=C1)C IIUKHAXOZDXSIT-UHFFFAOYSA-N 0.000 description 2
- ALODPBLTEOGSQL-UHFFFAOYSA-N CS(=O)(=O)C1=NC=CC(=N1)C=1C=C2C=CC=NC2=CC=1 Chemical compound CS(=O)(=O)C1=NC=CC(=N1)C=1C=C2C=CC=NC2=CC=1 ALODPBLTEOGSQL-UHFFFAOYSA-N 0.000 description 2
- VETCBUMSKZRGAO-UHFFFAOYSA-N CS(=O)(=O)C1=NC=CC(=N1)C=1C=C2C=CC=NC2=CN=1 Chemical compound CS(=O)(=O)C1=NC=CC(=N1)C=1C=C2C=CC=NC2=CN=1 VETCBUMSKZRGAO-UHFFFAOYSA-N 0.000 description 2
- DCEPKDWPFCCSHJ-UHFFFAOYSA-N CS(=O)(=O)CCNC1=CC=C(CNC2=C(F)C(C3=CC=C4N=CC=CC4=C3)=CC=N2)C=N1 Chemical compound CS(=O)(=O)CCNC1=CC=C(CNC2=C(F)C(C3=CC=C4N=CC=CC4=C3)=CC=N2)C=N1 DCEPKDWPFCCSHJ-UHFFFAOYSA-N 0.000 description 2
- JGLOQJKAWWSENV-UHFFFAOYSA-N CS(=O)(=O)CCNC1=CC=C(CNC2=NSC(C3=CC=C4N=CC=CC4=C3)=N2)C=N1 Chemical compound CS(=O)(=O)CCNC1=CC=C(CNC2=NSC(C3=CC=C4N=CC=CC4=C3)=N2)C=N1 JGLOQJKAWWSENV-UHFFFAOYSA-N 0.000 description 2
- MFLAMKPSJISRDY-UHFFFAOYSA-N CS(=O)(=O)CCNC1=NC=C(CNC2=NC(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)C=C1 Chemical compound CS(=O)(=O)CCNC1=NC=C(CNC2=NC(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)C=C1 MFLAMKPSJISRDY-UHFFFAOYSA-N 0.000 description 2
- IQKNZNCBDFRULJ-UHFFFAOYSA-N CSC1=NC(NCC2=CC=C(C3=CC(C)=NC=C3)C=C2)=CC(C2=CC=C3C=CC=CC3=C2)=N1 Chemical compound CSC1=NC(NCC2=CC=C(C3=CC(C)=NC=C3)C=C2)=CC(C2=CC=C3C=CC=CC3=C2)=N1 IQKNZNCBDFRULJ-UHFFFAOYSA-N 0.000 description 2
- RBNHUHTWGKVKJM-UHFFFAOYSA-N CSC1=NC=CC(=N1)C=1C=C2C=CC=NC2=C(N=1)O Chemical compound CSC1=NC=CC(=N1)C=1C=C2C=CC=NC2=C(N=1)O RBNHUHTWGKVKJM-UHFFFAOYSA-N 0.000 description 2
- WIWUPSKFMKRIEG-UHFFFAOYSA-N CSC1=NC=CC(=N1)C=1C=C2C=CC=NC2=CN=1 Chemical compound CSC1=NC=CC(=N1)C=1C=C2C=CC=NC2=CN=1 WIWUPSKFMKRIEG-UHFFFAOYSA-N 0.000 description 2
- DVCCERLXVXKWFL-UHFFFAOYSA-N C[Sn](C=1C=C2C=CC=NC2=CN=1)(C)C Chemical compound C[Sn](C=1C=C2C=CC=NC2=CN=1)(C)C DVCCERLXVXKWFL-UHFFFAOYSA-N 0.000 description 2
- NBGFARDUXWHUFY-UHFFFAOYSA-N ClC1=C(C(=NC=N1)C(=O)OCC)F Chemical compound ClC1=C(C(=NC=N1)C(=O)OCC)F NBGFARDUXWHUFY-UHFFFAOYSA-N 0.000 description 2
- BECDVNDOPZYROV-UHFFFAOYSA-N ClC1=C(C(=NC=N1)NCC1=CC=C(C=C1)C1=CC(=[N+](C=C1)[O-])C)F Chemical compound ClC1=C(C(=NC=N1)NCC1=CC=C(C=C1)C1=CC(=[N+](C=C1)[O-])C)F BECDVNDOPZYROV-UHFFFAOYSA-N 0.000 description 2
- BRGCCZGIFJELDG-UHFFFAOYSA-N ClC1=C(C(=NC=N1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)F)F Chemical compound ClC1=C(C(=NC=N1)NCC=1C=C(C(=NC=1)C1=CC(=NC=C1)C)F)F BRGCCZGIFJELDG-UHFFFAOYSA-N 0.000 description 2
- FQMCWSXIQFPHJI-UHFFFAOYSA-N ClC1=C(C(=NC=N1)NCC=1C=C2C=CC(=CC2=CC=1)C#N)F Chemical compound ClC1=C(C(=NC=N1)NCC=1C=C2C=CC(=CC2=CC=1)C#N)F FQMCWSXIQFPHJI-UHFFFAOYSA-N 0.000 description 2
- PULCHMADXXGMMI-UHFFFAOYSA-N ClC1=C(C(=NC=N1)NCC=1C=NC(=NC=1)C1=CC(=NC=C1)C)F Chemical compound ClC1=C(C(=NC=N1)NCC=1C=NC(=NC=1)C1=CC(=NC=C1)C)F PULCHMADXXGMMI-UHFFFAOYSA-N 0.000 description 2
- OCLJVHBXCDEXNR-UHFFFAOYSA-N ClC1=NSC(=N1)C=1C=C2C=CC=NC2=CN=1 Chemical compound ClC1=NSC(=N1)C=1C=C2C=CC=NC2=CN=1 OCLJVHBXCDEXNR-UHFFFAOYSA-N 0.000 description 2
- MRBLAAHTHGJGON-UHFFFAOYSA-N ClC=1N=C(C=C2C=CC=NC=12)C1=NC(=NC=C1)SC Chemical compound ClC=1N=C(C=C2C=CC=NC=12)C1=NC(=NC=C1)SC MRBLAAHTHGJGON-UHFFFAOYSA-N 0.000 description 2
- SUCQHLRGSRCFSU-UHFFFAOYSA-N ClC=1N=C(C=C2C=CC=NC=12)C1=NC=NC(=C1F)OC Chemical compound ClC=1N=C(C=C2C=CC=NC=12)C1=NC=NC(=C1F)OC SUCQHLRGSRCFSU-UHFFFAOYSA-N 0.000 description 2
- FVLJCAHCFKBSHX-UHFFFAOYSA-N FC1=C(C2=CC=C3N=CC=CC3=C2)N=CN=C1NCC1=CC=C(C2=CC=NC=N2)C=C1 Chemical compound FC1=C(C2=CC=C3N=CC=CC3=C2)N=CN=C1NCC1=CC=C(C2=CC=NC=N2)C=C1 FVLJCAHCFKBSHX-UHFFFAOYSA-N 0.000 description 2
- HAKJOUIXXJDJIX-UHFFFAOYSA-N FC1=C(NCC2=CC=C(C3=CC=NC=C3)C=C2)N=CC=C1C1=CC2=C(C=C1)N=CC=C2 Chemical compound FC1=C(NCC2=CC=C(C3=CC=NC=C3)C=C2)N=CC=C1C1=CC2=C(C=C1)N=CC=C2 HAKJOUIXXJDJIX-UHFFFAOYSA-N 0.000 description 2
- FILSQYSQRAWHAZ-UHFFFAOYSA-N FC1=C(NCC2=CC=C(C3=CC=NC=C3)C=C2)N=CN=C1C1=CC=C2C=CC=CC2=C1 Chemical compound FC1=C(NCC2=CC=C(C3=CC=NC=C3)C=C2)N=CN=C1C1=CC=C2C=CC=CC2=C1 FILSQYSQRAWHAZ-UHFFFAOYSA-N 0.000 description 2
- ZHZGAPTULFRBFJ-UHFFFAOYSA-N FC1=C(NCC2=CC=C(C3=CC=NN=C3)C=C2)N=CN=C1C1=CC2=C(C=C1)N=CC=C2 Chemical compound FC1=C(NCC2=CC=C(C3=CC=NN=C3)C=C2)N=CN=C1C1=CC2=C(C=C1)N=CC=C2 ZHZGAPTULFRBFJ-UHFFFAOYSA-N 0.000 description 2
- VPFDAWQKAYFBIA-UHFFFAOYSA-N FC1=C(NCC2=CC=C(N3C=CN=C3)C=C2)N=CC=C1C1=CC2=C(C=C1)N=CC=C2 Chemical compound FC1=C(NCC2=CC=C(N3C=CN=C3)C=C2)N=CC=C1C1=CC2=C(C=C1)N=CC=C2 VPFDAWQKAYFBIA-UHFFFAOYSA-N 0.000 description 2
- ISJMQPOEYMLOLJ-UHFFFAOYSA-N FC1=C(NCC2=CC=C(N3C=CN=C3)C=C2)N=CN=C1C1=CC=C2C=CC=CC2=C1 Chemical compound FC1=C(NCC2=CC=C(N3C=CN=C3)C=C2)N=CN=C1C1=CC=C2C=CC=CC2=C1 ISJMQPOEYMLOLJ-UHFFFAOYSA-N 0.000 description 2
- UPKFBIKVHRNEFA-UHFFFAOYSA-N FC1=NC=CC(=C1F)C1=NC2=CC=CN=C2C=C1 Chemical compound FC1=NC=CC(=C1F)C1=NC2=CC=CN=C2C=C1 UPKFBIKVHRNEFA-UHFFFAOYSA-N 0.000 description 2
- SOTKZRRGWRISNB-UHFFFAOYSA-N FC1=NC=CC(=C1F)C=1C=C2C=CC=NC2=CN=1 Chemical compound FC1=NC=CC(=C1F)C=1C=C2C=CC=NC2=CN=1 SOTKZRRGWRISNB-UHFFFAOYSA-N 0.000 description 2
- MCRRTVHMHIPALK-UHFFFAOYSA-N FC1=NC=CC(=C1F)N1CC=2C=CC=NC=2CC1 Chemical compound FC1=NC=CC(=C1F)N1CC=2C=CC=NC=2CC1 MCRRTVHMHIPALK-UHFFFAOYSA-N 0.000 description 2
- RCUJXXGXEXZORM-UHFFFAOYSA-N FC=1C(=NC=NC=1OC)C(=O)OCC Chemical compound FC=1C(=NC=NC=1OC)C(=O)OCC RCUJXXGXEXZORM-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- LRWBVEDOWGHEMX-UHFFFAOYSA-N IC1=C(C=C(C=N1)CN)OC Chemical compound IC1=C(C=C(C=N1)CN)OC LRWBVEDOWGHEMX-UHFFFAOYSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- ANDVMUOKDBZZNI-UHFFFAOYSA-N N#CC1=CC2=CC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)N=C2C=C1 Chemical compound N#CC1=CC2=CC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)N=C2C=C1 ANDVMUOKDBZZNI-UHFFFAOYSA-N 0.000 description 2
- DUNLXXJEMRYHLG-UHFFFAOYSA-N N(=[N+]=[N-])CC1=CC=C2C=C(C=NC2=C1)C#N Chemical compound N(=[N+]=[N-])CC1=CC=C2C=C(C=NC2=C1)C#N DUNLXXJEMRYHLG-UHFFFAOYSA-N 0.000 description 2
- YMZIZPQFUIWFGJ-UHFFFAOYSA-N N(=[N+]=[N-])CC=1C=C(C(=NC=1)I)OC Chemical compound N(=[N+]=[N-])CC=1C=C(C(=NC=1)I)OC YMZIZPQFUIWFGJ-UHFFFAOYSA-N 0.000 description 2
- LDRLPACNKWPUDK-UHFFFAOYSA-N N(=[N+]=[N-])CC=1C=NC2=CC(=CC=C2C=1)C#N Chemical compound N(=[N+]=[N-])CC=1C=NC2=CC(=CC=C2C=1)C#N LDRLPACNKWPUDK-UHFFFAOYSA-N 0.000 description 2
- BSZWLYBWWBPZFX-UHFFFAOYSA-N NCC1=CC=C2C=C(C=NC2=C1)C#N Chemical compound NCC1=CC=C2C=C(C=NC2=C1)C#N BSZWLYBWWBPZFX-UHFFFAOYSA-N 0.000 description 2
- CJZYCGXEGAPXOI-UHFFFAOYSA-N NCC=1C=NC(=C(C#N)C=1)Br Chemical compound NCC=1C=NC(=C(C#N)C=1)Br CJZYCGXEGAPXOI-UHFFFAOYSA-N 0.000 description 2
- SYRRVMTWHDXNJF-UHFFFAOYSA-N NCC=1C=NC2=CC(=CC=C2C=1)C#N Chemical compound NCC=1C=NC2=CC(=CC=C2C=1)C#N SYRRVMTWHDXNJF-UHFFFAOYSA-N 0.000 description 2
- NKJUEPQQGGDXHS-UHFFFAOYSA-N O=S1(=O)CCN(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=CC=N3)C=N2)CC1 Chemical compound O=S1(=O)CCN(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=CC=N3)C=N2)CC1 NKJUEPQQGGDXHS-UHFFFAOYSA-N 0.000 description 2
- FGIMCUDRMNIBQM-UHFFFAOYSA-N O=S1(=O)CCN(C2=CC=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=N2)CC1 Chemical compound O=S1(=O)CCN(C2=CC=C(CNC3=NSC(C4=CC=C5N=CC=CC5=C4)=N3)C=N2)CC1 FGIMCUDRMNIBQM-UHFFFAOYSA-N 0.000 description 2
- KIMQCMGJDRPHNZ-UHFFFAOYSA-N O=S1(=O)CCN(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=NC=N3)C=C2)CC1 Chemical compound O=S1(=O)CCN(C2=NC=C(CNC3=C(F)C(C4=CC5=C(C=C4)N=CC=C5)=NC=N3)C=C2)CC1 KIMQCMGJDRPHNZ-UHFFFAOYSA-N 0.000 description 2
- UDCZPACSNXZLQV-UHFFFAOYSA-N O=S1(=O)CCN(C2=NC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)CC1 Chemical compound O=S1(=O)CCN(C2=NC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2)CC1 UDCZPACSNXZLQV-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DRTSWIXOGBCNOJ-UHFFFAOYSA-N [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=C(F)C(C3=CC4=C(C=N3)N=CC=C4)=NC=N2)=C1 Chemical compound [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=C(F)C(C3=CC4=C(C=N3)N=CC=C4)=NC=N2)=C1 DRTSWIXOGBCNOJ-UHFFFAOYSA-N 0.000 description 2
- MPUSWVDASXZIOX-UHFFFAOYSA-N [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CC=C4N=CC=CC4=N3)=C2F)=C1 Chemical compound [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CC=C4N=CC=CC4=N3)=C2F)=C1 MPUSWVDASXZIOX-UHFFFAOYSA-N 0.000 description 2
- KCJHJSLHKQDNJZ-UHFFFAOYSA-N [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CN=CC(C#N)=C3)=C2F)=C1 Chemical compound [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CN=CC(C#N)=C3)=C2F)=C1 KCJHJSLHKQDNJZ-UHFFFAOYSA-N 0.000 description 2
- XICVHVWIUYPVJV-UHFFFAOYSA-N [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CN=CC(C)=C3)=C2F)=C1 Chemical compound [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CN=CC(C)=C3)=C2F)=C1 XICVHVWIUYPVJV-UHFFFAOYSA-N 0.000 description 2
- RBJRCBZJXVJMAG-UHFFFAOYSA-N [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CN=CC(Cl)=C3)=C2F)=C1 Chemical compound [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CN=CC(Cl)=C3)=C2F)=C1 RBJRCBZJXVJMAG-UHFFFAOYSA-N 0.000 description 2
- CANULYRUQPGCRN-UHFFFAOYSA-N [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CN=CC(OC)=C3)=C2F)=C1 Chemical compound [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NC=CC(C3=CN=CC(OC)=C3)=C2F)=C1 CANULYRUQPGCRN-UHFFFAOYSA-N 0.000 description 2
- AHQVNZLKUNRVRM-UHFFFAOYSA-N [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(C3=CC4=C(C=N3)N=CC=C4)=N2)=C1 Chemical compound [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(C3=CC4=C(C=N3)N=CC=C4)=N2)=C1 AHQVNZLKUNRVRM-UHFFFAOYSA-N 0.000 description 2
- VYOYFCFKKQWPND-UHFFFAOYSA-N [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(C3=CC=C4N=CC=CC4=C3)=N2)=C1 Chemical compound [C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(C3=CC=C4N=CC=CC4=C3)=N2)=C1 VYOYFCFKKQWPND-UHFFFAOYSA-N 0.000 description 2
- YUHOIZXUGIXDDV-UHFFFAOYSA-N [C-]#[N+]C1=CC(CNC2=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound [C-]#[N+]C1=CC(CNC2=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)=CN=C1C1=CC(C)=NC=C1 YUHOIZXUGIXDDV-UHFFFAOYSA-N 0.000 description 2
- HWNMATCWXIIBSZ-UHFFFAOYSA-N [C-]#[N+]C1=CC(CNC2=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=NC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound [C-]#[N+]C1=CC(CNC2=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=NC=N2)=CN=C1C1=CC(C)=NC=C1 HWNMATCWXIIBSZ-UHFFFAOYSA-N 0.000 description 2
- ZOJZLMQIHLLXFX-UHFFFAOYSA-N [C-]#[N+]C1=CC(CNC2=C(F)C(C3=CC=NC(C)=C3)=CC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound [C-]#[N+]C1=CC(CNC2=C(F)C(C3=CC=NC(C)=C3)=CC=N2)=CN=C1C1=CC(C)=NC=C1 ZOJZLMQIHLLXFX-UHFFFAOYSA-N 0.000 description 2
- MPCVFMRIPPZNAQ-UHFFFAOYSA-N [C-]#[N+]C1=CC(CNC2=C(F)C(C3=CN(C)N=C3)=CC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound [C-]#[N+]C1=CC(CNC2=C(F)C(C3=CN(C)N=C3)=CC=N2)=CN=C1C1=CC(C)=NC=C1 MPCVFMRIPPZNAQ-UHFFFAOYSA-N 0.000 description 2
- IHTJJJVJQXMEDR-UHFFFAOYSA-N [C-]#[N+]C1=CC(CNC2=C(F)C(N3CCN4N=NC=C4C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound [C-]#[N+]C1=CC(CNC2=C(F)C(N3CCN4N=NC=C4C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 IHTJJJVJQXMEDR-UHFFFAOYSA-N 0.000 description 2
- YPXQAPVUMSUVFT-UHFFFAOYSA-N [C-]#[N+]C1=CC(CNC2=C(F)C(N3CCN4N=NN=C4C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound [C-]#[N+]C1=CC(CNC2=C(F)C(N3CCN4N=NN=C4C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 YPXQAPVUMSUVFT-UHFFFAOYSA-N 0.000 description 2
- XPYYWAQLOMENRF-UHFFFAOYSA-N [C-]#[N+]C1=CC(CNC2=NC(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound [C-]#[N+]C1=CC(CNC2=NC(C3=CC4=C(C=C3)N=CC=C4)=CC=N2)=CN=C1C1=CC(C)=NC=C1 XPYYWAQLOMENRF-UHFFFAOYSA-N 0.000 description 2
- AYTUOIBOAIFGSR-UHFFFAOYSA-N [C-]#[N+]C1=CC(CNC2=NC=CC(C3=NC4=CC=NN4C=C3)=C2F)=CN=C1C1=CC(C)=NC=C1 Chemical compound [C-]#[N+]C1=CC(CNC2=NC=CC(C3=NC4=CC=NN4C=C3)=C2F)=CN=C1C1=CC(C)=NC=C1 AYTUOIBOAIFGSR-UHFFFAOYSA-N 0.000 description 2
- OWBXLKDZMRHHQH-UHFFFAOYSA-N [C-]#[N+]C1=CC(CNC2=NC=NC(N3CCN4N=CC=C4C3)=C2F)=CN=C1C1=CC(C)=NC=C1 Chemical compound [C-]#[N+]C1=CC(CNC2=NC=NC(N3CCN4N=CC=C4C3)=C2F)=CN=C1C1=CC(C)=NC=C1 OWBXLKDZMRHHQH-UHFFFAOYSA-N 0.000 description 2
- SXTVIGXTXBDAIX-UHFFFAOYSA-N [C-]#[N+]C1=CC2=C(C=C(CNC3=NC=NC(C4=CC=C5N=CC=CC5=C4)=C3F)C=C2)N=C1 Chemical compound [C-]#[N+]C1=CC2=C(C=C(CNC3=NC=NC(C4=CC=C5N=CC=CC5=C4)=C3F)C=C2)N=C1 SXTVIGXTXBDAIX-UHFFFAOYSA-N 0.000 description 2
- CHWXEWXFQYNFFX-UHFFFAOYSA-N [C-]#[N+]C1=CC2=C(C=C(CNC3=NC=NC(N4CCC5=C(C=CC=N5)C4)=C3F)C=C2)N=C1 Chemical compound [C-]#[N+]C1=CC2=C(C=C(CNC3=NC=NC(N4CCC5=C(C=CC=N5)C4)=C3F)C=C2)N=C1 CHWXEWXFQYNFFX-UHFFFAOYSA-N 0.000 description 2
- XGRCCVFHMKSUAW-UHFFFAOYSA-N [C-]#[N+]C1=CC2=C(C=C1)C=C(CNC1=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=CC=N1)C=N2 Chemical compound [C-]#[N+]C1=CC2=C(C=C1)C=C(CNC1=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=CC=N1)C=N2 XGRCCVFHMKSUAW-UHFFFAOYSA-N 0.000 description 2
- MYNAGESACFQOLO-UHFFFAOYSA-N [C-]#[N+]C1=CC2=C(C=C1)N=C(CNC1=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=CC=N1)C=C2 Chemical compound [C-]#[N+]C1=CC2=C(C=C1)N=C(CNC1=C(F)C(C3=CC4=C(C=C3)N=CC=C4)=CC=N1)C=C2 MYNAGESACFQOLO-UHFFFAOYSA-N 0.000 description 2
- VVZXRNSFENKXMP-UHFFFAOYSA-N [C-]#[N+]C1=CC2=C(C=C1)N=C(CNC1=NC=NC(C3=CC=C4N=CC=CC4=C3)=C1F)C=C2 Chemical compound [C-]#[N+]C1=CC2=C(C=C1)N=C(CNC1=NC=NC(C3=CC=C4N=CC=CC4=C3)=C1F)C=C2 VVZXRNSFENKXMP-UHFFFAOYSA-N 0.000 description 2
- HNLSRWPHQZFPAM-UHFFFAOYSA-N [C-]#[N+]C1=CC2=C(C=C1)N=C(CNC1=NC=NC(N3CCC4=C(C=CC=N4)C3)=C1F)C=C2 Chemical compound [C-]#[N+]C1=CC2=C(C=C1)N=C(CNC1=NC=NC(N3CCC4=C(C=CC=N4)C3)=C1F)C=C2 HNLSRWPHQZFPAM-UHFFFAOYSA-N 0.000 description 2
- GTYGJGJNPLWJCE-UHFFFAOYSA-N [C-]#[N+]C1=CC2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=C2C=C1 Chemical compound [C-]#[N+]C1=CC2=CC=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=C2C=C1 GTYGJGJNPLWJCE-UHFFFAOYSA-N 0.000 description 2
- CFIOOVMALHHTQC-UHFFFAOYSA-N [C-]#[N+]C1=CC=C(CCCNC2=NSC(C3=CC=C4N=CC=CC4=C3)=N2)N=C1 Chemical compound [C-]#[N+]C1=CC=C(CCCNC2=NSC(C3=CC=C4N=CC=CC4=C3)=N2)N=C1 CFIOOVMALHHTQC-UHFFFAOYSA-N 0.000 description 2
- WEEHPIULLIBPLV-UHFFFAOYSA-N [C-]#[N+]C1=CC=C2C=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=NC2=C1 Chemical compound [C-]#[N+]C1=CC=C2C=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=NC2=C1 WEEHPIULLIBPLV-UHFFFAOYSA-N 0.000 description 2
- KSUORLZOISYTJM-UHFFFAOYSA-N [C-]#[N+]C1=CC=C2C=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=NC2=C1 Chemical compound [C-]#[N+]C1=CC=C2C=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=NC2=C1 KSUORLZOISYTJM-UHFFFAOYSA-N 0.000 description 2
- KFTFGVKOQBCDED-UHFFFAOYSA-N [C-]#[N+]C1=CN=C(CCCNC2=NC=CC(C3=CC=C4N=CC=CC4=C3)=C2F)C=C1 Chemical compound [C-]#[N+]C1=CN=C(CCCNC2=NC=CC(C3=CC=C4N=CC=CC4=C3)=C2F)C=C1 KFTFGVKOQBCDED-UHFFFAOYSA-N 0.000 description 2
- FFBLXLIWTSEXQL-UHFFFAOYSA-N [C-]#[N+]C1=CN=C2C=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=CC=N3)C=CC2=C1 Chemical compound [C-]#[N+]C1=CN=C2C=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=CC=N3)C=CC2=C1 FFBLXLIWTSEXQL-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 150000001642 boronic acid derivatives Chemical group 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 2
- FAOQYBVMAYMMCJ-UHFFFAOYSA-N ethyl 5-fluoro-6-oxo-1H-pyrimidine-4-carboxylate Chemical compound FC=1C(=NC=NC=1O)C(=O)OCC FAOQYBVMAYMMCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XYBOIZQGIVYRFV-UHFFFAOYSA-N n-tert-butyl-3-methylpyridine-2-carboxamide Chemical compound CC1=CC=CN=C1C(=O)NC(C)(C)C XYBOIZQGIVYRFV-UHFFFAOYSA-N 0.000 description 2
- KPTRDYONBVUWPD-UHFFFAOYSA-N naphthalen-2-ylboronic acid Chemical compound C1=CC=CC2=CC(B(O)O)=CC=C21 KPTRDYONBVUWPD-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- MHCBYPRBJFPLPP-UHFFFAOYSA-N (2-chloropyrimidin-5-yl)methanamine Chemical compound NCC1=CN=C(Cl)N=C1 MHCBYPRBJFPLPP-UHFFFAOYSA-N 0.000 description 1
- HCBCJAFWOBCSRJ-UHFFFAOYSA-N (6-cyanonaphthalen-2-yl) trifluoromethanesulfonate Chemical compound C1=C(C#N)C=CC2=CC(OS(=O)(=O)C(F)(F)F)=CC=C21 HCBCJAFWOBCSRJ-UHFFFAOYSA-N 0.000 description 1
- QUIAPFCZANBSTK-UHFFFAOYSA-N (6-iodo-5-methoxypyridin-3-yl)methanol Chemical compound COC1=CC(CO)=CN=C1I QUIAPFCZANBSTK-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 1
- AIXBVJWFQNYGJA-UHFFFAOYSA-N 2,3-difluoro-4-iodopyridine Chemical compound FC1=NC=CC(I)=C1F AIXBVJWFQNYGJA-UHFFFAOYSA-N 0.000 description 1
- OXULGZNPTSIVHO-UHFFFAOYSA-N 2-bromo-5-methylpyridine-3-carbonitrile Chemical compound CC1=CN=C(Br)C(C#N)=C1 OXULGZNPTSIVHO-UHFFFAOYSA-N 0.000 description 1
- JUYRQGHDOBBUEA-UHFFFAOYSA-N 2-chloro-1,5-naphthyridine Chemical compound N1=CC=CC2=NC(Cl)=CC=C21 JUYRQGHDOBBUEA-UHFFFAOYSA-N 0.000 description 1
- PALTUKOARQNXFM-UHFFFAOYSA-N 2-methylsulfanyl-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-one Chemical compound O=C1NCCC2=NC(SC)=NC=C21 PALTUKOARQNXFM-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- CLRPXACRDTXENY-UHFFFAOYSA-N 3-ethynylpyridine Chemical compound C#CC1=CC=CN=C1 CLRPXACRDTXENY-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 1
- VYSZQJUFJGTSCJ-UHFFFAOYSA-N 5,6,7,8-tetrahydro-1,6-naphthyridine;hydrochloride Chemical compound Cl.C1=CC=C2CNCCC2=N1 VYSZQJUFJGTSCJ-UHFFFAOYSA-N 0.000 description 1
- URZFWMPMGOMSSY-UHFFFAOYSA-N 7-methylquinoline-3-carbonitrile Chemical compound C1=C(C#N)C=NC2=CC(C)=CC=C21 URZFWMPMGOMSSY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150030271 AXIN1 gene Proteins 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- 102000051172 Axin Human genes 0.000 description 1
- 108700012045 Axin Proteins 0.000 description 1
- CJDHCNGKFBVYEU-UHFFFAOYSA-N BrC1=CC=C(CNC2=CC(C3=CC=C4C=CC=CC4=C3)=CC=N2)C=C1.CC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1.CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=CC=N3)C=C2)=C1 Chemical compound BrC1=CC=C(CNC2=CC(C3=CC=C4C=CC=CC4=C3)=CC=N2)C=C1.CC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1.CC1=NC=CC(C2=CC=C(CNC3=CC(C4=CC=C5C=CC=CC5=C4)=CC=N3)C=C2)=C1 CJDHCNGKFBVYEU-UHFFFAOYSA-N 0.000 description 1
- YZAGGKLPKASNRN-UHFFFAOYSA-N BrC1=CC=C(CNC2=CC(C3=CC=C4C=CC=CC4=C3)=CC=N2)C=C1.NC1=NC=CC(C2=CC3=CC=CC=C3C=C2)=C1.[H]C(=O)C1=CC=C(Br)C=C1 Chemical compound BrC1=CC=C(CNC2=CC(C3=CC=C4C=CC=CC4=C3)=CC=N2)C=C1.NC1=NC=CC(C2=CC3=CC=CC=C3C=C2)=C1.[H]C(=O)C1=CC=C(Br)C=C1 YZAGGKLPKASNRN-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RDOFAQMPHPGANV-UHFFFAOYSA-N C#CC1=CN=CC=C1.CC1=NC=CC(C2=C(F)C=C(CNC3=C(F)C(C#CC4=CN=CC=C4)=NC=N3)C=N2)=C1.CC1=NC=CC(C2=C(F)C=C(CNC3=C(F)C(Cl)=NC=N3)C=N2)=C1 Chemical compound C#CC1=CN=CC=C1.CC1=NC=CC(C2=C(F)C=C(CNC3=C(F)C(C#CC4=CN=CC=C4)=NC=N3)C=N2)=C1.CC1=NC=CC(C2=C(F)C=C(CNC3=C(F)C(Cl)=NC=N3)C=N2)=C1 RDOFAQMPHPGANV-UHFFFAOYSA-N 0.000 description 1
- YOHNYGXDFZXZII-IPZCTEOASA-M C(C)OC(/C(=C(/C(=O)OCC)\F)/[O-])=O.[Na+] Chemical compound C(C)OC(/C(=C(/C(=O)OCC)\F)/[O-])=O.[Na+] YOHNYGXDFZXZII-IPZCTEOASA-M 0.000 description 1
- ZHRPJMSQKUSSQE-ZULXWOOMSA-N C.C/C=C/C1=CN=CC=C1.CC#CC1=CN=CC=C1.CC(=O)N1CCN(C)CC1.CC1C2=C(CCN1C)N=CC=N2.CN1CCC(O)CC1.CN1CCC2=C(C1)OC=N2.CN1CCC2=C(C1)SC=N2.CN1CCC2=C(CC=N2)C1.CN1CCC2=NN(C)C=C2C1.CN1CCN(C)C(=O)C1.CN1CCN(C)CC1.CN1CCN2N=CC=C2C1.CN1CCN2N=CN=C2C1.CN1CCN2N=NC=C2C1.CN1CCN2N=NN=C2C1.CN1CCNC(=O)C1.CN1CCNCC1.CN1CCOCC1.CN1CCS(=O)(=O)CC1.CN1CCS(=O)CC1.COC1CCN(C)CC1 Chemical compound C.C/C=C/C1=CN=CC=C1.CC#CC1=CN=CC=C1.CC(=O)N1CCN(C)CC1.CC1C2=C(CCN1C)N=CC=N2.CN1CCC(O)CC1.CN1CCC2=C(C1)OC=N2.CN1CCC2=C(C1)SC=N2.CN1CCC2=C(CC=N2)C1.CN1CCC2=NN(C)C=C2C1.CN1CCN(C)C(=O)C1.CN1CCN(C)CC1.CN1CCN2N=CC=C2C1.CN1CCN2N=CN=C2C1.CN1CCN2N=NC=C2C1.CN1CCN2N=NN=C2C1.CN1CCNC(=O)C1.CN1CCNCC1.CN1CCOCC1.CN1CCS(=O)(=O)CC1.CN1CCS(=O)CC1.COC1CCN(C)CC1 ZHRPJMSQKUSSQE-ZULXWOOMSA-N 0.000 description 1
- WCAMJGWBGHPBGC-UHFFFAOYSA-N C.CBr.CC.CC.CC(C)=O.CC(N)=O.CC1=CC=CC=C1.CC1=CC=CC=N1.CC1=CC=CN=C1.CC1=CC=N(=O)C(C)=C1.CC1=CC=NC(C)=C1.CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CN=CN1.CC1=CN=CO1.CC1=CN=CS1.CCC(=O)CC.CCC(=O)OC.CCC(C)=O.CCCCCS(C)(=O)=O.CCCCS(C)(=O)=O.CCNS(C)(=O)=O.CCS(C)(=O)=O.CCl.CF.CI.CN.CN1C=CN=C1.CN1C=NC=N1.CN1C=NN=C1.CN1CCN(C)CC1.CN1CCNCC1.CN1CCOCC1.CN1CCS(=O)(=O)CC1.CN1CCS(=O)CC1.CN1CCSCC1.CO.COC.COC(C)=O.COCCCS(C)(=O)=O.CS(C)(=O)=O.CS(N)(=O)=O.[C-]#[N+]C.[H]C Chemical compound C.CBr.CC.CC.CC(C)=O.CC(N)=O.CC1=CC=CC=C1.CC1=CC=CC=N1.CC1=CC=CN=C1.CC1=CC=N(=O)C(C)=C1.CC1=CC=NC(C)=C1.CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CN=CN1.CC1=CN=CO1.CC1=CN=CS1.CCC(=O)CC.CCC(=O)OC.CCC(C)=O.CCCCCS(C)(=O)=O.CCCCS(C)(=O)=O.CCNS(C)(=O)=O.CCS(C)(=O)=O.CCl.CF.CI.CN.CN1C=CN=C1.CN1C=NC=N1.CN1C=NN=C1.CN1CCN(C)CC1.CN1CCNCC1.CN1CCOCC1.CN1CCS(=O)(=O)CC1.CN1CCS(=O)CC1.CN1CCSCC1.CO.COC.COC(C)=O.COCCCS(C)(=O)=O.CS(C)(=O)=O.CS(N)(=O)=O.[C-]#[N+]C.[H]C WCAMJGWBGHPBGC-UHFFFAOYSA-N 0.000 description 1
- WLHXJEMSTXOTER-UHFFFAOYSA-N C.CBr.CC.CC.CC(C)=O.CC(N)=O.CC1=CC=CC=C1.CC1=CC=CC=N1.CC1=CC=CN=C1.CC1=CC=NC(C)=C1.CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CN=CN1.CC1=CN=CO1.CC1=CN=CS1.CCC(=O)CC.CCC(=O)OC.CCC(C)=O.CCl.CF.CI.CN.CN1C=CN=C1.CN1C=NC=N1.CN1C=NN=C1.CO.COC.COC(C)=O.CS(C)(=O)=O.CS(N)(=O)=O.[C-]#[N+]C.[H]C Chemical compound C.CBr.CC.CC.CC(C)=O.CC(N)=O.CC1=CC=CC=C1.CC1=CC=CC=N1.CC1=CC=CN=C1.CC1=CC=NC(C)=C1.CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CN=CN1.CC1=CN=CO1.CC1=CN=CS1.CCC(=O)CC.CCC(=O)OC.CCC(C)=O.CCl.CF.CI.CN.CN1C=CN=C1.CN1C=NC=N1.CN1C=NN=C1.CO.COC.COC(C)=O.CS(C)(=O)=O.CS(N)(=O)=O.[C-]#[N+]C.[H]C WLHXJEMSTXOTER-UHFFFAOYSA-N 0.000 description 1
- HXBMHXYVMLZYDO-UHFFFAOYSA-N C.CC(=N)N1C=C(C)C=CC1=N.CC1=CN2C(C)=NN=C2C=C1.CC1=CN=C(C)O1 Chemical compound C.CC(=N)N1C=C(C)C=CC1=N.CC1=CN2C(C)=NN=C2C=C1.CC1=CN=C(C)O1 HXBMHXYVMLZYDO-UHFFFAOYSA-N 0.000 description 1
- QFNCVBFLQQEAJH-UHFFFAOYSA-N C.CC1=C(F)N(C)C=N1.CC1=C(F)N(C)N=N1.CC1=CC(C)=NN1.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC(C)=NS1.CC1=CN(C)C=N1.CC1=CN(C)N=N1.CC1=NN(C)C(C)=C1F.CC1=NN(C)C(C)=N1.CC1=NN(C)C=N1.CC1=NN(C)N=N1.CC1=NN=C(C)N1.CC1=NN=C(C)N1C.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NNC(C)=C1F.CC1=NNC(C)=N1.CC1=NOC(C)=C1F.CC1=NOC(C)=N1.CC1=NSC(C)=C1F.CC1=NSC(C)=N1 Chemical compound C.CC1=C(F)N(C)C=N1.CC1=C(F)N(C)N=N1.CC1=CC(C)=NN1.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC(C)=NS1.CC1=CN(C)C=N1.CC1=CN(C)N=N1.CC1=NN(C)C(C)=C1F.CC1=NN(C)C(C)=N1.CC1=NN(C)C=N1.CC1=NN(C)N=N1.CC1=NN=C(C)N1.CC1=NN=C(C)N1C.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NNC(C)=C1F.CC1=NNC(C)=N1.CC1=NOC(C)=C1F.CC1=NOC(C)=N1.CC1=NSC(C)=C1F.CC1=NSC(C)=N1 QFNCVBFLQQEAJH-UHFFFAOYSA-N 0.000 description 1
- XZISOMWBYZEABZ-UHFFFAOYSA-N C.CC1=CC2=C(C=C1)C=C(C)S2.CC1=CC2=C(C=C1)N=C(C)S2.CC1=CN=C2C=C(C)C=CC2=C1.CC1=CN=C2C=C(C)C=NC2=C1 Chemical compound C.CC1=CC2=C(C=C1)C=C(C)S2.CC1=CC2=C(C=C1)N=C(C)S2.CC1=CN=C2C=C(C)C=CC2=C1.CC1=CN=C2C=C(C)C=NC2=C1 XZISOMWBYZEABZ-UHFFFAOYSA-N 0.000 description 1
- QPQRBBCFWSQTMB-UHFFFAOYSA-N C.CC1=CC2=CC=NN2C=C1.CC1=NC=C2N=CC=CC2=N1.CC1=NN=C2N=CC=CC2=C1.CN1CCC2=C(C=CC=C2)C1=O.CN1CCC2=C(C=CC=N2)C1=O.CN1CCC2=C(C=NC=N2)C1=O.CN1CCN2N=CC=C2C1.CN1CCN2N=CN=C2C1.CN1CCN2N=NC=C2C1.CNC1=NC2=C(C=N1)C(=O)N(C)CC2.CSC1=NC2=C(C=N1)C(=O)N(C)CC2 Chemical compound C.CC1=CC2=CC=NN2C=C1.CC1=NC=C2N=CC=CC2=N1.CC1=NN=C2N=CC=CC2=C1.CN1CCC2=C(C=CC=C2)C1=O.CN1CCC2=C(C=CC=N2)C1=O.CN1CCC2=C(C=NC=N2)C1=O.CN1CCN2N=CC=C2C1.CN1CCN2N=CN=C2C1.CN1CCN2N=NC=C2C1.CNC1=NC2=C(C=N1)C(=O)N(C)CC2.CSC1=NC2=C(C=N1)C(=O)N(C)CC2 QPQRBBCFWSQTMB-UHFFFAOYSA-N 0.000 description 1
- LGNMXVMNQQMIFL-UHFFFAOYSA-N C.CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CC=NO1.CC1=CC=NS1.CC1=CN(C)N=C1.CC1=CN=CN1.CC1=CN=NN1.CC1=CN=NO1.CC1=CN=NS1.CC1=CON=C1.CC1=CSN=C1.CC1=NN=CN1.CC1=NN=CO1.CC1=NN=CS1.CC1=NN=NN1.CC1=NNN=N1.CN1C=CN=C1.CN1C=CN=N1.CN1C=NC=N1.CN1C=NN=C1 Chemical compound C.CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CC=NO1.CC1=CC=NS1.CC1=CN(C)N=C1.CC1=CN=CN1.CC1=CN=NN1.CC1=CN=NO1.CC1=CN=NS1.CC1=CON=C1.CC1=CSN=C1.CC1=NN=CN1.CC1=NN=CO1.CC1=NN=CS1.CC1=NN=NN1.CC1=NNN=N1.CN1C=CN=C1.CN1C=CN=N1.CN1C=NC=N1.CN1C=NN=C1 LGNMXVMNQQMIFL-UHFFFAOYSA-N 0.000 description 1
- JQOVBEDFKOESKP-UHFFFAOYSA-N C.COC1=NC=NC(C2=NC(Cl)=C3N=CC=CC3=C2)=C1F.COC1=NC=NC(C2=NC=C3N=CC=CC3=C2)=C1F Chemical compound C.COC1=NC=NC(C2=NC(Cl)=C3N=CC=CC3=C2)=C1F.COC1=NC=NC(C2=NC=C3N=CC=CC3=C2)=C1F JQOVBEDFKOESKP-UHFFFAOYSA-N 0.000 description 1
- FPIJOSCSXOWKGX-UHFFFAOYSA-N C.COC1=NC=NC(C2=NC=C3N=CC=CC3=C2)=C1F.OC1=NC=NC(C2=NC=C3N=CC=CC3=C2)=C1F Chemical compound C.COC1=NC=NC(C2=NC=C3N=CC=CC3=C2)=C1F.OC1=NC=NC(C2=NC=C3N=CC=CC3=C2)=C1F FPIJOSCSXOWKGX-UHFFFAOYSA-N 0.000 description 1
- YQERGWJUDFTUQB-YQSSPJBWSA-N C/C=C/C1=CN=CC=C1.CC#CC1=CN=CC=C1.CC1C2=C(CCN1C)N=CC=C2.CC1C2=C(CCN1C)N=CC=N2.CN1CC2=C(C1)N=CC=C2.CN1CC2=C(C=CC=C2)C1.CN1CCC(O)CC1.CN1CCC2=C(C1)N=CC=N2.CN1CCC2=C(C1)OC=N2.CN1CCC2=C(C1)SC=N2.CN1CCC2=C(C=CC=N2)C1.CN1CCC2=C(C=CN=N2)C1.CN1CCC2=C(C=NC=N2)C1.CN1CCC2=C(CC=N2)C1.CN1CCC2=NN(C)C=C2C1.CN1CCCC2=C(C=CC=N2)C1.CN1CCN2N=CC=C2C1.CN1CCN2N=CN=C2C1.CN1CCN2N=NC=C2C1.CN1CCN2N=NN=C2C1.CN1CCOC2=C(C=CC=N2)C1.CN1CCS(=O)(=O)CC1.CN1CCS(=O)CC1.CNCC1=CC=CC=C1.CNCC1=CN=CC=C1.CNCC1CC1.COC1CCN(C)CC1 Chemical compound C/C=C/C1=CN=CC=C1.CC#CC1=CN=CC=C1.CC1C2=C(CCN1C)N=CC=C2.CC1C2=C(CCN1C)N=CC=N2.CN1CC2=C(C1)N=CC=C2.CN1CC2=C(C=CC=C2)C1.CN1CCC(O)CC1.CN1CCC2=C(C1)N=CC=N2.CN1CCC2=C(C1)OC=N2.CN1CCC2=C(C1)SC=N2.CN1CCC2=C(C=CC=N2)C1.CN1CCC2=C(C=CN=N2)C1.CN1CCC2=C(C=NC=N2)C1.CN1CCC2=C(CC=N2)C1.CN1CCC2=NN(C)C=C2C1.CN1CCCC2=C(C=CC=N2)C1.CN1CCN2N=CC=C2C1.CN1CCN2N=CN=C2C1.CN1CCN2N=NC=C2C1.CN1CCN2N=NN=C2C1.CN1CCOC2=C(C=CC=N2)C1.CN1CCS(=O)(=O)CC1.CN1CCS(=O)CC1.CNCC1=CC=CC=C1.CNCC1=CN=CC=C1.CNCC1CC1.COC1CCN(C)CC1 YQERGWJUDFTUQB-YQSSPJBWSA-N 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- IYBUDZWOTQCQNG-UHFFFAOYSA-N C1=CC2=C(CCNC2)N=C1.Cl.FC1=NC=CC(I)=C1F.FC1=NC=CC(N2CCC3=C(C=CC=N3)C2)=C1F Chemical compound C1=CC2=C(CCNC2)N=C1.Cl.FC1=NC=CC(I)=C1F.FC1=NC=CC(N2CCC3=C(C=CC=N3)C2)=C1F IYBUDZWOTQCQNG-UHFFFAOYSA-N 0.000 description 1
- YHISBJGWZQDIMN-UHFFFAOYSA-N C1=CC2=C(CCNC2)N=C1.ClC1=NSC(Cl)=N1.ClC1=NSC(N2CCC3=C(C=CC=N3)C2)=N1 Chemical compound C1=CC2=C(CCNC2)N=C1.ClC1=NSC(Cl)=N1.ClC1=NSC(N2CCC3=C(C=CC=N3)C2)=N1 YHISBJGWZQDIMN-UHFFFAOYSA-N 0.000 description 1
- URNFAEBOSBYZRX-UHFFFAOYSA-N C1=CN=C2CCNCC2=C1.CC1=NC=CC(C2=NC=C(CNC3=C(F)C(Cl)=NC=N3)C=N2)=C1.CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=N2)=C1 Chemical compound C1=CN=C2CCNCC2=C1.CC1=NC=CC(C2=NC=C(CNC3=C(F)C(Cl)=NC=N3)C=N2)=C1.CC1=NC=CC(C2=NC=C(CNC3=C(F)C(N4CCC5=C(C=CC=N5)C4)=NC=N3)C=N2)=C1 URNFAEBOSBYZRX-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- OLTSXDWJDHFKHQ-UHFFFAOYSA-N CBr.CC.CC(C)=O.CC(F)(F)F.CC(N)=O.CC1=CC=CC=C1.CC1=CC=CC=N1.CC1=CC=CN=C1.CC1=CC=N(=O)C(C)=C1.CC1=CC=NC(C)=C1.CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CN=CN1.CC1=CN=CO1.CC1=CN=CS1.CCC(=O)CC.CCC(=O)OC.CCC(C)=O.CCCCCS(C)(=O)=O.CCCCS(C)(=O)=O.CCNS(C)(=O)=O.CCS(C)(=O)=O.CCl.CF.CI.CN.CN1C=CN=C1.CN1C=NC=N1.CN1C=NN=C1.CN1CCN(C)CC1.CN1CCNCC1.CN1CCOCC1.CN1CCS(=O)(=O)CC1.CN1CCS(=O)CC1.CN1CCSCC1.CO.COC.COC(C)=O.COCCCS(C)(=O)=O.CS(C)(=O)=O.CS(N)(=O)=O.[C-]#[N+]C.[H]C Chemical compound CBr.CC.CC(C)=O.CC(F)(F)F.CC(N)=O.CC1=CC=CC=C1.CC1=CC=CC=N1.CC1=CC=CN=C1.CC1=CC=N(=O)C(C)=C1.CC1=CC=NC(C)=C1.CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CN=CN1.CC1=CN=CO1.CC1=CN=CS1.CCC(=O)CC.CCC(=O)OC.CCC(C)=O.CCCCCS(C)(=O)=O.CCCCS(C)(=O)=O.CCNS(C)(=O)=O.CCS(C)(=O)=O.CCl.CF.CI.CN.CN1C=CN=C1.CN1C=NC=N1.CN1C=NN=C1.CN1CCN(C)CC1.CN1CCNCC1.CN1CCOCC1.CN1CCS(=O)(=O)CC1.CN1CCS(=O)CC1.CN1CCSCC1.CO.COC.COC(C)=O.COCCCS(C)(=O)=O.CS(C)(=O)=O.CS(N)(=O)=O.[C-]#[N+]C.[H]C OLTSXDWJDHFKHQ-UHFFFAOYSA-N 0.000 description 1
- VDUPRVYHYACHHJ-UHFFFAOYSA-N CBr.CC.CC(C)=O.CC(F)(F)F.CC(N)=O.CC1=CC=CC=C1.CC1=CC=CC=N1.CC1=CC=CN=C1.CC1=CC=NC(C)=C1.CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CN=CN1.CC1=CN=CO1.CC1=CN=CS1.CCC(=O)CC.CCC(=O)OC.CCC(C)=O.CCl.CF.CI.CN.CN1C=CN=C1.CN1C=NC=N1.CN1C=NN=C1.CO.COC.COC(C)=O.CS(C)(=O)=O.CS(N)(=O)=O.[C-]#[N+]C.[H]C Chemical compound CBr.CC.CC(C)=O.CC(F)(F)F.CC(N)=O.CC1=CC=CC=C1.CC1=CC=CC=N1.CC1=CC=CN=C1.CC1=CC=NC(C)=C1.CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CN=CN1.CC1=CN=CO1.CC1=CN=CS1.CCC(=O)CC.CCC(=O)OC.CCC(C)=O.CCl.CF.CI.CN.CN1C=CN=C1.CN1C=NC=N1.CN1C=NN=C1.CO.COC.COC(C)=O.CS(C)(=O)=O.CS(N)(=O)=O.[C-]#[N+]C.[H]C VDUPRVYHYACHHJ-UHFFFAOYSA-N 0.000 description 1
- UGKZTBMJBOEVPF-AXBRHVBCSA-N CC(=N)N1C=C(C)C=CC1=N.CC(=N)N1C=C(C)C=CC1=N.CC1=CC2=C(C)C=NN2C=C1.CC1=CC2=C(C=C1)NC(=O)N(C)C2.CC1=CC2=C(C=C1)NC(=O)N2C.CC1=CC2=C(C=C1)NC(=O)[C@H](C)C2.CC1=CC=C2C=CN(C)C2=C1.CC1=CC=C2C=NN(C)C2=C1.CC1=CC=C2N=CN(C)C2=C1.CC1=CN2C(C)=CN=C2C=C1.CC1=CN=C(C)O1 Chemical compound CC(=N)N1C=C(C)C=CC1=N.CC(=N)N1C=C(C)C=CC1=N.CC1=CC2=C(C)C=NN2C=C1.CC1=CC2=C(C=C1)NC(=O)N(C)C2.CC1=CC2=C(C=C1)NC(=O)N2C.CC1=CC2=C(C=C1)NC(=O)[C@H](C)C2.CC1=CC=C2C=CN(C)C2=C1.CC1=CC=C2C=NN(C)C2=C1.CC1=CC=C2N=CN(C)C2=C1.CC1=CN2C(C)=CN=C2C=C1.CC1=CN=C(C)O1 UGKZTBMJBOEVPF-AXBRHVBCSA-N 0.000 description 1
- AEFQVGHVPIMAFY-UHFFFAOYSA-N CC(=O)N1CCN(C)CC1.CN1CCN(C)C(=O)C1.CN1CCN(C)CC1.CN1CCNC(=O)C1.CN1CCNCC1.CN1CCOCC1 Chemical compound CC(=O)N1CCN(C)CC1.CN1CCN(C)C(=O)C1.CN1CCN(C)CC1.CN1CCNC(=O)C1.CN1CCNCC1.CN1CCOCC1 AEFQVGHVPIMAFY-UHFFFAOYSA-N 0.000 description 1
- AUMMZBMNYJFBON-FWMLTEASSA-M CC(=O)O.CCOC(=O)/C(F)=C(\O[Na])C(=O)OCC.CCOC(=O)C1=C(F)C(O)=NC=N1.N=CN Chemical compound CC(=O)O.CCOC(=O)/C(F)=C(\O[Na])C(=O)OCC.CCOC(=O)C1=C(F)C(O)=NC=N1.N=CN AUMMZBMNYJFBON-FWMLTEASSA-M 0.000 description 1
- ZXIRNXDURWJICS-UHFFFAOYSA-N CC(=O)O.COC1=NC=NC(C(=O)CC2=C(C(=O)NC(C)(C)C)N=CC=C2)=C1F.COC1=NC=NC(C2=NC(O)=C3N=CC=CC3=C2)=C1F.N Chemical compound CC(=O)O.COC1=NC=NC(C(=O)CC2=C(C(=O)NC(C)(C)C)N=CC=C2)=C1F.COC1=NC=NC(C2=NC(O)=C3N=CC=CC3=C2)=C1F.N ZXIRNXDURWJICS-UHFFFAOYSA-N 0.000 description 1
- XZSWBVWUJNMGPU-UHFFFAOYSA-N CC1(C)OB(C2=CC=C3N=CC=CC3=C2)OC1(C)C.CC1=N(=O)C=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=C2)=C1.CC1=N(=O)C=CC(C2=CC=C(CNC3=C(F)C(Cl)=NC=N3)C=C2)=C1 Chemical compound CC1(C)OB(C2=CC=C3N=CC=CC3=C2)OC1(C)C.CC1=N(=O)C=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=C2)=C1.CC1=N(=O)C=CC(C2=CC=C(CNC3=C(F)C(Cl)=NC=N3)C=C2)=C1 XZSWBVWUJNMGPU-UHFFFAOYSA-N 0.000 description 1
- ZZDSVHOVRDEGAX-UHFFFAOYSA-N CC1(C)OB(C2=CC=C3N=CC=CC3=C2)OC1(C)C.CSC1=NC=CC(C2=CC=C3N=CC=CC3=C2)=N1.CSC1=NC=CC(Cl)=N1 Chemical compound CC1(C)OB(C2=CC=C3N=CC=CC3=C2)OC1(C)C.CSC1=NC=CC(C2=CC=C3N=CC=CC3=C2)=N1.CSC1=NC=CC(Cl)=N1 ZZDSVHOVRDEGAX-UHFFFAOYSA-N 0.000 description 1
- RJFQVNZAGJPOGS-UHFFFAOYSA-N CC1(C)OB(C2=CC=C3N=CC=CC3=C2)OC1(C)C.N#CC1=CC2=C(C=C1)C=C(CNC1=C(F)C(C3=CC=C4N=CC=CC4=C3)=NC=N1)C=C2.N#CC1=CC2=C(C=C1)C=C(CNC1=C(F)C(Cl)=NC=N1)C=C2 Chemical compound CC1(C)OB(C2=CC=C3N=CC=CC3=C2)OC1(C)C.N#CC1=CC2=C(C=C1)C=C(CNC1=C(F)C(C3=CC=C4N=CC=CC4=C3)=NC=N1)C=C2.N#CC1=CC2=C(C=C1)C=C(CNC1=C(F)C(Cl)=NC=N1)C=C2 RJFQVNZAGJPOGS-UHFFFAOYSA-N 0.000 description 1
- LARVJYPOHVEVPV-UHFFFAOYSA-N CC1(C)OB(c2cc3cccnc3cc2)OC1 Chemical compound CC1(C)OB(c2cc3cccnc3cc2)OC1 LARVJYPOHVEVPV-UHFFFAOYSA-N 0.000 description 1
- PWWFMXFJODHUBK-UHFFFAOYSA-N CC1=C(C(=O)CC(C)(C)C)N=CC=C1.CCOC(=O)C1=NC(SC)=NC=C1.CSC1=NC(C(=O)CC2=C(C(=O)NC(C)(C)C)N=CC=C2)=CC=N1 Chemical compound CC1=C(C(=O)CC(C)(C)C)N=CC=C1.CCOC(=O)C1=NC(SC)=NC=C1.CSC1=NC(C(=O)CC2=C(C(=O)NC(C)(C)C)N=CC=C2)=CC=N1 PWWFMXFJODHUBK-UHFFFAOYSA-N 0.000 description 1
- PWTAIDBPVFVABU-UHFFFAOYSA-N CC1=C(C(=O)NC(C)(C)C)N=CC=C1.CCOC(=O)C1=C(F)C(OC)=NC=N1.COC1=NC=NC(C(=O)CC2=C(C(=O)NC(C)(C)C)N=CC=C2)=C1F Chemical compound CC1=C(C(=O)NC(C)(C)C)N=CC=C1.CCOC(=O)C1=C(F)C(OC)=NC=N1.COC1=NC=NC(C(=O)CC2=C(C(=O)NC(C)(C)C)N=CC=C2)=C1F PWTAIDBPVFVABU-UHFFFAOYSA-N 0.000 description 1
- AEIKKQJPMMBUEU-UHFFFAOYSA-N CC1=C(F)N(C)C=N1.CC1=C(F)N(C)N=N1.CC1=CC(C)=NN1.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC(C)=NS1.CC1=CN(C)C=N1.CC1=CN(C)N=N1.CC1=NN(C)C(C)=C1F.CC1=NN(C)C(C)=N1.CC1=NN(C)C=N1.CC1=NN(C)N=N1.CC1=NN=C(C)N1.CC1=NN=C(C)N1C.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NNC(C)=C1F.CC1=NNC(C)=N1.CC1=NOC(C)=C1F.CC1=NOC(C)=N1.CC1=NSC(C)=C1F.CC1=NSC(C)=N1 Chemical compound CC1=C(F)N(C)C=N1.CC1=C(F)N(C)N=N1.CC1=CC(C)=NN1.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC(C)=NS1.CC1=CN(C)C=N1.CC1=CN(C)N=N1.CC1=NN(C)C(C)=C1F.CC1=NN(C)C(C)=N1.CC1=NN(C)C=N1.CC1=NN(C)N=N1.CC1=NN=C(C)N1.CC1=NN=C(C)N1C.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NNC(C)=C1F.CC1=NNC(C)=N1.CC1=NOC(C)=C1F.CC1=NOC(C)=N1.CC1=NSC(C)=C1F.CC1=NSC(C)=N1 AEIKKQJPMMBUEU-UHFFFAOYSA-N 0.000 description 1
- CLRMEFOGWUUCRQ-RJFAFJMKSA-N CC1=CC(=O)N(C)C=C1.CC1=CC(=O)N(C)C=C1.CC1=CC(C)=NN(C)C1=O.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC2=CC=NC(C)=C2C=C1.CC1=CC2=CN=C(C)C=C2C=C1.CC1=CC=C(C)C=C1.CC1=CC=C(C)N=N1.CC1=CC=C(C)S1.CC1=CC=C2C=C(C)C=CC2=C1.CC1=CN(C)C(=O)C(C)=C1.CC1=CN(C)N=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)O1.CC1=CN=C(C)S1.CC1=CN=C(C)S1.CC1=CN=C2C=C(C)C=CC2=C1.CC1=NN(C)C=C1.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NOC(C)=N1.CC1=NOC(C)=N1.CC1CC(C)C1.C[C@@H]1COC[C@@H]1C.C[C@H]1CCC[C@H]1C.C[C@H]1CCO[C@H]1C.C[C@H]1CC[C@@H](C)C1.C[C@H]1CC[C@@H](C)CC1.C[C@H]1CC[C@@H](C)CO1.C[C@H]1CN(C)[C@@H](C)CO1.C[C@H]1C[C@@H](C)CO1.C[C@H]1C[C@H]1C Chemical compound CC1=CC(=O)N(C)C=C1.CC1=CC(=O)N(C)C=C1.CC1=CC(C)=NN(C)C1=O.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC2=CC=NC(C)=C2C=C1.CC1=CC2=CN=C(C)C=C2C=C1.CC1=CC=C(C)C=C1.CC1=CC=C(C)N=N1.CC1=CC=C(C)S1.CC1=CC=C2C=C(C)C=CC2=C1.CC1=CN(C)C(=O)C(C)=C1.CC1=CN(C)N=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)O1.CC1=CN=C(C)S1.CC1=CN=C(C)S1.CC1=CN=C2C=C(C)C=CC2=C1.CC1=NN(C)C=C1.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NOC(C)=N1.CC1=NOC(C)=N1.CC1CC(C)C1.C[C@@H]1COC[C@@H]1C.C[C@H]1CCC[C@H]1C.C[C@H]1CCO[C@H]1C.C[C@H]1CC[C@@H](C)C1.C[C@H]1CC[C@@H](C)CC1.C[C@H]1CC[C@@H](C)CO1.C[C@H]1CN(C)[C@@H](C)CO1.C[C@H]1C[C@@H](C)CO1.C[C@H]1C[C@H]1C CLRMEFOGWUUCRQ-RJFAFJMKSA-N 0.000 description 1
- NOUODVNZQBANPI-UTJYGFDYSA-N CC1=CC(=O)N(C)C=C1.CC1=CC(=O)N(C)C=C1.CC1=CC(C)=NN(C)C1=O.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC=C(C)C=C1.CC1=CC=C(C)N=N1.CC1=CC=C(C)S1.CC1=CN(C)C(=O)C(C)=C1.CC1=CN(C)N=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)O1.CC1=CN=C(C)S1.CC1=CN=C(C)S1.CC1=NN(C)C=C1.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NOC(C)=N1.CC1=NOC(C)=N1.C[C@H]1CCC[C@H]1C.C[C@H]1CCO[C@H]1C.C[C@H]1CC[C@@H](C)C1.C[C@H]1CC[C@@H](C)CC1.C[C@H]1CC[C@@H](C)CO1.C[C@H]1CC[C@@H](C)O1.C[C@H]1CN(C)[C@@H](C)CO1.C[C@H]1C[C@@H](C)C1.C[C@H]1C[C@@H](C)CO1.C[C@H]1C[C@H]1C Chemical compound CC1=CC(=O)N(C)C=C1.CC1=CC(=O)N(C)C=C1.CC1=CC(C)=NN(C)C1=O.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC=C(C)C=C1.CC1=CC=C(C)N=N1.CC1=CC=C(C)S1.CC1=CN(C)C(=O)C(C)=C1.CC1=CN(C)N=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)O1.CC1=CN=C(C)S1.CC1=CN=C(C)S1.CC1=NN(C)C=C1.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NOC(C)=N1.CC1=NOC(C)=N1.C[C@H]1CCC[C@H]1C.C[C@H]1CCO[C@H]1C.C[C@H]1CC[C@@H](C)C1.C[C@H]1CC[C@@H](C)CC1.C[C@H]1CC[C@@H](C)CO1.C[C@H]1CC[C@@H](C)O1.C[C@H]1CN(C)[C@@H](C)CO1.C[C@H]1C[C@@H](C)C1.C[C@H]1C[C@@H](C)CO1.C[C@H]1C[C@H]1C NOUODVNZQBANPI-UTJYGFDYSA-N 0.000 description 1
- QHPQUIBEXNRKJR-UHFFFAOYSA-N CC1=CC(=O)N(C)C=C1.CC1=CC(=O)N(C)C=C1.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC2=C(C=C1)CN(C)CC2.CC1=CC2=C(C=C1)N=C(C)C2.CC1=CC2=C(C=C1)N=C(C)O2.CC1=CC2=CC=C(C)N=C2C=C1.CC1=CC2=CC=NC(C)=C2C=C1.CC1=CC2=CN=C(C)C=C2C=C1.CC1=CC=C(C)C=C1.CC1=CC=C(C)N=N1.CC1=CC=C(C)O1.CC1=CC=C(C)S1.CC1=CC=C2C=C(C)C=CC2=C1.CC1=CC=C2C=C(C)C=NC2=C1.CC1=CC=C2C=C(C)N=CC2=C1.CC1=CC=C2N=C(C)C=CC2=C1.CC1=CN(C)N=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)O1.CC1=CN=C(C)O1.CC1=CN=C(C)S1.CC1=CN=C(C)S1.CC1=NN(C)C=C1.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NOC(C)=N1.CC1=NOC(C)=N1 Chemical compound CC1=CC(=O)N(C)C=C1.CC1=CC(=O)N(C)C=C1.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC2=C(C=C1)CN(C)CC2.CC1=CC2=C(C=C1)N=C(C)C2.CC1=CC2=C(C=C1)N=C(C)O2.CC1=CC2=CC=C(C)N=C2C=C1.CC1=CC2=CC=NC(C)=C2C=C1.CC1=CC2=CN=C(C)C=C2C=C1.CC1=CC=C(C)C=C1.CC1=CC=C(C)N=N1.CC1=CC=C(C)O1.CC1=CC=C(C)S1.CC1=CC=C2C=C(C)C=CC2=C1.CC1=CC=C2C=C(C)C=NC2=C1.CC1=CC=C2C=C(C)N=CC2=C1.CC1=CC=C2N=C(C)C=CC2=C1.CC1=CN(C)N=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)O1.CC1=CN=C(C)O1.CC1=CN=C(C)S1.CC1=CN=C(C)S1.CC1=NN(C)C=C1.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NOC(C)=N1.CC1=NOC(C)=N1 QHPQUIBEXNRKJR-UHFFFAOYSA-N 0.000 description 1
- OCTSPCMPBYXGDU-UHFFFAOYSA-N CC1=CC(=O)N(C)C=C1.CC1=CC(=O)N(C)C=C1.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC2=C(C=C1)CN(C)CC2.CC1=CC2=C(C=C1)N=C(C)C2.CC1=CC2=C(C=C1)N=C(C)O2.CC1=CC2=CC=C(C)N=C2C=C1.CC1=CC2=CC=NC(C)=C2C=C1.CC1=CC=C(C)C=C1.CC1=CC=C(C)N=N1.CC1=CC=C(C)O1.CC1=CC=C(C)S1.CC1=CC=C2C=C(C)C=CC2=C1.CC1=CC=C2C=C(C)C=NC2=C1.CC1=CC=C2N=C(C)C=CC2=C1.CC1=CN(C)N=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)O1.CC1=CN=C(C)O1.CC1=CN=C(C)S1.CC1=CN=C(C)S1.CC1=NN(C)C=C1.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NOC(C)=N1.CC1=NOC(C)=N1 Chemical compound CC1=CC(=O)N(C)C=C1.CC1=CC(=O)N(C)C=C1.CC1=CC(C)=NN1C.CC1=CC(C)=NO1.CC1=CC2=C(C=C1)CN(C)CC2.CC1=CC2=C(C=C1)N=C(C)C2.CC1=CC2=C(C=C1)N=C(C)O2.CC1=CC2=CC=C(C)N=C2C=C1.CC1=CC2=CC=NC(C)=C2C=C1.CC1=CC=C(C)C=C1.CC1=CC=C(C)N=N1.CC1=CC=C(C)O1.CC1=CC=C(C)S1.CC1=CC=C2C=C(C)C=CC2=C1.CC1=CC=C2C=C(C)C=NC2=C1.CC1=CC=C2N=C(C)C=CC2=C1.CC1=CN(C)N=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=C1.CC1=CN=C(C)C=N1.CC1=CN=C(C)C=N1.CC1=CN=C(C)N=C1.CC1=CN=C(C)N=C1.CC1=CN=C(C)O1.CC1=CN=C(C)O1.CC1=CN=C(C)S1.CC1=CN=C(C)S1.CC1=NN(C)C=C1.CC1=NN=C(C)O1.CC1=NN=C(C)S1.CC1=NOC(C)=N1.CC1=NOC(C)=N1 OCTSPCMPBYXGDU-UHFFFAOYSA-N 0.000 description 1
- SIAGFNLFLUXBFD-UHFFFAOYSA-N CC1=CC(C#N)=C(Br)N=C1.N#CC1=C(Br)N=CC(CBr)=C1 Chemical compound CC1=CC(C#N)=C(Br)N=C1.N#CC1=C(Br)N=CC(CBr)=C1 SIAGFNLFLUXBFD-UHFFFAOYSA-N 0.000 description 1
- YNQHGYSKBRVWMU-FNCOJMSKSA-N CC1=CC2=C(C)C=NN2C=C1.CC1=CC2=C(C=C1)CN(C)CC2.CC1=CC2=C(C=C1)N=C(C)C2.CC1=CC2=C(C=C1)N=C(C)O2.CC1=CC2=C(C=C1)N=C(C)S2.CC1=CC2=C(C=C1)NC(=O)C(C)=C2.CC1=CC2=C(C=C1)NC(=O)C(C)=N2.CC1=CC2=C(C=C1)NC(=O)N(C)C2.CC1=CC2=C(C=C1)NC(=O)N2C.CC1=CC2=C(C=C1)NC(=O)[C@H](C)C2.CC1=CC2=C(C=C1)OC(=O)C(C)=C2.CC1=CC2=CC=C(C)N=C2C=C1.CC1=CC=C2C=C(C)C=NC2=C1.CC1=CC=C2C=C(C)N=CC2=C1.CC1=CC=C2C=C(C)NC(=O)C2=C1.CC1=CC=C2C=CN(C)C2=C1.CC1=CC=C2C=NN(C)C2=C1.CC1=CC=C2N=C(C)C=CC2=C1.CC1=CC=C2N=C(C)NC(=O)C2=C1.CC1=CC=C2N=CN(C)C2=C1.CC1=CC=C2O[C@H](C)CCC2=C1.CC1=CN2=C(C)C=NC2C=C1.CC1=CN2N=C(C)C=CC2=NC1=O.CC1=CN=C2C=C(C)C=NC2=C1 Chemical compound CC1=CC2=C(C)C=NN2C=C1.CC1=CC2=C(C=C1)CN(C)CC2.CC1=CC2=C(C=C1)N=C(C)C2.CC1=CC2=C(C=C1)N=C(C)O2.CC1=CC2=C(C=C1)N=C(C)S2.CC1=CC2=C(C=C1)NC(=O)C(C)=C2.CC1=CC2=C(C=C1)NC(=O)C(C)=N2.CC1=CC2=C(C=C1)NC(=O)N(C)C2.CC1=CC2=C(C=C1)NC(=O)N2C.CC1=CC2=C(C=C1)NC(=O)[C@H](C)C2.CC1=CC2=C(C=C1)OC(=O)C(C)=C2.CC1=CC2=CC=C(C)N=C2C=C1.CC1=CC=C2C=C(C)C=NC2=C1.CC1=CC=C2C=C(C)N=CC2=C1.CC1=CC=C2C=C(C)NC(=O)C2=C1.CC1=CC=C2C=CN(C)C2=C1.CC1=CC=C2C=NN(C)C2=C1.CC1=CC=C2N=C(C)C=CC2=C1.CC1=CC=C2N=C(C)NC(=O)C2=C1.CC1=CC=C2N=CN(C)C2=C1.CC1=CC=C2O[C@H](C)CCC2=C1.CC1=CN2=C(C)C=NC2C=C1.CC1=CN2N=C(C)C=CC2=NC1=O.CC1=CN=C2C=C(C)C=NC2=C1 YNQHGYSKBRVWMU-FNCOJMSKSA-N 0.000 description 1
- WXIGKGQVXGUCKK-UHFFFAOYSA-N CC1=CC2=C(C=C1)C=C(C)S2.CC1=CC2=C(C=C1)N=C(C)S2.CC1=CC2=CN=C(C)C=C2C=C1.CC1=CC=C2C=C(C)N=CC2=C1.CC1=CN=C2C=C(C)C=CC2=C1.CC1=CN=C2C=C(C)C=NC2=C1 Chemical compound CC1=CC2=C(C=C1)C=C(C)S2.CC1=CC2=C(C=C1)N=C(C)S2.CC1=CC2=CN=C(C)C=C2C=C1.CC1=CC=C2C=C(C)N=CC2=C1.CC1=CN=C2C=C(C)C=CC2=C1.CC1=CN=C2C=C(C)C=NC2=C1 WXIGKGQVXGUCKK-UHFFFAOYSA-N 0.000 description 1
- RWJOKXGSPKLVCP-KTRAHPNYSA-N CC1=CC2=C(C=C1)CN(C)CC2.CC1=CC2=C(C=C1)N=C(C)C2.CC1=CC2=C(C=C1)N=C(C)O2.CC1=CC2=C(C=C1)N=C(C)S2.CC1=CC2=C(C=C1)NC(=O)C(C)=C2.CC1=CC2=C(C=C1)NC(=O)C(C)=N2.CC1=CC2=C(C=C1)OC(=O)C(C)=C2.CC1=CC2=CC=C(C)N=C2C=C1.CC1=CC2=CC=NC(C)=C2C=C1.CC1=CC2=CN=C(C)C=C2C=C1.CC1=CC=C2C=C(C)C=CC2=C1.CC1=CC=C2C=C(C)C=NC2=C1.CC1=CC=C2C=C(C)N=CC2=C1.CC1=CC=C2C=C(C)NC(=O)C2=C1.CC1=CC=C2N=C(C)C=CC2=C1.CC1=CC=C2N=C(C)NC(=O)C2=C1.CC1=CC=C2O[C@H](C)CCC2=C1.CC1=CN2N=C(C)C=CC2=NC1=O.CC1=CN=C2C=C(C)C=CC2=C1.CC1=CN=C2C=C(C)C=NC2=C1 Chemical compound CC1=CC2=C(C=C1)CN(C)CC2.CC1=CC2=C(C=C1)N=C(C)C2.CC1=CC2=C(C=C1)N=C(C)O2.CC1=CC2=C(C=C1)N=C(C)S2.CC1=CC2=C(C=C1)NC(=O)C(C)=C2.CC1=CC2=C(C=C1)NC(=O)C(C)=N2.CC1=CC2=C(C=C1)OC(=O)C(C)=C2.CC1=CC2=CC=C(C)N=C2C=C1.CC1=CC2=CC=NC(C)=C2C=C1.CC1=CC2=CN=C(C)C=C2C=C1.CC1=CC=C2C=C(C)C=CC2=C1.CC1=CC=C2C=C(C)C=NC2=C1.CC1=CC=C2C=C(C)N=CC2=C1.CC1=CC=C2C=C(C)NC(=O)C2=C1.CC1=CC=C2N=C(C)C=CC2=C1.CC1=CC=C2N=C(C)NC(=O)C2=C1.CC1=CC=C2O[C@H](C)CCC2=C1.CC1=CN2N=C(C)C=CC2=NC1=O.CC1=CN=C2C=C(C)C=CC2=C1.CC1=CN=C2C=C(C)C=NC2=C1 RWJOKXGSPKLVCP-KTRAHPNYSA-N 0.000 description 1
- SFAZKNWXYGNRSO-UHFFFAOYSA-N CC1=CC2=C(C=C1)NN=C2.CC1=CC2=C(N=CC=C2)S1.CC1=CC2=CC=NN2C=C1.CC1=CC2=CN(C)N=C2C=C1.CC1=CC2=CN=NN2C=C1.CC1=CC2=CON=C2C=C1.CC1=CC2=CSN=C2C=C1.CC1=CC2=NC=NN2C=C1.CC1=CC2=NN=NN2C=C1.CC1=CC2=NON=C2C=C1.CC1=CC2=NSN=C2C=C1.CC1=CC=C2N=CCC2=C1.CC1=CC=C2N=COC2=C1.CC1=CC=C2N=CSC2=C1.CC1=CC=C2OCCOC2=C1.CC1=CC=C2OCOC2=C1.CC1=CN2C=CN=C2C=C1.CC1=CN2C=NN=C2C=C1.CC1=CN2N=CN=C2C=C1.CC1=CN2N=NN=C2C=C1.CC1=NC2=C(N=CC=C2)O1.CC1=NC2=C(N=CC=C2)S1.CC1=NC2=CC=NN2C=C1.CC1=NN2C=CN=C2C=C1.CN1CCC2=C(C=CC=C2)C1 Chemical compound CC1=CC2=C(C=C1)NN=C2.CC1=CC2=C(N=CC=C2)S1.CC1=CC2=CC=NN2C=C1.CC1=CC2=CN(C)N=C2C=C1.CC1=CC2=CN=NN2C=C1.CC1=CC2=CON=C2C=C1.CC1=CC2=CSN=C2C=C1.CC1=CC2=NC=NN2C=C1.CC1=CC2=NN=NN2C=C1.CC1=CC2=NON=C2C=C1.CC1=CC2=NSN=C2C=C1.CC1=CC=C2N=CCC2=C1.CC1=CC=C2N=COC2=C1.CC1=CC=C2N=CSC2=C1.CC1=CC=C2OCCOC2=C1.CC1=CC=C2OCOC2=C1.CC1=CN2C=CN=C2C=C1.CC1=CN2C=NN=C2C=C1.CC1=CN2N=CN=C2C=C1.CC1=CN2N=NN=C2C=C1.CC1=NC2=C(N=CC=C2)O1.CC1=NC2=C(N=CC=C2)S1.CC1=NC2=CC=NN2C=C1.CC1=NN2C=CN=C2C=C1.CN1CCC2=C(C=CC=C2)C1 SFAZKNWXYGNRSO-UHFFFAOYSA-N 0.000 description 1
- NKNBBRFSUIAPJM-UHFFFAOYSA-N CC1=CC2=C(C=C1)NN=C2.CC1=CC2=C(N=CC=C2)S1.CC1=CC2=CC=NN2C=C1.CC1=CC2=CN(C)N=C2C=C1.CC1=CC2=CN=NN2C=C1.CC1=CC2=CON=C2C=C1.CC1=CC2=CSN=C2C=C1.CC1=CC2=NC=NN2C=C1.CC1=CC2=NN=NN2C=C1.CC1=CC2=NON=C2C=C1.CC1=CC2=NSN=C2C=C1.CC1=CC=C2OCCOC2=C1.CC1=CC=C2OCOC2=C1.CC1=NC2=C(N=CC=C2)O1.CC1=NC2=C(N=CC=C2)S1.CC1=NC2=CC=NN2C=C1.CC1C2=C(CCN1C)N=CC=C2.CN1CC2=C(C1)N=CC=C2.CN1CC2=C(C=CC=C2)C1.CN1CCC2=C(C1)N=CC=N2.CN1CCC2=C(C=CC=C2)C1.CN1CCC2=C(C=CC=N2)C1.CN1CCC2=C(C=CN=N2)C1.CN1CCC2=C(C=NC=N2)C1.CN1CCCC2=C(C=CC=N2)C1.CN1CCOC2=C(C=CC=N2)C1.CNCC1=CC=CC=C1.CNCC1=CN=CC=C1.CNCC1CC1 Chemical compound CC1=CC2=C(C=C1)NN=C2.CC1=CC2=C(N=CC=C2)S1.CC1=CC2=CC=NN2C=C1.CC1=CC2=CN(C)N=C2C=C1.CC1=CC2=CN=NN2C=C1.CC1=CC2=CON=C2C=C1.CC1=CC2=CSN=C2C=C1.CC1=CC2=NC=NN2C=C1.CC1=CC2=NN=NN2C=C1.CC1=CC2=NON=C2C=C1.CC1=CC2=NSN=C2C=C1.CC1=CC=C2OCCOC2=C1.CC1=CC=C2OCOC2=C1.CC1=NC2=C(N=CC=C2)O1.CC1=NC2=C(N=CC=C2)S1.CC1=NC2=CC=NN2C=C1.CC1C2=C(CCN1C)N=CC=C2.CN1CC2=C(C1)N=CC=C2.CN1CC2=C(C=CC=C2)C1.CN1CCC2=C(C1)N=CC=N2.CN1CCC2=C(C=CC=C2)C1.CN1CCC2=C(C=CC=N2)C1.CN1CCC2=C(C=CN=N2)C1.CN1CCC2=C(C=NC=N2)C1.CN1CCCC2=C(C=CC=N2)C1.CN1CCOC2=C(C=CC=N2)C1.CNCC1=CC=CC=C1.CNCC1=CN=CC=C1.CNCC1CC1 NKNBBRFSUIAPJM-UHFFFAOYSA-N 0.000 description 1
- UOPWLWTXUJANRS-UHFFFAOYSA-N CC1=CC2=CC=NN2C=C1.CC1=NC=C2N=CC=CC2=N1.CC1=NN=C2N=CC=CC2=C1.CC1C2=C(CCN1C)N=CC=C2.CC1C2=C(CCN1C)N=CC=N2.CN1CCC2=C(C1)OC=N2.CN1CCC2=C(C1)SC=N2.CN1CCC2=C(C=CC=C2)C1=O.CN1CCC2=C(C=CC=N2)C1=O.CN1CCC2=C(C=CN=N2)C1.CN1CCC2=C(C=NC=N2)C1=O.CN1CCC2=C(CC=N2)C1.CN1CCN2N=CC=C2C1.CN1CCN2N=CN=C2C1.CN1CCN2N=NC=C2C1.CNC1=NC2=C(C=N1)C(=O)N(C)CC2.CSC1=NC2=C(C=N1)C(=O)N(C)CC2 Chemical compound CC1=CC2=CC=NN2C=C1.CC1=NC=C2N=CC=CC2=N1.CC1=NN=C2N=CC=CC2=C1.CC1C2=C(CCN1C)N=CC=C2.CC1C2=C(CCN1C)N=CC=N2.CN1CCC2=C(C1)OC=N2.CN1CCC2=C(C1)SC=N2.CN1CCC2=C(C=CC=C2)C1=O.CN1CCC2=C(C=CC=N2)C1=O.CN1CCC2=C(C=CN=N2)C1.CN1CCC2=C(C=NC=N2)C1=O.CN1CCC2=C(CC=N2)C1.CN1CCN2N=CC=C2C1.CN1CCN2N=CN=C2C1.CN1CCN2N=NC=C2C1.CNC1=NC2=C(C=N1)C(=O)N(C)CC2.CSC1=NC2=C(C=N1)C(=O)N(C)CC2 UOPWLWTXUJANRS-UHFFFAOYSA-N 0.000 description 1
- JXEMYLOFMPAMAC-UHFFFAOYSA-N CC1=CC2=NC=NN2C=C1.CC1=CC=C2C=CC=CC2=C1.CC1=CC=C2C=CC=CC2=N1.CC1=CC=C2C=CC=NC2=C1.CC1=CC=C2C=CN=CC2=C1.CC1=CC=C2C=NC=CC2=C1.CC1=CC=C2N=CC=CC2=C1.CC1=CC=C2N=CC=CC2=N1.CC1=CC=C2N=CC=NC2=C1.CC1=CC=C2N=CCC2=C1.CC1=CC=C2N=CN=CC2=C1.CC1=CC=C2N=COC2=C1.CC1=CC=C2N=CSC2=C1.CC1=CC=C2N=NC=CC2=C1.CC1=CN2C=CN=C2C=C1.CC1=CN2C=NN=C2C=C1.CC1=CN2N=CN=C2C=C1.CC1=CN=C2C=CC=CC2=C1.CC1=CN=C2N=CC=CC2=C1.CC1=NC=C2C=CC=CC2=C1.CC1=NC=C2N=CC=CC2=C1.CC1C2=C(CCN1C)N=CC=C2.CC1C2=C(CCN1C)N=CC=N2.CN1CCC2=C(C1)N=CC=N2.CN1CCC2=C(C1)OC=N2.CN1CCC2=C(C1)SC=N2.CN1CCC2=C(C=CC=C2)C1.CN1CCC2=C(C=CC=N2)C1.CN1CCC2=C(C=CN=N2)C1.CN1CCC2=C(C=NC=N2)C1.CN1CCC2=C(CC=N2)C1 Chemical compound CC1=CC2=NC=NN2C=C1.CC1=CC=C2C=CC=CC2=C1.CC1=CC=C2C=CC=CC2=N1.CC1=CC=C2C=CC=NC2=C1.CC1=CC=C2C=CN=CC2=C1.CC1=CC=C2C=NC=CC2=C1.CC1=CC=C2N=CC=CC2=C1.CC1=CC=C2N=CC=CC2=N1.CC1=CC=C2N=CC=NC2=C1.CC1=CC=C2N=CCC2=C1.CC1=CC=C2N=CN=CC2=C1.CC1=CC=C2N=COC2=C1.CC1=CC=C2N=CSC2=C1.CC1=CC=C2N=NC=CC2=C1.CC1=CN2C=CN=C2C=C1.CC1=CN2C=NN=C2C=C1.CC1=CN2N=CN=C2C=C1.CC1=CN=C2C=CC=CC2=C1.CC1=CN=C2N=CC=CC2=C1.CC1=NC=C2C=CC=CC2=C1.CC1=NC=C2N=CC=CC2=C1.CC1C2=C(CCN1C)N=CC=C2.CC1C2=C(CCN1C)N=CC=N2.CN1CCC2=C(C1)N=CC=N2.CN1CCC2=C(C1)OC=N2.CN1CCC2=C(C1)SC=N2.CN1CCC2=C(C=CC=C2)C1.CN1CCC2=C(C=CC=N2)C1.CN1CCC2=C(C=CN=N2)C1.CN1CCC2=C(C=NC=N2)C1.CN1CCC2=C(CC=N2)C1 JXEMYLOFMPAMAC-UHFFFAOYSA-N 0.000 description 1
- NWYWPUYUUNFLHG-UHFFFAOYSA-N CC1=CC2=NC=NN2C=C1.CC1=CC=C2C=CC=CC2=C1.CC1=CC=C2C=CC=CC2=N1.CC1=CC=C2C=CC=NC2=C1.CC1=CC=C2C=CN=CC2=C1.CC1=CC=C2C=NC=CC2=C1.CC1=CC=C2N=CC=CC2=C1.CC1=CC=C2N=CC=CC2=N1.CC1=CC=C2N=CC=NC2=C1.CC1=CC=C2N=CCC2=C1.CC1=CC=C2N=CN=CC2=C1.CC1=CC=C2N=COC2=C1.CC1=CC=C2N=CSC2=C1.CC1=CC=C2N=NC=CC2=C1.CC1=CN2C=CN=C2C=C1.CC1=CN2C=NN=C2C=C1.CC1=CN2N=CN=C2C=C1.CC1=CN=C2C=CC=CC2=C1.CC1=CN=C2N=CC=CC2=C1.CC1=NC=C2C=CC=CC2=C1.CC1=NC=C2N=CC=CC2=C1.CN1CCC2=C(C1)N=CC=N2.CN1CCC2=C(C=CC=C2)C1.CN1CCC2=C(C=CC=N2)C1.CN1CCC2=C(C=NC=N2)C1 Chemical compound CC1=CC2=NC=NN2C=C1.CC1=CC=C2C=CC=CC2=C1.CC1=CC=C2C=CC=CC2=N1.CC1=CC=C2C=CC=NC2=C1.CC1=CC=C2C=CN=CC2=C1.CC1=CC=C2C=NC=CC2=C1.CC1=CC=C2N=CC=CC2=C1.CC1=CC=C2N=CC=CC2=N1.CC1=CC=C2N=CC=NC2=C1.CC1=CC=C2N=CCC2=C1.CC1=CC=C2N=CN=CC2=C1.CC1=CC=C2N=COC2=C1.CC1=CC=C2N=CSC2=C1.CC1=CC=C2N=NC=CC2=C1.CC1=CN2C=CN=C2C=C1.CC1=CN2C=NN=C2C=C1.CC1=CN2N=CN=C2C=C1.CC1=CN=C2C=CC=CC2=C1.CC1=CN=C2N=CC=CC2=C1.CC1=NC=C2C=CC=CC2=C1.CC1=NC=C2N=CC=CC2=C1.CN1CCC2=C(C1)N=CC=N2.CN1CCC2=C(C=CC=C2)C1.CN1CCC2=C(C=CC=N2)C1.CN1CCC2=C(C=NC=N2)C1 NWYWPUYUUNFLHG-UHFFFAOYSA-N 0.000 description 1
- AYBXVYSSHQEQQR-UHFFFAOYSA-N CC1=CC=C2C=CC=CC2=C1.CC1=CC=C2C=CC=CC2=N1.CC1=CC=C2C=CC=NC2=C1.CC1=CC=C2C=CN=CC2=C1.CC1=CC=C2C=NC=CC2=C1.CC1=CC=C2N=CC=CC2=C1.CC1=CC=C2N=CC=CC2=N1.CC1=CC=C2N=CC=NC2=C1.CC1=CC=C2N=CCC2=C1.CC1=CC=C2N=CN=CC2=C1.CC1=CC=C2N=COC2=C1.CC1=CC=C2N=CSC2=C1.CC1=CC=C2N=NC=CC2=C1.CC1=CC=CC=C1.CC1=CC=CN=N1.CC1=CC=NC=C1.CC1=CN(C)C(=O)C=C1.CC1=CN2C=CN=C2C=C1.CC1=CN2C=NN=C2C=C1.CC1=CN2N=CN=C2C=C1.CC1=CN2N=NN=C2C=C1.CC1=CN=C2C=CC=CC2=C1.CC1=CN=C2N=CC=CC2=C1.CC1=CN=CC(Cl)=C1.CC1=CN=CC(F)=C1.CC1=CN=CC=C1.CC1=CN=CC=N1.CC1=CN=CN=C1.CC1=NC=C2C=CC=CC2=C1.CC1=NC=C2N=CC=CC2=C1.CC1=NC=C2N=CC=CC2=N1.CC1=NC=CC=C1.CC1=NN(C)C(=O)C=C1.CC1=NN2C=CN=C2C=C1.CC1=NN=C2N=CC=CC2=C1 Chemical compound CC1=CC=C2C=CC=CC2=C1.CC1=CC=C2C=CC=CC2=N1.CC1=CC=C2C=CC=NC2=C1.CC1=CC=C2C=CN=CC2=C1.CC1=CC=C2C=NC=CC2=C1.CC1=CC=C2N=CC=CC2=C1.CC1=CC=C2N=CC=CC2=N1.CC1=CC=C2N=CC=NC2=C1.CC1=CC=C2N=CCC2=C1.CC1=CC=C2N=CN=CC2=C1.CC1=CC=C2N=COC2=C1.CC1=CC=C2N=CSC2=C1.CC1=CC=C2N=NC=CC2=C1.CC1=CC=CC=C1.CC1=CC=CN=N1.CC1=CC=NC=C1.CC1=CN(C)C(=O)C=C1.CC1=CN2C=CN=C2C=C1.CC1=CN2C=NN=C2C=C1.CC1=CN2N=CN=C2C=C1.CC1=CN2N=NN=C2C=C1.CC1=CN=C2C=CC=CC2=C1.CC1=CN=C2N=CC=CC2=C1.CC1=CN=CC(Cl)=C1.CC1=CN=CC(F)=C1.CC1=CN=CC=C1.CC1=CN=CC=N1.CC1=CN=CN=C1.CC1=NC=C2C=CC=CC2=C1.CC1=NC=C2N=CC=CC2=C1.CC1=NC=C2N=CC=CC2=N1.CC1=NC=CC=C1.CC1=NN(C)C(=O)C=C1.CC1=NN2C=CN=C2C=C1.CC1=NN=C2N=CC=CC2=C1 AYBXVYSSHQEQQR-UHFFFAOYSA-N 0.000 description 1
- MMEVJSFZAQDZNL-UHFFFAOYSA-N CC1=CC=C2C=CC=CC2=C1.CC1=CC=C2C=CC=CC2=N1.CC1=CC=C2C=CC=NC2=C1.CC1=CC=C2C=CN=CC2=C1.CC1=CC=C2C=NC=CC2=C1.CC1=CC=C2N=CC=CC2=C1.CC1=CC=C2N=CC=CC2=N1.CC1=CC=C2N=CC=NC2=C1.CC1=CC=C2N=CN=CC2=C1.CC1=CC=C2N=NC=CC2=C1.CC1=CC=CC=C1.CC1=CC=CN=N1.CC1=CC=NC=C1.CC1=CN(C)C(=O)C=C1.CC1=CN=C2C=CC=CC2=C1.CC1=CN=C2N=CC=CC2=C1.CC1=CN=CC(Cl)=C1.CC1=CN=CC(F)=C1.CC1=CN=CC=C1.CC1=CN=CC=N1.CC1=CN=CN=C1.CC1=NC=C2C=CC=CC2=C1.CC1=NC=C2N=CC=CC2=C1.CC1=NC=C2N=CC=CC2=N1.CC1=NC=CC=C1.CC1=NN(C)C(=O)C=C1.CC1=NN=C2N=CC=CC2=C1 Chemical compound CC1=CC=C2C=CC=CC2=C1.CC1=CC=C2C=CC=CC2=N1.CC1=CC=C2C=CC=NC2=C1.CC1=CC=C2C=CN=CC2=C1.CC1=CC=C2C=NC=CC2=C1.CC1=CC=C2N=CC=CC2=C1.CC1=CC=C2N=CC=CC2=N1.CC1=CC=C2N=CC=NC2=C1.CC1=CC=C2N=CN=CC2=C1.CC1=CC=C2N=NC=CC2=C1.CC1=CC=CC=C1.CC1=CC=CN=N1.CC1=CC=NC=C1.CC1=CN(C)C(=O)C=C1.CC1=CN=C2C=CC=CC2=C1.CC1=CN=C2N=CC=CC2=C1.CC1=CN=CC(Cl)=C1.CC1=CN=CC(F)=C1.CC1=CN=CC=C1.CC1=CN=CC=N1.CC1=CN=CN=C1.CC1=NC=C2C=CC=CC2=C1.CC1=NC=C2N=CC=CC2=C1.CC1=NC=C2N=CC=CC2=N1.CC1=NC=CC=C1.CC1=NN(C)C(=O)C=C1.CC1=NN=C2N=CC=CC2=C1 MMEVJSFZAQDZNL-UHFFFAOYSA-N 0.000 description 1
- RCRVECCRJGDXIJ-UHFFFAOYSA-N CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CC=NO1.CC1=CC=NS1.CC1=CN(C)N=C1.CC1=CN=CN1.CC1=CN=NN1.CC1=CN=NO1.CC1=CN=NS1.CC1=CON=C1.CC1=CSN=C1.CC1=NN=CN1.CC1=NN=CO1.CC1=NN=CS1.CC1=NN=NN1.CC1=NNN=N1.CN1C=CN=C1.CN1C=CN=N1.CN1C=NC=N1.CN1C=NN=C1 Chemical compound CC1=CC=NC=C1.CC1=CC=NC=N1.CC1=CC=NN1C.CC1=CC=NN=C1.CC1=CC=NO1.CC1=CC=NS1.CC1=CN(C)N=C1.CC1=CN=CN1.CC1=CN=NN1.CC1=CN=NO1.CC1=CN=NS1.CC1=CON=C1.CC1=CSN=C1.CC1=NN=CN1.CC1=NN=CO1.CC1=NN=CS1.CC1=NN=NN1.CC1=NNN=N1.CN1C=CN=C1.CN1C=CN=N1.CN1C=NC=N1.CN1C=NN=C1 RCRVECCRJGDXIJ-UHFFFAOYSA-N 0.000 description 1
- KNJLNVKKMWINEX-UHFFFAOYSA-N CC1=N(=O)C=CC(C2=CC=C(CNC3=C(F)C(Cl)=NC=N3)C=C2)=C1.CC1=NC=CC(C2=CC=C(CNC3=C(F)C(Cl)=NC=N3)C=C2)=C1 Chemical compound CC1=N(=O)C=CC(C2=CC=C(CNC3=C(F)C(Cl)=NC=N3)C=C2)=C1.CC1=NC=CC(C2=CC=C(CNC3=C(F)C(Cl)=NC=N3)C=C2)=C1 KNJLNVKKMWINEX-UHFFFAOYSA-N 0.000 description 1
- LCVXMATYMNMDQU-UHFFFAOYSA-N CC1=NC=C2N=CC=CC2=C1.C[SnH](C)C.C[SnH](C)C.C[Sn](C)(C)C1=CC2=C(C=N1)N=CC=C2 Chemical compound CC1=NC=C2N=CC=CC2=C1.C[SnH](C)C.C[SnH](C)C.C[Sn](C)(C)C1=CC2=C(C=N1)N=CC=C2 LCVXMATYMNMDQU-UHFFFAOYSA-N 0.000 description 1
- AUJDSMPXAQQKFT-UHFFFAOYSA-N CC1=NC=C2N=CC=CC2=C1.FC1=NC=CC(C2=NC=C3N=CC=CC3=C2)=C1F.NC1=C(B(O)O)C=CN=C1F Chemical compound CC1=NC=C2N=CC=CC2=C1.FC1=NC=CC(C2=NC=C3N=CC=CC3=C2)=C1F.NC1=C(B(O)O)C=CN=C1F AUJDSMPXAQQKFT-UHFFFAOYSA-N 0.000 description 1
- MVQDNBFOQUXCNX-UHFFFAOYSA-N CC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1.CC1=NC=CC(C2=C(C#N)C=C(CN)C=N2)=C1.N#CC1=C(Br)N=CC(CN)=C1 Chemical compound CC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1.CC1=NC=CC(C2=C(C#N)C=C(CN)C=N2)=C1.N#CC1=C(Br)N=CC(CN)=C1 MVQDNBFOQUXCNX-UHFFFAOYSA-N 0.000 description 1
- LJISTCCNPLSDJU-UHFFFAOYSA-N CC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1.CC1=NC=CC(C2=C(F)C=C(CN)C=N2)=C1.NCC1=CC(F)=C(Cl)N=C1 Chemical compound CC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1.CC1=NC=CC(C2=C(F)C=C(CN)C=N2)=C1.NCC1=CC(F)=C(Cl)N=C1 LJISTCCNPLSDJU-UHFFFAOYSA-N 0.000 description 1
- GDXWIHCPWSTLQA-UHFFFAOYSA-N CC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1.CC1=NC=CC(C2=NC=C(CN)C=N2)=C1.NCC1=CN=C(Cl)N=C1 Chemical compound CC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1.CC1=NC=CC(C2=NC=C(CN)C=N2)=C1.NCC1=CN=C(Cl)N=C1 GDXWIHCPWSTLQA-UHFFFAOYSA-N 0.000 description 1
- XVYLTEIUYPZFAK-UHFFFAOYSA-N CC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1.COC1=C(C2=CC(C)=NC=C2)N=CC(CN)=C1.COC1=C(I)N=CC(CN)=C1 Chemical compound CC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1.COC1=C(C2=CC(C)=NC=C2)N=CC(CN)=C1.COC1=C(I)N=CC(CN)=C1 XVYLTEIUYPZFAK-UHFFFAOYSA-N 0.000 description 1
- YFWPSLBOGPBVFN-UHFFFAOYSA-N CC1=NC=CC(C2=C(C#N)C=C(CN)C=N2)=C1.CC1=NC=CC(C2=C(C#N)C=C(CNC3=NC(C4=CC5=C(C=N4)N=CC=C5)=CC=N3)C=N2)=C1.CS(=O)(=O)C1=NC(C2=C/C3=C(\C=N/2)N=CC=C3)=CC=N1 Chemical compound CC1=NC=CC(C2=C(C#N)C=C(CN)C=N2)=C1.CC1=NC=CC(C2=C(C#N)C=C(CNC3=NC(C4=CC5=C(C=N4)N=CC=C5)=CC=N3)C=N2)=C1.CS(=O)(=O)C1=NC(C2=C/C3=C(\C=N/2)N=CC=C3)=CC=N1 YFWPSLBOGPBVFN-UHFFFAOYSA-N 0.000 description 1
- TZZGRUYHMZJBRX-UHFFFAOYSA-N CC1=NC=CC(C2=C(C#N)C=C(CN)C=N2)=C1.CC1=NC=CC(C2=C(C#N)C=C(CNC3=NC=CC(C4=NC=C5N=CC=CC5=C4)=C3F)C=N2)=C1.FC1=NC=CC(C2=NC=C3N=CC=CC3=C2)=C1F Chemical compound CC1=NC=CC(C2=C(C#N)C=C(CN)C=N2)=C1.CC1=NC=CC(C2=C(C#N)C=C(CNC3=NC=CC(C4=NC=C5N=CC=CC5=C4)=C3F)C=N2)=C1.FC1=NC=CC(C2=NC=C3N=CC=CC3=C2)=C1F TZZGRUYHMZJBRX-UHFFFAOYSA-N 0.000 description 1
- SGXKPQYVCHOILL-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CN)C=N2)=C1.CC1=NC=CC(C2=C(F)C=C(CNC3=C(F)C(Cl)=NC=N3)C=N2)=C1.FC1=C(Cl)N=CN=C1Cl Chemical compound CC1=NC=CC(C2=C(F)C=C(CN)C=N2)=C1.CC1=NC=CC(C2=C(F)C=C(CNC3=C(F)C(Cl)=NC=N3)C=N2)=C1.FC1=C(Cl)N=CN=C1Cl SGXKPQYVCHOILL-UHFFFAOYSA-N 0.000 description 1
- BNIZLDNYSHABFZ-UHFFFAOYSA-N CC1=NC=CC(C2=C(F)C=C(CN)C=N2)=C1.CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(C4=NC=C5N=CC=CC5=C4)=C3F)C=N2)=C1.OC1=NC=NC(C2=NC=C3N=CC=CC3=C2)=C1F Chemical compound CC1=NC=CC(C2=C(F)C=C(CN)C=N2)=C1.CC1=NC=CC(C2=C(F)C=C(CNC3=NC=NC(C4=NC=C5N=CC=CC5=C4)=C3F)C=N2)=C1.OC1=NC=NC(C2=NC=C3N=CC=CC3=C2)=C1F BNIZLDNYSHABFZ-UHFFFAOYSA-N 0.000 description 1
- ZDDJOMKVBOLWGY-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CN(C)C3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1.CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CN(C)C3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1.CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1 ZDDJOMKVBOLWGY-UHFFFAOYSA-N 0.000 description 1
- GSHJMCGLQGBUHU-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CN)C=C2)=C1.CC1=NC=CC(C2=CC=C(CNC3=C(F)C(Cl)=NC=N3)C=C2)=C1.FC1=C(Cl)N=CN=C1Cl Chemical compound CC1=NC=CC(C2=CC=C(CN)C=C2)=C1.CC1=NC=CC(C2=CC=C(CNC3=C(F)C(Cl)=NC=N3)C=C2)=C1.FC1=C(Cl)N=CN=C1Cl GSHJMCGLQGBUHU-UHFFFAOYSA-N 0.000 description 1
- DEEAZGHECBMYSP-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC5=CN(C)N=C5C=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC5=CN(C)N=C5C=C4)=NC=N3)C=C2)=C1 DEEAZGHECBMYSP-UHFFFAOYSA-N 0.000 description 1
- OOXFMBGVFMAASA-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1.CC1=NC=CC(C2=CC=C(CNC3=C(F)C(Cl)=NC=N3)C=C2)=C1.OB(O)C1=CC=C2C=CC=CC2=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5C=CC=CC5=C4)=NC=N3)C=C2)=C1.CC1=NC=CC(C2=CC=C(CNC3=C(F)C(Cl)=NC=N3)C=C2)=C1.OB(O)C1=CC=C2C=CC=CC2=C1 OOXFMBGVFMAASA-UHFFFAOYSA-N 0.000 description 1
- RGVYMRDJOUHZDQ-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=NC5=C4)=CC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=NC5=C4)=CC=N3)C=C2)=C1 RGVYMRDJOUHZDQ-UHFFFAOYSA-N 0.000 description 1
- IYDJQRIDHBANEJ-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=NC5=C4)=NC=N3)C=C2)=C1 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=NC5=C4)=NC=N3)C=C2)=C1 IYDJQRIDHBANEJ-UHFFFAOYSA-N 0.000 description 1
- PWUQDTUOEJFUDB-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(Cl)=NC=N3)C=C2)=C1.CSC1=NC2=C(C=N1)C(=O)N(C1=NC=NC(NCC3=CC=C(C4=CC(C)=NC=C4)C=C3)=C1)CC2.CSC1=NC2=C(C=N1)C(=O)NCC2 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(Cl)=NC=N3)C=C2)=C1.CSC1=NC2=C(C=N1)C(=O)N(C1=NC=NC(NCC3=CC=C(C4=CC(C)=NC=C4)C=C3)=C1)CC2.CSC1=NC2=C(C=N1)C(=O)NCC2 PWUQDTUOEJFUDB-UHFFFAOYSA-N 0.000 description 1
- JDLZFUMNMNFVML-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(N4CCC5=C(C=NC(S(C)(=O)=O)=N5)C4=O)=NC=N3)C=C2)=C1.CN.CNC1=NC2=C(C=N1)C(=O)N(C1=NC=NC(NCC3=CC=C(C4=CC(C)=NC=C4)C=C3)=C1)CC2.Cl Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(N4CCC5=C(C=NC(S(C)(=O)=O)=N5)C4=O)=NC=N3)C=C2)=C1.CN.CNC1=NC2=C(C=N1)C(=O)N(C1=NC=NC(NCC3=CC=C(C4=CC(C)=NC=C4)C=C3)=C1)CC2.Cl JDLZFUMNMNFVML-UHFFFAOYSA-N 0.000 description 1
- QNTTVSNYNJOAIP-UHFFFAOYSA-N CC1=NC=CC(C2=CC=C(CNC3=CC(N4CCC5=C(C=NC(S(C)(=O)=O)=N5)C4=O)=NC=N3)C=C2)=C1.CSC1=NC2=C(C=N1)C(=O)N(C1=NC=NC(NCC3=CC=C(C4=CC(C)=NC=C4)C=C3)=C1)CC2 Chemical compound CC1=NC=CC(C2=CC=C(CNC3=CC(N4CCC5=C(C=NC(S(C)(=O)=O)=N5)C4=O)=NC=N3)C=C2)=C1.CSC1=NC2=C(C=N1)C(=O)N(C1=NC=NC(NCC3=CC=C(C4=CC(C)=NC=C4)C=C3)=C1)CC2 QNTTVSNYNJOAIP-UHFFFAOYSA-N 0.000 description 1
- UQYHBKKNCOZGFC-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CN)C=C2F)=C1.CC1=NC=CC(C2=NC=C(CNC3=NC=CC(N4CCC5=C(C=CC=N5)C4)=C3F)C=C2F)=C1.FC1=NC=CC(N2CCC3=C(C=CC=N3)C2)=C1F Chemical compound CC1=NC=CC(C2=NC=C(CN)C=C2F)=C1.CC1=NC=CC(C2=NC=C(CNC3=NC=CC(N4CCC5=C(C=CC=N5)C4)=C3F)C=C2F)=C1.FC1=NC=CC(N2CCC3=C(C=CC=N3)C2)=C1F UQYHBKKNCOZGFC-UHFFFAOYSA-N 0.000 description 1
- RMSMOCXVYWMMBY-UHFFFAOYSA-N CC1=NC=CC(C2=NC=C(CN)C=N2)=C1.CC1=NC=CC(C2=NC=C(CNC3=C(F)C(Cl)=NC=N3)C=N2)=C1.FC1=C(Cl)N=CN=C1Cl Chemical compound CC1=NC=CC(C2=NC=C(CN)C=N2)=C1.CC1=NC=CC(C2=NC=C(CNC3=C(F)C(Cl)=NC=N3)C=N2)=C1.FC1=C(Cl)N=CN=C1Cl RMSMOCXVYWMMBY-UHFFFAOYSA-N 0.000 description 1
- RAVXUBDLEUFQMP-UHFFFAOYSA-N CC=1C=NC2=CC(=CC=C2C=1)C#N Chemical compound CC=1C=NC2=CC(=CC=C2C=1)C#N RAVXUBDLEUFQMP-UHFFFAOYSA-N 0.000 description 1
- SHKQZQQJLVCWRD-UHFFFAOYSA-N CCN(CC)CC.CCOC(=O)C1=C(F)C(Cl)=NC=N1.CCOC(=O)C1=C(F)C(OC)=NC=N1 Chemical compound CCN(CC)CC.CCOC(=O)C1=C(F)C(Cl)=NC=N1.CCOC(=O)C1=C(F)C(OC)=NC=N1 SHKQZQQJLVCWRD-UHFFFAOYSA-N 0.000 description 1
- YJROLRXWXOTPAO-UHFFFAOYSA-N CCOC(=O)C1=C(F)C(Cl)=NC=N1.CCOC(=O)C1=C(F)C(O)=NC=N1.O=C(Cl)C1OCl1 Chemical compound CCOC(=O)C1=C(F)C(Cl)=NC=N1.CCOC(=O)C1=C(F)C(O)=NC=N1.O=C(Cl)C1OCl1 YJROLRXWXOTPAO-UHFFFAOYSA-N 0.000 description 1
- WQICQQXJBDESFT-UHFFFAOYSA-N COC(=O)C1=CC(OC)=C(I)N=C1.COC1=C(I)N=CC(CO)=C1 Chemical compound COC(=O)C1=CC(OC)=C(I)N=C1.COC1=C(I)N=CC(CO)=C1 WQICQQXJBDESFT-UHFFFAOYSA-N 0.000 description 1
- BXAYORVPSRENGY-UHFFFAOYSA-N COC1=C(C2=CC(C)=NC=C2)N=CC(CN)=C1.COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(C3=CC4=C(C=N3)N=CC=C4)=N2)=C1.ClC1=NSC(C2=CC3=C(C=N2)N=CC=C3)=N1 Chemical compound COC1=C(C2=CC(C)=NC=C2)N=CC(CN)=C1.COC1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(C3=CC4=C(C=N3)N=CC=C4)=N2)=C1.ClC1=NSC(C2=CC3=C(C=N2)N=CC=C3)=N1 BXAYORVPSRENGY-UHFFFAOYSA-N 0.000 description 1
- LQMGPKYISHCUAX-UHFFFAOYSA-N COC1=C(I)N=CC(CN)=C1.COC1=C(I)N=CC(CN=[N+]=[N-])=C1 Chemical compound COC1=C(I)N=CC(CN)=C1.COC1=C(I)N=CC(CN=[N+]=[N-])=C1 LQMGPKYISHCUAX-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOXLHSXNIH-UHFFFAOYSA-N COC1=C(I)N=CC(CN=[N+]=[N-])=C1.COC1=C(I)N=CC(CO)=C1 Chemical compound COC1=C(I)N=CC(CN=[N+]=[N-])=C1.COC1=C(I)N=CC(CO)=C1 ZXDDPOXLHSXNIH-UHFFFAOYSA-N 0.000 description 1
- MMVSRSQIWFAQBH-UHFFFAOYSA-N COC1=NC=NC(C2=NC(Cl)=C3N=CC=CC3=C2)=C1F.COC1=NC=NC(C2=NC(O)=C3N=CC=CC3=C2)=C1F.O=P(Cl)(Cl)Cl Chemical compound COC1=NC=NC(C2=NC(Cl)=C3N=CC=CC3=C2)=C1F.COC1=NC=NC(C2=NC(O)=C3N=CC=CC3=C2)=C1F.O=P(Cl)(Cl)Cl MMVSRSQIWFAQBH-UHFFFAOYSA-N 0.000 description 1
- FYKHXGOFCAABFE-UHFFFAOYSA-N CS(=O)(=O)C1=NC(C2=C/C3=C(\C=N/2)N=CC=C3)=CC=N1.CSC1=NC(C2=C/C3=C(\C=N/2)N=CC=C3)=CC=N1 Chemical compound CS(=O)(=O)C1=NC(C2=C/C3=C(\C=N/2)N=CC=C3)=CC=N1.CSC1=NC(C2=C/C3=C(\C=N/2)N=CC=C3)=CC=N1 FYKHXGOFCAABFE-UHFFFAOYSA-N 0.000 description 1
- HTWQKYCGXVDDMX-UHFFFAOYSA-N CS(=O)(=O)C1=NC=CC(C2=CC=C3N=CC=CC3=C2)=N1.CSC1=NC=CC(C2=CC=C3N=CC=CC3=C2)=N1 Chemical compound CS(=O)(=O)C1=NC=CC(C2=CC=C3N=CC=CC3=C2)=N1.CSC1=NC=CC(C2=CC=C3N=CC=CC3=C2)=N1 HTWQKYCGXVDDMX-UHFFFAOYSA-N 0.000 description 1
- XXQQZLVWLNEXSS-UHFFFAOYSA-N CS(=O)(=O)C1=NC=CC(C2=CC=C3N=CC=CC3=C2)=N1.N#CC1=CC2=CC=C(CN)C=C2N=C1.N#CC1=CC2=CC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2N=C1 Chemical compound CS(=O)(=O)C1=NC=CC(C2=CC=C3N=CC=CC3=C2)=N1.N#CC1=CC2=CC=C(CN)C=C2N=C1.N#CC1=CC2=CC=C(CNC3=NC(C4=CC5=C(C=C4)N=CC=C5)=CC=N3)C=C2N=C1 XXQQZLVWLNEXSS-UHFFFAOYSA-N 0.000 description 1
- QTAXGRLZURPGBQ-UHFFFAOYSA-N CSC1=NC(C(=O)CC2=C(C(=O)NC(C)(C)C)N=CC=C2)=CC=N1.CSC1=NC(C2=C/C3=C(N=CC=C3)/C(O)=N\2)=CC=N1 Chemical compound CSC1=NC(C(=O)CC2=C(C(=O)NC(C)(C)C)N=CC=C2)=CC=N1.CSC1=NC(C2=C/C3=C(N=CC=C3)/C(O)=N\2)=CC=N1 QTAXGRLZURPGBQ-UHFFFAOYSA-N 0.000 description 1
- GLPQPCCCWPYDRM-UHFFFAOYSA-N CSC1=NC(C2=C/C3=C(N=CC=C3)/C(Cl)=N\2)=CC=N1.CSC1=NC(C2=C/C3=C(N=CC=C3)/C(O)=N\2)=CC=N1.O=P(Cl)(Cl)Cl Chemical compound CSC1=NC(C2=C/C3=C(N=CC=C3)/C(Cl)=N\2)=CC=N1.CSC1=NC(C2=C/C3=C(N=CC=C3)/C(O)=N\2)=CC=N1.O=P(Cl)(Cl)Cl GLPQPCCCWPYDRM-UHFFFAOYSA-N 0.000 description 1
- VOGYYFMHNQNTRG-UHFFFAOYSA-N CSC1=NC(C2=C/C3=C(N=CC=C3)/C(Cl)=N\2)=CC=N1.CSC1=NC(C2=C/C3=C(\C=N/2)N=CC=C3)=CC=N1 Chemical compound CSC1=NC(C2=C/C3=C(N=CC=C3)/C(Cl)=N\2)=CC=N1.CSC1=NC(C2=C/C3=C(\C=N/2)N=CC=C3)=CC=N1 VOGYYFMHNQNTRG-UHFFFAOYSA-N 0.000 description 1
- DFOHHQRGDOQMKG-UHFFFAOYSA-N CSc1nccc(Cl)n1 Chemical compound CSc1nccc(Cl)n1 DFOHHQRGDOQMKG-UHFFFAOYSA-N 0.000 description 1
- LNVCMEAIDBQCJY-UHFFFAOYSA-N C[Sn](C)(C)C1=CC2=C(C=N1)N=CC=C2.ClC1=NSC(C2=CC3=C(C=N2)N=CC=C3)=N1.ClC1=NSC(Cl)=N1 Chemical compound C[Sn](C)(C)C1=CC2=C(C=N1)N=CC=C2.ClC1=NSC(C2=CC3=C(C=N2)N=CC=C3)=N1.ClC1=NSC(Cl)=N1 LNVCMEAIDBQCJY-UHFFFAOYSA-N 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 description 1
- PGGUINJHKQXRJU-UHFFFAOYSA-N Cc1nccc(-c(ncc(CNc(nccc2-c(cc3)nc4c3nccc4)c2F)c2)c2C#N)c1 Chemical compound Cc1nccc(-c(ncc(CNc(nccc2-c(cc3)nc4c3nccc4)c2F)c2)c2C#N)c1 PGGUINJHKQXRJU-UHFFFAOYSA-N 0.000 description 1
- GTHJJRVBBARXEH-UHFFFAOYSA-N Cc1nccc(-c(ncc(CNc(ncnc2-c(nc3)cc4c3nccc4)c2F)c2)c2C#N)c1 Chemical compound Cc1nccc(-c(ncc(CNc(ncnc2-c(nc3)cc4c3nccc4)c2F)c2)c2C#N)c1 GTHJJRVBBARXEH-UHFFFAOYSA-N 0.000 description 1
- JPIUTABWPPZAQV-UHFFFAOYSA-N Cc1nccc(-c(ncc(CNc(ncnc2N3Cc4cnn[n]4CC3)c2F)c2)c2C#N)c1 Chemical compound Cc1nccc(-c(ncc(CNc(ncnc2N3Cc4cnn[n]4CC3)c2F)c2)c2C#N)c1 JPIUTABWPPZAQV-UHFFFAOYSA-N 0.000 description 1
- RFTUXKCGULRGMX-UHFFFAOYSA-N Cc1nccc(-c2ccnc(NCc3cc(C#N)c(-c4cc(C)ncc4)nc3)c2F)c1 Chemical compound Cc1nccc(-c2ccnc(NCc3cc(C#N)c(-c4cc(C)ncc4)nc3)c2F)c1 RFTUXKCGULRGMX-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ZXZLMQIXYSYHOS-UHFFFAOYSA-N ClC1=CC(=NC=N1)NCC1=CC=C(C=C1)C1=CC(=NC=C1)C Chemical compound ClC1=CC(=NC=N1)NCC1=CC=C(C=C1)C1=CC(=NC=C1)C ZXZLMQIXYSYHOS-UHFFFAOYSA-N 0.000 description 1
- RFOVTIFFCIUBEC-UHFFFAOYSA-N ClC1=CC=C2N=CC=CC2=N1.FC1=NC=CC(C2=CC=C3N=CC=CC3=N2)=C1F.OB(O)C1=C(F)C(F)=NC=C1 Chemical compound ClC1=CC=C2N=CC=CC2=N1.FC1=NC=CC(C2=CC=C3N=CC=CC3=N2)=C1F.OB(O)C1=C(F)C(F)=NC=C1 RFOVTIFFCIUBEC-UHFFFAOYSA-N 0.000 description 1
- UKSPBXMYYVSEIZ-UHFFFAOYSA-N ClC1=NSC(C2=CC=C3N=CC=CC3=C2)=N1.[C-]#[N+]C1=CC2=C(C=C1)C=C(CN)C=N2.[C-]#[N+]C1=CC2=C(C=C1)C=C(CNC1=NSC(C3=CC=C4N=CC=CC4=C3)=N1)C=N2 Chemical compound ClC1=NSC(C2=CC=C3N=CC=CC3=C2)=N1.[C-]#[N+]C1=CC2=C(C=C1)C=C(CN)C=N2.[C-]#[N+]C1=CC2=C(C=C1)C=C(CNC1=NSC(C3=CC=C4N=CC=CC4=C3)=N1)C=N2 UKSPBXMYYVSEIZ-UHFFFAOYSA-N 0.000 description 1
- SCFWNCLOEBEJFX-UHFFFAOYSA-N ClC1=NSC(N2CCC3=C(C=CC=N3)C2)=N1.[C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CN)=C1.[C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(N3CCC4=C(C=CC=N4)C3)=N2)=C1 Chemical compound ClC1=NSC(N2CCC3=C(C=CC=N3)C2)=N1.[C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CN)=C1.[C-]#[N+]C1=C(C2=CC(C)=NC=C2)N=CC(CNC2=NSC(N3CCC4=C(C=CC=N4)C3)=N2)=C1 SCFWNCLOEBEJFX-UHFFFAOYSA-N 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102000017944 Dishevelled Human genes 0.000 description 1
- 108050007016 Dishevelled Proteins 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- BDHQWOUODRZXFG-UHFFFAOYSA-N FC1=C(Cl)N=CN=C1Cl.N#CC1=CC2=C(C=C1)C=C(CNC1=C(F)C(Cl)=NC=N1)C=C2.N#CC1=CC=C2C=C(CN)C=CC2=C1 Chemical compound FC1=C(Cl)N=CN=C1Cl.N#CC1=CC2=C(C=C1)C=C(CNC1=C(F)C(Cl)=NC=N1)C=C2.N#CC1=CC=C2C=C(CN)C=CC2=C1 BDHQWOUODRZXFG-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 description 1
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 108010015167 Low Density Lipoprotein Receptor-Related Protein-5 Proteins 0.000 description 1
- 102000001770 Low Density Lipoprotein Receptor-Related Protein-5 Human genes 0.000 description 1
- 102000001774 Low Density Lipoprotein Receptor-Related Protein-6 Human genes 0.000 description 1
- 108010015179 Low Density Lipoprotein Receptor-Related Protein-6 Proteins 0.000 description 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- SVYSLSAPNYQOMU-UHFFFAOYSA-N N#CC1=C(Br)N=CC(CBr)=C1.N#CC1=C(Br)N=CC(CN)=C1 Chemical compound N#CC1=C(Br)N=CC(CBr)=C1.N#CC1=C(Br)N=CC(CN)=C1 SVYSLSAPNYQOMU-UHFFFAOYSA-N 0.000 description 1
- CQIUDPZNLRRDKS-UHFFFAOYSA-N N#CC1=CC2=C(C=C1)C=C(CNC1=C(F)C(C3=CC=C4N=CC=CC4=C3)=NC=N1)C=C2.NC(=O)C1=CC2=C(C=C1)C=C(CNC1=C(F)C(C3=CC=C4N=CC=CC4=C3)=NC=N1)C=C2 Chemical compound N#CC1=CC2=C(C=C1)C=C(CNC1=C(F)C(C3=CC=C4N=CC=CC4=C3)=NC=N1)C=C2.NC(=O)C1=CC2=C(C=C1)C=C(CNC1=C(F)C(C3=CC=C4N=CC=CC4=C3)=NC=N1)C=C2 CQIUDPZNLRRDKS-UHFFFAOYSA-N 0.000 description 1
- FJRJHNDUHYLIAS-UHFFFAOYSA-N N#CC1=CC=C2C=C(CN)C=CC2=C1.N#CC1=CC=C2C=C(OS(=O)(=O)C(F)(F)F)C=CC2=C1 Chemical compound N#CC1=CC=C2C=C(CN)C=CC2=C1.N#CC1=CC=C2C=C(OS(=O)(=O)C(F)(F)F)C=CC2=C1 FJRJHNDUHYLIAS-UHFFFAOYSA-N 0.000 description 1
- RMFKJJIHTNMDTK-UHFFFAOYSA-N N#Cc(cc1)cnc1NCCNc(nccc1-c2ccc3ncccc3c2)c1F Chemical compound N#Cc(cc1)cnc1NCCNc(nccc1-c2ccc3ncccc3c2)c1F RMFKJJIHTNMDTK-UHFFFAOYSA-N 0.000 description 1
- JZBXGRQSXAKOOI-UHFFFAOYSA-N N#Cc1cc2ccc(CNc(nccc3-c4ccc5ncccc5c4)c3F)nc2cc1 Chemical compound N#Cc1cc2ccc(CNc(nccc3-c4ccc5ncccc5c4)c3F)nc2cc1 JZBXGRQSXAKOOI-UHFFFAOYSA-N 0.000 description 1
- WLKMIQJRDPDMKW-UHFFFAOYSA-N N#Cc1cc2ncc(CNc(ncnc3N(CC4)Cc5c4nccc5)c3F)cc2cc1 Chemical compound N#Cc1cc2ncc(CNc(ncnc3N(CC4)Cc5c4nccc5)c3F)cc2cc1 WLKMIQJRDPDMKW-UHFFFAOYSA-N 0.000 description 1
- GMFNWPGLESUBJB-UHFFFAOYSA-N NC1=NC=CC(C2=CC3=CC=CC=C3C=C2)=C1.NC1=NC=CC(Cl)=C1.OB(O)C1=CC2=CC=CC=C2C=C1 Chemical compound NC1=NC=CC(C2=CC3=CC=CC=C3C=C2)=C1.NC1=NC=CC(Cl)=C1.OB(O)C1=CC2=CC=CC=C2C=C1 GMFNWPGLESUBJB-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 102100021709 Rho guanine nucleotide exchange factor 4 Human genes 0.000 description 1
- 101710128386 Rho guanine nucleotide exchange factor 4 Proteins 0.000 description 1
- 102000000763 Survivin Human genes 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 102000000479 TCF Transcription Factors Human genes 0.000 description 1
- 108010016283 TCF Transcription Factors Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- UCPYNZJOMGURGF-UHFFFAOYSA-N [4-(2-methylpyridin-4-yl)phenyl]methanamine Chemical compound C1=NC(C)=CC(C=2C=CC(CN)=CC=2)=C1 UCPYNZJOMGURGF-UHFFFAOYSA-N 0.000 description 1
- ZFMIOEREPMZNFV-UHFFFAOYSA-N [C-]#[N+]C1=CC(CNC2=C(F)C(N3CCC4=C(C=CC=N4)C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 Chemical compound [C-]#[N+]C1=CC(CNC2=C(F)C(N3CCC4=C(C=CC=N4)C3)=NC=N2)=CN=C1C1=CC(C)=NC=C1 ZFMIOEREPMZNFV-UHFFFAOYSA-N 0.000 description 1
- HKRUZFKRSIJWES-UHFFFAOYSA-N [C-]#[N+]C1=CC2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=C2C=C1 Chemical compound [C-]#[N+]C1=CC2=CC=C(CNC3=C(F)C(C4=CC=C5N=CC=CC5=C4)=NC=N3)C=C2C=C1 HKRUZFKRSIJWES-UHFFFAOYSA-N 0.000 description 1
- RUBMEDBZVHPDSD-UHFFFAOYSA-N [C-]#[N+]C1=CC=C2C=C(C)C=NC2=C1.[C-]#[N+]C1=CC=C2C=C(CBr)C=NC2=C1 Chemical compound [C-]#[N+]C1=CC=C2C=C(C)C=NC2=C1.[C-]#[N+]C1=CC=C2C=C(CBr)C=NC2=C1 RUBMEDBZVHPDSD-UHFFFAOYSA-N 0.000 description 1
- BUIKPAXHVNVCOJ-UHFFFAOYSA-N [C-]#[N+]C1=CC=C2C=C(CBr)C=NC2=C1.[C-]#[N+]C1=CC=C2C=C(CN=[N+]=[N-])C=NC2=C1 Chemical compound [C-]#[N+]C1=CC=C2C=C(CBr)C=NC2=C1.[C-]#[N+]C1=CC=C2C=C(CN=[N+]=[N-])C=NC2=C1 BUIKPAXHVNVCOJ-UHFFFAOYSA-N 0.000 description 1
- RIENLJAKVULPJY-UHFFFAOYSA-N [C-]#[N+]C1=CC=C2C=C(CN)C=NC2=C1.[C-]#[N+]C1=CC=C2C=C(CN=[N+]=[N-])C=NC2=C1 Chemical compound [C-]#[N+]C1=CC=C2C=C(CN)C=NC2=C1.[C-]#[N+]C1=CC=C2C=C(CN=[N+]=[N-])C=NC2=C1 RIENLJAKVULPJY-UHFFFAOYSA-N 0.000 description 1
- XPDJPDPEHXBKNO-UHFFFAOYSA-N [C-]#[N+]C1=CN=C2C=C(C)C=CC2=C1.[C-]#[N+]C1=CN=C2C=C(CBr)C=CC2=C1 Chemical compound [C-]#[N+]C1=CN=C2C=C(C)C=CC2=C1.[C-]#[N+]C1=CN=C2C=C(CBr)C=CC2=C1 XPDJPDPEHXBKNO-UHFFFAOYSA-N 0.000 description 1
- AODPYIJFPSLWRD-UHFFFAOYSA-N [C-]#[N+]C1=CN=C2C=C(CBr)C=CC2=C1.[C-]#[N+]C1=CN=C2C=C(CN=[N+]=[N-])C=CC2=C1 Chemical compound [C-]#[N+]C1=CN=C2C=C(CBr)C=CC2=C1.[C-]#[N+]C1=CN=C2C=C(CN=[N+]=[N-])C=CC2=C1 AODPYIJFPSLWRD-UHFFFAOYSA-N 0.000 description 1
- OYDWCABJGDYYSK-UHFFFAOYSA-N [C-]#[N+]C1=CN=C2C=C(CN)C=CC2=C1.[C-]#[N+]C1=CN=C2C=C(CN=[N+]=[N-])C=CC2=C1 Chemical compound [C-]#[N+]C1=CN=C2C=C(CN)C=CC2=C1.[C-]#[N+]C1=CN=C2C=C(CN=[N+]=[N-])C=CC2=C1 OYDWCABJGDYYSK-UHFFFAOYSA-N 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- DOJUQNDTUGUKLL-UHFFFAOYSA-N ethyl 2-methylsulfanylpyrimidine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(SC)=N1 DOJUQNDTUGUKLL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001647 gastrula Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000009459 hedgehog signaling Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- IXWUNGYYIXCLLJ-UHFFFAOYSA-N methyl 6-iodo-5-methoxypyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(I)C(OC)=C1 IXWUNGYYIXCLLJ-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention generally relates to heterocyclic compounds and, more particularly, relates to novel heterocyclic compounds that are useful in therapies targeting the Wnt signaling pathway mediated diseases, such as cancer, in mammals.
- the Wnt signaling pathway has critical roles in developmental pathways, including regulatory roles in cell proliferation, tissue patterning, and cell fate, migration, morphogenesis and function, as well as cell survival and degeneration (Logan and Nusse, Annu. Rev. Cell Dev. Biol . (2004) 20:781-810). Recently during research on stem cells, Wnt signaling pathway has been found to regulate the maintenance of epidermal stem cells, intestinal stem cells, hematopoietic stem cells, neural stem cells, embryonic stem cells and tumor stem cells (Reya and Clevers, Nature (2005) 434:843-850).
- the canonical Wnt signaling pathway is activated by Wnt proteins that interact with seven-pass transmembrane receptors of the Frizzled (Fzd) family and single-pass transmembrane co-receptors, such as lipoprotein receptor-related protein 5/6 (LRP5/6).
- Wnt proteins that interact with seven-pass transmembrane receptors of the Frizzled (Fzd) family and single-pass transmembrane co-receptors, such as lipoprotein receptor-related protein 5/6 (LRP5/6).
- Such interaction activates the Wnt signaling pathway by recruiting and activating the Dishevelled (Dvl) protein, which, in turn, silences glycogen synthase kinase 3 ⁇ (GSK3 ⁇ ) within a destructive complex formed by adenomatous polyposis coli (APC) protein, GSK3 ⁇ , Axin, and a priming kinase for ⁇ -catenin called casein kinase 1 ⁇ (CK1 ⁇ ).
- the destructive complex can phosphorylate ⁇ -catenin for its degradation.
- cytoplasmic ⁇ -catenin By inhibiting the destructive complex, cytoplasmic ⁇ -catenin can be stabilized and accumulated in the presence of lymphoid enhancing factor/T-cell factor (LEF/TCF) transcription factors so that ⁇ -catenin can be translocated into the nucleus to activate ⁇ -catenin mediated gene expressions of disease-causing products, including c-Myc cyclin-D1 survivin gastrin VEGF ASEF, etc., to increase cell proliferation (Boutros and Mlodzik, Mech. Dev . (1999) 83:27-37; and Perrimon, Cell (1994) 76:781-4).
- LEF/TCF lymphoid enhancing factor/T-cell factor
- Mutations or deregulated expression of components of the Wnt signaling pathway have been linked to the formation and metastasis of numerous tumors.
- gene mutations have been observed in regulators of the Wnt cascade, including APC, ⁇ -catenin, Axin and TCF, leading to over-expression of genes associated with cell proliferation (Klaus and Birchmeier, Nat. Rev. Cancer (2008) 8:387-98).
- Aberrant activation of the Wnt signaling pathway is associated with a variety of diseases including various cancers (Hoang et al., Int. J.
- the present invention provides compounds of Formula I:
- X 13 and X 15 are independently O, N, S or C—R 4c , and X 14 is N or C;
- Y 2 is blank, —O—, —S—, —N(R 18b )— or —C(R 18b )(R 19b )—;
- the compound of Formula I comprises Q which is
- Q 1 to Q 10 are independently N or C—R 17 .
- the compound of Formula I comprises A which is
- the compound of Formula I comprises U which is
- X 20 to X 23 are independently N or C—R 15 .
- the compound of Formula I comprises U which is selected from:
- the compound of Formula I comprises Q which is selected from:
- the compound of Formula I comprises Z which is selected from:
- the compound of Formula I comprises Q which is selected from:
- the compound of Formula I comprises Z which is selected from:
- the compound of Formula I comprises U which is selected from:
- the compound of Formula I comprises Z which is
- the compound of Formula I comprises A which is selected from:
- herein provides a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- herein provides a method for regulating the Wnt signaling pathway and/or treating a Wnt-mediated disorder in a mammal suffering therefrom.
- the method comprises administrating to a mammalian subject a therapeutically effective amount of at least one compound of formula I, or a pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent.
- the method can treat a cell proliferative disorder selected from the group consisting of systemic sclerosis, skin fibrosis, idiopathic pulmonary fibrosis, renal fibrosis, liver fibrosis, drug-induced fibrosis, radiation-induced fibrosis, colorectal cancer, breast cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, pancreatic cancer, leukemia, lymphoma, neuroblastoma, retinoblastoma, sarcoma, osteosarcoma, chondosarcoma, Ewing's sarcoma, rhabdomysarcoma, brain tumor, Wilms' tumor, basal cell carcinoma, melanoma, head and neck cancer, cervical cancer and prostate cancer.
- a cell proliferative disorder selected from the group consisting of systemic sclerosis, skin fibrosis, idiopathic pulmonary fibro
- FIG. 1 depicts the IC50 curve of compound A-12 of the present invention in the primary assay
- FIG. 2 depicts the IC50 curve of compound A-36 of the present invention in the primary assay
- FIG. 3 depicts the IC50 curve of compound A-100 of the present invention in the primary assay
- FIG. 4 depicts the IC50 curve of compound A-103 of the present invention in the primary assay
- FIG. 5 depicts the IC50 curve of compound A-166 of the present invention in the primary assay
- FIG. 6 depicts the IC50 curve of compound A-168 of the present invention in the primary assay
- FIG. 7 depicts the IC50 curve of compound A-194 of the present invention in the primary assay.
- FIG. 8 depicts the IC50 curve of compound A-198 of the present invention in the primary assay.
- alkyl refers to a straight or branched chain saturated aliphatic hydrocarbon.
- Alkyl groups include groups having from 1 to 8 carbon atoms (C 1-8 alkyl), from 1 to 6 carbon atoms (C 1-6 alkyl) and from 1 to 4 carbon atoms (C 1-4 alkyl), including, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl and 3-methylpentyl.
- a substituent of an alkyl group is specifically indicated.
- cyanoalkyl refers to an alkyl group substituted with at least one cyano substituent.
- Alkenyl refers to straight or branched chain alkene groups, which comprise at least one unsaturated carbon-carbon double bond. Alkenyl groups include C 2-8 alkenyl, C 2-6 alkenyl and C 2-4 alkenyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively, including, for example, ethenyl, allyl or isopropenyl. “Alkynyl” refers to straight or branched chain alkyne groups, which have one or more unsaturated carbon-carbon bonds, at least one of which is a triple bond. Alkynyl groups include C 2-8 alkynyl, C 2-6 alkynyl and C 2-4 alkynyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively.
- a “cycloalkyl” is a group that comprises one or more saturated rings in which all ring members are carbon, including, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl. Cycloalkyl groups do not comprise an aromatic ring or a heterocyclic ring. Certain cycloalkyl groups are C 3-7 cycloalkyl, in which the cycloalkyl group contains a single ring having from 3 to 7 ring members, all of which are carbon.
- a “cycloalkenyl” is a group that comprises one or more unsaturated rings in which all ring members are carbon.
- Alkoxy is meant an alkyl group as described above attached via an oxygen bridge.
- Alkoxy groups include C 1-6 alkoxy and C 1-4 groups, which have from 1 to 6 or from 1 to 4 carbon atoms, respectively.
- Methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy are representative alkoxy groups.
- Alkylamino refers to a secondary or tertiary amine that has the general structure —NH-alkyl or —N(alkyl)(alkyl), wherein each alkyl is selected independently from alkyl, cycloalkyl and (cycloalkyl)alkyl groups.
- groups include, for example, mono- and di-(C 1-6 alkyl)amino groups, in which each C 1-6 alkyl may be the same or different. It will be apparent that the definition of “alkyl” as used in the term “alkylamino” differs from the definition of “alkyl” used for all other alkyl-containing groups, in the inclusion of cycloalkyl and (cycloalkyl)alkyl groups.
- Halogen means fluorine, chlorine, bromine, and iodine.
- a “haloalkyl” is an alkyl group that is substituted with 1 or more independently chosen halogens (e.g., “C 1-6 haloalkyl” groups have from 1 to 6 carbon atoms and at least one halogen).
- haloalkyl groups include, but are not limited to, mono-, di- or tri-fluoromethyl; mono-, di- or tri-chloromethyl; mono-, di-, tri-, tetra- or penta-fluoroethyl; mono-, di-, tri-, tetra- or penta-chloroethyl; and 1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl.
- heteroaryl is an aromatic group in which at least one aromatic ring comprises at least one heteroatom selected from N, O and S.
- Heteroaryls include, for example, 5-12 membered heteroaryls. Examples included but are not limited to imidazole, furan, furazan, isothiazole, isoxazole, oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, tetrazole, thiazole and thiophene.
- heterocyclic refers to a ring structure containing 3-12 ring atoms, in which at least one ring atom is carbon and at least one ring atom is heteroatom selected from N, O, and S.
- a heterocyclic group may be aromatic or non-aromatic.
- Piperidine and oxetane are non-limiting examples of non-aromatic heterocycles.
- Thiazole and pyridine are non-limiting examples of aromatic heterocycles.
- a ring substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a ring member.
- Substituents of aromatic groups are generally covalently bonded to a ring carbon atom.
- a pharmaceutically acceptable when used with reference to a compound of formula I is intended to refer to a form of the compound that is safe for administration to a subject.
- a free base, a salt form, a solvate, a hydrate, a prodrug or derivative form of a compound of formula I which has been approved for mammalian use, via oral ingestion or any other route of administration, by a governing authority or regulatory agency, such as the Food and Drug Administration (FDA) of the United States, is pharmaceutically acceptable.
- FDA Food and Drug Administration
- salts include salts, commonly used to form alkali metal salts and to form addition salts of free acids or free bases, which have been approved by a regulatory agency. Salts are formed from ionic associations, charge-charge interactions, covalent bonding, complexation, coordination, etc. The nature of the salt is not critical, provided that it is pharmaceutically acceptable.
- the compound(s) of formula I is used to treat a subject by administering the compound(s) as a pharmaceutical composition.
- the compound(s) in one embodiment, is combined with one or more pharmaceutically acceptable excipients, including carriers, diluents or adjuvants, to form a suitable composition, which is described in more detail herein.
- excipient denotes any pharmaceutically acceptable additive, carrier, adjuvant, or other suitable ingredient, other than the active pharmaceutical ingredient (API), which is typically included for formulation and/or administration purposes.
- API active pharmaceutical ingredient
- treat refers to therapy, including without limitation, curative therapy, prophylactic therapy, and preventative therapy.
- Prophylactic treatment generally constitutes either preventing the onset of disorders altogether or delaying the onset of a pre-clinically evident stage of disorders in individuals.
- the phrase “effective amount” is intended to quantify the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies.
- the effective amount in one embodiment, is administered in a single dosage form or in multiple dosage forms.
- the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms or by other conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an effective amount of the active ingredient to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular hedgehog inhibitor employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient will range from about 0.0001 to about 100 mg per kilogram of body weight per day. The mode of administration can have a large effect on dosage. Higher doses may be used for localized routes of delivery.
- the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Dosages for a given compound disclosed herein are readily determinable by those of skill in the art by a variety of means.
- One embodiment provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula I, or a stereoisomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
- the present invention provides methods for regulating the Wnt signaling pathway and/or treating a Wnt-mediated disorder in a mammal suffering therefrom.
- the method comprises administrating to a mammalian subject a therapeutically effective amount of at least one compound of formula I, or a pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent.
- the method comprises treating or preventing disorder is a cell proliferative disorder selected from the group consisting of systemic sclerosis, skin fibrosis, idiopathic pulmonary fibrosis, renal fibrosis, liver fibrosis, drug-induced fibrosis, radiation-induced fibrosis, colorectal cancer, breast cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, pancreatic cancer, leukemia, lymphoma, neuroblastoma, retinoblastoma, sarcoma, osteosarcoma, chondosarcoma, Ewing's sarcoma, rhabdomysarcoma, brain tumor, Wilm's tumor, basal cell carcinoma, melanoma, head and neck cancer, cervical cancer and prostate cancer.
- a cell proliferative disorder selected from the group consisting of systemic sclerosis, skin fibrosis, idi
- the compounds described herein are formulated into pharmaceutical compositions.
- Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- a summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy , Nineteenth Ed., Easton, Pa.: Mack Publishing Company (1995); Hoover, John E., Remington's Pharmaceutical Sciences , Mack Publishing Co., Easton, Pa. (1975); Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms , Marcel Decker, New York, N.Y. (1980); and Pharmaceutical Dosage Forms and Drug Delivery Systems , Seventh Ed., Lippincott Williams & Wilkins (1999), herein incorporated by reference for such disclosure.
- a pharmaceutical composition refers to a mixture of a compound of formula I with other chemical components (i.e. pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof.
- the pharmaceutical composition facilitates administration of the compound to an organism.
- therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated.
- the mammal is a human.
- a therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors.
- the compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.
- the pharmaceutical formulations described herein are administered to a subject by appropriate administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes.
- the pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
- All formulations for oral administration are in dosages suitable for such administration.
- dosage units are tablets or capsules.
- these contain an amount of active ingredient from about 1 to 2000 mg, advantageously from about 1 to 500 mg, and typically from about 5 to 150 mg.
- a suitable daily dose for a human or other mammal vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods and practices.
- Conventional formulation techniques include, e.g., one or a combination of methods: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion.
- Other methods include, e.g., spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., wurster coating), tangential coating, top spraying, tableting, extruding and the like.
- Methods of the present invention include the use of at least one compound of formula I, which inhibits hedgehog signaling in the regulation of repair and/or functional performance of a wide range of cells, tissues and organs, and have therapeutic and cosmetic applications ranging from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth muscle, regulation of lung, liver and other organs arising from the primitive gut, regulation of hematopoietic function, regulation of skin and hair growth, etc. Accordingly, the methods and compositions of the present invention include the use of the subject inhibitors for all such uses as inhibitors of hedgehog proteins may be implicated. Moreover, the subject methods can be performed on cells which are provided in culture (in vitro), or on cells in a whole animal (in vivo).
- the compounds of the present invention can be prepared using various synthetic routes, including those described below, starting from commercially available materials.
- Starting materials of the invention are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Functional groups may be removed according to known procedures in the art.
- the invention further encompasses “intermediate” compounds, including structures produced from the synthetic procedures described, whether isolated or not, prior to obtaining the finally desired compound. Structures resulting from carrying out steps from a transient starting material, structures resulting from divergence from the described method(s) at any stage, and structures forming starting materials under the reaction conditions are all “intermediates” included in the invention. Further, structures produced by using starting materials in the form of a reactive derivative or salt, or produced by a compound obtainable by means of the process according to the invention and structures resulting from processing the compounds of the invention in situ are also within the scope of the invention.
- New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention.
- such starting materials are used and reaction conditions so selected as to obtain the desired compound(s).
- Starting materials of the invention are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Protecting groups, their introduction and removal are described above.
- Scheme 1 depicts a general synthetic route leading to the synthesis of compounds of Formula I.
- Components of Formula I can be assembled from three components: M1, M2, and M4.
- Component M1 can be formed from other precursors, as shown in examples vide infra.
- Component M2 has two leaving groups (LG 1 and LG 2 ) which can undergo reactions with an amino group in component M1 and a chemical group (CG 1 ) in component M4 to form compounds of Formula I.
- LG 1 and LG 2 can be selected from halide, CH 3 S(O) 2 —, triflate, tosylate, and mesylate.
- CG 1 can be selected from borate, organotin, alkyne, amino, and amide groups.
- Palladium catalyzed reactions of borate, organotin, alkyne, amide, or amino in CG 1 , or treating amino group in CG 1 with a base can form a covalent bond between A and U in M. Further modifications of A or U may be needed to complete the syntheses of compounds of Formula I. Alternatively, LG 2 can be converted to borate and CG 1 can be selected from Br, I, and triflate so that a palladium catalyzed reaction may form the covalent bond between A and U. Further, M1 may only contains shorter tails, such as Q-L- or L- to start with, and Z or Z-Q may be added later to complete the synthesis of compounds of Formula I.
- Conditions for steps a and d can be: DIPEA, t-BuOH, 50-60° C., overnight; DIPEA, i-PrOH, 60-80° C. overnight; Et 3 N, THF, rt, overnight; DIPEA, cyclohexanol, ZnCl 2 , 120° C., 40 h; K 2 CO 3 , DMSO, 120-135° C., 10 h; Pd(AcO) 2 , BINAP, t-BuONa, dioxane, 100° C., 12 h; and DIPEA, THF, 50° C., overnight.
- Conditions for steps b and c can be: DIPEA, NMP, 120-130° C., overnight; DIPEA, THF, reflux, overnight; DIPEA, t-BuOH, 50° C.; NMP, 130° C., 24 h; Pd(PPh 3 ) 4 , K 2 CO 3 , dioxane/H 2 O, 100-120° C., overnight; Cs 2 CO 3 , Pd(PPh 3 ) 4 , dioxane/H 2 O, 100° C., 12 h; Pd(dppf)Cl 2 , dppf, K 3 PO 4 , dioxane, H 2 O, 100° C., 12 h; Pd(dppf)Cl 2 , dioxane/H 2 O, 100° C., 10 h; and Pd(PPh 3 ) 4 , xantphos, Cs 2 CO 3 , dioxane, reflux, overnight.
- Scheme 2 illustrates another general synthetic route leading the synthesis of compounds of Formula I.
- LG 3 can be selected from halide, triflate, tosylate, and mesylate, while CG 2 can be a borate group.
- LG 3 can be selected from halide, triflate, tosylate, and mesylate; and CG 2 can be a borate group.
- Palladium catalyzed reaction can lead to the covalent bond formation between A and U in M8.
- An ensuing reductive amination between M8 and M9 form the covalent bond between L and the amino group on A. Further alkylation of the amino group, if needed, may lead to compounds of Formula I.
- Step e can be Na 2 CO 3 , Pd(PPh 3 ) 4 , EtOH, toluene, H 2 O, 90° C., 12 h; and K 2 CO 3 , Pd(PPh 3 ) 4 , dioxane/H 2 O, 80° C., 10-12 h.
- Step f can be 1) EtOH, 90° C., 12 h, 2) NaBH 4 ; and TFA, Et 3 SiH, MeCN, 80° C.
- Scheme 3 depicts a general synthetic route leading to the synthesis of compounds of Formula I.
- Component M10 can be formed from other precursors, as shown in examples vide infra.
- the OH group of M13 was converted to hydrogen in two steps to give M14.
- the CG 3 group of M14 was converted to leaving group (LG 4 ) which can undergo reactions with an amino group in component M1 to form compounds of Formula I.
- CG 3 can be selected from CH 3 S— and CH 3 O— groups.
- LG 4 can be selected from CH 3 S(O) 2 — and HO— groups.
- Conditions for steps 1 can be: LDA, THF, ⁇ 60° C., 1 h.
- Conditions for steps m can be: NH 4 OAc, AcOH, 108° C., 8 h.
- Conditions for steps n can be: POCl 3 , 100° C., 1 h.
- Conditions for steps o can be: Pd(PPh 3 ) 4 , HCOOH, Et 3 N, DMSO, 100° C., 1-3 h.
- Conditions for steps p can be: HBr, H 2 O, 100° C., 1 h; and Oxone, THF, H 2 O, r.t., 10 h.
- Conditions for steps q can be: PyBOP, DIPEA, DMF, r.t., 12 h; and DIPEA, NMP, 135° C., 16 h.
- LC-MS was run using an Agilent 1100 system using an Agela Durashell C18 3.5 ⁇ m 4.6 ⁇ 50 mm column. Gradients were run using 0.1 NH 4 HCO 3 aqueous solution and acetonitrile with gradient 5/95 to 95/5 in the run time indicated (for example, 5 min), flow rate at 1.8 mL/min.
- Step b 5-fluoro-N-(4-(2-methylpyridin-4-yl)benzyl)-6-(naphthalen-2-yl)pyrimidin-4-amine
- Step a 6-chloro-5-fluoro-N-((2-(2-methylpyridin-4-yl)pyrimidin-5-yl)methyl) pyrimidin-4-amine
- Step b 6-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-5-fluoro-N-((2-(2-methylpyridin-4-yl)pyrimidin-5-yl)methyl)pyrimidin-4-amine
- Step k 4-(4-((5-fluoro-6-(quinolin-6-yl)pyrimidin-4-ylamino)methyl)phenyl)-2-methylpyridine 1-oxide
- Step a 6-chloro-5-fluoro-N-((3-fluoro-2′-methyl-2,4′-bipyridin-5-yl)methyl)pyrimidin-4-amine
- Step b 5-fluoro-N-((3-fluoro-2′-methyl-2,4′-bipyridin-5-yl)methyl)-6-(pyridin-3-ylethynyl)pyrimidin-4-amine
- Step b 6-(6-(4-(2-methylpyridin-4-yl)benzylamino)pyrimidin-4-yl)-2-(methylthio)-7,8-dihydropyrido[4,3-d]pyrimidin-5 (6H)-one
- Step d N-((3-methoxy-2′-methyl-2,4′-bipyridin-5-yl)methyl)-5-(1,7-naphthyridin-6-yl)-1,2,4-thiadiazol-3-amine
- Step d 4-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-3-fluoro-N-((3-fluoro-2′-methyl-2,4′-bipyridin-5-yl)methyl)pyridin-2-amine
- Table 2 shows a selection of compounds prepared according to the methods discussed above in detail and indicated in the Third column of the table:
- the primary assay is based on Wnt pathway Super-top flash (STF) reporter gene assay:
- HEK293 STF stable clones (HEK293 cells stably transfected with “Super-Top Flash” TCF-luciferase reporter plasmid) were kept in complete culture medium (DMEM with 4 mM L-Gln, 1.5 g/L sodium bicarbonate and 4.5 g/L glucose containing 6 ⁇ g/mL Blasticidin and 10% FBS).
- L Wnt3A cells (CRL-2647, ATCC) were kept in DMEM (Gibico) containing 10% FBS (Hyclone).
- HEK293 STF and L Wnt3A cells were harvested when 90% confluence and cell suspension was mixed with a fixed ratio of 1:1 (HEK293 STF:L Wnt3A). 100 ⁇ L/well of mixed cells suspension was added to the 96-well-plate with final cell concentration of 12,000 cells/well and then cultured for an additional 24 hours before adding compounds.
- luciferase solution 50 ⁇ L luciferase solution (Bright-Glo, Promega) was added to each well during the 48 h incubation. The plates were incubated at room temperature for 5 min under gentle shaking. Luminescence signaling was measured with a plate reader (PHERAstar FS, BMG). The IC 50 (potency) of compounds was calculated based on the inhibition of luminescence signaling.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Inhibitors of Wnt signaling pathway with structures of Formula I are disclosed, together with their pharmaceutical salts. Applications of compounds of Formula I in inhibiting or modulating the Wnt signaling pathway are also disclosed. Compounds of Formula I can treat disorders caused by aberrant activation of the Wnt signaling pathway.
Description
- This application is a Continuation of U.S. patent application Ser. No. 15/766,799, filed on Apr. 6, 2018, which is the U.S. National Phase of International Application No. PCT/US2016/055851, filed on Oct. 6, 2016, which claims the benefit of Chinese Patent Applications 201510645986.2, filed on Oct. 8, 2015; 201610195733.4, filed on Mar. 31, 2016; 201610195731.5, filed on Mar. 31, 2016; 201610670828.7, filed on Aug. 16, 2016; 201610850360.X, filed on Sep. 26, 2016; 201610850358.2, filed on Sep. 26, 2016; and 201610850357.8, filed on Sep. 26, 2016; all of which are hereby incorporated by reference.
- The present invention generally relates to heterocyclic compounds and, more particularly, relates to novel heterocyclic compounds that are useful in therapies targeting the Wnt signaling pathway mediated diseases, such as cancer, in mammals.
- The Wnt signaling pathway has critical roles in developmental pathways, including regulatory roles in cell proliferation, tissue patterning, and cell fate, migration, morphogenesis and function, as well as cell survival and degeneration (Logan and Nusse, Annu. Rev. Cell Dev. Biol. (2004) 20:781-810). Recently during research on stem cells, Wnt signaling pathway has been found to regulate the maintenance of epidermal stem cells, intestinal stem cells, hematopoietic stem cells, neural stem cells, embryonic stem cells and tumor stem cells (Reya and Clevers, Nature (2005) 434:843-850).
- The canonical Wnt signaling pathway is activated by Wnt proteins that interact with seven-pass transmembrane receptors of the Frizzled (Fzd) family and single-pass transmembrane co-receptors, such as lipoprotein receptor-related protein 5/6 (LRP5/6). Such interaction activates the Wnt signaling pathway by recruiting and activating the Dishevelled (Dvl) protein, which, in turn, silences glycogen synthase kinase 3β (GSK3β) within a destructive complex formed by adenomatous polyposis coli (APC) protein, GSK3β, Axin, and a priming kinase for β-catenin called casein kinase 1α (CK1α). The destructive complex can phosphorylate β-catenin for its degradation. By inhibiting the destructive complex, cytoplasmic β-catenin can be stabilized and accumulated in the presence of lymphoid enhancing factor/T-cell factor (LEF/TCF) transcription factors so that β-catenin can be translocated into the nucleus to activate β-catenin mediated gene expressions of disease-causing products, including c-Myc cyclin-D1 survivin gastrin VEGF ASEF, etc., to increase cell proliferation (Boutros and Mlodzik, Mech. Dev. (1999) 83:27-37; and Perrimon, Cell (1994) 76:781-4).
- Mutations or deregulated expression of components of the Wnt signaling pathway have been linked to the formation and metastasis of numerous tumors. For example, in patients with colon cancer, gene mutations have been observed in regulators of the Wnt cascade, including APC, β-catenin, Axin and TCF, leading to over-expression of genes associated with cell proliferation (Klaus and Birchmeier, Nat. Rev. Cancer (2008) 8:387-98). Aberrant activation of the Wnt signaling pathway is associated with a variety of diseases including various cancers (Hoang et al., Int. J. Cancer (2004) 109:106-111), decrease of neural precursor cells (Chenn and Walsh, Science (2002) 297:365-9), pathogenesis of sporadic medulloblastoma (Dahmen et al., Cancer Res. (2001) 61:7039-43), malignant proliferation of cancer cells due to disruption of Wnt signaling pathway in stem and progenitor cells (Reya and Clevers, Nature (2005) 434:843-850).
- Thus, there is a need for agents and methods that modulate the Wnt signaling pathway, thereby treating, and/or ameliorating Wnt signaling-related disorders.
- In one aspect, the present invention provides compounds of Formula I:
- or a pharmaceutically acceptable salt, solvate, stereoisomer or a tautomer thereof, wherein
-
- A is A1, A2, A3 or A4;
- U is U1, U2, U3 or U4;
- L is L1, L2, or L3;
- Q is Q1, Q2, Q3 or Q4;
- Z is Z1, Z2, Z3 or Z4;
- A1 is
- wherein
-
- X1 to X7 are independently selected from N and C—R13;
- A2 is
-
- A3 is
-
- A4 is
- wherein X13 and X15 are independently O, N, S or C—R4c, and X14 is N or C;
-
- U1 is
-
- wherein X8 to X10 are independently selected from N and C—R14;
- G1 and G2 are independently selected from N and C;
- V1 and V2 are independently selected from N, O, S and C—R15;
- W is V3, V4—V5 or V4═V5, wherein V3 to V5 are independently selected from N, O, S and C—R16, wherein V4 connects with V1; and
- V5 connects with V2;
- U2 is C6-C10 aryl, 5-12 membered heteroaryl, 11-13 membered heterocyclophenyl or 10-13 membered heterocycloheteroaryl, wherein heterocyclo and heteroaryl comprises 1 to 4 heteroatoms independently selected from N, O and S; and
- C6-C10 aryl, 5-12 membered heteroaryl, 11-13 membered heterocyclophenyl and 10-13 membered heterocycloheteroaryl are unsubstituted or substituted with 1 to 4 R6a groups;
- U3 is —OR14b, —NR14bR15b, C6-C12 aryl unsubstituted or substituted with 1-6 R13b group, 5-14 membered heteroaryl unsubstituted or substituted with 1-6 R13b group, 11-13 membered heterocyclophenyl unsubstituted or substituted with 1-6 R13b group, 10-13 membered heterocycloheteroaryl unsubstituted or substituted with 1-6 R13b group, C2-C8 alkenyl substituted with 5-6 membered aryl or heteroaryl, C2-C8 alkynyl substituted with 5-6 membered aryl or heteroaryl, or
- wherein X8 to X10 are independently selected from N and C—R14;
-
-
- unsubstituted or substituted with 1 to 2 R13b groups, wherein heterocyclo and heteroaryl comprises 1 to 4 heteroatoms independently selected from N, O and S; and
- X11 is N or C—R13b;
- unsubstituted or substituted with 1 to 2 R13b groups, wherein heterocyclo and heteroaryl comprises 1 to 4 heteroatoms independently selected from N, O and S; and
- U4 is
-
-
- wherein X8 to X10 are independently selected from N and C—R15c;
- G1 and G2 are independently selected from N and C;
- V1 and V2 are independently selected from N, O, S and C—R16c;
- W is V3, V4—V5 or V4═V5, wherein V3 to V5 are independently selected from N, O, S and C—R17c, wherein V4 connects with V1; and
- V5 connects with V2;
- L1 is
- wherein X8 to X10 are independently selected from N and C—R15c;
-
- L2 is
- wherein Y2 is blank, —O—, —S—, —N(R18b)— or —C(R18b)(R19b)—;
-
- L3 is —C(R2c)(R3c)— or —NHCH2CH2—;
- Q1 is C6-C10 arylene or 5-12 membered heteroarylene, wherein 5-12 membered heteroarylene comprises 1 to 4 heteroatoms independently selected from N, O and S; and
- C6-C10 aryl and 5-12 membered heteroarylene are unsubstituted or substituted with 1 to 4 R17 groups;
- Q2 is C6-C10 arylene or 5-10 membered heteroarylene, wherein 5-10 membered heteroarylene comprises 1 to 4 heteroatoms independently selected from N, O and S; and
- C6-C10 arylene and 5-10 membered heteroarylene are unsubstituted or substituted with 1 to 4 R4a groups;
- Q3 is C6-C12 arylene unsubstituted or substituted with 1-6 R6b group, 5-14 membered heteroarylene unsubstituted or substituted with 1-6 R6b group, C3-C6 cycloalkylene unsubstituted or substituted with 1-6 R6b group, C3-C6 heterocylene unsubstituted or substituted with 1-6 R6b group, or
-
- unsubstituted or substituted with 1 to 2 R6b groups, wherein heterocyclene and heteroarylene comprises 1 to 4 heteroatoms independently selected from N, O and S; and
- X12 is N or C—R6b;
- Q4 is C6-C10 arylene or 5-12 membered heteroarylene, wherein 5-12 membered heteroarylene comprises 1 to 4 heteroatoms independently selected from N, O and S; and
- C6-C10 arylene and 5-12 membered heteroarylene are unsubstituted or substituted with 1 to 4 R5c groups;
- Z1 is —CN, C6 aryl, 5-6 membered heteroaryl, or
- unsubstituted or substituted with 1 to 2 R6b groups, wherein heterocyclene and heteroarylene comprises 1 to 4 heteroatoms independently selected from N, O and S; and
-
- wherein 5-6 membered heteroaryl comprises 1 to 3 heteroatoms independently selected from N, O and S;
- C6 aryl and 5-6 membered heteroaryl are unsubstituted or substituted with 1 to 3 R18 groups;
- Y1 is O or NR20; and
- q is 0, 1, 2, or 3;
- Z2 is H, —CN, halide, —OH, C1-C8 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkylsulfonyl, C1-C8 acyl, aminoacyl, C1-C8 acylamino, C1-C8 alkylcarbamoylamino, C1-C8 alkoxycarbamoyl, C1-C8 alkylsulfonamido, C1-C8 alkylaminosulphonyl, C1-C8 alkoxy, C2-C8 alkoxyacyl, phenyl, 5-6 membered heteroaryl, or 5-7 membered heterocyclo, wherein 5-6 membered heteroaryl and 5-7 membered heterocyclo comprise one or more hetero atoms independently selected from N, O and S; and
- phenyl, 5-6 membered heteroaryl and 5-7 membered heterocycle are unsubstituted or substituted with 1 to 3 R5a groups;
- Z3 is H, —CN, halide, —OH, C1-C8 alkyl unsubstituted or substituted with 1 to 3 R12b groups, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkylsulfonyl, C1-C8 acyl, aminoacyl, C1-C8 acylamino, C1-C8 alkylcarbamoylamino, C1-C8 alkoxycarbamoyl, C1-C8 alkylsulfonamido, C1-C8 alkylaminosulphonyl, C1-C8 alkoxy, C2-C8 alkoxyacyl, —N(R7b)(R8b) unsubstituted or substituted with 1 to 3 R12b groups, phenyl unsubstituted or substituted with 1 to 3 R9b groups, 5-6 membered heteroaryl unsubstituted or substituted with 1 to 3 R10b groups, or 5-7 membered heterocyclo unsubstituted or substituted with 1 to 3 R11b groups, wherein 5-6 membered heteroaryl and 5-7 membered heterocyclo comprises 1-3 hetero atoms independently selected from N, O and S;
- Z4 is —CN, C6 aryl, 5-6 membered heteroaryl, or
- wherein 5-6 membered heteroaryl comprises 1 to 3 heteroatoms independently selected from N, O and S;
-
- wherein 5-6 membered heteroaryl comprises 1 to 3 heteroatoms independently selected from N, O and S;
- C6 aryl and 5-6 membered heteroaryl are unsubstituted or substituted with 1 to 3 R6c groups;
- Y3 is O or NR8c; and
- q is 0, 1, 2, or 3;
- R1 to R3 are independently selected from H and C1-C6 alkyl, wherein C1-C6 alkyl is unsubstituted or substituted with 1 to 3 halide, —CN, —OH, C1-C3 alkyl, C3-C5 cycloalkyl, or C1-C3 alkoxy groups;
- R4 is H, halide, —CN, —OH, —NO2, C1-C6 alkyl, C3-C8 cycloalkyl, or C1-C6 alkoxy, wherein C1-C6 alkyl, C3-C8 cycloalkyl and C1-C6 alkoxy are unsubstituted or substituted with 1 to 3 halide;
- R5 and R6 are independently selected from H, halide, —CN, —OH, amino, C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 alkoxy, wherein C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 alkoxy are unsubstituted or substituted with 1 to 3 halide;
- R7 and R8 are independently selected from H and C1-C6 alkyl, or R7 and R8 together are oxo (═O);
- R9 to R12 are independently selected from H, C1-C6 alkyl;
- R13 is H, halide, —CN, —OH, amino, —NO2, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylthio or 1-pyrrolidino, wherein amino, C1-C6 alkyl and C1-C6 alkoxy are unsubstituted or substituted with 1 to 3 halide, C1-C3 alkyl or C3-C6 cycloalkyl groups;
- R14 to R17 are independently selected from H, halide, —CN, —OH, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy and C1-C6 alkylthio, wherein amino, C1-C6 alkyl and C1-C6 alkoxy are unsubstituted or substituted with 1 to 3 halide, C1-C3 alkyl or C3-C6 cycloalkyl groups;
- R18 is H, halide, —CN, —OH, amino, C1-C6 alkyl, C3-C6 cycloalkyl or C1-C6 alkoxy, wherein amino, C1-C6 alkyl and C1-C6 alkoxy are unsubstituted or substituted with 1 to 3 halide, C1-C3 alkyl or C3-C6 cycloalkyl groups;
- R19 and R20 are independently selected from H and C1-C3 alkyl, or R19 and R20 together, with adjacent atoms they attached to, form a cyclic structure;
- R4a, R5a and R6a are independently selected from halide, —CN, and —OH, or R4a, R5a and R6a are independently selected from C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkylsulfonyl, C1-C8 acyl, aminoacyl, C1-C8 acylamino, C1-C8 alkylcarbamoylamino, C1-C8 alkoxycarbamoyl, C1-C8 alkylsulfonamido, C1-C8 alkylaminosulphonyl, C2-C8 alkoxyacyl, and 3-8 membered heterocycle, all of which are unsubstituted or substituted with 1-3 halide, —OH, —CN, C1-C3 alkyl, C1-C3 alkoxyl or C3-C8 cycloalkyl groups, wherein 3-8 membered heterocycle comprises one or more hetero atoms from N, O or S;
- R2m is H, deuterium, tritium, halide, —OH, —CN, C1-C8 alkyl, C3-C8 cycloalkyl or C1-C8 alkoxy;
- R2b and R3b are independently selected from H, C1-C6 alkyl unsubstituted or substituted with 1-3 groups selected from halide, —CN, —OH, C1-C6 alkyl, C3-C5 cycloalkyl and C1-C3 alkoxy;
- R4b and R5b are independently selected from H, halide, —CN, amino, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, and C1-C3 alkylamino;
- R6b is H, halide, —CN or —OH, or R6b is selected from amino, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, and C1-C3 alkylamino, all of which are unsubstituted or substituted with 1-3 halide, C1-C3 alkyl, or C3-C6 cycloalkyl groups;
- R7b and R8b are independently selected from H, C1-C8 alkyl and C3-C8 cycloalkyl, the latter two of which are unsubstituted or substituted with 1-3 R12b, or R7 and R8 together, with adjacent atoms they attached to, form a cyclic structure;
- R9b and R10b are independently selected from H, halide, —CN and —OH, or R9b and R10b are independently selected from amino, C1-C6 alkyl, C3-C6 cycloalkyl, and C1-C6 alkoxy, all of which are unsubstituted or substituted with 1-3 halide, C1-C3 alkyl, or C3-C6 cycloalkyl groups;
- R11b is H, halide, —CN, —OH, amino, C1-C6 alkyl unsubstituted or substituted with halide, C3-C6 cycloalkyl, oxo, or C1-C6 alkoxy;
- R12b is H, —CN, —OH, amino, C1-C6 alkyl unsubstituted or substituted with halide, C3-C6 cycloalkyl, oxo, or C1-C6 alkoxy;
- R13b is H, halide, —CN, —OH, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C2-C6 alkylcarbamoylamino, C2-C6 alkoxycarbamoyl, C1-C3 alkylsulphonyl, —N(R16b)S(O)2—C1-C3 alkyl, or —N(R16b)C(O)—C1-C3 alkyl;
- R14b and R15b are independently selected from H, C3-C6 cycloalkyl unsubstituted or substituted with 1 to 3 R20b groups, C1-C6 alkyl unsubstituted or substituted with 1 to 3 R20b groups, 5-6 membered aryl unsubstituted or substituted with 1 to 3 R20b groups, 5-6 membered heteroaryl unsubstituted or substituted with 1 to 3 R20b groups, and 5-6 membered heterocyclo unsubstituted or substituted with 1 to 3 R20b groups, wherein 5-6 membered heteroaryl and 5-7 membered heterocyclo comprise 1 to 3 hetero atoms independently selected from N, O and S, or R14b and R15b together, with adjacent atoms they attached to, form a cyclic structure;
- R16b to R19b are independently selected from H and C1-C6 alkyl unsubstituted or substituted with halide;
- R20b is H, —CN, —OH, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, 5-6 membered aryl, or 5-6 membered heteroaryl, wherein 5-6 membered heteroaryl comprises 1 to 3 hetero atoms independently selected from N, O and S;
- R21b is H or C1-C6 alkyl;
- R2c and R3c are independently selected from H and C1-C6 alkyl unsubstituted or substituted with 1-3 halide;
- R4c is H, halide, C1-C3 alkyl, C3-C5 cycloalkyl, or C1-C3 alkoxy;
- R5c and R6c are independently selected from H, halide, —CN, —OH, amino, C1-C6 alkyl unsubstituted or substituted with 1-3 halide, C3-C5 cycloalkyl, and C1-C6 alkoxy;
- R7c and R8c are independently selected from H and C1-C6 alkyl, or R7c and R8c together, with adjacent atoms they attached to, form a cyclic structure;
- R9c to R14c are independently selected from H, C1-C6 alkyl and —CF3;
- R15c to R17c are independently selected from H, halide, —CN, —OH, amino, C1-C6 alkyl unsubstituted or substituted with 1-3 halide, C3-C5 cycloalkyl, and C1-C6 alkoxy.
- wherein 5-6 membered heteroaryl comprises 1 to 3 heteroatoms independently selected from N, O and S;
- In one embodiment, the compound of Formula I comprises Q which is
- wherein Q1 to Q10 are independently N or C—R17.
- In another embodiment, the compound of Formula I comprises A which is
- In one embodiment, the compound of Formula I comprises U which is
- wherein X20 to X23 are independently N or C—R15.
- In another embodiment, the compound of Formula I comprises U which is selected from:
- unsubstituted or substituted with 1 to 3 R15 groups.
- In one embodiment, the compound of Formula I comprises Q which is selected from:
- unsubstituted or substituted with 1 to 3 R4a groups.
- In one embodiment, the compound of Formula I comprises Z which is selected from:
- unsubstituted or substituted with 1 to 3 R5a groups.
- In another embodiment, the compound of Formula I comprises Q which is selected from:
- unsubstituted or substituted with 1 to 6 R6b groups.
- In one embodiment, the compound of Formula I comprises Z which is selected from:
- unsubstituted or substituted with 1-2 R10b groups.
- In another embodiment, the compound of Formula I comprises U which is selected from:
- unsubstituted or substituted with 1-6 R13c groups.
- In another embodiment, the compound of Formula I comprises Z which is
- or Z is selected from:
- unsubstituted or substituted with 1-3 R6c groups.
- In one embodiment, the compound of Formula I comprises A which is selected from:
- In another aspect, herein provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
- In another aspect, herein provides a method for regulating the Wnt signaling pathway and/or treating a Wnt-mediated disorder in a mammal suffering therefrom. The method comprises administrating to a mammalian subject a therapeutically effective amount of at least one compound of formula I, or a pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent.
- In one embodiment, the method can treat a cell proliferative disorder selected from the group consisting of systemic sclerosis, skin fibrosis, idiopathic pulmonary fibrosis, renal fibrosis, liver fibrosis, drug-induced fibrosis, radiation-induced fibrosis, colorectal cancer, breast cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, pancreatic cancer, leukemia, lymphoma, neuroblastoma, retinoblastoma, sarcoma, osteosarcoma, chondosarcoma, Ewing's sarcoma, rhabdomysarcoma, brain tumor, Wilms' tumor, basal cell carcinoma, melanoma, head and neck cancer, cervical cancer and prostate cancer.
- In another aspect, herein provides compounds of formula I, wherein the compounds are the molecules shown in Table 1:
-
TABLE 1 Compounds of Formula I A-1 A-2 A-3 A-4 A-5 A-6 A-7 A-8 A-9 A-10 A-11 A-12 A-13 A-14 A-15 A-16 A-17 A-18 A-19 A-20 A-21 A-22 A-23 A-24 A-25 A-26 A-27 A-28 A-29 A-30 A-31 A-32 A-33 A-34 A-35 A-36 A-37 A-38 A-39 A-40 A-41 A-42 A-43 A-44 A-45 A-46 A-47 A-48 A-49 A-50 A-51 A-52 A-53 A-54 A-55 A-56 A-57 A-58 A-59 A-60 A-61 A-62 A-63 A-64 A-65 A-66 A-67 A-68 A-69 A-70 A-71 A-72 A-73 A-74 A-75 A-76 A-77 A-78 A-79 A-80 A-81 A-82 A-83 A-84 A-85 A-86 A-87 A-88 A-89 A-90 A-91 A-92 A-93 A-94 A-95 A-96 A-97 A-98 A-99 A-100 A-101 A-102 A-103 A-104 A-105 A-106 A-107 A-108 A-109 A-110 A-111 A-112 A-113 A-114 A-115 A-116 A-117 A-118 A-119 A-120 A-121 A-122 A-123 A-124 A-125 A-126 A-127 A-128 A-129 A-130 A-131 A-132 A-133 A-134 A-135 A-136 A-137 A-138 A-139 A-140 A-141 A-142 A-143 A-144 A-145 A-146 A-147 A-148 A-149 A-150 A-151 A-152 A-153 A-154 A-155 A-156 A-157 A-158 A-159 A-160 A-161 A-162 A-163 A-164 A-165 A-166 A-167 A-168 A-169 A-170 A-171 A-172 A-173 A-174 A-175 A-176 A-177 A-178 A-179 A-180 A-181 A-182 A-183 A-184 A-185 A-186 A-187 A-188 A-189 A-190 A-191 A-192 A-193 A-194 A-195 A-196 A-197 A-198 A-199 A-200 A-201 A-202 -
FIG. 1 depicts the IC50 curve of compound A-12 of the present invention in the primary assay; -
FIG. 2 depicts the IC50 curve of compound A-36 of the present invention in the primary assay; -
FIG. 3 depicts the IC50 curve of compound A-100 of the present invention in the primary assay; -
FIG. 4 depicts the IC50 curve of compound A-103 of the present invention in the primary assay; -
FIG. 5 depicts the IC50 curve of compound A-166 of the present invention in the primary assay; -
FIG. 6 depicts the IC50 curve of compound A-168 of the present invention in the primary assay; -
FIG. 7 depicts the IC50 curve of compound A-194 of the present invention in the primary assay; and -
FIG. 8 depicts the IC50 curve of compound A-198 of the present invention in the primary assay. - Before proceeding with the detailed description, it is to be appreciated that the following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and uses thereof. Hence, although the present disclosure is, for convenience of explanation, depicted and described as shown in certain illustrative embodiments, it will be appreciated that it can be implemented in various other types of embodiments and equivalents, and in various other systems and environments. Furthermore, there is no intention to be bound by any theory presented in the preceding background or the following detailed description.
- Compounds are generally described herein using standard nomenclature. For compounds having asymmetric centers, it should be understood that (unless otherwise specified) all of the optical isomers and mixtures thereof are encompassed. In addition, compounds with carbon-carbon double bonds may occur in Z- and E-forms, with all isomeric forms of the compounds being included in the present invention unless otherwise specified. Where a compound exists in various tautomeric forms, a recited compound is not limited to any one specific tautomer, but rather is intended to encompass all tautomeric forms.
- As used herein, the term “alkyl” refers to a straight or branched chain saturated aliphatic hydrocarbon. Alkyl groups include groups having from 1 to 8 carbon atoms (C1-8 alkyl), from 1 to 6 carbon atoms (C1-6 alkyl) and from 1 to 4 carbon atoms (C1-4 alkyl), including, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl and 3-methylpentyl. In some instances, a substituent of an alkyl group is specifically indicated. For example, “cyanoalkyl” refers to an alkyl group substituted with at least one cyano substituent.
- “Alkenyl” refers to straight or branched chain alkene groups, which comprise at least one unsaturated carbon-carbon double bond. Alkenyl groups include C2-8 alkenyl, C2-6 alkenyl and C2-4 alkenyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively, including, for example, ethenyl, allyl or isopropenyl. “Alkynyl” refers to straight or branched chain alkyne groups, which have one or more unsaturated carbon-carbon bonds, at least one of which is a triple bond. Alkynyl groups include C2-8 alkynyl, C2-6 alkynyl and C2-4 alkynyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively.
- A “cycloalkyl” is a group that comprises one or more saturated rings in which all ring members are carbon, including, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl. Cycloalkyl groups do not comprise an aromatic ring or a heterocyclic ring. Certain cycloalkyl groups are C3-7 cycloalkyl, in which the cycloalkyl group contains a single ring having from 3 to 7 ring members, all of which are carbon. A “cycloalkenyl” is a group that comprises one or more unsaturated rings in which all ring members are carbon.
- “Alkoxy” is meant an alkyl group as described above attached via an oxygen bridge. Alkoxy groups include C1-6 alkoxy and C1-4 groups, which have from 1 to 6 or from 1 to 4 carbon atoms, respectively. Methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy are representative alkoxy groups.
- “Alkylamino” refers to a secondary or tertiary amine that has the general structure —NH-alkyl or —N(alkyl)(alkyl), wherein each alkyl is selected independently from alkyl, cycloalkyl and (cycloalkyl)alkyl groups. Such groups include, for example, mono- and di-(C1-6 alkyl)amino groups, in which each C1-6 alkyl may be the same or different. It will be apparent that the definition of “alkyl” as used in the term “alkylamino” differs from the definition of “alkyl” used for all other alkyl-containing groups, in the inclusion of cycloalkyl and (cycloalkyl)alkyl groups.
- “Halogen” means fluorine, chlorine, bromine, and iodine. A “haloalkyl” is an alkyl group that is substituted with 1 or more independently chosen halogens (e.g., “C1-6 haloalkyl” groups have from 1 to 6 carbon atoms and at least one halogen). Examples of haloalkyl groups include, but are not limited to, mono-, di- or tri-fluoromethyl; mono-, di- or tri-chloromethyl; mono-, di-, tri-, tetra- or penta-fluoroethyl; mono-, di-, tri-, tetra- or penta-chloroethyl; and 1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl.
- A “heteroaryl” is an aromatic group in which at least one aromatic ring comprises at least one heteroatom selected from N, O and S. Heteroaryls include, for example, 5-12 membered heteroaryls. Examples included but are not limited to imidazole, furan, furazan, isothiazole, isoxazole, oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, tetrazole, thiazole and thiophene.
- The term “heterocyclic” refers to a ring structure containing 3-12 ring atoms, in which at least one ring atom is carbon and at least one ring atom is heteroatom selected from N, O, and S. A heterocyclic group may be aromatic or non-aromatic. Piperidine and oxetane are non-limiting examples of non-aromatic heterocycles. Thiazole and pyridine are non-limiting examples of aromatic heterocycles.
- A “substituent” and “substituted,” as used herein, denote that a molecular moiety is covalently bonded to an atom within a molecule of interest. For example, a ring substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a ring member. Substituents of aromatic groups are generally covalently bonded to a ring carbon atom.
- The term “pharmaceutically acceptable” when used with reference to a compound of formula I is intended to refer to a form of the compound that is safe for administration to a subject. For example, a free base, a salt form, a solvate, a hydrate, a prodrug or derivative form of a compound of formula I, which has been approved for mammalian use, via oral ingestion or any other route of administration, by a governing authority or regulatory agency, such as the Food and Drug Administration (FDA) of the United States, is pharmaceutically acceptable.
- Included in the compounds of formula I are the pharmaceutically acceptable salt forms of the free-base compounds. The term “pharmaceutically-acceptable salts” embraces salts, commonly used to form alkali metal salts and to form addition salts of free acids or free bases, which have been approved by a regulatory agency. Salts are formed from ionic associations, charge-charge interactions, covalent bonding, complexation, coordination, etc. The nature of the salt is not critical, provided that it is pharmaceutically acceptable.
- In some embodiments, the compound(s) of formula I is used to treat a subject by administering the compound(s) as a pharmaceutical composition. To this end, the compound(s), in one embodiment, is combined with one or more pharmaceutically acceptable excipients, including carriers, diluents or adjuvants, to form a suitable composition, which is described in more detail herein.
- The term “excipient”, as used herein, denotes any pharmaceutically acceptable additive, carrier, adjuvant, or other suitable ingredient, other than the active pharmaceutical ingredient (API), which is typically included for formulation and/or administration purposes. “Diluent” and “adjuvant” are defined hereinafter.
- The terms “treat”, “treating,” “treatment,” and “therapy” as used herein refer to therapy, including without limitation, curative therapy, prophylactic therapy, and preventative therapy. Prophylactic treatment generally constitutes either preventing the onset of disorders altogether or delaying the onset of a pre-clinically evident stage of disorders in individuals.
- The phrase “effective amount” is intended to quantify the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies. The effective amount, in one embodiment, is administered in a single dosage form or in multiple dosage forms.
- Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms or by other conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an effective amount of the active ingredient to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular hedgehog inhibitor employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient will range from about 0.0001 to about 100 mg per kilogram of body weight per day. The mode of administration can have a large effect on dosage. Higher doses may be used for localized routes of delivery.
- If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Those of skill in the art will readily appreciate that dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Dosages for a given compound disclosed herein are readily determinable by those of skill in the art by a variety of means.
- One embodiment provides a pharmaceutical composition comprising a compound of formula I, or a stereoisomer, tautomer, hydrate, solvate or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
- In some embodiments, the present invention provides methods for regulating the Wnt signaling pathway and/or treating a Wnt-mediated disorder in a mammal suffering therefrom. The method comprises administrating to a mammalian subject a therapeutically effective amount of at least one compound of formula I, or a pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent. The method comprises treating or preventing disorder is a cell proliferative disorder selected from the group consisting of systemic sclerosis, skin fibrosis, idiopathic pulmonary fibrosis, renal fibrosis, liver fibrosis, drug-induced fibrosis, radiation-induced fibrosis, colorectal cancer, breast cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, pancreatic cancer, leukemia, lymphoma, neuroblastoma, retinoblastoma, sarcoma, osteosarcoma, chondosarcoma, Ewing's sarcoma, rhabdomysarcoma, brain tumor, Wilm's tumor, basal cell carcinoma, melanoma, head and neck cancer, cervical cancer and prostate cancer.
- In some embodiments, the compounds described herein are formulated into pharmaceutical compositions. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. A summary of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed., Easton, Pa.: Mack Publishing Company (1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. (1975); Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y. (1980); and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed., Lippincott Williams & Wilkins (1999), herein incorporated by reference for such disclosure.
- A pharmaceutical composition, as used herein, refers to a mixture of a compound of formula I with other chemical components (i.e. pharmaceutically acceptable inactive ingredients), such as carriers, excipients, binders, filling agents, suspending agents, flavoring agents, sweetening agents, disintegrating agents, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, moistening agents, plasticizers, stabilizers, penetration enhancers, wetting agents, anti-foaming agents, antioxidants, preservatives, or one or more combination thereof. The pharmaceutical composition facilitates administration of the compound to an organism. In practicing the methods of treatment or use provided herein, therapeutically effective amounts of compounds described herein are administered in a pharmaceutical composition to a mammal having a disease, disorder, or condition to be treated. In some embodiments, the mammal is a human. A therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. The compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.
- The pharmaceutical formulations described herein are administered to a subject by appropriate administration routes, including but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal administration routes. The pharmaceutical formulations described herein include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
- All formulations for oral administration are in dosages suitable for such administration. Examples of such dosage units are tablets or capsules. In some embodiments, these contain an amount of active ingredient from about 1 to 2000 mg, advantageously from about 1 to 500 mg, and typically from about 5 to 150 mg. A suitable daily dose for a human or other mammal vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods and practices.
- Conventional formulation techniques include, e.g., one or a combination of methods: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion. Other methods include, e.g., spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., wurster coating), tangential coating, top spraying, tableting, extruding and the like.
- Methods of the present invention include the use of at least one compound of formula I, which inhibits hedgehog signaling in the regulation of repair and/or functional performance of a wide range of cells, tissues and organs, and have therapeutic and cosmetic applications ranging from regulation of neural tissues, bone and cartilage formation and repair, regulation of spermatogenesis, regulation of smooth muscle, regulation of lung, liver and other organs arising from the primitive gut, regulation of hematopoietic function, regulation of skin and hair growth, etc. Accordingly, the methods and compositions of the present invention include the use of the subject inhibitors for all such uses as inhibitors of hedgehog proteins may be implicated. Moreover, the subject methods can be performed on cells which are provided in culture (in vitro), or on cells in a whole animal (in vivo).
- The examples and preparations provided below illustrated and exemplify the compounds described herein and methods of preparing such compounds. In general, the compounds described herein may be prepared by processes known in the general chemical arts.
- The compounds of the present invention can be prepared using various synthetic routes, including those described below, starting from commercially available materials. Starting materials of the invention, are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Functional groups may be removed according to known procedures in the art.
- The protection of functional groups by protecting groups, the protecting groups themselves, and their removal reactions (commonly referred to as “deprotection”) are described, for example, in standard reference works, such as J. F. W. McOmie, Protective Groups in Organic Chemistry, Plenum Press, London and New York (1973), in T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York (1981), in The Peptides, Volume 3, E. Gross and J. Meienhofer editors, Academic Press, London and New York (1981).
- All synthetic procedures described herein can be carried out under known reaction conditions, advantageously under those described herein, either in the absence or in the presence (usually) of solvents or diluents.
- The invention further encompasses “intermediate” compounds, including structures produced from the synthetic procedures described, whether isolated or not, prior to obtaining the finally desired compound. Structures resulting from carrying out steps from a transient starting material, structures resulting from divergence from the described method(s) at any stage, and structures forming starting materials under the reaction conditions are all “intermediates” included in the invention. Further, structures produced by using starting materials in the form of a reactive derivative or salt, or produced by a compound obtainable by means of the process according to the invention and structures resulting from processing the compounds of the invention in situ are also within the scope of the invention.
- New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention. In select embodiments, such starting materials are used and reaction conditions so selected as to obtain the desired compound(s).
- Starting materials of the invention, are either known, commercially available, or can be synthesized in analogy to or according to methods that are known in the art. Many starting materials may be prepared according to known processes and, in particular, can be prepared using processes described in the examples. In synthesizing starting materials, functional groups in some cases are protected with suitable protecting groups when necessary. Protecting groups, their introduction and removal are described above.
- General Method A:
- Scheme 1 depicts a general synthetic route leading to the synthesis of compounds of Formula I. Compounds of Formula I can be assembled from three components: M1, M2, and M4. Component M1 can be formed from other precursors, as shown in examples vide infra. Component M2 has two leaving groups (LG1 and LG2) which can undergo reactions with an amino group in component M1 and a chemical group (CG1) in component M4 to form compounds of Formula I. LG1 and LG2 can be selected from halide, CH3S(O)2—, triflate, tosylate, and mesylate. CG1 can be selected from borate, organotin, alkyne, amino, and amide groups. Palladium catalyzed reactions of borate, organotin, alkyne, amide, or amino in CG1, or treating amino group in CG1 with a base can form a covalent bond between A and U in M. Further modifications of A or U may be needed to complete the syntheses of compounds of Formula I. Alternatively, LG2 can be converted to borate and CG1 can be selected from Br, I, and triflate so that a palladium catalyzed reaction may form the covalent bond between A and U. Further, M1 may only contains shorter tails, such as Q-L- or L- to start with, and Z or Z-Q may be added later to complete the synthesis of compounds of Formula I. Conditions for steps a and d can be: DIPEA, t-BuOH, 50-60° C., overnight; DIPEA, i-PrOH, 60-80° C. overnight; Et3N, THF, rt, overnight; DIPEA, cyclohexanol, ZnCl2, 120° C., 40 h; K2CO3, DMSO, 120-135° C., 10 h; Pd(AcO)2, BINAP, t-BuONa, dioxane, 100° C., 12 h; and DIPEA, THF, 50° C., overnight. Conditions for steps b and c can be: DIPEA, NMP, 120-130° C., overnight; DIPEA, THF, reflux, overnight; DIPEA, t-BuOH, 50° C.; NMP, 130° C., 24 h; Pd(PPh3)4, K2CO3, dioxane/H2O, 100-120° C., overnight; Cs2CO3, Pd(PPh3)4, dioxane/H2O, 100° C., 12 h; Pd(dppf)Cl2, dppf, K3PO4, dioxane, H2O, 100° C., 12 h; Pd(dppf)Cl2, dioxane/H2O, 100° C., 10 h; and Pd(PPh3)4, xantphos, Cs2CO3, dioxane, reflux, overnight.
- General Method B:
- Scheme 2 illustrates another general synthetic route leading the synthesis of compounds of Formula I. LG3 can be selected from halide, triflate, tosylate, and mesylate, while CG2 can be a borate group. Alternatively, LG3 can be selected from halide, triflate, tosylate, and mesylate; and CG2 can be a borate group. Palladium catalyzed reaction can lead to the covalent bond formation between A and U in M8. An ensuing reductive amination between M8 and M9 form the covalent bond between L and the amino group on A. Further alkylation of the amino group, if needed, may lead to compounds of Formula I. Step e can be Na2CO3, Pd(PPh3)4, EtOH, toluene, H2O, 90° C., 12 h; and K2CO3, Pd(PPh3)4, dioxane/H2O, 80° C., 10-12 h. Step f can be 1) EtOH, 90° C., 12 h, 2) NaBH4; and TFA, Et3SiH, MeCN, 80° C.
- Scheme 3 depicts a general synthetic route leading to the synthesis of compounds of Formula I. Compounds of Formula I can be assembled from three components: M1, M10, and M11. Component M10 can be formed from other precursors, as shown in examples vide infra. Component M10 has a ester group (R=Me or Et) which can undergo reaction with the methyl group in component M11 to afford M12. Ring closure of M12 with loss of tert-butylamine afforded M13. The OH group of M13 was converted to hydrogen in two steps to give M14. The CG3 group of M14 was converted to leaving group (LG4) which can undergo reactions with an amino group in component M1 to form compounds of Formula I. CG3 can be selected from CH3S— and CH3O— groups. LG4 can be selected from CH3S(O)2— and HO— groups. Conditions for steps 1 can be: LDA, THF, −60° C., 1 h. Conditions for steps m can be: NH4OAc, AcOH, 108° C., 8 h. Conditions for steps n can be: POCl3, 100° C., 1 h. Conditions for steps o can be: Pd(PPh3)4, HCOOH, Et3N, DMSO, 100° C., 1-3 h. Conditions for steps p can be: HBr, H2O, 100° C., 1 h; and Oxone, THF, H2O, r.t., 10 h. Conditions for steps q can be: PyBOP, DIPEA, DMF, r.t., 12 h; and DIPEA, NMP, 135° C., 16 h.
- Method G:
- All reagents and solvents were obtained commercially. When required, all reagents and solvents were purified by standard techniques: tetrahydrofuran was purified by distillation from sodium. All thin-layer chromatography (TLC, GF254) analyses and column purification (100-200 mesh) were performed on silica gel (Qingdao Haiyang Chemical Co.Ltd. or Yantai Chemical Co. Ltd.) and spots revealed by UV visualization at 254 nm and I2 vapor or phosphomolybdic acid. All nuclear magnetic resonance spectra were recorded using a Varian unity INOVA 400NB spectrometer at 400 MHz or a Varian Vnmrs spectrometer at 300 MHz as indicated. LC-MS was run using an Agilent 1100 system using an Agela Durashell C18 3.5 μm 4.6×50 mm column. Gradients were run using 0.1 NH4HCO3 aqueous solution and acetonitrile with gradient 5/95 to 95/5 in the run time indicated (for example, 5 min), flow rate at 1.8 mL/min.
-
-
- To a solution of (4-(2-methylpyridin-4-yl)phenyl)methanamine (100 mg, 0.51 mmol) in THF (10 mL), was added 4,6-dichloro-5-fluoropyrimidine (101 mg, 0.61 mmol) and N,N-diisopropylethylamine (260 mg, 2.0 mmol), and the reaction mixture was stirred at 50° C. overnight. After cooling to room temperature, the mixture was concentrated and the resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=100:1) to give the title compound (140 mg, 84%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.54 (d, J=5.2 Hz, 1H), 8.23 (s, 1H), 7.62 (d, J=8.4 Hz, 2H), 7.45 (d, J=8.4 Hz, 2H), 7.36 (s, 1H), 7.30 (d, J=5.2 Hz, 1H), 5.60 (s, 1H), 4.79 (d, J=6.0 Hz, 2H), 2.62 (s, 3H).
-
- To a solution of 6-chloro-5-fluoro-N-(4-(2-methylpyridin-4-yl)benzyl)pyrimidin-4-amine (66 mg, 0.20 mmol), naphthalen-2-ylboronic acid (52 mg, 0.30 mmol) in dioxane (5 mL) and H2O (1 mL), was added K2CO3 (116 mg, 0.84 mmol) and Pd(PPh3)4 (12 mg, 0.01 mmol). The mixture was stirred at 100° C. overnight under N2 atmosphere. After cooling to room temperature, the mixture was filtered through Celite. The filtrate was diluted with EtOAc (15 mL), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=200:1-50:1) to give the title compound (45 mg, 54%) as a white solid.
-
-
- To a solution of 5-fluoro-N-(4-(2-methylpyridin-4-yl)benzyl)-6-(naphthalen-2-yl)pyrimidin-4-amine (30 mg, 0.07 mmol) in THF (3 mL) at 0° C., was added NaH (6 mg, 80%, 0.20 mmol). The mixture was stirred for 30 min before MeI (20 mg, 0.14 mmol) was added. After stirring for further 6 h, the mixture was concentrated and the resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=100:1) to give the title compound (30 mg, 97%) as a pale yellow oil.
-
-
- A mixture of 6-cyanonaphthalen-2-yl trifluoromethanesulfonate (1.35 g, 4.49 mmol), K3PO4 (1.27 g, 5.99 mmol), Pd(dba)2 (114 mg, 0.20 mmol), and XPhos (143 mg, 0.30 mmol) in MeNO2 (4 mL) and 1,4-dioxane (25 mL) was heated to 80° C. under N2 atmosphere for 18 h. After cooling to room temperature, AcOH (8 mL) was added, followed by Zn power (2.93 g, 45 mmol). The mixture was stirred at 35° C. for another 3 h. After filtration, the filtrate was diluted with H2O (30 mL) and washed with EtOAc (20 mL×2). The aqueous phase was treated with 1 N NaOH to adjust PH=10, and extracted with EtOAc (50 mL×3). The combined organic layers was washed with brine, dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=3:1-0:1) to give the title compound (280 mg, 34%) as a yellow solid.
-
- To a solution of 6-(aminomethyl)-2-naphthonitrile (182 mg, 1.0 mmol) in THF (1 mL), was added 4,6-dichloro-5-fluoropyrimidine (167 mg, 1.0 mmol) and N,N-diisopropylethylamine (260 mg, 2.0 mmol), and the reaction mixture was stirred at 50° C. overnight. After cooling to room temperature, the mixture was concentrated and the resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=5:1-3:1) to give the title compound (120 mg, 38%) as a pale yellow solid.
-
- To a solution of 6-((6-chloro-5-fluoropyrimidin-4-ylamino)methyl)-2-naphthonitrile (53 mg, 0.17 mmol), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (66 mg, 0.26 mmol) in dioxane (5 mL) and H2O (1 mL), was added K2CO3 (96 mg, 0.69 mmol) and Pd(PPh3)4 (20 mg, 0.017 mmol). The mixture was stirred at 100° C. overnight under N2 atmosphere. After cooling to room temperature, the mixture was filtered through Celite. The filtrate was diluted with EtOAc (15 mL), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=100:1-50:1) to give the title compound (35 mg, 66%) as a pale yellow solid.
-
-
- To a suspension of 6-((5-fluoro-6-(quinolin-6-yl)pyrimidin-4-ylamino)methyl)-2-naphthonitrile (17 mg, 0.04 mmol) and K2CO3 (2.8 mg, 0.02 mmol) in DMSO (1 mL), was added 30% H2O2 (6 mg, 0.05 mmol). The mixture was stirred at room temperature for 3 h, and then poured into H2O (5 mL). The resulting precipitate was filtered, washed with water followed by hexane, and dried in vacuum to give the title compound (14 mg, 83%) as a pale yellow solid.
-
-
- To a solution of (2-chloropyrimidin-5-yl)methanamine (1.0 g, 7.0 mmol) in dioxane (30 mL) and H2O (6 mL) was added 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (45%, 3.7 g, 7.7 mmol), K2CO3 (2.9 g, 21 mmol) and Pd(PPh3)4 (809 mg, 0.7 mmol). The mixture was stirred at 100° C. under N2 atmosphere for 8 h. After cooling to room temperature, the mixture was filtered through Celite. The filtrate was diluted with H2O (10 mL), and extracted with EtOAc (50 mL×3). The combined organic layers was washed with brine (15 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=2:1-1:1) to give the title compound (1.3 g, 93%) as a gray solid.
-
- To a solution of (2-(2-methylpyridin-4-yl)pyrimidin-5-yl)methanamine (300 mg, 1.51 mmol) in THF (6 mL) was added 4,6-dichloro-5-fluoropyrimidine (278 mg, 1.51 mmol) and N,N-diisopropylethylamine (580 mg, 4.53 mmol), and the reaction mixture was stirred at 50° C. overnight. After cooling to room temperature, the mixture was concentrated and the resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=1:1-0:1) to give the title compound (200 mg, 40%) as a yellow solid.
-
- A mixture of 6-chloro-5-fluoro-N-((2-(2-methylpyridin-4-yl)pyrimidin-5-yl)methyl)pyrimidin-4-amine (80 mg, 0.24 mmol), 5,6,7,8-tetrahydro-1,6-naphthyridine (129 mg, 0.97 mmol) and N,N-diisopropylethylamine (467 mg, 3.6 mmol) in NMP (2 mL) was stirred at 135° C. for 8 h. After cooling to room temperature, the mixture was diluted with H2O (5 mL), and extracted with EtOAc (5 mL×3). The combined organic layers was washed with brine (5 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=5:1-1:1) to give the title compound (30 mg, 50%) as a brown solid.
-
-
- To a solution of 6-chloro-5-fluoro-N-(4-(2-methylpyridin-4-yl)benzyl)pyrimidin-4-amine (133 mg, 0.404 mmol) in CH2Cl2 (5 mL) at room temperature, was added m-CPBA (174 mg, 1.01 mmol). The mixture was stirred at room temperature overnight, and then diluted with CH2Cl2 (15 mL). A mixture of sat. Na2S2O3 (5 mL) and sat. NaHCO3 (5 mL) was added, and the mixture was stirred for another 30 min. The organic layer was separated, washed with brine (5 mL), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=100:1-50:1) to give the title compound (130 mg, 96%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J=6.8 Hz, 1H), 8.22 (s, 1H), 7.54 (d, J=8.0 Hz, 2H), 7.43 (d, J=8.0 Hz, 3H), 7.35-7.29 (m, 1H), 5.91 (s, 1H), 4.79 (d, J=6.0 Hz, 2H), 2.57 (s, 3H).
-
- To a solution of 4-(4-((6-chloro-5-fluoropyrimidin-4-ylamino)methyl)phenyl)-2-methylpyridine 1-oxide (67 mg, 0.19 mmol), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (74 mg, 0.29 mmol) in dioxane (5 mL) and H2O (1 mL), was added K2CO3 (107 mg, 0.78 mmol) and Pd(PPh3)4 (22 mg, 0.02 mmol). The mixture was stirred at reflux overnight under N2 atmosphere. After cooling to room temperature, the mixture was filtered through Celite. The filtrate was diluted with EtOAc (15 mL), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=50:1-30:1) to give the title compound (65 mg, 77%) as a white solid.
-
-
- To a solution of (6-chloro-5-fluoropyridin-3-yl)methanamine (2.36 g, 14.6 mmol) in dioxane (50 mL) and H2O (10 mL) was added 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.7 g, 16.1 mmol), K2CO3 (8.09 g, 58.6 mmol) and Pd(PPh3)4 (847 mg, 0.73 mmol). The mixture was stirred at 100° C. under N2 atmosphere for 8 h. After cooling to room temperature, the mixture was filtered through Celite. The filtrate was diluted with H2O (100 mL), and extracted with CH2Cl2 (100 mL×6). The combined organic layers was dried over Na2SO4 and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH:NH4OH=50:1:0.1-20:1:0.1) to give the title compound (2.5 g, 79%) as a brown solid. 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J=4.8 Hz, 1H), 8.50 (s, 1H), 7.77 (s, 1H), 7.69 (d, J=4.0 Hz, 1H), 7.58 (d, J=12.0 Hz, 1H), 4.01 (s, 2H), 2.65 (s, 3H).
-
- To a solution of (3-fluoro-2′-methyl-2,4′-bipyridin-5-yl)methanamine (200 mg, 0.92 mmol) in THF (10 mL), was added 4,6-dichloro-5-fluoropyrimidine (154 mg, 0.92 mmol) and N,N-diisopropylethylamine (357 mg, 2.77 mmol), and the reaction mixture was stirred at 50° C. overnight. After cooling to room temperature, the mixture was concentrated and the resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=50:1) to give the title compound (200 mg, 62%) as a gray solid. 1HNMR (400 MHz, CDCl3) δ 8.61 (d, J=4.8 Hz, 1H), 8.56 (s, 1H), 8.24 (s, 1H), 7.76 (s, 1H), 7.69 (s, 1H), 7.55 (d, J=11.6 Hz, 1H), 5.78 (s, 1H), 4.84 (d, J=6.0 Hz, 2H), 2.65 (s, 3H).
-
- A mixture of 6-chloro-5-fluoro-N-((3-fluoro-2′-methyl-2,4′-bipyridin-5-yl)methyl)pyrimidin-4-amine (100 mg, 0.29 mmol), 3-ethynylpyridine (92 mg, 0.87 mmol), Pd(PPh3)2Cl12 (9 mg, 0.012 mmol), PPh3 (6.1 mg, 0.023 mmol), and CuI (0.55 mg, 0.023 mmol) in diisopropylanmine (2 mL) and NMP (2 mL) was heated at 100° C. under N2 atmosphere for 24 h. After cooling to room temperature, the mixture was filtered through Celite. The filtrate was diluted with H2O (10 mL), and extracted with EtOAc (10 mL×3). The combined organic layers was washed with brine (5 mL×2), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=2:1-1:1) to give the title compound (17 mg, 14%) as a white solid.
-
-
- A solution of sodium (E)-1,4-diethoxy-3-fluoro-1,4-dioxobut-2-en-2-olate (45.6 g, 200 mmol), formamidine acetate (20.8 g, 200 mmol) and EtONa (13.6 g, 200 mmol) in anhydrous EtOH (200 mL) was heated at reflux overnight. After cooling to room temperature, the solvent was removed by vacuum. The residue was neutralized with 2 N HCl and extracted with ethyl acetate (100 mL×3). The combined organic layers was dried over Na2SO4, and concentrated to give the title compound (22 g, 59%) as a brown solid, which was used directly in the next step without further purification.
-
- To a stirred solution of ethyl 5-fluoro-6-hydroxypyrimidine-4-carboxylate (21.0 g, 113 mmol) and DMF (0.5 mL) in CH2Cl2 (200 mL) at room temperature, was added (COCl)2 (43.0 g, 339 mmol) dropwise. The reaction was heated at reflux overnight. After cooling to room temperature, the solvent was removed by vacuum. The residue was dissolved in ethyl acetate (300 mL) and washed with sat. NaHCO3 and brine successively. The organic layer was dried over Na2SO4, and concentrated. The resulting residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1) to give the title compound (17.8 g, 77%) as a colerless oil. 1H NMR (400 MHz, CDCl3) δ 8.90 (s, 1H), 4.52 (q, J=7.1 Hz, 2H), 1.44 (t, J=7.2 Hz, 3H).
-
- A mixture of ethyl 6-chloro-5-fluoropyrimidine-4-carboxylate (6.14 g, 30.0 mmol) and triethylamine (3.03 g, 30.0 mmol) in methanol (50 mL) was stirred at room temperature overnight. After concentration, the residue was purified by column chromatography (petroleum ether:ethyl acetate=10:1) to give the title compound (4.14 g, 74%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 8.59 (s, 1H), 4.11 (s, 3H), 4.01 (s, 3H).
-
- To a stirred solution of N-(tert-butyl)-3-methylpicolinamide (2.69 g, 14 mmol) in anhydrous tetrahydrofuran (50 mL) at −40° C., was added lithium diisopropylamide (2 M in THF, 28 mL, 56 mmol) dropwise. The mixture was stirred at this temperature for 30 min and then cooled to −60° C. Ethyl 5-fluoro-6-methoxypyrimidine-4-carboxylate (2.60 g, 14.0 mmol) in 5 mL anhydrous tetrahydrofuran was added and the reaction mixture was stirred at −60° C. for another 1 h. The reaction was quenched with sat. NH4Cl (50 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layers dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate=3:1) to give the title compound (1.36 g, 28%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.61 (s, 1H), 8.48 (d, J=4.4 Hz, 1H), 8.08 (s, 1H), 7.60 (d, J=7.6 Hz, 1H), 7.41-7.37 (m, 1H), 4.86 (s, 2H), 4.13 (s, 3H), 1.40 (s, 9H).
-
- A mixture of N-(tert-butyl)-3-(2-(5-fluoro-6-methoxypyrimidin-4-yl)-2-oxoethyl)picolinamide (1.36 g, 3.93 mmol) and NH4OAc (3.03 g, 39.3 mmol) in HOAc (20 mL) was heated to 108° C. for 8 h. After concentration, the resulting residue was dissolved in ethyl acetate (30 mL) and washed with sat. NaHCO3 (5 mL). The organic layer was dried over Na2SO4 and concentrated to give the title compound (880 mg, 82%) as a yellow solid without further purification.
-
- A mixture of 6-(5-fluoro-6-methoxypyrimidin-4-yl)-1,7-naphthyridin-8-ol (440 mg, 1.62 mmol) and triethylamine (327 mg, 3.24 mmol) in POCl3 (7.5 mL) and toluene (2.5 mL) was heated to 100° C. for 1 h. After concentration, the residue was dissolved in ethyl acetate (20 mL) and washed with sat. NaHCO3 (5 mL). The organic layer was dried over Na2SO4 and concentrated. The resulting residue was purified by column chromatography (petroleum ether:ethyl acetate=2:1) to give the title compound (440 mg, 100%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 8.68 (s, 1H), 8.47 (s, 1H), 8.34 (d, J=8.2 Hz, 1H), 7.78-7.74 (m, 1H), 4.16 (s, 3H).
-
- A mixture of 8-chloro-6-(5-fluoro-6-methoxypyrimidin-4-yl)-1,7-naphthyridine (440 mg, 1.62 mmol), triethylamine (924 mg, 9.15 mmol), formic acid (253 mg, 5.50 mmol) and Pd(PPh3)4 (200 mg, 0.173 mmol) in DMSO (10 mL) was stirred at 100° C. under N2 atmosphere for 1 h. After cooling to room temperature, the mixture was diluted with ethyl acetate (40 mL) and filtered. The filtrate was washed with brine (10 mL×3), dried over Na2SO4, and concentrated. The residue was purified by column chromatography (petroleum ether:ethyl acetate=3:1) to give the title compound (400 mg, 96%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 9.70 (s, 1H), 9.12 (d, J=3.6 Hz, 1H), 8.70 (s, 1H), 8.52 (s, 1H), 8.30 (d, J=8.4 Hz, 1H), 7.56-7.53 (m, 1H), 4.16 (s, 3H).
-
- A mixture of 6-(5-fluoro-6-methoxypyrimidin-4-yl)-1,7-naphthyridine (400 mg, 1.56 mmol) in 37% HBr (10 mL) was heated at reflux for 1 h. After concentration, the resulting residue was suspended in isopropanol (10 mL). The precipitate was filtered and washed with ether (3 mL) to give the title compound (400 mg, quantitative) as a yellow solid.
-
- To a stirred solution of 5-fluoro-6-(1,7-naphthyridin-6-yl)pyrimidin-4-ol (25 mg, 0.1 mmol), (3-fluoro-2′-methyl-2,4′-bipyridin-5-yl)methanamine (22 mg, 0.1 mmol), and N,N-diisopropylethylamine (26 mg, 0.2 mmol) in N,N-Dimethylformamide (1 mL) at room temperature, was added PyBOP (78 mg, 0.15 mmol) in portions. The mixture was stirred at room temperature for 12 h and then diluted with ethyl acetate (5 mL). The organic phase was washed with brine (2 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography (CH2Cl2:MeOH=100:4) to give the title compound (30 mg, 68%) as a white solid.
-
-
- To a solution of 2-bromo-5-methylnicotinonitrile (5 g, 25.4 mmol) in MeCN (100 mL) was added NBS (6.8 g, 38 mmol) and BPO (100 mg, 0.41 mmol). The mixture was heated at reflux overnight, and then BPO (50 mg, 0.21 mmol) was added. The mixture was heated at reflux for another 12 h. After cooling to room temperature, the mixture was concentrated and purified by column chromatography (petroleum ether:ethyl acetate=100:1-50:1) to give the title compound (4.3 g, 61%) as a brown solid.
-
- To a solution of 2-bromo-5-(bromomethyl)nicotinonitrile (2.3 g, 8.2 mmol) in DMSO (40 mL) in ice bath, was added NaN3 (637 mg, 9.8 mmol). The mixture was stirred at room temperature for 30 min before H2O (100 mL) was added. The mixture was extracted with EtOAc (100 mL×3). The combined organic layers was washed with brine (50 mL×3), dried over Na2SO4 and concentrated to give a white solid (940 mg). THF (15 mL) was added followed by PPh3 (1.14 g, 4.34 mmol) and H2O (3 mL) and the mixture was heated at reflux 10 h. After cooling to room temperature, the mixture was diluted with EtOAc (100 mL), and extracted with 0.2 N HCl (20 mL×2). The combined aqueous layers was washed with EtOAc (20 mL) before sat. Na2CO3 was added to adjust PH=9. The aqueous layer was extracted with CH2Cl2 (40 mL×5). The combined organic layers was washed with brine (20 mL), dried over Na2SO4 and concentrated to give a yellow solid (570 mg, 33%).
-
- To a solution of (6-chloro-5-fluoropyridin-3-yl)methanamine (570 mg, 2.69 mmol) in dioxane (15 mL) and H2O (3 mL) was added 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.43 g, 45%, 2.96 mmol), K2CO3 (1.12 g, 8.07 mmol) and Pd(PPh3)4 (310 mg, 0.27 mmol). The mixture was stirred at 100° C. under N2 atmosphere for 8 h. After cooling to room temperature, the mixture was filtered through Celite. The filtrate was diluted with H2O (10 mL), and extracted with EtOAc (50 mL×6). The combined organic layers was dried over Na2SO4 and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate=2:1-1:1) to give the title compound (570 mg, 95%) as a gray solid.
-
- To a solution of 2,3-difluoropyridin-4-ylboronic acid (105 mg, 0.66 mmol) and 1,7-naphthyridin-6-yl trifluoromethanesulfonate (167 mg, 0.6 mmol) in dioxane (4 mL) and H2O (1 mL), was added Pd(dppf)Cl2 (39 mg, 0.048 mmol), dppf (26 mg, 0.048 mmol) and K3PO4 (254 mg, 1.2 mmol). The mixture was stirred at 100° C. under N2 atmosphere for 8 h. After cooling to room temperature, the mixture was concentrated and purified by silica gel column chromatography (petroleum ether:EtOAc=1:1) to give the title compound (80 mg, 47%) as a white solid.
-
- To a solution of 5-(aminomethyl)-2′-methyl-2,4′-bipyridine-3-carbonitrile (89 mg, 0.4 mmol) and N,N-diisopropylethylamine (206 mg, 1.6 mmol) in NMP (1 mL), was added 6-(2,3-difluoropyridin-4-yl)-1,7-naphthyridine (49 mg, 0.2 mmol). The mixture was stirred at 135° C. under N2 atmosphere for 18 h. After cooling to room temperature, the mixture was diluted with H2O (10 mL), and extracted with EtOAc (20 mL×3). The combined organic layers was washed with brine (10 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=50:1) to give the title compound (42 mg, 48%) as a yellow solid.
-
-
- To a solution of 6-chloro-N-(4-(2-methylpyridin-4-yl)benzyl)pyrimidin-4-amine (400 mg, 1.29 mmol) and 2-(methylthio)-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one (305 mg, 1.55 mmol) in dioxane (10 mL) was added Pd(PPh3)4 (60 mg, 0.05 mmol), Xantphos (60 mg, 0.11 mmol) and Cs2CO3 (1.0 g, 3.23 mmol). The mixture was stirred at reflux overnight. After cooling to room temperature, the mixture was diluted with EtOAc (20 mL), and washed with H2O (6 mL×3). The organic layer was dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=1:2) to give the title compound (180 mg, 31%) as a white solid.
-
-
- To a solution of 6-(6-(4-(2-methylpyridin-4-yl)benzylamino)pyrimidin-4-yl)-2-(methylthio)-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one (50 mg, 0.11 mmol) in THF (3 mL) and H2O (1 mL) was added oxone (69 mg, 0.22 mmol), and the mixture was stirred at room temperature for 4 h. After concentration, the title compound (120 mg, crude) was obtained as a yellow solid, which was used directly in the next step without further purification.
-
- A mixture of 6-(6-(4-(2-methylpyridin-4-yl)benzylamino)pyrimidin-4-yl)-2-(methylthio)-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one (50 mg, 0.1 mmol), methanamine hydrochloride (68 mg, 1.0 mmol), and N,N-diisopropylethylamine (194 mg, 1.5 mmol) in t-BuOH (3 mL) was stirred at 120° C. overnight. After cooling to room temperature, the mixture was diluted with EtOAc (40 mL) and washed with H2O (8 mL×3). The organic layer was dried over Na2SO4 and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=60:1) to give the title compound (31 mg, 68%) as a white solid.
-
-
- To a solution of naphthalen-2-ylboronic acid (206 mg, 1.20 mmol) and 4-chloropyridin-2-amine (128 mg, 1.00 mmol) in dioxane (16 mL) and H2O (4 mL), was added Pd(PPh3)4 (115 mg, 0.10 mmol) and K2CO3 (276 mg, 2.00 mmol). The mixture was stirred at 80° C. under N2 atmosphere for 12 h. After cooling to room temperature, the mixture was filtered through Celite. The filtrate was diluted with EtOAc (40 mL), washed with brine (20 mL), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=100:3) to give the title compound (120 mg, 55%) as a yellow solid.
-
- To a solution of 4-(naphthalen-2-yl)pyridin-2-amine (110 mg, 0.50 mmol) and 4-bromobenzaldehyde (95 mg, 0.50 mmol) in MeCN (10 mL), was added trifluoroacetic acid (574 mg, 5.00 mmol) and triethylsilane (580 mg, 5.00 mmol). The mixture was stirred at 80° C. for 12 h. After cooling to room temperature, the mixture was diluted with EtOAc (40 mL), washed with sat. NaHCO3 (10 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=5:1) to give the title compound (80 mg, 41%) as a yellow solid.
-
- To a solution of N-(4-bromobenzyl)-4-(naphthalen-2-yl)pyridin-2-amine (130 mg, 0.33 mmol) and 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (27%, 406 mg, 0.50 mmol) in dioxane (20 mL), was added IM aqueous Na2CO3 (1 mL) and Pd(dppf)Cl2 (28 mg, 0.034 mmol). The mixture was stirred at 100° C. under N2 atmosphere for 12 h. After cooling to room temperature, the mixture was filtered through Celite. The filtrate was diluted with EtOAc (40 mL), washed with brine (10 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=100:3) to give the title compound (50 mg, 37%) as a yellow solid.
-
-
- To a solution of 7-methylquinoline-3-carbonitrile (1.5 g, 8.9 mmol) in MeCN (50 mL) was added NBS (2.1 g, 11.8 mmol) and BPO (216 mg, 0.9 mmol). The mixture was heated at reflux overnight. After cooling to room temperature, H2O (100 mL) and EtOAc (100 mL) was added. The aqueous layer was extracted with EtOAc (40 mL×3). The combined organic layers was dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:petroleum ether=3:2) to give the title compound (743 g, 34%) as a white solid.
-
- To a solution of 7-(bromomethyl)quinoline-3-carbonitrile (743 mg, 3 mmol) in DMSO (15 mL), was added NaN3 (293 mg, 4.5 mmol). The mixture was stirred at 50° C. for 1 h. After cooling to room temperature, H2O (75 mL) and EtOAc (75 mL) was added. The organic layer was dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=10:1-5:1) to give the title compound (392 mg, 62%) as a white solid.
-
- To a solution of 7-(azidomethyl)quinoline-3-carbonitrile (392 mg, 1.87 mmol) in THF (10 mL) was added PPh3 (541 mg, 2.1 mmol). The mixture was heated at reflux for 5 min before H2O (1 mL) was added. The mixture was heated at reflux for another 1 h. After cooling to room temperature, the mixture was diluted with EtOAc (100 mL), and extracted with 1 N HCl (100 mL). To the aqueous layer was added NH4OH to adjust PH=8. The mixture was extracted with EtOAc (100 mL). The organic layer was dried over Na2SO4 and concentrated to give the title compound (340 mg, 99%) as a pale yellow solid.
-
- To a solution of 4-chloro-2-(methy thio)pyrimidine (1.6 g, 0 mmol) and 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (3.06 g, 12 mmol) in dioxane (50 mL) and H2O (12.5 mL), was added Pd(dppf)Cl2 (653 mg, 0.80 mmol), dppf (443 mg, 0.80 mmol) and K3PO4 (4.24 g, 20 mmol). The mixture was stirred at 100° C. under N2 atmosphere for 12 h. After cooling to room temperature, the mixture was concentrated and purified by silica gel column chromatography (CH2Cl2:MeOH=25:1) to give the title compound (2.0 g, 80%) as a yellow solid.
-
- To a solution of 6-(2-(methylthio)pyrimidin-4-yl)quinoline (1.24 g, 4.9 mmol) in CH2Cl2 (50 mL) was added m-CPBA (1.79 g, 85%, 8.82 mmol). The mixture was stirred at room temperature for 2 h and sat. Na2S2O3 (15 mL) and sat. NaHCO3 (15 mL) was added to quench the reaction. The mixture was extracted with CH2Cl2 (100 mL×3), dried over Na2SO4, and concentrated to give the title compound (1.1 g, 78%) as a yellow solid.
-
- To a solution of 7-(aminomethyl)quinoline-3-carbonitrile (39 mg, 0.21 mmol) in NMP (1.5 mL) was added 6-(2-(methylsulfonyl)pyrimidin-4-yl)quinoline (50 mg, 0.18 mmol) and N,N-diisopropylethylamine (190 mg, 1.4 mmol). The mixture was stirred at 130° C. overnight. After cooling to room temperature, the mixture was diluted with H2O (50 mL) and EtOAc (50 mL). The aqueous layer was separated and extracted with EtOAc (30 mL×3). The combined organic layers was dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=100:1-20:1) to give the title compound (25 mg, 36%) as a yellow solid.
-
-
- To a solution of 2,3-difluoropyridin-4-ylboronic acid mg, 1.1 mmol) and 2-chloro-1,5-naphthyridine (164 mg, 1.0 mmol) in dioxane (4 mL) and H2O (1 mL), was added Pd(dppf)Cl2 (65 mg, 0.08 mmol), dppf (44 mg, 0.08 mmol) and K3PO4 (424 mg, 2.0 mmol). The mixture was stirred at 100° C. under N2 atmosphere for 12 h. After cooling to room temperature, the mixture was concentrated and purified by silica gel column chromatography (petroleum ether:EtOAc=1:1) to give the title compound (130 mg, 53%) as a white solid.
-
- To a solution of 2-(2,3-difluoropyridin-4-yl)-1,5-naphthyridine (70 mg, 0.29 mmol) in DMSO (2 mL) was added (3-fluoro-2′-methyl-2,4′-bipyridin-5-yl)methanamine (93 mg, 0.43 mmol) and K2CO3 (80 mg, 0.58 mmol). The mixture was stirred at 135° C. for 18 h. After cooling to room temperature, the mixture was diluted with H2O (30 mL), and extracted with EtOAc (30 mL×3). The combined organic layers was washed with brine (30 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=30:1) to give the title compound (10 mg, 8%) as a yellow solid.
-
-
- To a stirred solution of N-(tert-butyl)-3-methylpicolinamide (2.0 g, 10 mmol) in anhydrous tetrahydrofuran (100 mL) at −40° C., was added lithium diisopropylamide (2 M in THF, 12.5 mL, 25 mmol) dropwise. The mixture was stirred at this temperature for 30 min and then cooled to −60° C. Ethyl 2-(methylthio)pyrimidine-4-carboxylate (2.0 g, 10 mmol) in anhydrous THF (10 mL) was added and the reaction mixture was stirred at −60° C. for another 1 h. The reaction was quenched with sat. NH4Cl (50 mL) and extracted with ethyl acetate (80 mL×3). The combined organic layers dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate=5:1) to give the title compound (1.2 g, 35%) as a yellow solid.
-
- A mixture of N-tert-butyl-3-(2-(2-(methylthio)pyrimidin-4-yl)-2-oxoethyl)picolinamide (500 mg, 1.45 mmol) and NH4OAc (1.11 g, 14.5 mmol) in HOAc (10 mL) was heated to 108° C. for 8 h. After concentration, the resulting residue was dissolved in ethyl acetate (30 mL) and washed with sat. NaHCO3 (5 mL). The organic layer was dried over Na2SO4 and concentrated to give the title compound (350 mg, 89%) as a yellow solid without further purification.
-
- A solution of 6-(2-(methylthio)pyrimidin-4-yl)-1,7-naphthyridin-8-ol (350 mg, 1.3 mmol) in POCl3 (6 mL) was heated to 100° C. for 1 h. After concentration, the residue was dissolved in ethyl acetate (20 mL) and washed with sat. NaHCO3 (5 mL). The organic layer was dried over Na2SO4 and concentrated. The resulting residue was purified by column chromatography (petroleum ether:ethyl acetate=5:1) to give the title compound (350 mg, 93%) as a pale yellow solid.
-
- A mixture of 8-chloro-6-(2-(methylthio)pyrimidin-4-yl)-1,7-naphthyridine (350 mg, 1.2 mmol), triethylamine (924 mg, 9.15 mmol), formic acid (253 mg, 5.50 mmol) and Pd(PPh3)4 (138 mg, 0.12 mmol) in DMSO (5 mL) was stirred at 100° C. under N2 atmosphere for 3 h. After cooling to room temperature, the mixture was diluted with ethyl acetate (40 mL) and filtered. The filtrate was washed with brine (10 mL×3), dried over Na2SO4, and concentrated. The residue was purified by column chromatography (petroleum ether:ethyl acetate=5:1) to give the title compound (180 mg, 59%) as a pale yellow solid.
-
- To a solution of 6-(2-(methylthio)pyrimidin-4-yl)-1,7-naphthyridine (180 mg, 0.71 mmol) in THF (5 mL) and H2O (0.5 mL) was added oxone (497 mg, 1.56 mmol), and the mixture was stirred at room temperature for 10 h. After concentration, the title compound (680 mg, crude) was obtained as a yellow solid, which was used directly in the next step without further purification.
-
- To a solution of 5-(aminomethyl)-2′-methyl-2,4′-bipyridine-3-carbonitrile (68 mg, 0.3 mmol) and N,N-diisopropylethylamine (194 mg, 1.5 mmol) in NMP (1 mL), was added 6-(2-(methylsulfonyl)pyrimidin-4-yl)-1,7-naphthyridine (140 mg, 30%, 0.15 mmol). The mixture was stirred at 135° C. under N2 atmosphere for 16 h. After cooling to room temperature, the mixture was diluted with H2O (10 mL), and extracted with EtOAc (20 mL×3). The combined organic layers was washed with brine (10 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=50:1) to give the title compound (12 mg, 19%) as a pale yellow solid.
-
-
- To a solution of 3-methylquinoline-7-carbonitrile (1.5 g, 8.9 mmol) in MeCN (80 mL) was added NBS (1.9 g, 10.7 mmol) and BPO (216 mg, 0.9 mmol). The mixture was heated at reflux overnight. After cooling to room temperature, H2O (100 mL) and EtOAc (100 mL) was added. The aqueous layer was extracted with EtOAc (40 mL×3). The combined organic layers was dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:petroleum ether=8:1) to give the title compound (1.0 g, 45%) as a pale yellow solid.
-
- To a solution of 3-(bromomethyl)quinoline-7-carbonitrile (1 g, 4.1 mmol) in DMSO (20 mL), was added NaN3 (395 mg, 6.2 mmol). The mixture was stirred at 50° C. for 1 h. After cooling to room temperature, H2O (100 mL) and EtOAc (100 mL) was added. The aqueous layer was extracted with EtOAc (40 mL×3). The combined organic layers was dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=10:1-5:1) to give the title compound (800 mg, 93%) as a yellow solid.
-
- To a solution of 3-(azidomethyl)quinoline-7-carbonitrile (800 mg, 3.8 mmol) in THF (20 mL) was added PPh3 (1.1 g, 4.2 mmol). The mixture was heated at reflux for 5 min before H2O (2 mL) was added. The mixture was heated at reflux for another 1 h. After cooling to room temperature, the mixture was diluted with EtOAc (100 mL), and extracted with 1 N HCl (100 mL). To the aqueous layer was added NH4OH to adjust PH=8. The mixture was extracted with EtOAc (30 mL×3). The combined organic layers was washed with brine (30 mL×3), dried over Na2SO4 and concentrated to give the title compound (400 mg, 56%) as a pale yellow solid.
-
- To a solution of 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (280 mg, 1.1 mmol) and 3,5-dichloro-1,2,4-thiadiazole (155 mg, 1.0 mmol) in dioxane (6 mL) and H2O (1.5 mL), was added Pd(dppf)Cl2 (65 mg, 0.08 mmol), dppf (44 mg, 0.08 mmol) and K3PO4 (420 mg, 2.0 mmol). The mixture was stirred at 100° C. under N2 atmosphere for 12 h. After cooling to room temperature, the mixture was concentrated and purified by silica gel column chromatography (petroleum ether:EtOAc=3:1) to give the title compound (200 mg, 81%) as a gray solid. 1H NMR (400 MHz, CDCl3) δ 9.03 (d, J=3.2 Hz, 1H), 8.53 (s, 1H), 8.29 (d, J=8.0 Hz, 1H), 8.24 (d, J=8.8 Hz, 1H), 8.18 (d, J=8.8 Hz, 1H), 7.53 (dd, J=8.0, 4.0 Hz, 1H).
-
- To a solution of 3-(aminomethyl)quinoline-7-carbonitrile (59 mg, 0.32 mmol) in NMP (1.5 mL) was added 3-chloro-5-(quinolin-6-yl)-1,2,4-thiadiazole (40 mg, 0.16 mmol) and N,N-diisopropylethylamine (165 mg, 1.28 mmol). The mixture was stirred at 135° C. for 40 h. After cooling to room temperature, the mixture was diluted with H2O (30 mL), and extracted with EtOAc (30 mL×3). The combined organic layers was washed with brine (30 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=30:1) to give the title compound (12 mg, 19%) as an orange solid.
-
-
- To a suspension of NaBH4 (1.65 g, 43.3 mmol) in EtOH (100 mL) at 0° C. was added a solution of methyl 6-iodo-5-methoxynicotinate (2.54 g, 8.67 mmol) in EtOH (30 mL) dropwise. The mixture was stirred at room temperature for 20 h. After concentration, H2O (100 mL) was added and the mixture was extracted with CH2Cl2 (100 mL×3). The combined organic layers was dried over Na2SO4, and concentrated to give the title compound (2.0 g, 87%) as a colorless oil. 1HNMR (400 MHz, CDCl3) δ 8.18 (d, J=2.0 Hz, 1H), 8.13 (s, 1H), 7.94 (s, 1H), 7.09 (s, 1H), 4.71 (s, 2H), 3.92 (s, 3H).
-
- To a solution of (6-iodo-5-methoxypyridin-3-yl)methanol (2.0 g, 7.55 mmol) and Et3N (3.05 g, 30.2 mmol), was added MsCl (1.72 g, 15.1 mmol). The mixture was stirred at room temperature overnight and then washed with brine (50 mL×2). The combined organic layers was dried over Na2SO4, and concentrated. The resulting residue was dissolved in DMSO (40 mL), and NaN3 (873 mg, 13.4 mmol) was added. After stirring at room temperature for 8 h, H2O (50 mL) was added and the mixture was extracted with EtOAc (50 mL×3). The combined organic layers was washed with brine (100 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=10:1) to give the title compound (1.35 g, 61%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J=1.6 Hz, 1H), 6.96 (d, J=1.6 Hz, 1H), 4.38 (s, 2H), 3.94 (s, 3H).
-
- To a solution of 5-(azidomethyl)-2-iodo-3-methoxypyridine (1.35 g, 4.66 mmol) in THF (20 mL) was added PPh3 (1.14 g, 4.34 mmol). The mixture was heated at reflux and H2O (3 mL) was added. The mixture was heated at reflux for 8 h. After cooling to room temperature, the mixture was diluted with EtOAc (40 mL), and extracted with 0.2 N HCl (50 mL). The aqueous layer was washed with EtOAc (50 mL) before NaOH was added to adjust PH=10. The aqueous layer was extracted with CH2Cl2 (50 mL×6). The combined organic layers was dried over Na2SO4 and concentrated to give the title compound (1.18 g, 96%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.07 (s, 1H), 3.92 (s, 3H), 3.89 (s, 2H).
-
- To a solution of (6-iodo-5-methoxypyridin-3-yl)methanamine (1.12 g, 4.24 mmol) in dioxane (20 mL) and H2O (4 mL) was added 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (1.51 g, 50%, 5.52 mmol), K2CO3 (2.34 g, 17.0 mmol) and Pd(PPh3)4 (245 mg, 0.21 mmol). The mixture was stirred at reflux under N2 atmosphere overnight. After cooling to room temperature, the mixture was filtered through Celite. The filtrate was diluted with EtOAc (100 mL). The organic layer was separated, dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=100:1-50:1) to give the title compound (730 mg, 75%) as a brown oil. 1H NMR (400 MHz, CDCl3) δ 8.55 (d, J=5.2 Hz, 1H), 8.27 (s, 1H), 7.71 (s, 1H), 7.67 (d, J=5.2 Hz, 1H), 7.38 (s, 1H), 3.99 (s, 2H), 3.93 (s, 3H), 2.62 (s, 3H).
-
- A mixture of 1,7-naphthyridin-6-yl trifluoromethanesulfonate (1.3 g, 4.76 mmol), 1,1,1,2,2,2-hexamethyldistannane (2.3 g, 7.0 mmol), LiCl (590 mg, 14.0 mmol), and Pd(PPh3)4 (270 mg, 0.23 mmol) in dioxane (20 mL) was heated at reflux under N2 atmosphere for 3 h. After cooling to room temperature, the mixture was concentrated. The residue was dissolved in EtOAc (30 mL) and washed with brine (30 mL). The organic layer was dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=10:1) to give the title compound (600 mg, 43%) as an colorless oil.
-
- To a solution of 6-(trimethylstannyl)-1,7-naphthyridine (29 mg, 0.1 mmol) and 3,5-dichloro-1,2,4-thiadiazole (21 mg, 0.17 mmol) in toluene (1 mL) was added Pd(PPh3)4 (12 mg, 0.01 mmol) and CuI (2 mg, 0.01 mmol). The mixture was stirred at 110° C. under N2 atmosphere overnight. After cooling to room temperature, the mixture was concentrated and purified by silica gel column chromatography (CH2Cl2:MeOH=80:1) to give the title compound (17 mg, 70%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 9.52 (s, 1H), 9.14 (d, J=3.6 Hz, 1H), 8.60 (s, 1H), 8.33 (d, J=8.4 Hz, 1H), 7.73 (dd, J=8.0, 4.0 Hz, 1H).
-
- To a solution of (3-methoxy-2′-methyl-2,4′-bipyridin-5-yl)methanamine (37 mg, 0.16 mmol) in NMP (1.5 mL) was added 3-chloro-5-(1,7-naphthyridin-6-yl)-1,2,4-thiadiazole (20 mg, 0.08 mmol) and N,N-diisopropylethylamine (83 mg, 0.64 mmol). The mixture was stirred at 135° C. for 40 h. After cooling to room temperature, the mixture was diluted with H2O (30 mL), and extracted with EtOAc (30 mL×3). The combined organic layers was washed with brine (30 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (CH2Cl2:MeOH=30:1) to give the title compound (8 mg, 23%) as a pale yellow solid.
-
-
- To a solution of 3,5-dichloro-1,2,4-thiadiazole (155 mg, 1.0 mmol) in i-PrOH (10 mL) was added 5,6,7,8-tetrahydro-1,6-naphthyridine (134 mg, 1.0 mmol) and N,N-diisopropylethylamine (645 mg, 5.0 mmol), and the mixture was stirred at room temperature overnight. The mixture was diluted with H2O (30 mL), and extracted with EtOAc (30 mL×3). The combined organic layers was washed with brine (30 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=2:1) to give the title compound (180 mg, 71%) as a gray solid.
-
- To a solution of 5-(aminomethyl)-2′-methyl-2,4′-bipyridine-3-carbonitrile (185 mg, 0.83 mmol) and N,N-diisopropylethylamine (213 mg, 1.65 mmol) in cyclohexanol (3 mL) in sealed tube was added 3-chloro-5-(7,8-dihydro-1,6-naphthyridin-6(5H)-yl)-1,2,4-thiadiazole (140 mg, 0.55 mmol) and ZnCl2 (83 mg, 0.61 mmol). The mixture was stirred at 120° C. for 40 h. After cooling to room temperature, the mixture was purified by silica gel column chromatography (petroleum ether:EtOAc=5:1-CH2Cl2:MeOH=30:1) to give the title compound (12 mg, 5%) as a yellow solid.
-
-
- A mixture of 5,6,7,8-tetrahydro-1,6-naphthyridine hydrochloride (1.7 g, 10 mmol), 2,3-difluoro-4-iodopyridine (4.8 g, 20 mmol), Cs2CO3 (16.3 g, 50 mmol), Pd2(dba)3 (460 mg, 0.5 mmol) in toluene (20 mL) was heated at reflux under N2 atmosphere for 12 h. After cooling to room temperature, the mixture was filtered through Celite and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=4:1-1:1) to give the title compound (2.3 g, 88%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.48 (d, J=4.2 Hz, 1H), 7.72 (d, J=5.6 Hz, 1H), 7.45 (d, J=7.6 Hz, 1H), 7.17 (m, 1H), 6.69 (m, 1H), 4.57 (s, 2H), 3.81 (m, 2H), 3.18 (m, 2H).
-
- To a solution of 6-(2,3-difluoropyridin-4-yl)-5,6,7,8-tetrahydro-1,6-naphthyridine (50 mg, 0.21 mmol) and (3-fluoro-2′-methyl-2,4′-bipyridin-5-yl)methanamine (66 mg, 0.3 mmol) in NMP (1 mL), was added K2CO3 (131 mg, 1.0 mmol). The mixture was stirred at 160° C. for 12 h. After cooling to room temperature, the mixture was diluted with H2O (5 mL), and extracted with EtOAc (10 mL×3). The combined organic layers was washed with brine (10 mL×3), dried over Na2SO4, and concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc=1:1-0:1) to give the title compound (4 mg, 5%) as a yellow solid.
- Table 2 shows a selection of compounds prepared according to the methods discussed above in detail and indicated in the Third column of the table:
-
TABLE 2 Selected compounds (A-1 to A-202) of the present invention. ESI- MS Compd Meth- (m/z): NO. Structure od 1HNMR [M + 1]+ A-1 A 1H NMR (400 MHz, CDCl3) δ 8.55 (d, J = 5.0 Hz, 3H), 8.13 (d, J = 8.8 Hz, 1H), 7.95 (d, J = 8.8 Hz, 2H), 7.89(d, J = 7.2 Hz, 1H), 7.64(d, J = 8.0 Hz, 2H), 7.58- 7.51(m, 4H), 7.38(s, 1H), 7.32(d, J = 4.0 Hz, 1H), 5.59(s, 1H), 4.86(d, J = 6.0 Hz, 2H), 2.63(s, 3H). 421.0 A-2 A 1HNMR(400 MHz, CDCl3)δ9.55(s, 1H), 8.86(s, 1H), 8.57(d, J = 2.0 Hz, 1H), 8.55(d, J = 5.2 Hz, 1H), 8.17(d, J = 8.8 Hz, 1H), 7.95(d, J = 8.0 Hz, 1H), 7.80(t, J = 7.8 Hz, 1H), 7.66-7.60(m, 3H), 7.52(d, J = 8.4 Hz, 2H), 7.37(s, 1H), 7.31(d, J = 4.0 Hz, 1H), 5.68(s, 1H), 4.87(d, J = 6.0 Hz, 2H), 2.63(s, 3H). 422.0 A-3 A 1HNMR(400 MHz, CDCl3)δ8.99-8.98(m, 1H), 8.78(s, 1H), 8.59-8.51(m, 2H), 8.26(d, J = 8.4 Hz, 1H), 8.21(d, J = 8.4 Hz, 1H), 7.95(d, J = 8.4 Hz, 1H), 7.64(d, J = 8.4 Hz, 2H), 7.52(d, J = 8.4 Hz, 2H), 7.48- 7.45(m, 1H), 7.37(s, 1H), 7.32(d, J = 4.8 Hz, 1H), 5.70(s, 1H), 4.86(d, J = 6.0 Hz, 2H), 2.63(s, 3H). 422.0 A-4 A 1HNMR (400 MHz, CDCl3)δ8.99-8.98(m, 1H), 8.55- 8.54(m, 3H), 8.38(d, J = 9.2 Hz, 1H), 8.27(d, J = 8.0 Hz, 1H), 8.21(d, J = 8.8 Hz, 1H), 7.65(d, J = 8.0 Hz, 2H), 7.52(d, J = 8.0 Hz, 2H), 7.48-7.45(m, 1H), 7.37(s, 1H), 7.31(d, J = 5.2 Hz, 1H), 5.65(s, 1H), 4.87(d, J = 5.6 Hz, 2H), 2.63(s, 3H). 422.0 A-5 A 1HNMR(400 MHz, CDCl3)δ8.55-8.54(m, 2H), 8.51(s, 1H), 8.34(d, J = 9.2 Hz, 1H), 8.15(d, J = 8.8 Hz, 1H), 8.11(d, J = 8.8 Hz, 1H), 7.64(d, J = 8.0 Hz, 2H), 7.51(d, J = 7.6 Hz, 2H), 7.37(s, 1H), 7.34(d, J = 8.4 Hz, 1H), 7.31(d, J = 4.8 Hz, 1H), 5.62(s, 1H), 4.86(d, J = 6.0 Hz, 2H), 2.78(s, 3H), 2.63(s, 3H). 436.0 A-6 A 1HNMR(400 MHz, CDCl3)δ9.32(s, 1H), 8.60(d, J = 5.6 Hz, 1H), 8.57(d, J = 2.0 Hz, 1H), 8.55(d, J = 5.6 Hz, 1H), 8.52(s, 1H), 8.25(d, J = 8.4 Hz, 1H), 8.10(d, J = 8.8 Hz, 1H), 7.76(d, J = 5.6 Hz, 1H), 7.65(d, J = 8.0 Hz, 2H), 7.52(d, J = 8.0 Hz, 2H), 7.37(s, 1H), 7.32(d, J = 5.2 Hz, 1H), 5.65(s, 1H), 4.87(d, J = 6.0 Hz, 2H), 2.63(s, 3H). 422.0 A-7 A 1HNMR(400 MHz, CDCl3)δ9.37(s, 1H), 8.70(s, 1H), 8.60(d, J = 5.6 Hz, 1H), 8.56(s, 2H), 8.38(d, J = 8.8 Hz, 1H), 7.95(d, J = 8.4 Hz, 1H), 7.71(d, J = 5.6 Hz, 1H), 7.66(d, J = 8.0 Hz, 2H), 7.53(d, J = 8.0 Hz, 2H), 7.41(s, 1H), 7.36(d, J = 5.6 Hz, 1H), 5.64(s, 1H), 4.88(d, J = 6.0 Hz, 2H), 2.66(s, 3H). 422.0 A-8 A 1HNMR(400 MHz, CDCl3)δ8.91(d, J = 2.8 Hz, 2H), 8.79(s, 1H), 8.57(s, 1H), 8.55(d, J = 5.2 Hz, 1H), 8.49(d, J = 8.4 Hz, 1H), 8.23(d, J = 8.8 Hz, 1H), 7.65(d, J = 8.0 Hz, 2H), 7.52(d, J = 8.0 Hz, 2H), 7.37(s, 1H), 7.31(d, J = 4.8 Hz, 1H), 5.68(s, 1H), 4.87(d, J = 5.6 Hz, 2H), 2.63(s, 3H). 423.0 A-9 A 1HNMR(400 MHz, CDCl3)δ9.51(s, 1H), 9.40(s, 1H), 8.67(s, 1H), 8.62(d, J = 8.4 Hz, 1H), 8.56-8.54(m, 2H), 8.17(d, J = 8.4 Hz, 1H), 7.65(d, J = 8.0 Hz, 2H), 7.52(d, J = 8.0 Hz, 2H), 7.38(s, 1H), 7.32(d, J = 5.2 Hz, 1H), 5.69(s, 1H), 4.88(d, J = 5.6 Hz, 2H), 2.64(s, 3H). 423.0 A-10 A 1HNMR(400 MHz, DMSO)δ8.49(d, J = 5.2 Hz, 1H), 8.42-8.34(m, 2H), 8.33(s, 1H), 8.23(s, 1H), 7.88(d, J = 9.2 Hz, 1H), 7.76(d, J = 8.4 Hz, 2H), 7.71(d, J = 8.4 Hz, 1H), 7.59(s, 1H), 7.50(d, J = 7.6 Hz, 3H), 4.71(d, J = 6.0 Hz, 2H), 2.53(s, 3H). A-11 A 1HNMR(400 MHz, CDCl3)δ9.00(s, 1H), 8.55(d, J = 4.8 Hz, 1H), 8.46(s, 1H), 7.97(s, 2H), 7.76(s, 1H), 7.69(s, 1H), 7.63(d, J = 7.6 Hz, 2H), 7.51(d, J = 8.0 Hz, 2H), 7.36(s, 1H), 7.31(d, J = 4.8 Hz, 1H), 5.77(s, 1H), 4.85(d, J = 5.6 Hz, 2H), 2.63(s, 3H). 411.0 A-12 A 1HNMR(400 MHz, CDCl3) δ 9.10 (s, 1H), 8.70 (s, 1H), 8.55-8.52 (m, 2H), 8.27-8.17 (m, 2H), 7.64 (d, J = 8.4 Hz, 2H), 7.51(d, J = 8.0 Hz, 2H), 7.37(s, 1H), 7.31(d, J = 5.2 Hz, 1H), 5.63(s, 1H), 4.86(d, J = 5.6 Hz, 2H), 2.63(s, 3H). 427.9 A-13 A 1HNMR(400 MHz, DMSO)δ13.28(s, 1H), 8.47(d, J = 5.2 Hz, 1H), 8.43(s, 1H), 8.39(t, J = 6.0 Hz, 1H), 8.33(d, J = 2.0 Hz, 1H), 8.22(s, 1H), 8.01(d, J = 9.2 Hz, 1H), 7.75(d, J = 8.0 Hz, 2H), 7.66(d, J = 8.8 Hz, 1H), 7.56(s, 1H), 7.50-7.47(m, 3H), 4.71(d, J = 6.0 Hz, 2H), 2.52(s, 3H). 411.0 A-14 A 1HNMR(400 MHz, CDCl3)δ8.54(d, J = 5.2 Hz, 1H), 8.50(s, 1H), 8.40(s, 1H), 8.01(s, 1H), 7.96(d, J = 9.2 Hz, 1H), 7.78(d, J = 9.2 Hz, 1H), 7.63(d, J = 8.0 Hz, 2H), 7.50(d, J = 8.0 Hz, 2H), 7.36(s, 1H), 7.31(d, J = 5.2 Hz, 1H), 5.56(s, 1H), 4.84(d, J = 5.6 Hz, 2H), 4.25(s, 3H), 2.62(s, 3H). 425.0 A-15 A 1HNMR(400 MHz, CDCl3)δ8.55(d, J = 5.2 Hz, 1H), 8.51(d, J = 1.6 Hz, 1H), 8.46(s, 1H), 8.12(d, J = 9.2 Hz, 1H), 8.08(s, 1H), 7.64(d, J = 8.4 Hz, 2H), 7.54- 7.47(m, 3H), 7.37(s, 1H), 7.31(d, J = 5.2 Hz, 1H), 5.57(s, 1H), 4.85(d, J = 6.0 Hz, 2H), 4.12(s, 3H), 2.63(s, 3H). 425.0 A-16 A 1HNMR(400 MHz, CDCl3)δ8.54(d, J = 4.8 Hz, 1H), 8.45(s, 1H), 7.63(d, J = 8.0 Hz, 3H), 7.58(d, J = 8.8 Hz, 1H), 7.49(d, J = 8.0 Hz, 2H), 7.37(s, 1H), 7.31(d, J = 5.2 Hz, 1H), 6.96(d, J = 8.8 Hz, 1H), 5.52(s, 1H), 4.82(d, J = 5.8 Hz, 2H), 4.31(d, J = 2.4 Hz, 4H), 2.62(s, 3H). 429.0 A-17 A 1HNMR(400 MHz, CDCl3)δ8.54(d, J = 5.2 Hz, 1H), 8.50(d, J = 1.6 Hz, 1H), 8.01(d, J = 7.6 Hz, 2H), 7.63(d, J = 8.0 Hz, 2H), 7.51-7.48(m, 5H), 7.36(s, 1H), 7.31(d, J = 4.8 Hz, 1H), 5.54(s, 1H), 4.84(d, J = 5.8 Hz, 2H), 2.62(s, 3H). 371.0 A-18 A 1HNMR(400 MHz, CDCl3)δ8.54(d, J = 5.2 Hz, 1H), 8.50(d, J = 1.6 Hz, 1H), 8.01(d, J = 7.6 Hz, 2H), 7.63(d, J = 8.4 Hz, 2H), 7.51-7.48(m, 4H), 7.36(s, 1H), 7.31(d, J = 5.2 Hz, 1H), 5.55(s, 1H), 4.84(d, J = 5.6 Hz, 2H), 2.63(s, 3H). A-19 A 1HNMR(400 MHz, CDCl3)δ8.54(d, J = 4.8 Hz, 1H), 8.49(d, J = 1.6 Hz, 1H), 8.04(s, 1H), 7.91(d, J = 7.2 Hz, 1H), 7.63(d, J = 8.0 Hz, 2H), 7.49(d, J = 8.0 Hz, 2H), 7.47-7.39(m, 2H), 7.36(s, 1H), 7.30(d, J = 5.2 Hz, 1H), 5.59(s, 1H), 4.83(d, J = 6.0 Hz, 2H), 2.62(s, 3H). 405.0 A-20 A 1HNMR(400 MHz, CDCl3)δ8.54(d, J = 5.2 Hz, 1H), 8.48(d, J = 1.6 Hz, 1H), 7.99(d, J = 8.0 Hz, 2H), 7.63(d, J = 8.0 Hz, 2H), 7.50-7.45(m, 4H), 7.36(s, 1H), 7.30(d, J = 4.4 Hz, 1H), 5.54(s, 1H), 4.83(d, J = 6.0 Hz, 2H), 2.62(s, 3H). 405.0 A-21 A 1HNMR(400 MHz, CDCl3)δ8.55(d, J = 4.8 Hz, 1H), 8.48(s, 1H), 8.18(s, 1H), 7.90(d, J = 8.4 Hz, 1H), 7.63(d, J = 8.4 Hz, 2H), 7.56(d, J = 8.4 Hz, 1H), 7.49(d, J = 8.0 Hz, 2H), 7.36(s, 1H), 7.30(d, J = 4.8 Hz, 1H), 5.58(s, 1H), 4.83(d, J = 5.6 Hz, 2H), 2.63(s, 3H). 438.9 A-22 A 1HNMR(400 MHz, CDCl3)δ8.53(d, J = 5.2 Hz, 1H), 8.06(s, 1H), 7.60(d, J = 8.0 Hz, 2H), 7.45(d, J = 8.0 Hz, 2H), 7.35(s, 1H), 7.29(d, J = 5.2 Hz, 1H), 7.22- 7.12(m, 4H), 5.10(s, 1H), 4.85(s, 2H), 4.74(d, J = 6.0 Hz, 2H), 3.94(t, J = 5.8 Hz, 2H), 2.97(t, J = 5.8 Hz, 2H), 2.62(s, 3H). A-23 A 1HNMR(400 MHz, CDCl3)δ8.53(d, J = 4.8 Hz, 1H), 8.05(s, 1H), 7.60(d, J = 7.6 Hz, 2H), 7.45(d, J = 7.6 Hz, 2H), 7.35(s, 1H), 7.30(d, J = 4.8 Hz, 1H), 7.20- 7.08(m, 1H), 6.91(m, 2H), 5.10(s, 1H), 4.85(s, 2H), 4.74(d, J = 8 Hz, 2H), 3.94(m, 2H), 2.93(m, 2H), 2.62(s, 3H). 444.0 A-24 A 1HNMR(400 MHz, CDCl3)δ8.53(d, J = 4.8 Hz, 1H), 8.04(s, 1H), 7.60(d, J = 8 Hz, 2H), 7.45(d, J = 8 Hz, 2H), 7.36(s, 1H), 7.31(d, J = 4.8 Hz, 1H), 7.12- 7.07(m, 1H), 6.87(m, 2H), 5.09(s, 1H), 4.81(s, 2H), 4.74(d, J = 6 Hz, 2H), 3.92(m, 2H), 2.92(m, 2H), 2.62(s, 3H). 444.0 A-25 A 1HNMR(400 MHz, CDCl3)δ8.53(d, J = 4.8 Hz, 1H), 8.05(s, 1H), 7.60(d, J = 8.0 Hz, 2H), 7.45(d, J = 8.0 Hz, 3H), 7.36(s, 1H), 7.30(d, J = 4.8 Hz, 1H), 7.09(m, 2H), 5.09(s, 1H), 4.83(s, 2H), 4.74(d, J = 6 Hz, 2H), 3.95(m, 2H), 2.96(m, 2H), 2.62(s, 3H). 503.9 A-26 A 1HNMR(400 MHz, CDCl3)δ8.53(d, J = 5.2 Hz, 1H), 8.44(d, J = 4.4 Hz, 1H), 8.06(s, 1H), 7.60(d, J = 8.0 Hz, 2H), 7.46(d, J = 7.6 Hz, 3H), 7.36(s, 1H), 7.30(d, J = 5.2 Hz, 1H), 7.16-7.13(m, 1H), 5.13(s, 1H), 4.85(s, 2H), 4.75(d, J = 5.6 Hz, 2H), 4.03(t, J = 6.0 Hz, 2H), 3.14(t, J = 5.8 Hz, 2H), 2.62(s, 3H). 427.0 A-27 C 1HNMR(400 MHz, CDCl3)δ8.54-8.53(m, 2H), 8.48(s, 1H), 8.06(d, J = 8.4 Hz, 1H), 7.93(d, J = 8.4 Hz, 2H), 7.87(d, J = 7.6 Hz, 1H), 7.62(d, J = 8.0 Hz, 2H), 7.58-7.48(m, 2H), 7.43(d, J = 8.0 Hz, 2H), 7.36(s, 1H), 7.30(d, J = 4.8 Hz, 1H), 4.98(s, 2H), 3.32(d, J = 3.6 Hz, 3H), 2.62(s, 3H). 435.0 A-28 A 1HNMR(400 MHz, DMSO)δ8.54(s, 1H), 8.48(d, J = 5.2 Hz, 1H), 8.37-8.28(m, 2H), 8.08-8.06(m, 3H), 7.98(d, J = 8.0 Hz, 1H), 7.75(d, J = 8.4 Hz, 2H), 7.64- 7.55(m, 5H), 7.48(d, J = 5.2 Hz, 1H), 5.46-5.39(m, 1H), 2.52(s, 3H), 1.59(d, J = 6.8 Hz, 3H). 435.0 A-29 A 1HNMR(400 MHz, CDCl3)δ8.59(s, 1H), 8.55(s, 1H), 8.46(d, J = 5.2 Hz, 1H), 8.12(d, J = 8.8 Hz, 1H), 7.95(d, J = 8.8 Hz, 2H), 7.88(d, J = 8.0 Hz, 1H), 7.59-7.50(m, 2H), 7.36(d, J = 3.6 Hz, 1H), 7.30(s, 1H), 7.25(d, J = 3.6 Hz, 1H), 7.10(d, J = 3.6 Hz, 1H), 5.63(s, 1H), 4.98(d, J = 6.0 Hz, 2H), 2.58(s, 3H). 427.0 A-30 A 1HNMR(400 MHz, CDCl3)δ8.79(s, 1H), 8.60(d, J = 5.2 Hz, 1H), 8.55(s, 2H), 8.12(d, J = 8.4 Hz, 1H), 7.95(d, J = 8.8 Hz, 2H), 7.89-7.86(m, 2H), 7.82- 7.76(m, 2H), 7.66(d, J = 4.8 Hz, 1H), 7.58-7.51(m, 2H), 5.69(s, 1H), 4.88(d, J = 6.0 Hz, 2H), 2.65(s, 3H). 422.0 A-31 A 1HNMR(400 MHz, CDCl3)δ8.99-8.98(m, 1H), 8.80(d, J = 1.6 Hz, 1H), 8.61(d, J = 5.2 Hz, 1H), 8.55(d, J = 1.6 Hz, 2H), 8.37(d, J = 8.8 Hz, 1H), 8.28(d, J = 7.6 Hz, 1H), 8.21(d, J = 8.8 Hz, 1H), 7.90-7.87(m, 1H), 7.80(d, J = 8.0 Hz, 2H), 7.66(d, J = 4.4 Hz, 1H), 7.49-7.46(m, 1H), 5.73(s, 1H), 4.89(d, J = 6.0 Hz, 2H), 2.65(s, 3H). A-32 A 1HNMR(400 MHz, CDCl3)δ8.72(s, 1H), 8.59(d, J = 5.2 Hz, 1H), 8.44(d, J = 4.4 Hz, 1H), 8.04(s, 1H), 7.84-7.71(m, 3H), 7.65(d, J = 5.2 Hz, 1H), 7.46(d, J = 7.6 Hz, 1H), 7.16-7.13(m, 1H), 5.19(s, 1H), 4.85(s, 2H), 4.78(d, J = 6.0 Hz, 2H), 4.03(t, J = 5.8 Hz, 2H), 3.14(t, J = 5.6 Hz, 2H), 2.65(s, 3H). 428.0 A-33 A 1HNMR(400 MHz, CDCl3)δ8.60-8.58(m, 2H), 8.56(s, 2H), 8.13(d, J = 8.4 Hz, 1H), 7.96(d, J = 8.0 Hz, 2H), 7.89(d, J = 7.6 Hz, 1H), 7.67(s, 1H), 7.59- 7.50(m, 2H), 7.34(s, 1H), 7.24(d, J = 8.4 Hz, 1H), 5.63(s, 1H), 4.85(d, J = 5.6 Hz, 2H), 2.63(s, 3H), 2.38(s, 3H). 436.0 A-34 A 1HNMR (400 MHz, CDCl3) δ 8.99(d, J = 3.6 Hz, 1H), 8.63-8.57(m, 2H), 8.56(s, 2H), 8.38(d, J = 8.8 Hz, 1H), 8.28(d, J = 8.4 Hz, 1H), 8.22(d, J = 9.2 Hz, 1H), 7.68(s, 1H), 7.49-7.46(m, 1H), 7.33(s, 1H), 7.25(d, J = 5.2 Hz, 1H), 5.69(s, 1H), 4.86(d, J = 6.0 Hz, 2H), 2.63(s, 3H), 2.39(s, 3H). 437.0 A-35 A 1HNMR (400 MHz, CDCl3) δ 8.61(s, 2H), 8.58-8.52 (m, 2H), 8.12 (d, J = 8.4 Hz, 1H), 7.96(d, J = 8.4 Hz, 2H), 7.89(d, J = 7.2 Hz, 1H), 7.77(s, 1H), 7.69(s, 1H), 7.61(d, J = 11.2 Hz, 1H), 7.59-7.51(m, 2H), 5.73(s, 1H), 4.90(d, J = 6.0 Hz, 2H), 2.65(s, 3H). 440.0 A-36 A 1HNMR(400 MHz, DMSO)δ8.98(d, J = 4.0 Hz, 1H), 8.63(d, J = 4.4 Hz, 2H), 8.58-8.53(m, 3H), 8.42(s, 1H), 8.33(d, J = 8.8 Hz, 1H), 8.15(d, J = 8.8 Hz, 1H), 7.87(d, J = 12.4 Hz, 1H), 7.74(s, 1H), 7.67(d, J = 5.2 Hz, 1H), 7.63-7.60(m, 1H), 4.79(d, J = 6.0 Hz, 2H), 2.55(s, 3H). A-37 A 1HNMR(400 MHz, CDCl3)δ8.87(s, 1H), 8.61(d, J = 5.2 Hz, 1H), 8.58(s, 1H), 8.54(s, 1H), 8.15(d, J = 8.8 Hz, 1H), 7.97-7.93(m, 3H), 7.89(d, J = 7.6 Hz, 1H), 7.59-7.51(m, 2H), 7.49(d, J = 8.4 Hz, 1H), 7.38(s, 1H), 7.33(d, J = 5.2 Hz, 1H), 6.60(s, 1H), 4.95(d, J = 5.2 Hz, 2H), 2.66(s, 3H). 422.0 A-38 A 1HNMR(400 MHz, CDCl3)δ8.68(brs, 2H), 8.55(s, 2H), 8.13(d, J = 8.8 Hz, 1H), 7.95(d, J = 8.8 Hz, 2H), 7.88(d, J = 7.2 Hz, 1H), 7.66(d, J = 8.4 Hz, 2H), 7.57- 7.53(m, 6H), 5.63(s, 1H), 4.87(d, J = 5.6 Hz, 2H). 407.0 A-39 A 1HNMR(400 MHz, CDCl3)δ8.55(s, 2H), 8.13(d, J = 8.8 Hz, 1H), 7.95(d, J = 8.4 Hz, 2H), 7.88(d, J = 7.2 Hz, 1H), 7.59-7.46(m, 5H), 7.43(d, J = 8.0 Hz, 2H), 6.31(s, 1H), 5.60(s, 1H), 4.86(d, J = 6.0 Hz, 2H), 3.90(s, 3H). 410.0 A-40 A 1HNMR(400 MHz, CDCl3)δ8.55(s, 1H), 8.54(s, 1H), 8.12(d, J = 8.8 Hz, 1H), 7.95(d, J = 8.4 Hz, 2H), 7.89(d, J = 7.6 Hz, 1H), 7.86(s, 1H), 7.56-7.52(m, 4H), 7.40(d, J = 8.0 Hz, 2H), 7.29(s, 1H), 7.22(s, 1H), 5.64(s, 1H), 4.85(d, J = 6.0 Hz, 2H). 396.0 A-41 A 1HNMR(400 MHz, CDCl3)δ9.26(s, 1H), 8.99(d, J = 4.0 Hz, 1H), 8.57-8.54(m, 3H), 8.39(d, J = 8.8 Hz, 1H), 8.28(d, J = 8.4 Hz, 1H), 8.22(d, J = 8.8 Hz, 1H), 8.00(d, J = 8.4 Hz, 1H), 7.82(s, 1H), 7.65(d, J = 6.8 Hz, 2H), 7.49-7.46(m, 1H), 5.77(s, 1H), 5.02(d, J = 6.0 Hz, 2H). 382.0 A-42 A 1HNMR(400 MHz, CDCl3)δ8.99(d, J = 4.4 Hz, 1H), 8.67-8.59(m, 2H), 8.58-8.53(m, 2H), 8.39(s, 1H), 8.34(d, J = 8.8 Hz, 1H), 8.16(d, J = 8.8 Hz, 1H), 8.10(d, J = 8.8 Hz, 1H), 8.05(d, J = 8.8 Hz, 1H), 7.98(s, 1H), 7.77(d, J = 8.4 Hz, 1H), 7.72(d, J = 8.4 Hz, 1H), 7.62(dd, J = 8.4, 4.4 Hz, 1H), 4.89(d, J = 6.0 Hz, 2H). A-43 D 1HNMR(400 MHz, CDCl3)δ8.96(d, J = 2.8 Hz, 1H), 8.63-8.55(m, 2H), 8.53(d, J = 8.4 Hz, 1H), 8.43(s, 1H), 8.37(s, 1H), 8.32(d, J = 8.8 Hz, 1H), 8.18-8.12(m, 2H), 7.98(d, J = 8.4 Hz, 1H), 7.97-7.91(m, 2H), 7.89(s, 1H), 7.65-7.58(m, 1H), 7.42(s, 1H), 4.86(d, J = 6.0 Hz, 2H). 424.0 A-44 A 1H NMR (400 MHz, CDCl3) δ 8.45 (d, J = 3.6 Hz, 1H), 8.22 (s, 1H), 8.05 (s, 1H), 7.88 (d, J = 8.4 Hz, 2H), 7.82 (s, 1H), 7.60 (m, 2H), 7.47 (d, J = 7.6 Hz, 1H), 7.20 (m, 1H), 5.24 (s, 1H), 4.91 (d, J = 6.0 Hz, 2H), 4.87 (s, 2H), 4.05 (m, 2H), 3.15 (m, 2H). A-45 A 1H NMR (400 MHz, CDCl3) δ 8.59 (s, 1H), 8.53 (s, 1H), 8.44 (s, 1H), 8.02 (s, 1H), 7.75 (s, 1H), 7.67 (s, 1H), 7.54 (d, J = 11.6 Hz, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.14 (s, 1H), 5.27 (s, 1H), 4.85 (s, 2H), 4.79 (d, J = 5.6 Hz, 2H), 4.03 (d, J = 5.6 Hz, 2H), 3.14 (s, 2H), 2.88 (s, 1H), 2.64 (s, 3H). A-46 A 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 2H), 8.45 (s, 1H), 8.05 (s, 1H), 7.61 (s, 1H), 7.46 (d, J = 7.6 Hz, 1H), 7.33 (s, 1H), 7.24 (s, 1H), 7.15 (s, 1H), 5.24 (s, 1H), 4.86 (s, 2H), 4.74 (d, J = 5.6 Hz, 2H), 4.04 (t, J = 5.2 Hz, 2H), 3.14 (s, 2H), 2.62 (s, 3H), 2.35 (s, 3H). A-47 A 1H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 8.53 (d, J = 5.2 Hz, 1H), 8.04 (s, 1H), 7.60 (d, J = 7.8 Hz, 2H), 7.45 (d, J = 7.2 Hz, 2H), 7.36 (s, 1H), 7.30 (d, J = 4.8 Hz, 1H), 5.13 (s, 1H), 4.94 (s, 2H), 4.75 (d, J = 5.6 Hz, 2H), 4.02 (d, J = 5.2 Hz, 2H), 3.07 (s, 2H), 2.62 (s, 3H). 433.0 A-48 A 1H NMR (400 MHz, CDCl3) δ 9.39 (s, 1H), 8.53 (d, J = 15.6 Hz, 2H), 8.42 (s, 1H), 8.33 (d, J = 9.4 Hz, 1H), 7.86 (d, J = 9.4 Hz, 1H), 7.64 (d, J = 6.4 Hz, 2H), 7.51 (d, J = 7.6 Hz, 2H), 7.37 (s, 1H), 7.31 (s, 1H), 5.67 (s, 1H), 4.86 (s, 2H), 2.63 (s, 3H). 451.0 A-49 A 1H NMR (400 MHz, CDCl3) δ 9.11 (s, 1H), 8.70 (s, 1H), 8.62 (d, J = 5.2 Hz, 2H), 8.52 (s, 1H), 8.22 (m 2H), 7.77 (s, 1H), 7.69 (d, J = 4.8 Hz, 1H), 7.61 (d, J = 11.2 Hz, 1H), 5.74 (s, 1H), 4.90 (d, J = 6.0 Hz, 2H), 2.65 (s, 3H). A-50 A 1H NMR (400 MHz, CDCl3) δ 9.10 (s, 1H), 8.79 (s, 1H), 8.70 (s, 1H), 8.60 (d, J = 5.2 Hz, 1H), 8.52 (s, 1H), 8.22 (m, 2H), 7.90 (m, 1H), 7.79 (d, J = 7.8 Hz, 2H), 7.66 (d, J = 4.8 Hz, 1H), 5.69 (s, 1H), 4.88 (d, J = 6.0 Hz, 2H), 2.65 (s, 3H). A-51 A 1H NMR (400 MHz, CDCl3) δ 9.10 (s, 1H), 8.70 (s, 1H), 8.59 (d, J = 5.6 Hz, 2H), 8.53 (s, 1H), 8.22 (q, J = 8.4 Hz, 2H), 7.67 (s, 1H), 7.33 (s, 1H), 7.23 (s, 1H), 5.64 (s, 1H), 4.85 (d, J = 5.6 Hz, 2H), 2.63 (s, 3H), 2.38 (s, 3H). A-52 A 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 5.2 Hz, 1H), 8.08 (s, 1H), 7.61 (d, J = 7.9 Hz, 2H), 7.48 (d, J = 8 Hz, 2H), 7.36 (s, 1H), 7.31 (s, 5H), 5.03 (d, J = 2.4 Hz, 5H), 4.85 (m, 1H), 4.77 (d, J = 6 Hz, 2H), 4.60 (m, 1H), 2.62 (s, 3H). 412.0 A-53 A 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 5.2 Hz, 1H), 8.05 (s, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.53 (d, J = 7.6 Hz, 1H), 7.45 (d, J = 8.0 Hz, 2H), 7.40 (m, 2H), 7.30 (d, J = 6.8 Hz, 2H), 5.13 (s, 1H), 4.86 (s, 2H), 4.75 (d, J = 6 Hz, 2H), 3.99 (t, J = 5.8 Hz, 2H), 3.16 (t, J = 5.8 Hz, 2H), 2.62 (s, 3H). A -54 A 1H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 8.60 (d, J = 5.2 Hz, 1H), 8.54 (s, 1H), 8.02 (s, 1H), 7.76 (s, 1H), 7.67 (d, J = 4.8 Hz, 1H), 7.54 (d, J = 11.6 Hz, 1H), 5.23 (s, 1H), 4.95 (s, 2H), 4.79 (d, J = 6 Hz, 2H), 4.03 (t, J = 5.6 Hz, 2H), 3.07 (s, 2H), 2.64 (s, 3H). A-55 A 1H NMR (400 MHz, CDCl3) δ 8.96 (s, 1H), 8.91 (s, 1H), 8.55 (d, J = 5.2 Hz, 1H), 8.49 (s, 1H), 8.03 (d, J = 9.6 Hz, 1H), 7.87 (d, J = 9.6 Hz, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.36 (s, 1H), 7.31 (d, J = 5.2 Hz, 1H), 5.69 (s, 1H), 4.85 (d, J = 5.8 Hz, 2H), 2.63 (s, 3H). 412.0 A-56 A 1H NMR (400 MHz, CDCl3) δ 8.89 (s, 1H), 8.67 (d, J = 5.2 Hz, 1H), 8.45 (d, J = 4.4 Hz, 1H), 8.10 (s, 1H), 8.02 (s, 1H), 7.67 (s, 1H), 7.62 (d, J = 5.0 Hz, 1H), 7.46 (d, J = 8 Hz, 1H), 7.15 (m, 1H), 5.28 (s, 1H), 4.87 (s, 2H), 4.81 (d, J = 6.2 Hz, 2H), 4.06 (t, J = 5.8 Hz, 2H), 3.15 (m, 2H), 2.67 (s, 3H). A-57 A 1H NMR (400 MHz, CDCl3) δ 9.0 (m, 2H), 8.69 (d, J = 5.2 Hz, 1H), 8.55 (d, J = 11.2 Hz, 2H), 8.38 (d, J = 9.0 Hz, 1H), 8.29 (d, J = 8.2 Hz, 1H), 8.23 (d, J = 9 Hz, 1H), 8.18 (s, 1H), 7.70 (s, 1H), 7.66 (d, J = 4.6 Hz, 1H), 7.48 (dd, J = 8.2, 4.2 Hz, 1H), 5.86 (s, 1H), 5.3 (m, 1H), 4.93 (d, J = 6 Hz, 2H), 2.68 (s, 3H). A-58 A 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 5.2 Hz, 1H), 8.54 (s, 1H), 8.05 (s, 1H), 7.92 (s, 1H), 7.75 (s, 1H), 7.67 (d, J = 4.8 Hz, 1H), 7.54 (d, J = 12.0 Hz, 1H), 5.35 (s, 1H), 5.01 (s, 2H), 4.80 (d, J = 6.2 Hz, 2H), 4.33 (m, 2H), 4.21 (m, 2H), 2.64 (s, 3H). 436.0 A-59 A 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 4.6 Hz, 1H), 8.07 (s, 1H), 7.9 (m, 1H), 7.61 (d, J = 7.6 Hz, 2H), 7.45 (d, J = 7.8 Hz, 2H), 7.35 (s, 1H), 7.28 (s, 1H), 5.24 (s, 1H), 5.12 (s, 2H), 4.76 (d, J = 5.6 Hz, 2H), 4.28 (s, 2H), 4.15 (s, 2H), 2.62 (s, 3H). 485.0 A-60 A 1H NMR (400 MHz, CDCl3) δ 9.0 (m, 3H), 8.61 (d, J = 5.2 Hz, 2H), 8.54 (d, J = 7.8 Hz, 2H), 8.43 (s, 1H), 8.32 (d, J = 8.6 Hz, 1H), 8.15 (m, 2H), 8.04 (d, J = 5.2 Hz, 1H), 7.61 (m, 1H), 4.76 (d, J = 5.6 Hz, 2H), 2.57 (s, 3H). 424.0 A-61 A 1H NMR (400 MHz, CDCl3) δ 8.87 (s, 2H), 8.64 (d, J = 5.2 Hz, 1H), 8.44 (d, J = 4 Hz, 1H), 8.14 (s, 1H), 8.06 (d, J = 4.8 Hz, 1H), 8.03 (s, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.16 (m, 1H), 5.23 (s, 1H), 4.85 (s, 2H), 4.76 (d, J = 6 Hz, 2H), 4.03 (m, 2H), 3.13 (m, 2H), 2.66 (s, 3H). 430.9 A-62 A 1H NMR (400 MHz, CDCl3) δ 9.02 (s, 1H), 8.61 (d, J = 5.2 Hz, 1H), 8.53 (d, J = 7.8 Hz, 2H), 8.04 (s, 1H), 7.76 (s, 1H), 7.68 (d, J = 4.8 Hz, 1H), 7.54 (d, J = 11.0 Hz, 1H), 5.26 (s, 1H), 4.87 (s, 2H), 4.80 (d, J = 6.2 Hz, 2H), 4.04 (t, J = 5.9 Hz, 2H), 3.10 (t, J = 5.8 Hz, 2H), 2.64 (s, 3H). 447.0 A-63 A 1H NMR (400 MHz, CDCl3) δ 9.05 (s, 1H), 8.99 (d, J = 3.6 Hz, 1H), 8.82 (s, 1H), 8.66 (d, J = 5.2 Hz, 1H), 8.56 (d, J = 9.6 Hz, 2H), 8.39 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.22 (d, J = 9.2 Hz, 1H), 7.81 (s, 1H), 7.71 (d, J = 5.2 Hz, 1H), 7.47 (dd, J = 8.2, 4.2 Hz, 1H), 6.39 (s, 1H), 5.01 (d, J = 5.2 Hz, 2H), 2.68 (s, 3H). A-64 E 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 6.8 Hz, 1H), 8.22 (s, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 8.0 Hz, 3H), 7.35-7.29 (m, 1H), 5.91 (s, 1H), 4.79 (d, J = 6.0 Hz, 2H), 2.57 (s, 3H). A-65 A 1H NMR (400 MHz, CDCl3) δ 8.99 (d, J = 4.0 Hz, 1H), 8.57 (s, 1H), 8.56 (s, 2H), 8.38 (d, J = 9.6 Hz, 2H), 8.28 (d, J = 8.4 Hz, 1H), 8.22 (d, J = 8.8 Hz, 1H), 7.73 (s, 1H), 7.68 (d, J = 5.2 Hz, 1H), 7.47 (dd, J = 8.2, 4.2 Hz, 1H), 7.43 (s, 1H), 5.74 (s, 1H), 4.88 (d, J = 6.0 Hz, 2H), 3.92 (s, 3H), 2.63 (s, 3H). 452.9 A-66 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 3.2 Hz, 1H), 8.53 (s, 2H), 8.35 (d, J = 8.8 Hz, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 8.16 (s, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.46 (dd, J = 8.2, 4.2 Hz, 1H), 6.49 (d, J = 8.4 Hz, 1H), 5.46 (s, 1H), 5.04 (s, 1H), 4.65 (d, J = 5.6 Hz, 2H), 3.98-3.94 (m, 2H), 3.39 (t, J = 5.8 Hz, 2H), 2.96 (s, 3H). A-67 A 1H NMR (400 MHz, CDCl3) δ 9.47 (s, 1H), 9.24 (d, J = 5.2 Hz, 1H), 8.99 (d, J = 3.2 Hz, 1H), 8.56 (d, J = 4.0 Hz, 2H), 8.38 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.22 (d, J = 8.8 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 5.2 Hz, 1H), 7.59 (d, J = 7.6 Hz, 2H), 7.48 (dd, J = 8.2, 4.2 Hz, 1H), 5.70 (s, 1H), 4.90 (d, J = 6.0 Hz, 2H). 409.0 A-68 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 3.2 Hz, 1H), 8.54 (d, J = 3.2 Hz, 2H), 8.35 (d, J = 8.8 Hz, 1H), 8.27 (d, J = 7.8 Hz, 2H), 8.20 (d, J = 8.8 Hz, 1H), 7.66 (d, J = 8.8 Hz, 1H), 7.47 (dd, J = 8.2, 4.2 Hz, 1H), 6.76 (d, J = 8.4 Hz, 1H), 5.51 (s, 1H), 4.70 (d, J = 5.6 Hz, 2H), 4.18 (s, 4H), 3.05 (s, 4H). A-69 A 1H NMR (400 MHz, DMSO) δ 8.83 (s, 1H), 8.67 (m, 2H), 8.60(m, 2H), 8.29 (s, 1H), 8.08 (d, J = 7.8 Hz, 1H), 7.85 (d, J = 12.2 Hz, 1H), 7.76 (s, 1H), 7.68 (d, J = 4.6 Hz, 1H), 7.53 (m, 1H), 4.75 (d, J = 5.6 Hz, 2H), 2.56 (s, 3H). 414.9 A-70 A 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 5.2 Hz, 1H), 8.23 (s, 1H), 8.04 (s, 1H), 7.60 (d, J = 8.2 Hz, 2H), 7.52 (m, 1H), 7.45 (d, J = 8.0 Hz, 2H), 7.35 (s, 1H), 7.30 (d, J = 4.8 Hz, 1H), 7.17 (m, 4H), 5.54 (m, 1H), 5.04 (s, 1H), 4.74 (d, J = 5.6 Hz, 2H), 4.48 (d, J = 10.2 Hz, 1H), 3.48 (m, 1H), 3.16 (m, 1H), 2.80 (d, J = 16.2 Hz, 1H), 2.62 (s, 3H), 1.58 (s, 3H). A-71 A 1H NMR (400 MHz, DMSO-d6) δ 9.14 (d, J = 2.0 Hz, 1H), 9.06 (s, 1H), 8.99 (d, J = 2.8 Hz, 1H), 8.68 (t, J = 5.4 Hz, 1H), 8.65 (s, 1H), 8.55 (d, J = 8.4 Hz, 1H), 8.39 (s, 1H), 8.34 (d, J = 9.2 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 8.04 (s, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.62 (dd, J = 8.4, 4.4 Hz, 1H), 4.94 (d, J = 6.0 Hz, 2H). A-72 A 1H NMR (400 MHz, CDCl3) δ 9.02 (d, J = 2.0 Hz, 1H), 8.52 (s, 1H), 8.45 (d, J = 4.8 Hz, 1H), 8.08 (s, 1H), 8.02 (s, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.15 (dd, J = 8.0, 4.8 Hz, 1H), 5.30 (s, 1H), 4.98 (d, J = 6.0 Hz, 2H), 4.87 (s, 2H), 4.05 (t, J = 5.8 Hz, 2H), 3.15 (t, J = 6.0 Hz, 2H). A-73 A 1H NMR (400 MHz, DMSO-d6) δ 8.99 (d, J = 2.4 Hz, 1H), 8.68-8.62 (m, 3H), 8.56 (d, J = 8.4 Hz, 1H), 8.46 (d, J = 8.8 Hz, 1H), 8.36 (s, 1H), 8.34 (s, 1H), 8.15 (dd, J = 14.8, 8.8 Hz, 2H), 8.05 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 8.8 Hz, 1H), 7.62 (dd, J = 8.4, 4.0 Hz, 1H), 4.98 (d, J = 6.0 Hz, 2H). 447.0 A-74 A 1H NMR (400 MHz, CDCl3) δ 8.45 (d, J = 4.8 Hz, 1H), 8.24 (s, 1H), 8.19 (d, J = 8.8 Hz, 2H), 8.06 (s, 1H), 7.90 (d, J = 2.0 Hz, 1H), 7.54 (d, J = 8.8 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 7.19-7.12 (m, 1H), 6.38 (s, 1H), 4.99 (d, J = 4.8 Hz, 2H), 4.88 (s, 2H), 4.07 (t, J = 5.8 Hz, 2H), 3.16 (t, J = 6.0 Hz, 2H). A-75 A 1H NMR (400 MHz, CDCl3) δ 9.11 (d, J = 2.2 Hz, 1H), 8.99 (d, J = 4.2 Hz, 1H), 8.55 (d, J = 8.6 Hz, 2H), 8.49 (s, 1H), 8.38 (d, J = 9.0 Hz, 1H), 8.28 (d, J = 8.3 Hz, 1H), 8.23 (m, 2H), 7.93 (d, J = 8.4 Hz, 1H), 7.72 (d, J = 8..4 Hz, 1H), 7.48 (m, 1H), 5.81 (s, 1H), 5.05 (d, J = 6.1 Hz, −2H). A-76 A 1H NMR (400 MHz, CDCl3) δ 9.04 (s, 1H), 8.45 (d, J = 6.8 Hz, 2H), 8.14 (s, 1H), 8.02 (s, 1H), 7.88 (s, 1H), 7.69 (d, J = 8.2 Hz, 1H), 7.46 (d, J = 7.2 Hz, 1H), 7.15 (s, 1H), 5.30 (s, 2H), 4.94 (d, J = 6.2 Hz, 2H), 4.86 (s, 2H), 4.05 (m, 2H), 3.14 (m, 2H). 412.0 A-77 A 1H NMR (400 MHz, CDCl3) δ 9.28 (s, 1H), 8.99 (d, J = 3.2 Hz, 1H), 8.78 (d, J = 5.2 Hz, 1H), 8.56 (s, 2H), 8.38 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.22 (d, J = 8.8 Hz, 1H), 8.12 (d, J = 8.0 Hz, 2H), 7.73 (d, J = 5.2 Hz, 1H), 7.56 (d, J = 8.0 Hz, 2H), 7.50-7.44 (m, 1H), 5.67 (s, 1H), 4.89 (d, J = 5.6 Hz, 2H). 409.0 A-78 A 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 5.2 Hz, 1H), 8.54 (s, 1H), 8.00 (s, 1H), 7.76 (s, 1H), 7.68 (d, J = 4.8 Hz, 1H), 7.55 (d, J = 11.6 Hz, 1H), 5.18 (s, 1H), 4.79 (d, J = 6.0 Hz, 2H), 4.18-4.10 (m, 2H), 3.99-3.90 (m, 1H), 3.34-3.24 (m, 2H), 2.64 (s, 3H), 2.02-1.94 (m, 2H), 1.66-1.58 (m, 2H). A-79 A 1H NMR (400 MHz, CDCl3) δ 8.62 (d, J = 5.2 Hz, 1H), 8.55 (s, 1H), 8.04 (s, 1H), 7.76 (s, 1H), 7.68 (d, J = 4.4 Hz, 1H), 7.55 (d, J = 11.2 Hz, 1H), 5.34 (s, 1H), 4.81 (d, J = 6.0 Hz, 2H), 4.20 (s, 4H), 3.12 (s, 4H), 2.65 (s, 3H). A-80 A 1H NMR (400 MHz, DMSO) δ 8.59-8.54 (m, 2H), 8.07 (s, 1H), 7.90 (s, 1H), 7.80-7.72 (m, 3H), 7.65 (d, J = 4.4 Hz, 1H), 4.66 (d, J = 5.6 Hz, 2H), 4.10 (s, 2H), 3.76 (s, 2H), 3.26 (s, 2H), 2.55 (s, 3H). A-81 A 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 5.2 Hz, 1H), 8.54 (s, 1H), 8.01 (s, 1H), 7.76 (s, 1H), 7.68 (d, J = 4.8 Hz, 1H), 7.55 (d, J = 11.6 Hz, 1H), 5.01 (s, 1H), 4.79 (d, J = 6.0 Hz, 2H), 4.76 (s, 1H), 3.33 (t, J = 6.2 Hz, 2H), 2.65 (s, 3H), 1.13-1.02 (m, 1H), 0.56 (d, J = 7.6 Hz, 2H), 0.27 (d, J = 4.8 Hz, 2H). A-82 A 1H NMR (400 MHz, DMSO) δ 8.56 (d, J = 5.2 Hz, 1H), 8.54 (s, 1H), 8.51 (s, 1H), 8.41 (d, J = 4.0 Hz, 1H), 7.80 (s, 1H), 7.78-7.71 (m, 2H), 7.69 (d, J = 8.0 Hz, 1H), 7.65 (d, J = 4.8 Hz, 1H), 7.58-7.51 (m, 2H), 7.34-7.29 (m, 1H), 4.62 (d, J = 6.0 Hz, 2H), 4.54 (d, J = 6.0 Hz, 2H), 2.54 (s, 3H). 420.0 A-83 A 1H NMR (400 MHz, DMSO) δ 8.98 (d, J = 3.2 Hz, 1H), 8.63 (s, 1H), 8.55 (d, J = 8.0 Hz, 1H), 8.43 (s, 2H), 8.32 (d, J = 8.8 Hz, 1H), 8.15 (d, J = 8.8 Hz, 1H), 7.64-7.59 (m, 1H), 7.49 (d, J = 9.6 Hz, 1H), 6.93 (d, J = 9.6 Hz, 1H), 4.58 (d, J = 6.0 Hz, 2H), 3.63 (s, 3H). A-84 F 1H NMR (400 MHz, DMSO-d6) δ 9.52 (s, 1H), 9.14 (d, J = 2.8 Hz, 1H), 8.67 (s, 1H), 8.63 (d, J = 8.4 Hz, 1H), 8.54 (s, 1H), 8.50 (d, J = 5.2 Hz, 1H), 8.43 (s, 1H), 8.36 (s, 1H), 7.87-7.84 (m, 1H), 7.75 (s, 1H), 7.69 (d, J = 4.9 Hz, 1H), 7.67 (s, 1H), 4.77 (d, J = 5.6 Hz, 2H), 3.89 (s, 3H), 2.52 (s, 3H). 454.0 A-85 F 1H NMR (400 MHz, CDCl3) δ 9.68 (s, 1H), 9.12 (d, J = 3.2 Hz, 1H), 8.63-8.61 (m, 2H), 8.56 (d, J = 9.6 Hz, 2H), 8.30 (d, J = 8.4 Hz, 1H), 7.78 (s, 1H), 7.71- 7.67 (m, 2H), 7.61 (d, J = 11.6 Hz, 1H), 5.87 (br s, 1H), 4.93 (d, J = 6.0 Hz, 2H), 2.66 (s, 3H). 441.9 A-86 F 1H NMR (400 MHz, CDCl3) δ 9.67 (s, 1H), 9.12 (d, J = 2.8 Hz, 1H), 8.97 (s, 1H), 8.68 (d, J = 5.2 Hz, 1H), 8.56 (s, 2H), 8.30 (d, J = 8.4 Hz, 1H), 8.17 (s, 1H), 7.71-7.67 (m, 2H), 7.64 (d, J = 4.8 Hz, 1H), 5.94 (br s, 1H), 4.94 (d, J = 6.0 Hz, 2H), 2.67 (s, 3H). 449.0 A-87 A 1H NMR (400 MHz, CDCl3) δ 8.60 (d, J = 5.2 Hz, 1H), 8.54 (s, 1H), 8.04 (s, 1H), 7.75 (s, 1H), 7.67 (d, J = 4.8 Hz, 1H), 7.54 (d, J = 11.6 Hz, 1H), 7.49 (s, 1H), 6.09 (s, 1H), 5.27 (s, 1H), 4.92 (s, 2H), 4.80 (d, J = 6.2 Hz, 2H), 4.31 (t, J = 5.2 Hz, 2H), 4.16 (t, J = 5.2 Hz, 2H), 2.64 (s, 3H). 435.0 A-88 A 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 5.2 Hz, 1H), 8.58-8.50 (m, 2H), 8.07 (s, 1H), 7.76 (s, 1H), 7.66 (dd, J = 12.4, 6.0 Hz, 2H), 7.57 (d, J = 11.6 Hz, 1H), 7.22 (s, 1H), 5.19 (s, 1H), 5.06 (d, J = 8.2 Hz, 4H), 4.82 (d, J = 6.0 Hz, 2H), 2.64 (s, 3H). A-89 A 1H NMR (400 MHz, CDCl3) δ 8.60 (d, J = 5.2 Hz, 1H), 8.51 (s, 1H), 8.18 (d, J = 3.8 Hz, 1H), 7.95 (s, 1H), 7.74 (s, 1H), 7.68 (d, J = 9.0 Hz, 2H), 7.52 (d, J = 11.6 Hz, 1H), 7.08-6.92 (m, 1H), 5.15 (s, 1H), 4.79 (s, 2H), 4.75 (d, J = 6.2 Hz, 2H), 4.32 (d, J = 4.0 Hz, 2H), 4.21 (d, J = 3.8 Hz, 2H), 2.64 (s, 3H). A-90 A 1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 5.2 Hz, 1H), 8.53 (s, 1H), 8.41 (s, 2H), 8.21 (s, 1H), 8.04 (s, 1H), 7.75 (s, 1H), 7.67 (d, J = 4.8 Hz, 1H), 7.54 (d, J = 11.6 Hz, 1H), 5.30 (s, 1H), 4.98 (s, 2H), 4.79 (d, J = 6.2 Hz, 2H), 4.09 (t, J = 5.6 Hz, 2H), 3.17 (t, J = 5.6 Hz, 2H), 2.63 (s, 3H). A-91 A 1H NMR (400 MHz, DMSO) δ 8.92 (s, 1H), 8.63 (d, J = 5.0 Hz, 1H), 8.34 (s, 1H), 7.95 (s, 2H), 7.67 (s, 1H), 7.61 (d, J = 4.8 Hz, 1H), 5.10 (s, 2H), 4.69 (d, J = 5.8 Hz, 2H), 4.53 (s, 2H), 4.15 (d, J = 4.8 Hz, 2H), 2.56 (s, 3H). A-92 A 1H NMR (400 MHz, DMSO) δ 8.92 (s, 1H), 8.63 (d, J = 4.6 Hz, 1H), 8.35 (s, 1H), 7.94 (s, 1H), 7.88 (s, 1H), 7.64 (m, 3H), 4.93 (s, 2H), 4.69 (d, J = 5.6 Hz, 2H), 4.47 (s, 2H), 4.10 (s, 2H), 2.56 (s, 3H) A-93 A 1H NMR (400 MHz, CDCl3) δ 8.60 (d, J = 5.2 Hz, 1H), 8.55 (s, 1H), 8.06 (s, 1H), 7.75 (s, 1H), 7.67 (d, J = 4.6 Hz, 1H), 7.54 (d, J = 11.6 Hz, 1H), 5.52 (s, 1H), 5.18 (s, 2H), 4.81 (d, J = 6.2 Hz, 2H), 4.58 (m, 2H), 4.22 (m, 2H), 2.64 (s, 3H). A-94 A 1H NMR (400 MHz, CDCl3) δ 8.55 (d, J = 5.2 Hz, 1H), 8.31 (s, 1H), 8.06 (s, 1H), 7.70 (s, 1H), 7.65 (d, J = 4.8 Hz, 1H), 7.49 (s, 1H), 7.36 (s, 1H), 6.09 (s, 1H), 5.21 (s, 1H), 4.92 (s, 2H), 4.77 (d, J = 6.0 Hz, 2H), 4.31 (m, 2H), 4.16 (m, 2H), 3.88 (s, 3H), 2.62 (s, 3H). A-95 A 1H NMR (400 MHz, DMSO) δ 8.92 (s, 1H), 8.63 (d, J = 4.8 Hz, 1H), 8.35 (s, 1H), 7.94 (s, 1H), 7.88 (s, 1H), 7.64 (m, 3H), 4.93 (s, 2H), 4.69 (d, J = 5.6 Hz, 2H), 4.47 (s, 2H), 4.10 (s, 2H), 2.56 (s, 3H). A-96 A 1H NMR (400 MHz, DMSO) δ 9.25 (d, J = 7.2 Hz, 1H), 8.85 (s, 1H), 8.63 (d, J = 5.0 Hz, 1H), 8.42 8.20 (m, 3H), 7.65 (m,, 4H), 7.53 (d, J = 7.2 Hz, 1H), 6.81 (s, 1H), 4.68 (s, 2H), 2.57 (s, 3H). A-97 A 1H NMR (400 MHz, CDCl3) δ 8.98 (s, 1H), 8.54 (s, 1H), 8.22 (m, 2H), 8.06 (s, 1H), 8.02 (d, J = 5.2 Hz, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 7.8 Hz, 2H), 7.53 (d, J = 7.8 Hz, 2H), 7.47 (m, 4.0 Hz, 1H), 7.38 (s, 1H), 7.32 (s, 1H), 6.79 (m, 1H), 5.14 (s, 1H), 4.83 (d, J = 5.6 Hz, 2H), 2.63 (s, 3H). A-98 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 3.2 Hz, 1H), 8.62 (s, 2H), 8.22 (m, 2H), 8.06 (s, 1H), 8.00 (d, J = 5.2 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.78 (s, 1H), 7.70 (d, J = 5.0 Hz, 1H), 7.62 (d, J = 12 Hz, 1H), 7.48 (m, 4.2 Hz, 1H), 6.83 (m, 1H), 5.28 (s, 1H), 4.88 (d, J = 6.0 Hz, 2H), 2.65 (s, 3H). 429.9 A-99 A 1H NMR (400 MHz, CDCl3) δ 8.97 (d, J = 9.6 Hz, 2H), 8.68 (d, J = 5.2 Hz, 1H), 8.22 (m, 3H), 8.07 (s, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.69 (s, 1H), 7.64 (d, J = 4 Hz, 1H), 7.48 (m, 1H), 6.86 (m, 1H), 5.35 (s, 1H), 4.89 (d, J = 6.2 Hz, 2H), 2.67 (s, 3H). A-100 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 2.6 Hz, 1H), 8.94 (s, 2H), 8.65 (d, J = 5.2 Hz, 1H), 8.20 (m, 3H), 8.07 (d, J = 17.8 Hz, 2H), 7.99 (d, J = 5.2 Hz, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.47 (m, 1H), 6.83 (m, 1H), 5.28 (s, 1H), 4.84 (d, J = 6.0 Hz, 2H), 2.68 (s, 3H). A-101 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 4 Hz, 1H), 8.80 (s, 1H), 8.60 (d, J = 5.2 Hz, 1H), 8.22 (m, 2H), 8.06 (s, 1H), 8.00 (d, J = 5.2 Hz, 1H), 7.91 (m, 2H), 7.84-7.74 (m, 2H), 7.68 (d, J = 5.0 Hz, 1H), 7.47 (m, 1H), 6.81 (m, 1H), 5.21 (s, 1H), 4.86 (m, 2H), 2.66 (s, 3H). A-102 A 1H NMR (400 MHz, CDCl3) δ 8.97 (d, J = 2.8 Hz, 1H), 8.53 (d, J = 5.2 Hz, 1H), 8.27-8.15 (m, 2H), 8.04 (s, 1H), 7.95-7.89 (m, 2H), 7.62 (d, J = 8.0 Hz, 2H), 7.55 (d, J = 8.0 Hz, 2H), 7.47 (dd, J = 8.4, 4.4 Hz, 1H), 7.37 (s, 1H), 7.31 (d, J = 4.4 Hz, 1H), 6.76- 6.70 (m, 1H), 5.48-5.39 (m, 1H), 5.06 (d, J = 5.6 Hz, 1H), 2.62 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H). 435.0 A-103 A 1H NMR (400 MHz, CDCl3) δ 9.64 (s, 1H), 9.09 (d, J = 2.4 Hz, 1H), 8.61 (d, J = 4.8 Hz, 2H), 8.26 (d, J = 9.2 Hz, 2H), 8.05 (d, J = 5.2 Hz, 1H), 7.78 (s, 1H), 7.72-7.65 (m, 2H), 7.62 (d, J = 11.6 Hz, 1H), 7.41 (t, J = 5.2 Hz, 1H), 5.28 (s, 1H), 4.89 (d, J = 6.0 Hz, 2H), 2.65 (s, 3H). 441.0 A-104 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 2.8 Hz, 1H), 8.66 (d, J = 6.0 Hz, 2H), 8.26-8.17 (m, 2H), 8.06 (s, 1H), 8.02 (d, J = 5.2 Hz, 1H),7.94 (d, J = 8.8 Hz, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.58-7.50 (m, 4H), 7.47 (dd, J = 8.4, 4.4 Hz, 1H), 6.81-6.77 (m, 1H), 5.15 (s, 1H), 4.83 (d, J = 6.0 Hz, 2H). 407.0 A-105 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 3.2 Hz, 1H), 8.26-8.18 (m, 2H), 8.06 (s, 2H), 8.00 (d, J = 5.2 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.55 (d, J = 8.0 Hz, 2H), 7.47 (dd, J = 8.0, 4.0 Hz, 1H), 7.39 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 10.0 Hz, 2H), 6.83-6.77 (m, 1H), 5.19 (s, 1H), 4.83 (d, J = 6.0 Hz, 2H). A-106 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 3.6 Hz, 1H), 8.56 (d, J = 4.8 Hz, 1H), 8.39 (s, 1H), 8.26-8.18 (m, 2H), 8.06 (s, 1H), 8.02 (d, J = 5.2 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.72 (s, 1H), 7.67 (d, J = 4.8 Hz, 1H), 7.50-7.43 (m, 2H), 6.85-6.80 (m, 1H), 5.20 (s, 1H), 4.84 (d, J = 6.0 Hz, 2H), 3.90 (s, 3H), 2.62 (s, 3H). 452.0 A-107 A 1H NMR (400 MHz, DMSO) δ 8.97 (d, J = 3.2 Hz, 1H), 8.48 (d, J = 8.0 Hz, 1H), 8.27 (s, 1H), 8.17-8.07 (m, 2H), 7.98 (d, J = 8.8 Hz, 1H), 7.90 (d, J = 5.2 Hz, 1H), 7.61 (dd, J = 8.0, 4.0 Hz, 1H), 7.53 (d, J = 8.4 Hz, 3H), 7.47 (d, J = 8.4 Hz, 2H), 7.41 (s, 1H), 6.83-6.77 (m, 1H), 4.65 (d, J = 5.6 Hz, 2H), 2.16 (s, 3H). A-108 A 1H NMR (400 MHz, CDCl3) δ 9.04 (s, 1H), 8.61 (s, 2H), 8.50 (dd, J = 13.2, 8.8 Hz, 2H), 8.13 (d, J = 8.4 Hz, 1H), 8.06 (d, J = 5.2 Hz, 1H), 7.81-7.67 (m, 3H), 7.61 (d, J = 11.6 Hz, 1H), 7.32-7.29 (m, 1H), 5.31 (s, 1H), 4.88 (d, J = 5.6 Hz, 2H), 2.64 (s, 3H). 441.0 A-109 A 1H NMR (400 MHz, CDCl3) δ 8.99 (d, J = 4.4 Hz, 1H), 8.19-8.25 (m, 5H), 8.11 (s, 1H), 8.02 (d, J = 5.2 Hz, 1H), 7.97 (d, J = 8.8 Hz, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.52-7.45 (m, 1H), 6.82 (d, J = 5.2 Hz, 1H), 6.38 (s, 1H), 5.08 (d, J = 4.8 Hz, 2H). A-110 A 1H NMR (400 MHz, CDCl3) δ 9.39 (d, J = 5.6 Hz, 1H), 8.65 (d, J = 8.8 Hz, 1H), 8.62 (s, 2H), 8.08-8.01 (m, 3H), 7.93 (d, J = 6.0 Hz, 1H), 7.78 (s, 1H), 7.70 (d, J = 4.0 Hz, 1H), 7.62 (d, J = 11.6 Hz, 1H), 6.84- 6.79 (m, 1H), 5.33 (s, 1H), 4.88 (d, J = 6.0 Hz, 2H), 2.66 (s, 3H). 441.0 A-111 A 1H NMR (400 MHz, CDCl3) δ 8.97 (d, J = 3.2 Hz, 1H), 8.28 (s, 1H), 8.24-8.16 (m, 2H), 8.04 (s, 1H), 8.01 (d, J = 5.2 Hz, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.66 (d, J = 7.2 Hz, 1H), 7.47 (dd, J = 8.4, 4.4 Hz, 1H), 6.82-6.72 (m, 2H), 5.01 (s, 1H), 4.66 (d, J = 5.6 Hz, 2H), 4.17 (s, 4H), 3.05 (s, 4H). A-112 A 1H NMR (400 MHz, CDCl3) δ 8.97 (d, J = 3.2 Hz, 1H), 8.24-8.14 (m, 3H), 8.04 (s, 1H), 8.01 (d, J = 5.2 Hz, 1H), 7.91 (d, J = 8.8 Hz, 1H), 7.52 (d, J = 6.8 Hz, 1H), 7.46 (dd, J = 8.4, 4.0 Hz, 1H), 6.80-6.74 (m, 1H), 6.47 (d, J = 8.4 Hz, 1H), 4.94 (d, J = 6.0 Hz, 2H), 4.60 (d, J = 5.6 Hz, 2H), 3.95 (q, J = 6.0 Hz, 2H), 3.39 (t, J = 5.6 Hz, 2H), 2.95 (s, 3H). 452.0 A-113 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 3.2 Hz, 1H), 8.26-8.18 (m, 2H), 8.06 (s, 1H), 8.02 (d, J = 5.2 Hz, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 6.4 Hz, 3H), 7.47 (dd, J = 8.0, 4.0 Hz, 1H), 7.42 (d, J = 8.0 Hz, 2H), 6.82-6.77 (m, 1H), 6.31 (s, 1H), 5.15 (s, 1H), 4.83 (d, J = 5.6 Hz, 2H), 3.90 (s, 3H). A-114 A 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 5.2 Hz, 2H), 8.06 (s, 1H), 8.02 (d, J = 5.2 Hz, 1H), 7.96 (d, J = 9.2 Hz, 1H), 7.77 (s, 1H), 7.69 (d, J = 4.8 Hz, 1H), 7.61 (d, J = 10.8 Hz, 2H), 6.77-6.72 (m, 1H), 5.32 (s, 1H), 4.87 (d, J = 6.0 Hz, 2H), 2.65 (s, 3H). A-115 A 1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 8.61 (d, J = 6.0 Hz, 2H), 8.55 (s, 1H), 8.00 (d, J = 5.2 Hz, 1H), 7.77 (s, 1H), 7.69 (d, J = 4.0 Hz, 1H), 7.65 (d, J = 9.2 Hz, 1H), 7.60 (d, J = 11.6 Hz, 1H), 6.73-6.68 (m, 1H), 5.30 (s, 1H), 4.85 (d, J = 6.0 Hz, 2H), 2.65 (s, 3H). A-116 A 1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 8.65- 8.57 (m, 3H), 7.99 (d, J = 5.2 Hz, 1H), 7.90 (s, 1H), 7.77 (s, 1H), 7.69 (d, J = 4.4 Hz, 1H), 7.59 (d, J = 11.6 Hz, 1H), 6.71-6.65 (m, 1H), 5.28 (s, 1H), 4.85 (d, J = 6.0 Hz, 2H), 2.65 (s, 3H). A-117 A 1H NMR (400 MHz, CDCl3) δ 8.61 (d, J = 5.2 Hz, 1H), 8.58 (s, 1H), 7.91 (d, J = 5.2 Hz, 1H), 7.77 (s, 1H), 7.68 (s, 2H), 7.62-7.55 (m, 2H), 6.68 (d, J = 9.6 Hz, 1H), 6.62-6.58 (m, 1H), 5.20 (s, 1H), 4.83 (d, J = 6.0 Hz, 2H), 3.63 (s, 3H), 2.65 (s, 3H). A--118 A 1H NMR (400 MHz, CDCl3) δ 9.27 (d, J = 2.0 Hz, 1H), 8.98 (d, J = 4.0 Hz, 1H), 8.65 (d, J = 2.0 Hz, 1H), 8.21-8.26 (m, 2H), 8.16 (s, 1H), 8.08 (s, 1H), 7.99 (d, J = 5.2 Hz, 1H), 7.97-7.89 (m, 2H), 7.70 (d, J = 4.8 Hz, 1H), 7.46-7.49 (m, 1H), 6.80 (t, J = 6.8 Hz, 1H), 5.34 (s, 1H), 5.05 (d, J = 6.0 Hz, 2H). A-119 A 1H NMR (400 MHz, CDCl3) δ 9.12 (s, 1H), 8.99 (d, J = 2.0 Hz 1H), 8.48 (s, 1H), 8.27-8.18 (m, 3H), 8.07 (s, 1H), 7.99 (d, J = 5.2 Hz, 1H), 7.92 (t, J = 8.6 Hz, 2H), 7.70 (d, J = 8.4 Hz, 1H), 7.5-7.46 (m, 1H), 6.83 (t, J = 5.2 Hz, 1H), 5.34 (s, 1H), 5.01 (d, J = 6.0 Hz, 3H). A-120 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 2.8 Hz, 1H), 8.39 (s, 1H), 8.24 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 8.8 Hz, 1H), 8.04 (s, 1H), 8.00 (d, J = 5.2 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 7.48 (dd, J = 8.2, 4.2 Hz, 1H), 6.79 (t, J = 5.2 Hz, 1H), 6.41 (d, J = 9.2 Hz, 1H), 6.30 (s, 1H), 5.35 (s, 1H), 3.84 (m, 2H), 3.69 (m, 2H). A-121 A 1H NMR (400 MHz, DMSO) δ 9.54 (s, 1H), 9.13 (d, J = 3.2 Hz, 1H), 8.99 (s, 1H), 8.64 (d, J = 4.8 Hz, 1H), 8.60 (d, J = 8.4 Hz, 1H), 8.47 (s, 1H), 8.43 (s, 1H), 7.95 (d, J = 5.2 Hz, 1H), 7.86 (dd, J = 8.4, 4.4 Hz, 1H), 7.69 (s, 1H), 7.64 (d, J = 5.2 Hz, 2H), 7.26- 7.20 (m, 1H), 4.77 (d, J = 5.6 Hz, 2H), 2.57 (s, 3H). 448.0 A-122 A 1H NMR (400 MHz, DMSO) δ 9.54 (s, 1H), 9.13 (d, J = 3.6 Hz, 1H), 8.60 (d, J = 8.0 Hz, 1H), 8.47 (d, J = 7.2 Hz, 2H), 8.32 (s, 1H), 7.96 (d, J = 5.2 Hz, 1H), 7.86 (dd, J = 8.0, 4.0 Hz, 1H), 7.73 (s, 1H), 7.66 (s, 2H), 7.60-7.54 (m, 1H), 7.23-7.19 (m, 1H), 4.72 (d, J = 5.6 Hz, 2H), 3.88 (s, 3H), 2.51 (s, 3H). 452.9 A--123 A 1H NMR (400 MHz, DMSO) δ 9.30 (s, 1H), 8.61 (d, J = 6.0 Hz, 2H), 8.57 (d, J = 5.2 Hz, 1H), 7.99 (d, J = 9.2 Hz, 1H), 7.95-7.87 (m, 2H), 7.82 (d, J = 12.2 Hz, 1H), 7.74 (s, 1H), 7.66 (d, J = 5.2 Hz, 2H), 6.87 (t, J = 5.0 Hz, 1H), 4.72 (d, J = 5.8 Hz, 2H), 2.55 (s, 3H). 430.0 A124 A 1H NMR (400 MHz, CDCl3) δ 8.91 (s, 2H), 8.61 (d, J = 5.2 Hz, 2H), 8.36 (s, 1H), 8.22 (d, J = 8.8 Hz, 1H), 8.01 (t, J = 7.6 Hz, 2H), 7.77 (s, 1H), 7.69 (d, J = 4.8 Hz, 1H), 7.63 (d, J = 11.6 Hz, 1H), 6.85 (t, J = 5.2 Hz, 1H), 5.31 (s, 1H), 4.88 (d, J = 5.8 Hz, 2H), 2.65 (s, 3H). 440.9 A-125 F 1H NMR (400 MHz, CDCl3) δ 9.02 (s, 1H), 8.51 (d, J = 10.3 Hz, 3H), 8.38 (s, 1H), 8.09 (d, J = 9.2 Hz, 2H), 7.69 (s, 3H), 7.44 (s, 1H), 7.26 (s, 1H), 5.28 (s, 1H), 4.83 (s, 2H), 3.88 (s, 3H), 2.62 (s, 3H). 453.0 A-126 A 1H NMR (400 MHz, CDCl3) δ 8.98 (d, J = 3.4 Hz, 1H), 8.91 (s, 1H), 8.62 (d, J = 5.2 Hz, 1H), 8.45 (m, 2H), 8.12 (s, 1H), 8.08 (d, J = 8.6 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), 7.65 (m, 2H), 7.58 (d, J = 4.8 Hz, 1H), 7.28 (m, 1H), 5.33 (s, 1H), 4.84 (d, J = 6.0 Hz, 2H), 2.62 (s, 3H). 447.9 A-127 A 1H NMR (400 MHz, CDCl3) δ 8.94 (s, 1H), 8.68 (s, 1H), 8.61 (s, 1H), 8.16 (s, 1H), 7.96 (s, 1H), 7.68 (s, 1H), 7.64 (s, 1H), 7.35 (s, 1H), 7.29 (s, 1H), 6.73 (s, 1H), 5.34 (s, 1H), 4.87 (d, J = 4.4 Hz, 2H), 2.66 (d, J = 10.6 Hz, 6H). 411.0 A-128 A 1H NMR (400 MHz, CDCl3) δ 8.93 (s, 1H), 8.67 (d, J = 5.2 Hz, 1H), 8.15 (s, 1H), 7.90 (s, 1H), 7.83 (d, J = 5.6 Hz, 2H), 7.67 (s, 1H), 7.63 (d, J = 4.8 Hz, 1H), 7.52 (s, 1H), 6.81 (t, J = 5.2 Hz, 1H), 5.23 (s, 1H), 4.84 (d, J = 6.0 Hz, 2H), 3.96 (d, J = 17.6 Hz, 3H), 2.66 (s, 3H). A-129 A 1H NMR (400 MHz, CDCl3) δ 8.94 (s, 1H), 8.67 (d, J = 5.2 Hz, 1H), 8.44 (s, 1H), 8.38 (s, 1H), 8.16 (s, 1H), 7.96 (d, J = 5.2 Hz, 1H), 7.68 (s, 1H), 7.63 (d, J = 4.8 Hz, 1H), 7.40 (s, 1H), 6.74 (t, J = 5.0 Hz, 1H), 5.34 (s, 1H), 4.87 (d, J = 6 Hz, 2H), 3.93 (s, 3H), 2.67 (s, 3H). 427.0 A-130 A 1H NMR (400 MHz, CDCl3) δ 8.94 (s, 1H), 8.72 (s, 1H), 8.68 (d, J = 4.8 Hz, 1H), 8.64 (s, 1H), 8.15 (s, 1H), 7.98 (d, J = 5.0 Hz, 1H), 7.91 (s, 1H), 7.68 (s, 1H), 7.63 (d, J = 4.6 Hz, 1H), 6.72 (d, J = 4.8 Hz, 1H), 5.37 (s, 1H), 4.87 (d, J = 5.8 Hz, 2H), 2.67 (s, 3H). A-131 A 1H NMR (400 MHz, CDCl3) δ 9.03 (s, 1H), 8.95 (s, 2H), 8.68 (d, J = 4.6 Hz, 1H), 8.17 (d, J = 14.4 Hz, 2H), 8.02 (d, J = 4.8 Hz, 1H), 7.69 (s, 1H), 7.64 (s, 1H), 6.72 (s, 1H), 5.41 (s, 1H), 4.88 (d, J = 5.8 Hz, 2H), 2.68 (s, 3H). A-132 A 1H NMR (400 MHz, CDCl3) δ 8.94 (s, 1H), 8.81- 8.59 (m, 2H), 8.51 (s, 1H), 8.16 (s, 1H), 7.95 (d, J = 5.2 Hz, 1H), 7.69 (d, J = 10.2 Hz, 2H), 7.63 (d, J = 4.8 Hz, 1H), 6.73 (t, J = 5.2 Hz, 1H), 5.33 (s, 1H), 4.86 (d, J = 6.0 Hz, 2H), 2.67 (s, 3H), 2.43 (s, 3H). 411.0 A-133 A 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.22 (s, 1H), 7.61 (d, J = 7.2 Hz, 2H), 7.45 (d, J = 7.2 Hz, 2H), 7.36 (s, 1H), 7.30 (s, 1H), 7.17 (s, 4H), 5.44 (s, 1H), 5.20 (s, 1H), 4.64 (s, 2H), 4.56 (s, 2H), 3.77 (s, 2H), 2.91 (s, 2H), 2.61 (s, 3H). 408.0 A-134 A 1H NMR (400 MHz, CDCl3) δ 8.76 (s, 1H), 8.54 (d, J = 5.2 Hz, 1H), 8.51 (s, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.93 (t, J = 8.0 Hz, 2H), 7.90-7.85 (m, 1H), 7.65 (s, 1H), 7.63 (s, 1H), 7.54 (t, J = 5.0 Hz, 1H), 7.51 (s, 2H), 7.49 (s, 1H), 7.37 (s, 1H), 7.31 (d, J = 5.2 Hz, 1H), 6.89 (s, 1H), 5.45 (s, 1H), 4.74 (d, J = 5.6 Hz, 2H), 2.62 (s, 3H). 403.0 A-135 A 1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 5.2 Hz, 1H), 7.61 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 7.36 (s, 1H), 7.30 (d, J = 5.2 Hz, 1H), 7.16 (brs, 4H), 5.74 (s, 1H), 5.12 (brs, 1H), 4.85 (s, 2H), 4.61 (brs, 2H), 3.99 (t, J = 5.8 Hz, 2H), 2.88 (t, J = 5.4 Hz, 2H), 2.62 (s, 3H). 442.0 A-136 A 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 5.2 Hz, 1H), 7.58 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.36 (s, 1H), 7.30 (d, J = 5.2 Hz, 1H), 7.18-7.10 (m, 4H), 4.88 (s, 2H), 4.76 (s, 2H), 4.53 (d, J = 5.6 Hz, 2H), 4.01 (t, J = 5.6 Hz, 2H), 3.41 (s, 4H), 2.87 (t, J = 5.6 Hz, 2H), 2.62 (s, 3H), 1.92 (s, 4H). 477.1 A-137 A 1H NMR (400 MHz, CDCl3) δ 9.09 (s, 1H), 8.54 (d, J = 5.2 Hz, 1H), 8.49 (s, 1H), 7.63 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 7.39 (s, 1H), 7.38 (s, 1H), 7.32 (d, J = 4.8 Hz, 1H), 5.36 (br s, 1H), 4.68 (s, 2H), 4.44 (t, J = 6.0 Hz, 2H), 3.15 (t, J = 6.8 Hz, 2H), 2.64 (s, 6H). 470.0 A-138 A 1H NMR (400 MHz, CDCl3) δ 8.98 (s, 0.4H), 8.84 (s, 0.6H), 8.60-8.55 (m, 1H), 8.46 (s, 1H), 7.61 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.40-7.30 (m, 2H), 7.27 (s, 1H), 5.73-5.51 (m, 1H), 5.38 (br s, 1H), 4.65 (s, 2H), 4.37 (s, 2H), 3.09 (s, 3H), 3.09- 2.88 (m, 2H), 2.62 (s, 3H). 453.0 A-139 A 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 5.2 Hz, 1H), 8.47 (s, 1H), 8.00 (m, 1H), 7.89 (m, 3H), 7.63 (d, J = 8.4 Hz, 2H), 7.54-7.47 (m, 4H), 7.36 (s, 1H), 7.30 (d, J = 4.0 Hz, 1H), 6.67 (s, 1H), 5.49 (s, 1H), 4.70 (d, J = 6.0 Hz, 2H), 2.66 (s, 3H), 2.62 (s, 3H). 417.0 A-140 A 1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 5.2 Hz, 1H), 8.50 (s, 1H), 8.05-8.03 (m, 1H), 7.96-7.82 (m, 3H), 7.62 (d, J = 8.4 Hz, 2H), 7.55-7.49 (m, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.36 (s, 1H), 7.30 (d, J = 4.0 Hz, 1H), 6.58 (s, 1H), 5.38 (s, 1H), 4.72 (d, J = 4.4 Hz, 2H), 2.63 (s, 3H), 2.62 (s, 3H). 449.0 A-141 A 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 5.2 Hz, 1H), 8.48 (s, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.94- 7.81 (m, 3H), 7.61 (d, J = 8.0 Hz, 2H), 7.51-7.47 (m, 4H), 7.36 (s, 1H), 7.30 (d, J = 5.2 Hz, 1H), 6.27 (s, 1H), 5.08 (s, 1H), 4.71 (d, J = 6.0 Hz, 2H), 3.69 (s, 4H), 2.62 (s, 3H), 1.99 (t, J = 6.5 Hz, 4H). 472.0 A-142 A 1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 4.8 Hz, 1H), 8.45 (s, 1H), 8.01 (d, J = 8.0 Hz, 1H), 7.95- 7.82 (m, 3H), 7.62 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 7.6 Hz, 4H), 7.37 (s, 1H), 7.31 (d, J = 5.2 Hz, 1H), 6.29 (s, 1H), 5.10 (s, 1H), 4.95 (s, 1H), 4.70 (d, J = 5.2 Hz, 2H), 3.54 (s, 2H), 2.62 (s, 3H), 1.26 (t, J = 7.0 Hz, 3H). 446.1 A-143 A 1H NMR (400 MHz, CDCl3) δ 8.68 (s, 1H), 8.55 (d, J = 5.2 Hz, 1H), 7.99 (s, 1H), 7.96-7.86 (m, 3H), 7.64 (d, J = 8.0 Hz, 3H), 7.52 (t, J = 6.8 Hz, 4H), 7.37 (s, 1H), 7.31 (d, J = 4.8 Hz, 1H), 5.10 (s, 1H), 4.87 (d, J = 5.2 Hz, 2H), 2.63 (s, 3H), 2.18 (s, 3H). 417.0 A-144 A 1H NMR (400 MHz, CDCl3) δ 8.84 (s, 1H), 8.56 (d, J = 5.2 Hz, 1H), 8.54 (s, 1H), 8.06 (d, J = 8.8 Hz, 1H), 7.99 (d, J = 8.8 Hz, 2H), 7.91 (d, J = 7.6 Hz, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.62-7.55 (m, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.37 (s, 1H), 7.31 (d, J = 4.0 Hz, 1H), 6.14 (s, 1H), 4.90 (d, J = 5.6 Hz, 2H), 2.63 (s, 3H). 428.0 A-145 A 1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 5.2 Hz, 1H), 8.48 (s, 1H), 8.14 (d, J = 7.6 Hz, 1H), 7.55-7.42 (m, 4H), 7.40 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.31 (d, J = 9.2 Hz, 1H), 7.25 (s, 1H), 5.43 (br s, 1H), 4.66 (d, J = 5.6 Hz, 2H), 4.36 (d, J = 6.4 Hz, 2H), 3.07 (d, J = 6.4 Hz, 2H), 2.62 (s, 3H). A-146 A 1H NMR (400 MHz, CDCl3) δ 8.65-8.58 (m, 3H), 8.57 (s, 1H), 8.20-7.95 (m, 5H), 7.79 (d, J = 8.0 Hz, 2H), 7.70 (d, J = 5.2 Hz, 2H), 7.57 (d, J = 9.2 Hz, 2H), 7.52 (d, J = 6.4 Hz, 1H), 7.19 (s, 1H), 4.69 (d, J = 6.0 Hz, 2H). 389.0 A-147 A 1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 8.53 (d, J = 5.2 Hz, 1H), 8.42 (s, 1H), 7.95-7.80 (m, 4H), 7.64 (d, J = 8.4 Hz, 2H), 7.54-7.50 (m, 4H), 7.35 (s, 1H), 7.29 (d, J = 5.2 Hz, 2H), 6.73 (s, 1H), 5.39 (br s, 1H), 5.08 (m, 1H) 2.61 (s, 3H), 1.67 (d, J = 6.8 Hz, 3H). 417.0 A-148 A 1H NMR (400 MHz, CDCl3) δ 9.30 (s, 1H), 8.77 (s, 1H), 8.57 (d, J = 6.0 Hz, 1H), 8.54 (d, J = 6.0 Hz, 1H), 8.47 (s, 1H), 8.13 (d, J = 8.0 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 6.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.37 (s, 1H), 7.31 (d, J = 4.8 Hz, 1H), 6.90 (s, 1H), 5.30 (br s, 1H), 4.75 (s, 2H) 2.62 (s, 3H). 404.0 A-149 B 1H NMR (400 MHz, CDCl3) δ 8.55 (d, J = 5.2 Hz, 1H), 7.99 (s, 1H), 7.91-7.83 (m, 3H), 7.71 (m, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 7.51-7.44 (m, 2H), 7.39 (s, 1H), 7.31 (m, 2H), 7.10 (d, J = 7.6 Hz, 1H), 7.00 (s, 1H), 6.68 (m, 1H), 4.50 (s, 2H), 4.30 (s, 1H), 2.65 (s, 3H). 401.1 A-150 A 1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 5.2 Hz, 1H), 8.46 (s, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 8.4 Hz, 2H), 7.84 (s, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.55 (m, 3H), 7.51-7.45 (m, 2H), 7.38 (s, 1H), 7.33 (s, 1H), 7.24 (d, J = 8.0 Hz, 1H), 6.40 (d, J = 8.0 Hz, 1H), 4.72 (d, J = 5.6 Hz, 2H), 2.62 (s, 3H). 402.0 A-151 A 1H NMR (400 MHz, CDCl3) δ 8.91 (s, 1H), 8.55 (s, 1H), 8.49 (d, J = 8.2 Hz, 1H), 8.37 (s, 1H), 7.97 (d, J = 6.4 Hz, 1H), 7.89 (dd, J = 16.2, 7.8 Hz, 2H), 7.63 (d, J = 7.2 Hz, 2H), 7.52 (d, J = 6.2 Hz, 4H), 7.37 (s, 1H), 7.31 (s, 1H), 6.31 (d, J = 5.2 Hz, 1H), 5.43 (s, 1H), 4.78 (s, 2H), 2.62 (s, 3H), 1.74 (s, 1H), 1.24 (s, 1H). 403.0 A-152 A 1H NMR (400 MHz, CDCl3) δ 8.53 (s, 2H), 8.41 (s, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.94 (s, 2H), 7.87 (s, 1H), 7.62 (d, J = 6.4 Hz, 2H), 7.55 (d, J = 4.2 Hz, 4H), 7.37 (s, 1H), 7.31 (s, 1H), 7.18 (s, 1H), 5.67 (s, 1H), 4.85 (s, 2H), 2.62 (s, 3H). 403.0 A-153 A 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 5.2 Hz, 1H), 8.42 (s, 1H), 7.96 (d, J = 8.8 Hz, 1H), 7.93-7.82 (m, 3H), 7.61 (d, J = 8.4 Hz, 2H), 7.53-7.48 (m, 2H), 7.46 (d, J = 8.4 Hz, 2H), 7.35 (s, 1H), 7.29 (d, J = 5.2 Hz, 1H), 6.34 (s, 1H), 5.25 (s, 1H), 4.94 (s, 2H), 4.67 (d, J = 5.6 Hz, 2H), 2.61 (s, 3H). 418.0 A-154 A 1H NMR (400 MHz, CDCl3) δ 8.96 (s, 1H), 8.52 (d, J = 8.8 Hz, 2H), 8.44 (d, J = 4.0 Hz, 1H), 8.36 (d, J = 8.8 Hz, 1H), 8.25 (d, J = 8.0 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.62 (d, J = 7.6 Hz, 2H), 7.54 (d, J = 7.6 Hz, 2H), 7.46 (dd, J = 7.6, 4.4 Hz, 1H), 7.36 (s, 1H), 7.30 (d, J = 4.4 Hz, 1H), 7.18 (d, J = 5.2 Hz, 1H), 5.65 (s, 1H), 4.84 (d, J = 5.2 Hz, 2H), 2.61 (s, 3H). 404.0 A-155 A 1H NMR (400 MHz, CDCl3) δ 8.52 (d, J = 5.2 Hz, 1H), 7.81 (d, J = 5.6 Hz, 1H), 7.59 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 7.35 (s, 1H), 7.30 (d, J = 4.8 Hz, 1H), 7.26 (s, 1H), 7.22-7.10 (m, 4H), 5.98 (d, J = 6.4 Hz, 1H), 4.69 (s, 2H), 4.68 (s, 2H), 3.80 (s, 2H), 2.91 (t, J = 5.6 Hz, 2H), 2.61 (s, 3H). 408.1 A156 A 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 5.2 Hz, 1H), 8.44 (d, J = 4.4 Hz, 1H), 7.89 (d, J = 4.4 Hz, 1H), 7.59 (d, J = 7.6 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 7.2 Hz, 1H), 7.35 (s, 1H), 7.29 (d, J = 4.8 Hz, 1H), 7.16-7.10 (m, 1H), 6.02 (d, J = 6.0 Hz, 1H), 4.72 (s, 2H), 4.68 (d, J = 5.6 Hz, 2H), 3.92 (t, J = 5.6 Hz, 2H), 3.09 (t, J = 5.6 Hz, 2H), 2.61 (s, 3H). 409.0 A-157 A 1H NMR (400 MHz, CDCl3) δ 8.94 (d, J = 4.0 Hz, 1H), 8.89 (s, 1H), 8.74 (d, J = 8.8 Hz, 1H), 8.54 (d, J = 4.8 Hz, 1H), 8.37 (d, J = 5.6 Hz, 1H), 8.27 (d, J = 8.0 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 7.64 (d, J = 7.6 Hz, 2H), 7.52 (d, J = 8.0 Hz, 2H), 7.43 (dd, J = 8.0, 4.4 Hz, 1H), 7.37 (s, 1H), 7.31 (d, J = 4.8 Hz, 1H), 6.34 (d, J = 5.6 Hz, 1H), 5.45 (s, 1H), 4.79 (s, 2H), 2.62 (s, 3H). 404.0 A-158 A 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 5.2 Hz, 1H), 8.41 (d, J = 4.0 Hz, 1H), 7.94 (d, J = 5.6 Hz, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.45 (d, J = 7.6 Hz, 3H), 7.36 (s, 1H), 7.30 (d, J = 5.2 Hz, 1H), 7.11 (dd, J = 7.2, 4.8 Hz, 1H), 5.76 (d, J = 6.0 Hz, 1H), 5.11 (s, 1H), 4.90 (s, 2H), 4.64 (d, J = 4.4 Hz, 2H), 4.13 (t, J = 6.0 Hz, 2H), 3.06 (t, J = 6.0 Hz, 2H), 2.62 (s, 3H). 409.0 A-159 A 1H NMR (400 MHz, CDCl3) δ 9.50 (s, 1H), 9.37 (s, 1H), 8.61 (s, 1H), 8.58 (d, J = 8.8 Hz, 1H), 8.53 (d, J = 4.8 Hz, 1H), 8.48 (d, J = 5.2 Hz, 1H), 8.14 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 7.6 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 7.37 (s, 1H), 7.31 (d, J = 4.8 Hz, 1H), 7.18 (d, J = 4.8 Hz, 1H), 5.70 (s, 1H), 4.85 (d, J = 5.2 Hz, 2H), 2.62 (s, 3H). 405.0 A-160 A 1H NMR (400 MHz, CDCl3) δ 8.99 (s, 2H), 8.79 (s, 1H), 8.74 (d, J = 8.6 Hz, 1H), 8.67 (s, 1H), 8.55 (s, 1H), 8.30 (d, J = 6.8 Hz, 1H), 8.19 (d, J = 8.6 Hz, 1H), 7.63 (d, J = 6.4 Hz, 2H), 7.51 (dd, J = 15.4, 8.5 Hz, 3H), 7.37 (s, 1H), 7.32 (s, 1H), 6.18 (s, 1H), 6.05 (s, 1H), 4.92 (s, 1H), 4.83 (s, 1H), 2.62 (s, 3H). 405.0 A-161 A 1H NMR (400 MHz, CDCl3) δ 8.55 (d, J = 4.8 Hz, 1H), 8.41 (d, J = 4.0 Hz, 1H), 7.82 (d, J = 2.8 Hz, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.0 Hz, 1H), 7.38 (s, 1H), 7.33 (d, J = 4.8 Hz, 1H), 7.11 (dd, J = 7.2, 4.4 Hz, 1H), 5.30 (s, 1H), 4.84 (s, 2H), 4.76 (d, J = 5.2 Hz, 2H), 4.08 (t, J = 5.6 Hz, 2H), 3.06 (t, J = 6.0 Hz, 2H), 2.64 (s, 3H). 427.0 A-162 B 1H NMR (400 MHz, DMSO) δ 8.46 (d, J = 5.2 Hz, 1H), 8.18 (d, J = 15.6 Hz, 2H), 8.07-7.89 (m, 5H), 7.77 (d, J = 8.0 Hz, 3H), 7.55 (m, 5H), 7.48 (d, J = 4.8 Hz, 1H), 7.30 (s, 1H), 6.74 (s, 1H), 4.50 (d, J = 5.6 Hz, 2H). 402.0 A-163 B 1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 4.8 Hz, 1H), 8.18 (d, J = 4.8 Hz, 1H), 8.02 (s, 1H), 7.96- 7.82 (m, 3H), 7.68-7.56 (m, 4H), 7.52 (d, J = 8.0 Hz, 5H), 7.37 (s, 1H), 7.31 (d, J = 4.4 Hz, 1H), 6.75 (s, 1H), 4.68 (d, J = 5.2 Hz, 2H), 2.62 (s, 3H). A-164 B 1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 5.2 Hz, 1H), 8.39 (s, 1H), 8.23 (d, J = 5.6 Hz, 1H), 7.97-7.78 (m, 4H), 7.63 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 5.6 Hz, 4H), 7.35 (s, 1H), 7.29 (d, J = 5.6 Hz, 1H), 7.09 (s, 1H), 6.53 (s, 1H), 4.54 (d, J = 5.2 Hz, 2H), 2.62 (s, 3H). 402.0 A-165 A 1H NMR (400 MHz, CDCl3) δ 8.99 (s, 1H), 8.62 (s, 2H), 8.23 (t, J = 7.8 Hz, 2H), 8.16 (s, 1H), 8.03 (s, 1H), 7.90 (d, J = 9.2 Hz, 1H), 7.83 (s, 1H), 7.76 (s, 1H), 7.66 (d, J = 11.6 Hz, 1H), 7.50 (d, J = 4.2 Hz, 1H), 7.08 (s, 1H), 6.83 (s, 1H), 6.64 (s, 1H), 4.79 (s, 2H), 2.68 (s, 3H). 454.0 A-166 A 1H NMR (400 MHz, CDCl3) δ 9.00 (s, 1H), 8.55 (s, 1H), 8.21 (d, J = 8.4 Hz, 2H), 7.99 (s, 2H), 7.82 (d, J = 8.8 Hz, 1H), 7.66 (d, J = 7.6 Hz, 2H), 7.55 (d, J = 7.8 Hz, 2H), 7.52-7.46 (m, 1H), 7.40 (d, J = 15.8 Hz, 2H), 7.09 (s, 1H), 6.89 (s, 1H), 4.72 (s, 2H), 2.68 (s, 3H). A-167 A 1H NMR (400 MHz, CDCl3) δ 8.99 (d, J = 10 Hz, 1H), 8.79 (s, 1H), 8.69 (s, 1H), 8.53 (s, 1H), 8.49 (d, J = 8.4 Hz, 1H), 8.44 (d, J = 8.8 Hz, 1H), 7.99 (d, J = 7.6 Hz, 1H), 7.91 (m, 2H), 7.64 (d, J = 7.6 Hz, 2H), 7.5 (m, 4H), 7.37 (s, 1H), 7.31 (d, J = 4.8 Hz, 1H), 5.91 (s, 1H), 4.93 (d, J = 5.6 Hz, 1H), 4.82 (d, J = 6 Hz, 1H), 2.62 (s, 3H). 404.0 A-168 A 1H NMR (400 MHz, DMSO) δ 8.96 (d, J = 2.8 Hz, 1H), 8.75 (s, 1H), 8.68 (s, 1H), 8.56 (d, J = 5.2 Hz, 1H), 8.50-8.44 (m, 3H), 8.11 (d, J = 8.8 Hz, 1H), 8.07-8.01 (m, 1H), 7.88 (s, 1H), 7.74 (s, 1H), 7.66 (d, J = 4.4 Hz, 1H), 7.61 (dd, J = 8.4, 4.0 Hz, 1H), 7.40 (d, J = 5.2 Hz, 1H), 4.74 (s, 2H), 2.53 (s, 3H). 423.0 A-169 A 1H NMR (400 MHz, CDCl3) δ 8.96 (d, J = 4.0 Hz, 1H), 8.79 (s, 1H), 8.73 (s, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.50-8.43 (m, 3H), 8.11 (d, J = 8.8 Hz, 1H), 8.08-7.89 (m, 4H), 7.82 (d, J = 4.8 Hz, 1H), 7.60 (dd, J = 8.4, 4.4 Hz, 1H), 7.37 (d, J = 5.2 Hz, 1H), 4.70 (s, 2H), 2.53 (s, 3H). 405.0 A-170 A 1H NMR (400 MHz, DMSO) δ 8.96 (d, J = 2.4 Hz, 1H), 8.76 (s, 1H), 8.59 (s, 1H), 8.52-8.43 (m, 4H), 8.12 (d, J = 8.8 Hz, 1H), 8.04-7.97 (m, 1H), 7.79 (s, 1H), 7.61 (dd, J = 8.4, 4.4 Hz, 1H), 7.42 (s, 1H), 7.39-7.32 (m, 2H), 4.66 (s, 2H), 2.51 (s, 3H), 2.32 (s, 3H). 419.0 A-171 A 1H NMR (400 MHz, DMSO) δ 9.04 (s, 1H), 8.96 (d, J = 3.6 Hz, 1H), 8.76 (s, 1H), 8.62 (d, J = 4.8 Hz, 1H), 8.56-8.39 (m, 4H), 8.12 (d, J = 8.8 Hz, 1H), 8.08-8.02 (m, 1H), 7.68 (s, 1H), 7.65-7.59 (m, 2H), 7.41 (d, J = 4.8 Hz, 1H), 4.75 (s, 2H), 2.55 (s, 3H). 430.0 A-172 A 1H NMR (400 MHz, DMSO) δ 9.03 (s, 2H), 8.96 (d, J = 2.8 Hz, 1H), 8.76 (s, 1H), 8.60 (d, J = 5.2 Hz, 1H), 8.51-8.44 (m, 3H), 8.12 (d, J = 8.0 Hz, 2H), 8.06-8.00 (m, 2H), 7.61 (dd, J = 8.4, 4.4 Hz, 1H), 7.40 (d, J = 5.2 Hz, 1H), 4.71 (s, 2H), 2.56 (s, 3H). 406.0 A-173 A 1H NMR (400 MHz, CDCl3) δ 8.97 (s, 1H), 8.51 (s, 1H), 8.44 (s, 1H), 8.36 (d, J = 8.8 Hz, 1H), 8.26 (d, J = 7.6 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.85 (s, 1H), 7.55 (d, J = 7.6 Hz, 2H), 7.46 (s, 1H), 7.38 (d, J = 7.2 Hz, 2H), 7.27 (s, 1H), 7.22-7.18 (m, 2H), 5.67 (s, 1H), 4.83 (d, J = 4.4 Hz, 2H). 379.0 A-174 A 1H NMR (400 MHz, CDCl3) δ 9.04 (s, 1H), 8.97 (d, J = 2.8 Hz, 1H), 8.83 (s, 1H), 8.64 (d, J = 5.2 Hz, 1H), 8.50 (s, 1H), 8.45 (d, J = 4.8 Hz, 1H), 8.35 (dd, J = 8.8, 1.6 Hz, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.79 (s, 1H), 7.70 (d, J = 4.8 Hz, 1H), 7.46 (dd, J = 8.0, 4.0 Hz, 1H), 7.21 (d, J = 5.2 Hz, 1H), 6.17 (t, J = 5.2 Hz, 1H), 5.00 (d, J = 5.6 Hz, 2H), 2.67 (s, 3H). 406.0 A-175 A 1H NMR (400 MHz, CDCl3) δ 8.97 (d, J = 2.8 Hz, 1H), 8.55 (d, J = 4.4 Hz, 1H), 8.50 (s, 1H), 8.47-8.41 (m, 2H), 8.36 (d, J = 8.4 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.82 (d, J = 10.8 Hz, 2H), 7.49-7.43 (m, 2H), 7.22 (d, J = 4.4 Hz, 1H), 5.73 (s, 1H), 4.86 (d, J = 4.8 Hz, 2H), 3.87 (s, 3H), 2.68 (s, 3H). 435.0 A-176 G 1H NMR (400 MHz, CDCl3) δ 9.04 (d, J = 3.2 Hz, 1H), 8.65-8.55 (m, 3H), 8.38 (d, J = 8.4 Hz, 1H), 8.30 (d, J = 9.2 Hz, 1H), 7.79 (d, J = 6.0 Hz, 2H), 7.74 (dd, J = 8.4, 4.0 Hz, 1H), 7.69 (d, J = 4.4 Hz, 1H), 7.62 (d, J = 11.6 Hz, 1H), 7.14 (d, J = 5.6 Hz, 1H), 5.77 (t, J = 5.2 Hz, 1H), 4.89 (d, J = 6.0 Hz, 2H), 2.65 (s, 3H). A-177 A 1H NMR (400 MHz, CDCl3) δ 9.14 (s, 1H), 8.97 (d, J = 4.0 Hz, 1H), 8.48 (s, 1H), 8.45 (s, 1H), 8.44 (s, 1H) 8.32 (d, J = 9.2 Hz, 1H), 8.24 (d, J = 6.8 Hz, 2H), 8.18 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.47 (m, 1H), 7.22 (d, J = 5.2 Hz, 1H), 5.85 (s, 1H), 5.02 (d, J = 6.4 Hz, 2H). 389.1 A-178 A 1H NMR (400 MHz, CDCl3) δ 8.97 (d, J = 3.2 Hz, 1H), 8.52 (s, 1H), 8.48 (d, J = 5.2 Hz, 1H), 8.39 (d, J = 8.8 Hz, 1H), 8.18-8.25 (m, 5H), 7.89 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.47 (dd, J = 8.0, 4.0 Hz, 1H), 7.21 (d, J = 4.8 Hz, 1H), 6.67 (s, 1H), 5.10 (d, J = 4.0 Hz, 2H). 389.0 A-179 A 1H NMR (400 MHz, CDCl3) δ 9.03 (s, 1H), 8.96 (d, J = 2.8 Hz, 1H), 8.52 (s, 1H), 8.48 (s, 1H), 8.44 (d, J = 5.2 Hz, 1H), 8.32 (d, J = 8.8 Hz, 1H), 8.24 (d, J = 8.0 Hz, 1H), 8.21 (s, 1H), 8.16 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 8.4 Hz, 1H), 7.47-7.44 (m, 1H), 7.20 (d, J = 4.8 Hz, 1H), 5.86 (s, 1H), 5.05 (d, J = 6.0 Hz, 2H). 389.1 A-180 A 1H NMR (400 MHz, DMSO) δ 8.96 (d, J = 3.2 Hz, 1H), 8.76 (s, 1H), 8.50 (d, J = 7.6 Hz, 2H), 8.43 (d, J = 4.4 Hz, 1H), 8.23 (s, 1H), 8.13 (d, J = 8.8 Hz, 1H), 7.86-7.78 (m, 1H), 7.67 (s, 1H), 7.61 (dd, J = 8.0, 4.0 Hz, 1H), 7.34 (d, J = 5.2 Hz, 1H), 6.99 (d, J = 8.8 Hz, 1H), 4.51 (s, 2H), 4.01 (s, 4H), 3.05 (s, 4H). 447.0 A-181 A 1H NMR (400 MHz, CDCl3) δ 8.97 (d, J = 3.6 Hz, 1H), 8.52 (s, 1H), 8.43 (d, J = 5.2 Hz, 1H), 8.37 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.21-8.16 (m, 2H), 7.53 (d, J = 8.0 Hz, 1H), 7.47 (dd, J = 8.2, 4.2 Hz, 1H), 7.17 (d, J = 5.2 Hz, 1H), 6.46 (d, J = 8.8 Hz, 1H), 5.48 (s, 1H), 4.93 (s, 1H), 4.63 (d, J = 5.6 Hz, 2H), 3.97-3.91 (m, 2H), 3.38 (t, J = 5.8 Hz, 2H), 2.94 (s, 3H). A182 F 1H NMR (400 MHz, CDCl3) δ 9.58 (s, 1H), 9.07 (s, 1H), 8.72 (s, 1H), 8.55 (d, J = 4.8 Hz, 2H), 8.44 (s, 1H), 8.28 (s, 1H), 7.83 (d, J = 3.6 Hz, 1H), 7.71 (s, 1H), 7.68-7.63 (m, 2H), 7.44 (s, 1H), 5.66 (s, 1H), 4.87 (d, J = 5.6 Hz, 2H), 3.86 (s, 3H), 2.62 (s, 3H). 436.0 A-183 F 1H NMR (400 MHz, CDCl3) δ 9.57 (s, 1H), 9.07 (s, 1H), 8.67 (d, J = 8.4 Hz, 2H), 8.61 (d, J = 5.2 Hz, 1H), 8.54 (d, J = 5.2 Hz, 1H), 8.27 (d, J = 8.4 Hz, 1H), 7.85 (d, J = 5.2 Hz, 1H), 7.76 (s, 1H), 7.71-7.63 (m, 3H), 5.71 (s, 1H), 4.89 (d, J = 5.6 Hz, 2H), 2.64 (s, 3H). A184 F 1H NMR (400 MHz, CDCl3) δ 9.58 (s, 1H), 9.09 (d, J = 3.2 Hz, 1H), 9.01 (s, 1H), 8.69-8.64 (m, 2H), 8.54 (d, J = 4.8 Hz, 1H), 8.29 (d, J = 8.4 Hz, 1H), 8.22 (s, 1H), 7.88 (d, J = 4.8 Hz, 1H), 7.70-7.60 (m, 3H), 5.77 (m, 1H), 4.90 (d, J = 6.0 Hz, 2H), 2.86 (s, 3H). A185 A 1H NMR (400 MHz, CDCl3) δ 8.99 (s, 1H), 8.95 (d, J = 3.2 Hz, 1H), 8.68 (d, J = 5.2 Hz, 1H), 8.26 (s, 1H), 8.22-8.13 (m, 4H), 7.68 (s, 1H), 7.64 (d, J = 5.2 Hz, 1H), 7.46 (dd, J = 8.0, 4.4 Hz, 1H), 7.26 (s, 1H), 4.84 (s, 2H), 2.66 (s, 3H). 436.0 A-186 A 1H NMR (400 MHz, DMSO) δ 9.00 (d, J = 2.8 Hz, 1H), 8.62 (s, 1H), 8.57 (d, J = 8.4 Hz, 1H), 8.47 (d, J = 5.2 Hz, 1H), 8.30-8.25 (m, 1H), 8.22 (d, J = 8.4 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 8.0 Hz, 2H), 7.64 (dd, J = 8.4, 4.4 Hz, 1H), 7.57 (s, 1H), 7.52 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 4.8 Hz, 1H), 4.61 (d, J = 6.0 Hz, 2H), 2.51 (s, 3H). 410.0 A-187 A 1H NMR (400 MHz, DMSO) δ 9.00 (d, J = 3.2 Hz, 1H), 8.61 (s, 1H), 8.56 (d, J = 8.0 Hz, 1H), 8.29-8.24 (m, 1H), 8.23-8.14 (m, 3H), 7.64 (dd, J = 8.0, 4.0 Hz, 1H), 7.58 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.8 Hz, 3H), 4.57 (d, J = 6.0 Hz, 2H), 2.19 (s, 3H). A-188 A 1H NMR (400 MHz, DMSO) δ 9.00 (d, J = 2.8 Hz, 1H), 8.61 (s, 1H), 8.56 (d, J = 8.4 Hz, 1H), 8.23-8.07 (m, 4H), 7.68-7.61 (m, 2H), 7.00 (d, J = 8.8 Hz, 1H), 4.42 (d, J = 6.0 Hz, 2H), 4.03 (s, 4H), 3.06 (s, 4H). A-189 A 1H NMR (400 MHz, DMSO) δ 9.00 (d, J = 3.2 Hz, 1H), 8.60 (s, 1H), 8.56 (d, J = 8.4 Hz, 1H), 8.21 (d, J = 9.6 Hz, 1H), 8.15 (d, J = 8.8 Hz, 1H), 8.04 (s, 2H), 7.64 (dd, J = 8.4, 4.4 Hz, 1H), 7.48 (d, J = 8.0 Hz, 1H), 6.74 (s, 1H), 6.50 (d, J = 8.4 Hz, 1H), 4.35 (d, J = 6.0 Hz, 2H), 3.69-3.61 (m, 2H), 3.32-3.30 (m, 2H), 2.99 (s, 3H). A-190 A 1H NMR (400 MHz, DMSO) δ 9.00 (d, J = 2.8 Hz, 1H), 8.76 (s, 1H), 8.62 (s, 1H), 8.59-8.51 (m, 2H), 8.34-8.29 (m, 1H), 8.22 (d, J = 8.8 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.92 (s, 1H), 7.82 (d, J = 5.2 Hz, 1H), 7.64 (dd, J = 8.0, 4.0 Hz, 1H), 4.63 (d, J = 6.0 Hz, 2H), 2.54 (s, 3H). 411.0 A-191 A 1H NMR (400 MHz, CDCl3) δ 9.00 (d, J = 2.8 Hz, 1H), 8.61 (s, 1H), 8.58 (d, J = 4.8 Hz, 1H), 8.40 (s, 1H), 8.26 (d, J = 8.0 Hz, 1H), 8.22-8.14 (m, 2H), 7.69 (s, 1H), 7.49 (dd, J = 8.0, 4.0 Hz, 1H), 7.33 (s, 1H), 7.24 (d, J = 5.6 Hz, 1H), 5.66 (s, 1H), 4.76 (d, J = 6.0 Hz, 2H), 2.62 (s, 3H), 2.37 (s, 3H). 425.0 A-192 A 1H NMR (400 MHz, DMSO) δ 9.00 (d, J = 2.8 Hz, 1H), 8.64 (d, J = 9.2 Hz, 2H), 8.60-8.54 (m, 2H), 8.38-8.32 (m, 1H), 8.22 (d, J = 8.8 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 7.88 (d, J = 12.0 Hz, 1H), 7.77 (s, 1H), 7.69 (d, J = 4.4 Hz, 1H), 7.64 (dd, J = 8.0, 4.0 Hz, 1H), 4.67 (d, J = 6.0 Hz, 2H), 2.55 (s, 3H). 429.0 A-193 A 1H NMR (400 MHz, CDCl3) δ 9.00 (d, J = 2.8 Hz, 1H), 8.55 (d, J = 4.8 Hz, 1H), 8.40 (s, 2H), 8.26 (d, J = 8.0 Hz, 1H), 8.22-8.14 (m, 2H), 7.73 (s, 1H), 7.69 (d, J = 4.4 Hz, 1H), 7.49 (dd, J = 8.0, 4.0 Hz, 1H), 7.45 (s, 1H), 5.70 (t, J = 5.6 Hz, 1H), 4.79 (d, J = 6.0 Hz, 2H), 3.90 (s, 3H), 2.63 (s, 3H). 440.9 A-194 A 1H NMR (400 MHz, CDCl3) δ 9.00 (d, J = 3.2 Hz, 1H), 8.98 (s, 1H), 8.68 (d, J = 4.8 Hz, 1H), 8.39 (s, 1H), 8.27 (d, J = 8.4 Hz, 1H), 8.21 (d, J = 7.2 Hz, 2H), 8.15 (d, J = 8.8 Hz, 1H), 7.69 (s, 1H), 7.64 (d, J = 4.8 Hz, 1H), 7.50 (dd, J = 8.0, 4.0 Hz, 1H), 5.83 (t, J = 5.6 Hz, 1H), 4.83 (d, J = 6.0 Hz, 2H), 2.67 (s, 3H). 435.9 A-195 A 1H NMR (400 MHz, DMSO) δ 9.47 (s, 1H), 9.15 (d, J = 3.2 Hz, 1H), 8.71 (d, J = 8.4 Hz, 1H), 8.64 (d, J = 8.4 Hz, 2H), 8.57 (d, J = 5.2 Hz, 1H), 8.28-8.22 (m, 1H), 7.92-7.84 (m, 2H), 7.75 (s, 1H), 7.67 (d, J = 4.4 Hz, 1H), 4.68 (d, J = 6.0 Hz, 2H), 2.55 (s, 3H). 429.9 A-196 A 1H NMR (400 MHz, DMSO) δ 9.47 (s, 1H), 9.15 (d, J = 3.2 Hz, 1H), 8.70 (d, J = 8.4 Hz, 1H), 8.64 (s, 1H), 8.48 (d, J = 4.8 Hz, 1H), 8.35 (s, 1H), 8.23-8.17 (m, 1H), 7.90 (dd, J = 8.4, 4.0 Hz, 1H), 7.73 (s, 1H), 7.68 (s, 1H), 7.67 (d, J = 6.0 Hz, 1H), 4.65 (d, J = 6.0 Hz, 2H), 3.89 (s, 3H), 2.51 (s, 3H). 441.9 A-197 A 1H NMR (400 MHz, DMSO) δ 9.47 (s, 1H), 9.16 (d, J = 3.2 Hz, 1H), 9.01 (s, 1H), 8.71 (d, J = 8.4 Hz, 1H), 8.64 (s, 2H), 8.46 (s, 1H), 8.29-8.23 (m, 1H), 7.90 (dd, J = 8.4, 4.0 Hz, 1H), 7.69 (s, 1H), 7.64 (d, J = 4.8 Hz, 1H), 4.69 (d, J = 6.0 Hz, 2H), 2.57 (s, 3H). 437.0 A-198 A 1H NMR (400 MHz, CDCl3) δ 8.89 (s, 1H), 8.67 (d, J = 4.8 Hz, 1H), 8.48 (d, J = 4.4 Hz, 1H), 8.15 (s, 1H), 7.67 (s, 1H), 7.62 (d, J = 4.8 Hz, 1H), 7.48 (d, J = 7.6 Hz, 1H), 7.20 (dd, J = 6.8, 4.8 Hz, 1H), 5.33 (t, J = 5.6 Hz, 1H), 4.68 (d, J = 6.4 Hz, 2H), 4.65 (s, 2H), 3.80 (t, J = 4.8 Hz, 2H), 3.19 (t, J = 6.0 Hz, 2H), 2.67 (s, 3H). 441.0 A-199 A 1H NMR (400 MHz, DMSO) δ 9.12 (s, 1H), 9.00 (d, J = 3.2 Hz, 1H), 8.62 (s, 1H), 8.56 (d, J = 10.8 Hz, 2H), 8.45-8.39 (m, 2H), 8.21 (d, J = 8.0 Hz, 2H), 8.15 (d, J = 8.8 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.64 (dd, J = 8.0, 4.0 Hz, 1H), 4.79 (d, J = 5.6 Hz, 2H). A-200 A 1H NMR (400 MHz, DMSO) δ 9.00 (d, J = 2.8 Hz, 1H), 8.59 (s, 1H), 8.56 (d, J = 8.0 Hz, 1H), 8.41 (s, 1H), 8.21-8.12 (m, 2H), 7.78-7.60 (m, 4H), 6.57 (d, J = 8.8 Hz, 1H), 3.57 (s, 2H), 3.52 (t, J = 5.2 Hz, 2H). A-201 A 1H NMR (400 MHz, CDCl3) δ 8.89 (s, 1H), 8.67 (d, J = 5.0 Hz, 1H), 8.10 (s, 1H), 8.02 (s, 1H), 7.67 (s, 1H), 7.62 (d, J = 4.8 Hz, 1H), 7.50 (s, 1H), 6.10 (s, 1H), 5.34 (s, 1H), 4.94 (s, 2H), 4.81 (d, J = 6.2 Hz, 2H), 4.32 (m, 2H), 4.18 (m, 2H), 2.67 (s, 3H). A-202 A 1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 5.0 Hz, 1H), 8.54 (s, 1H), 8.45 (d, J = 3.2 Hz, 1H), 7.75 (s, 1H), 7.71 (d, J = 5.6 Hz, 1H), 7.67 (d, J = 4.6 Hz, 1H), 7.55 (d, J = 11.8 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.18 (m, 1H), 6.30 (m, 1H), 5.02 (s, 1H), 4.78 (d, J = 5.8 Hz, 2H), 4.48 (s, 2H), 3.71 (m, 2H), 3.15 (m, 2H), 2.63 (s, 3H). 445.0 - The primary assay is based on Wnt pathway Super-top flash (STF) reporter gene assay:
- HEK293 STF stable clones (HEK293 cells stably transfected with “Super-Top Flash” TCF-luciferase reporter plasmid) were kept in complete culture medium (DMEM with 4 mM L-Gln, 1.5 g/L sodium bicarbonate and 4.5 g/L glucose containing 6 μg/mL Blasticidin and 10% FBS). L Wnt3A cells (CRL-2647, ATCC) were kept in DMEM (Gibico) containing 10% FBS (Hyclone). HEK293 STF and L Wnt3A cells were harvested when 90% confluence and cell suspension was mixed with a fixed ratio of 1:1 (HEK293 STF:L Wnt3A). 100 μL/well of mixed cells suspension was added to the 96-well-plate with final cell concentration of 12,000 cells/well and then cultured for an additional 24 hours before adding compounds.
- Compounds were diluted in DMSO in sequence and then diluted with DMEM medium. 20 μL medium containing compound was added to the cells according to the pre-setting dose. Cell plates were incubated at 37° C. for an additional 48 hours.
- 50 μL luciferase solution (Bright-Glo, Promega) was added to each well during the 48 h incubation. The plates were incubated at room temperature for 5 min under gentle shaking. Luminescence signaling was measured with a plate reader (PHERAstar FS, BMG). The IC50 (potency) of compounds was calculated based on the inhibition of luminescence signaling.
- The above mentioned compounds were tested in the primary assay described above and the data were summarized in Table 3. In particular, IC50 curves for compounds A-12, A-36, A-100, A-103, A-166, A-168, A-194, and A-198 are shown in
FIGS. 1-8 , respectively. -
TABLE 3 Results of selected compounds (A-1 to A-202) of the present invention when tested in the primary assay. Com- Compound IC50 Compound IC50 pound IC50 number (nM) number (nM) number (nM) A-1 1.4 A-2 2.9 A-3 36 A-4 0.3 A-5 2.1 A-6 4.7 A-7 7.4 A-8 1.5 A-9 2.8 A-10 285 A-11 1.6 A-12 0.3 A-13 99 A-14 5.9 A-15 19 A-16 27 A-17 >1000 A-18 480 A-19 14 A-20 211 A-21 14 A-22 14 A-23 15 A-24 37 A-25 >1000 A-26 1.5 A-27 937 A-28 17 A-29 577 A-30 23 A-31 1 A-32 2 A-33 1.4 A-34 3 A-35 4 A-36 0.5 A-37 2.4 A-38 5 A-39 129 A-40 >1000 A-41 55 A-42 0.7 A-43 75 A-44 1 A-45 0.4 A-46 4.9 A-47 0.94 A-48 2.1 A-49 0.39 A-50 1.0 A-51 1.0 A-52 17 A-53 89 A-54 0.67 A-55 3000 A-56 1 A-57 0.39 A-58 34 A-59 230 A-60 0.81 A-61 1.3 A-62 6.2 A-63 2 A-64 16 A-65 0.44 A-66 58 A-67 10 A-68 16 A-69 73 A-70 147 A-71 0.29 A-72 0.64 A-73 1.3 A-74 1.6 A-75 0.52 A-76 1.3 A-77 1.6 A-78 777 A-79 416 A-80 768 A-81 625 A-82 338 A-83 3000 A-84 0.26 A-85 0.14 A-86 0.34 A-87 0.51 A-88 7.7 A-89 14 A-90 1.2 A-91 53 A-92 10 A-93 40 A-94 0.8 A-95 15 A-96 0.2 A-97 0.18 A-98 0.06 A-99 0.11 A-100 0.27 A-101 0.31 A-102 0.54 A-103 0.12 A-104 0.11 A-105 5.2 A-106 0.24 A-107 16 A-108 1 A-109 10 A-110 1 A-111 10 A-112 10 A-113 16 A-114 8 A-115 7 A-116 8 A-117 2 A-118 318 A-119 10 A-120 12 A-121 0.06 A-122 0.13 A-123 0.12 A-124 0.12 A-125 0.06 A-126 0.04 A-127 0.34 A-128 1.8 A-129 0.4 A-130 0.11 A-131 1.0 A-132 0.25 A-133 34 A-134 24 A-135 3000 A-136 4000 A-137 3000 A-138 712 A-139 3000 A-140 3000 A-141 3000 A-142 3000 A-143 2000 A-144 40 A-145 1131 A-146 68 A-147 40 A-148 10 A-149 603 A-150 250 A-151 2000 A-152 4.9 A-153 3000 A-154 1.2 A-155 229 A-156 12 A-157 3000 A-158 3000 A-159 17 A-160 6.7 A-161 3000 A-162 2000 A-162 3.2 A-164 3000 A-165 0.71 A-166 3.6 A-167 120 A-168 0.85 A-169 4.9 A-170 3.7 A-171 0.31 A-172 1.7 A-173 106 A-174 2.7 A-175 0.74 A-176 18 A-177 100 A-178 200 A-179 500 A-180 300 A-181 350 A-182 0.64 A-183 2.1 A-184 1 A-185 4.3 A-186 0.27 A-187 51 A-188 4.6 A-189 3000 A-190 0.4 A-191 0.38 A-192 0.1 A-193 0.07 A-194 0.09 A-195 0.84 A-196 0.78 A-197 0.31 A-198 0.42 A-199 0.17 A-200 25 A-201 0.8 A-202 0.5
Claims (16)
1. A compound of Formula I:
or a pharmaceutically acceptable salt, solvate, stereoisomer or a tautomer thereof, wherein
A is A1, A2, A3 or A4;
U is U1, U2, U3 or U4;
L is L, L2, or L3;
Q is Q1, Q2, Q3 or Q4;
Z is Z1, Z2, Z3 or Z4;
A1 is
wherein X8 to X10 are independently selected from N and C—R14;
G1 and G2 are independently selected from N and C;
V1 and V2 are independently selected from N, O, S and C—R15;
W is V3, V4—V5 or V4═V5, wherein V3 to V5 are independently selected from N, O, S and C—R16, wherein V4 connects with V1; and
V5 connects with V2;
U2 is C6-C10 aryl, 5-12 membered heteroaryl, 11-13 membered heterocyclophenyl or 10-13 membered heterocycloheteroaryl, wherein heterocyclo and heteroaryl comprises 1 to 4 heteroatoms independently selected from N, O and S; and
C6-C10 aryl, 5-12 membered heteroaryl, 11-13 membered heterocyclophenyl and 10-13 membered heterocycloheteroaryl are unsubstituted or substituted with 1 to 4 R6a groups;
U3 is —OR14b, —NR14bR15b, C6-C12 aryl unsubstituted or substituted with 1-6 R13b group, 5-14 membered heteroaryl unsubstituted or substituted with 1-6 R13b group, 11-13 membered heterocyclophenyl unsubstituted or substituted with 1-6 R13b group, 10-13 membered heterocycloheteroaryl unsubstituted or substituted with 1-6 R13b group, C2-C8 alkenyl substituted with 5-6 membered aryl or heteroaryl, C2-C8 alkynyl substituted with 5-6 membered aryl or heteroaryl, or
unsubstituted or substituted with 1 to 2 R13b groups, wherein heterocyclo and heteroaryl comprises 1 to 4 heteroatoms independently selected from N, O and S; and
X11 is N or C—R13b;
U4 is
wherein X8 to X10 are independently selected from N and C—R15c;
G1 and G2 are independently selected from N and C;
V1 and V2 are independently selected from N, O, S and C—R16c;
W is V3, V4—V5 or V4═V5, wherein V3 to V5 are independently selected from N, O, S and C—R17c, wherein V4 connects with V1; and
V5 connects with V2;
L1 is
wherein Y2 is blank, —O—, —S—, —N(R18b)— or —C(R18b)(R19b)—;
L3 is —C(R2c)(R3c)— or —NHCH2CH2—;
Q1 is C6-C10 arylene or 5-12 membered heteroarylene, wherein 5-12 membered heteroarylene comprises 1 to 4 heteroatoms independently selected from N, O and S; and
C6-C10 aryl and 5-12 membered heteroarylene are unsubstituted or substituted with 1 to 4 R17 groups;
Q2 is C6-C10 arylene or 5-10 membered heteroarylene, wherein 5-10 membered heteroarylene comprises 1 to 4 heteroatoms independently selected from N, O and S; and
C6-C10 arylene and 5-10 membered heteroarylene are unsubstituted or substituted with 1 to 4 R4a groups;
Q3 is C6-C12 arylene unsubstituted or substituted with 1-6 R6b group, 5-14 membered heteroarylene unsubstituted or substituted with 1-6 R6b group, C3-C6 cycloalkylene unsubstituted or substituted with 1-6 R6b group, C3-C6 heterocylene unsubstituted or substituted with 1-6 R6b group, or
unsubstituted or substituted with 1 to 2 R6b groups, wherein heterocyclene and heteroarylene comprises 1 to 4 heteroatoms independently selected from N, O and S; and
X12 is N or C—R6b;
Q4 is C6-C10 arylene or 5-12 membered heteroarylene, wherein 5-12 membered heteroarylene comprises 1 to 4 heteroatoms independently selected from N, O and S; and
C6-C10 arylene and 5-12 membered heteroarylene are unsubstituted or substituted with 1 to 4 R5c groups;
Z1 is —CN, C6 aryl, 5-6 membered heteroaryl, or
wherein 5-6 membered heteroaryl comprises 1 to 3 heteroatoms independently selected from N, O and S;
C6 aryl and 5-6 membered heteroaryl are unsubstituted or substituted with 1 to 3 R18 groups;
Y1 is O or NR20; and
q is 0, 1, 2, or 3;
Z2 is H, —CN, halide, —OH, C1-C8 alkyl, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkylsulfonyl, C1-C8 acyl, aminoacyl, C1-C8 acylamino, C1-C8 alkylcarbamoylamino, C1-C8 alkoxycarbamoyl, C1-C8 alkylsulfonamido, C1-C8 alkylaminosulphonyl, C1-C8 alkoxy, C2-C8 alkoxyacyl, phenyl, 5-6 membered heteroaryl, or 5-7 membered heterocyclo, wherein 5-6 membered heteroaryl and 5-7 membered heterocyclo comprise one or more hetero atoms independently selected from N, O and S; and
phenyl, 5-6 membered heteroaryl and 5-7 membered heterocycle are unsubstituted or substituted with 1 to 3 R5a groups;
Z3 is H, —CN, halide, —OH, C1-C8 alkyl unsubstituted or substituted with 1 to 3 R12b groups, C3-C8 cycloalkyl, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkylsulfonyl, C1-C8 acyl, aminoacyl, C1-C8 acylamino, C1-C8 alkylcarbamoylamino, C1-C8 alkoxycarbamoyl, C1-C8 alkylsulfonamido, C1-C8 alkylaminosulphonyl, C1-C8 alkoxy, C2-C8 alkoxyacyl, —N(R7b)(R8b) unsubstituted or substituted with 1 to 3 R12b groups, phenyl unsubstituted or substituted with 1 to 3 R9b groups, 5-6 membered heteroaryl unsubstituted or substituted with 1 to 3 R10b groups, or 5-7 membered heterocyclo unsubstituted or substituted with 1 to 3 R11b groups, wherein 5-6 membered heteroaryl and 5-7 membered heterocyclo comprises 1-3 hetero atoms independently selected from N, O and S;
Z4 is —CN, C6 aryl, 5-6 membered heteroaryl, or
wherein 5-6 membered heteroaryl comprises 1 to 3 heteroatoms independently selected from N, O and S;
C6 aryl and 5-6 membered heteroaryl are unsubstituted or substituted with 1 to 3 R6c groups;
Y3 is O or NR8c; and
q is 0, 1, 2, or 3;
R1 to R3 are independently selected from H and C1-C6 alkyl, wherein C1-C6 alkyl is unsubstituted or substituted with 1 to 3 halide, —CN, —OH, C1-C3 alkyl, C3-C5 cycloalkyl, or C1-C3 alkoxy groups;
R4 is H, halide, —CN, —OH, —NO2, C1-C6 alkyl, C3-C8 cycloalkyl, or C1-C6 alkoxy, wherein C1-C6 alkyl, C3-C8 cycloalkyl and C1-C6 alkoxy are unsubstituted or substituted with 1 to 3 halide;
R5 and R6 are independently selected from H, halide, —CN, —OH, amino, C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 alkoxy, wherein C1-C6 alkyl, C3-C6 cycloalkyl and C1-C6 alkoxy are unsubstituted or substituted with 1 to 3 halide;
R7 and R8 are independently selected from H and C1-C6 alkyl, or R7 and R8 together are oxo (═O);
R9 to R12 are independently selected from H, C1-C6 alkyl;
R13 is H, halide, —CN, —OH, amino, —NO2, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylthio or 1-pyrrolidino, wherein amino, C1-C6 alkyl and C1-C6 alkoxy are unsubstituted or substituted with 1 to 3 halide, C1-C3 alkyl or C3-C6 cycloalkyl groups;
R14 to R17 are independently selected from H, halide, —CN, —OH, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy and C1-C6 alkylthio, wherein amino, C1-C6 alkyl and C1-C6 alkoxy are unsubstituted or substituted with 1 to 3 halide, C1-C3 alkyl or C3-C6 cycloalkyl groups;
R18 is H, halide, —CN, —OH, amino, C1-C6 alkyl, C3-C6 cycloalkyl or C1-C6 alkoxy, wherein amino, C1-C6 alkyl and C1-C6 alkoxy are unsubstituted or substituted with 1 to 3 halide, C1-C3 alkyl or C3-C6 cycloalkyl groups;
R19 and R20 are independently selected from H and C1-C3 alkyl, or R19 and R20 together, with adjacent atoms they attached to, form a cyclic structure;
R4a, R5a and R6a are independently selected from halide, —CN, and —OH, or R4a, R5a and R6a are independently selected from C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, C2-C8 alkenyl, C2-C8 alkynyl, C1-C8 alkylsulfonyl, C1-C8 acyl, aminoacyl, C1-C8 acylamino, C1-C8 alkylcarbamoylamino, C1-C8 alkoxycarbamoyl, C1-C8 alkylsulfonamido, C1-C8 alkylaminosulphonyl, C2-C8 alkoxyacyl, and 3-8 membered heterocycle, all of which are unsubstituted or substituted with 1-3 halide, —OH, —CN, C1-C3 alkyl, C1-C3 alkoxyl or C3-C8 cycloalkyl groups, wherein 3-8 membered heterocycle comprises one or more hetero atoms from N, O or S;
R2m is H, deuterium, tritium, halide, —OH, —CN, C1-C8 alkyl, C3-C8 cycloalkyl or C1-C5 alkoxy;
R2b and R3b are independently selected from H, C1-C6 alkyl unsubstituted or substituted with 1-3 groups selected from halide, —CN, —OH, C1-C6 alkyl, C3-C5 cycloalkyl and C1-C3 alkoxy;
R4b and R5b are independently selected from H, halide, —CN, amino, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, and C1-C3 alkylamino;
R6b is H, halide, —CN or —OH, or R6b is selected from amino, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, and C1-C3 alkylamino, all of which are unsubstituted or substituted with 1-3 halide, C1-C3 alkyl, or C3-C6 cycloalkyl groups;
R7b and R8b are independently selected from H, C1-C8 alkyl and C3-C8 cycloalkyl, the latter two of which are unsubstituted or substituted with 1-3 R12b, or R7 and R8 together, with adjacent atoms they attached to, form a cyclic structure;
R9b and R10b are independently selected from H, halide, —CN and —OH, or R9b and R10b are independently selected from amino, C1-C6 alkyl, C3-C6 cycloalkyl, and C1-C6 alkoxy, all of which are unsubstituted or substituted with 1-3 halide, C1-C3 alkyl, or C3-C6 cycloalkyl groups;
R11b is H, halide, —CN, —OH, amino, C1-C6 alkyl unsubstituted or substituted with halide, C3-C6 cycloalkyl, oxo, or C1-C6 alkoxy;
R12b is H, —CN, —OH, amino, C1-C6 alkyl unsubstituted or substituted with halide, C3-C6 cycloalkyl, oxo, or C1-C6 alkoxy;
R13b is H, halide, —CN, —OH, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C2-C6 alkylcarbamoylamino, C2-C6 alkoxycarbamoyl, C1-C3 alkylsulphonyl, —N(R16b)S(O)2—C1-C3 alkyl, or —N(R16b)C(O)—C1-C3 alkyl;
R14b and R15b are independently selected from H, C3-C6 cycloalkyl unsubstituted or substituted with 1 to 3 R20b groups, C1-C6 alkyl unsubstituted or substituted with 1 to 3 R20b groups, 5-6 membered aryl unsubstituted or substituted with 1 to 3 R20b groups, 5-6 membered heteroaryl unsubstituted or substituted with 1 to 3 R20b groups, and 5-6 membered heterocyclo unsubstituted or substituted with 1 to 3 R20b groups, wherein 5-6 membered heteroaryl and 5-7 membered heterocyclo comprise 1 to 3 hetero atoms independently selected from N, O and S, or R14b and R15b together, with adjacent atoms they attached to, form a cyclic structure;
R16b to R19b are independently selected from H and C1-C6 alkyl unsubstituted or substituted with halide;
R20b is H, —CN, —OH, amino, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, 5-6 membered aryl, or 5-6 membered heteroaryl, wherein 5-6 membered heteroaryl comprises 1 to 3 hetero atoms independently selected from N, O and S;
R21b is H or C1-C6 alkyl;
R2c and R3c are independently selected from H and C1-C6 alkyl unsubstituted or substituted with 1-3 halide;
R4c is H, halide, C1-C3 alkyl, C3-C5 cycloalkyl, or C1-C3 alkoxy;
R5c and R6c are independently selected from H, halide, —CN, —OH, amino, C1-C6 alkyl unsubstituted or substituted with 1-3 halide, C3-C5 cycloalkyl, and C1-C6 alkoxy;
R7c and R8c are independently selected from H and C1-C6 alkyl, or R7c and R8c together, with adjacent atoms they attached to, form a cyclic structure;
R9c to R14c are independently selected from H, C1-C6 alkyl and —CF3;
R15c to R17c are independently selected from H, halide, —CN, —OH, amino, C1-C6 alkyl unsubstituted or substituted with 1-3 halide, C3-C5 cycloalkyl, and C1-C6 alkoxy.
13. The compound of claim 1 , wherein the compound is selected from Table 1.
14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
15. A method for treating a Wnt-mediated disorder in a mammal suffering therefrom, comprising administering to the mammal a therapeutically effective amount of at least one compound of claim 1 , or a pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent.
16. The method of claim 15 , wherein the disorder is a cell proliferative disorder selected from the group consisting of systemic sclerosis, skin fibrosis, idiopathic pulmonary fibrosis, renal fibrosis, liver fibrosis, drug-induced fibrosis, radiation-induced fibrosis, colorectal cancer, breast cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, pancreatic cancer, leukemia, lymphoma, neuroblastoma, retinoblastoma, sarcoma, osteosarcoma, chondosarcoma, Ewing's sarcoma, rhabdomysarcoma, brain tumor, Wilms' tumor, basal cell carcinoma, melanoma, head and neck cancer, cervical cancer and prostate cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/653,217 US20200048223A1 (en) | 2015-10-08 | 2019-10-15 | Wnt signaling pathway inhibitors and therapeutic applications thereof |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510645986.2 | 2015-10-08 | ||
| CN201510645986.2A CN105254613A (en) | 2015-10-08 | 2015-10-08 | Heterocyclic compound with Wnt signal path inhibitory activity and application thereof |
| CN201610195731.5 | 2016-03-31 | ||
| CN201610195733 | 2016-03-31 | ||
| CN201610195733.4 | 2016-03-31 | ||
| CN201610195731 | 2016-03-31 | ||
| CN201610670828.7A CN107759584B (en) | 2016-08-16 | 2016-08-16 | An amino five-membered heterocyclic compound with Wnt signaling pathway inhibitory activity and its application |
| CN201610670828.7 | 2016-08-16 | ||
| CN201610850360.XA CN106565673B (en) | 2015-10-08 | 2016-09-26 | 5-fluoropyrimidine heterocyclic compound with Wnt signal channel inhibition activity and application thereof |
| CN201610850357.8A CN107286135B (en) | 2016-03-31 | 2016-09-26 | Heterocyclic compound with Wnt signal channel inhibition activity and application thereof |
| CN201610850357.8 | 2016-09-26 | ||
| CN201610850360.X | 2016-09-26 | ||
| CN201610850358.2A CN107286136B (en) | 2016-03-31 | 2016-09-26 | 3-fluoropyridine heterocyclic compound and application thereof |
| CN201610850358.2 | 2016-09-26 | ||
| PCT/US2016/055851 WO2017062688A1 (en) | 2015-10-08 | 2016-10-06 | Wnt signaling pathway inhibitors and therapeutic applications thereof |
| US201815766799A | 2018-04-06 | 2018-04-06 | |
| US16/653,217 US20200048223A1 (en) | 2015-10-08 | 2019-10-15 | Wnt signaling pathway inhibitors and therapeutic applications thereof |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/766,799 Continuation US10450300B2 (en) | 2015-10-08 | 2016-10-06 | Wnt signaling pathway inhibitors and therapeutic applications thereof |
| PCT/US2016/055851 Continuation WO2017062688A1 (en) | 2015-10-08 | 2016-10-06 | Wnt signaling pathway inhibitors and therapeutic applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20200048223A1 true US20200048223A1 (en) | 2020-02-13 |
Family
ID=62621830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/766,799 Active US10450300B2 (en) | 2015-10-08 | 2016-10-06 | Wnt signaling pathway inhibitors and therapeutic applications thereof |
| US16/653,217 Abandoned US20200048223A1 (en) | 2015-10-08 | 2019-10-15 | Wnt signaling pathway inhibitors and therapeutic applications thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/766,799 Active US10450300B2 (en) | 2015-10-08 | 2016-10-06 | Wnt signaling pathway inhibitors and therapeutic applications thereof |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10450300B2 (en) |
| EP (1) | EP3359154B1 (en) |
| JP (1) | JP6853819B2 (en) |
| KR (1) | KR102698411B1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4085057B1 (en) * | 2020-01-02 | 2025-10-08 | Helmholtz-Zentrum für Infektionsforschung GmbH | Pyridine and pyrimidine derivatives useful as pqsr inverse agonists |
| US12528783B2 (en) | 2020-01-02 | 2026-01-20 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | PqsR inverse agonists |
| CN112612873B (en) * | 2020-12-25 | 2023-07-07 | 上海德拓信息技术股份有限公司 | Centralized event mining method based on NLP technology |
| CN117903116A (en) * | 2021-08-27 | 2024-04-19 | 杭州阿诺生物医药科技有限公司 | Cyclin K degrading agent |
| KR20250100559A (en) * | 2023-12-26 | 2025-07-03 | (주)아이젠사이언스 | Novel Inhibitors of Ubiquitin-Specific Peptidase 1 |
| WO2026047509A1 (en) * | 2024-08-26 | 2026-03-05 | Avelos Therapeutics Inc. | Substituted triazine compound derivatives and their pharmaceutical use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61205261A (en) * | 1985-03-08 | 1986-09-11 | Sagami Chem Res Center | 6-substituted-5-fluorouracil derivative and production thereof |
| US4617393A (en) | 1985-07-19 | 1986-10-14 | American Home Products Corporation | 5-substituted-6-aminopyrimidines, composition and uses as cardiotonic agents for increasing cardiac contractility |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| WO2008132502A1 (en) * | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
| US20090054392A1 (en) * | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| TW201011017A (en) | 2008-08-19 | 2010-03-16 | Astrazeneca Ab | Chemical compounds 495-1 |
| GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| US20110189097A1 (en) * | 2009-11-09 | 2011-08-04 | Dritan Agalliu | Use of WNT inhibitor to inhibit angiogenesis in the CNS |
| WO2012149528A1 (en) * | 2011-04-29 | 2012-11-01 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
| CN104080773B (en) | 2012-01-28 | 2016-12-28 | 默克专利股份公司 | Nitrogen heterocyclic |
| PH12017500997A1 (en) * | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| JP2016518328A (en) * | 2013-03-12 | 2016-06-23 | キュアジェニックス インコーポレイテッド | Compounds for cancer treatment |
| CA2905841A1 (en) | 2013-03-14 | 2014-10-02 | Curegenix, Inc. | Quinazoline and naphthyridine derivatives useful in the treatment of fibrotic disorders |
| MY195016A (en) * | 2014-08-04 | 2023-01-03 | Nuevolution As | Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases |
| WO2016044787A1 (en) * | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| CN107001358A (en) * | 2014-10-29 | 2017-08-01 | 东亚St株式会社 | Adjust the new pyridine hepyramine compound of istone lysine demethylase (KDM) catalytic activity |
-
2016
- 2016-10-06 JP JP2018518629A patent/JP6853819B2/en active Active
- 2016-10-06 EP EP16854369.2A patent/EP3359154B1/en active Active
- 2016-10-06 US US15/766,799 patent/US10450300B2/en active Active
- 2016-10-06 KR KR1020187013073A patent/KR102698411B1/en active Active
-
2019
- 2019-10-15 US US16/653,217 patent/US20200048223A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102698411B1 (en) | 2024-08-26 |
| US10450300B2 (en) | 2019-10-22 |
| JP2018535949A (en) | 2018-12-06 |
| JP6853819B2 (en) | 2021-03-31 |
| EP3359154B1 (en) | 2021-05-26 |
| KR20180061363A (en) | 2018-06-07 |
| US20180244651A1 (en) | 2018-08-30 |
| EP3359154A1 (en) | 2018-08-15 |
| EP3359154A4 (en) | 2019-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10450300B2 (en) | Wnt signaling pathway inhibitors and therapeutic applications thereof | |
| US10251893B2 (en) | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | |
| US20240294524A1 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| EP2861590B1 (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| US11661397B2 (en) | 1,4-disubstituted imidazole derivative | |
| US20250313561A1 (en) | Next-generation modulators of stimulator of interferon genes (sting) | |
| EP4107146A1 (en) | Gcn2 modulator compounds | |
| US20200338084A1 (en) | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof | |
| US20250382297A1 (en) | Inhibitors of fgfr2 and fgfr3 and uses thereof | |
| WO2017062688A1 (en) | Wnt signaling pathway inhibitors and therapeutic applications thereof | |
| AU2012203023C1 (en) | N-(hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as Wnt signaling modulators | |
| KR20250043288A (en) | Composition for treating pulmonary fibrosis comprising thiazole derivative compound | |
| JP2025510205A (en) | Thiazole derivative compounds and their uses | |
| JP2024505258A (en) | Novel compounds as protein kinase inhibitors | |
| HK1182392A (en) | N-(hetero)aryl,2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators | |
| HK1160464B (en) | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators | |
| HK1209732B (en) | Compound as wnt signaling inhibitor, composition, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |




































































































































































































































































































































































































































































































































































